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Abstract 
Background: 
Until 2007, the polyomaviruses, BKPyV and JCPyV were the only known human 
polyomaviruses, and were shown to be ubiquitous in the population. First infection is 
generally asymptomatic, but these viruses may re-emergence leading to significant 
disease in immunocompromised subjects. Also, polyomaviruses produce T-antigens 
that have the ability to transform cells in vitro. Since 2007, eleven new polyomaviruses 
have been discovered, including Merkel cell polyomavirus which was shown to be 
integrated into the host genome of patients with Merkel cell carcinoma. It is imperative 
therefore that the biology, epidemiology and pathogenesis of the newly discovered 
human polyomaviruses be closely examined in order to gain a better understanding of 
their role in clinical disease. This study aimed at determining the nature and extent of 
infection of the new polyomaviruses WUPyV, KIPyV, MCPyV, HPyV6, 7, 9 12, TSPyV, 
MWPyV, STLPyV in children and adults.  
 
Methods: 
Specimen cohorts: In this study, four separate sample cohorts were used to examine 
the epidemiology and pathogenesis of the newly described polyomaviruses. 1) The 
first cohort consisted of approximately 2000 hospital-based samples of convenience, 
including healthy controls. These specimens were used to determine the prevalence 
of HPyV 6, 7, 9, TSPyV and MWPyV in respiratory and faecal specimens, blood, urine, 
and cerebrospinal fluid. 2) Sample cohort 2 consisted of approximately 8000 samples 
longitudinally collected in a birth cohort from the respiratory and gastroenterial tract of 
infants. This cohort was used to determine the age of acquisition, infection dynamics 
and clinical association of the newly described polyomaviruses. 3) A third sample 
cohort of longitudinally collected blood, urine and respiratory swabs from 167 renal 
transplant recipients was examined to determine the prevalence and clinical burden 
of human polyomaviruses. 4) The last sample cohort consisted of carcinoma 
specimens; including two micropapillary urothelial bladder carcinomas from renal 
transplant recipents, 52 frozen breast carcinoma biopsies and 100 fresh frozen lung 
carcinoma tissues paired with matched histologically normal controls.  
Molecular methods: A range of molecular techniques were developed for this study, 
including real-time PCR assays to screen the specimen cohorts for human 
polyomaviruses, and sequencing procedures to generate whole genome sequence 
data. In addition a novel viral enrichment procedure was applied using targeted rolling 
circle PCR amplification, and two molecular-based techniques were designed to 
investigate polyomavirus genome integration in carcinoma tissues.     
Histology methods: Immunohistochemical staining was conducted using monoclonal 
antibodies specific for BKPyV, MCPyV, HPyV 6 and HPyV 7 antigens. This method 
was applied to confirm the molecular detection of polyomaviruses in carcinoma 
tissues.   
 
Results: 
Specimen Cohort 1): Results demonstrated that the newly described polyomaviruses 
MCPyV, HPyV 6, 7 and TSPyV could be detected in respiratory swabs and faecal 
specimens, but not in blood, urine or cerebrospinal fluid. MWPyV was the most 
prevalent polyomavirus but was only detected in patients younger than 10 years. 
MWPyV was detected at a higher frequency in asymptomatic children than 
symptomatic patients suggesting this polyomavirus may not be associated with 
pathology.  
Specimen Cohort 2): Results from the birth cohort demonstrated that WUPyV, KIPyV 
and MWPyV were first acquired around year 1, and were associated with mild 
respiratory symptoms in one-third of sole detections. Viral mRNA could be detected 
for WUPyV and KIPyV suggesting active replication in the respiratory tract.  
Specimen Cohort 3): Most new polyomaviruses were commonly detected within the 
respiratory tract of renal transplant recipients at low viral load, in the absence of clinical 
symptoms. In contrast, only KIPyV, and no other virus, was detected at high viral load 
in sequential detections from two patients who displayed respiratory symptoms.  This 
suggested KIPyV may be a significant pathogen in the immunocompromised. 
Specimen Cohort 4): Examination of the carcinoma samples demonstrated that 
BKPyV was detected in bladder carcinoma tissues from two renal transplant recipients 
and, in one patient, was integrated within the coding sequence for the VP1 protein.  
This finding was confirmed by histological staining which demonstrated that BKPyV 
antigens were present in the nucleus of tumour cells but not surrounding normal tissue.  
MCPyV, HPyV 6 and 7 were detected within a subset of breast and lung carcinomas. 
In several cases, MCPyV was detected in tumour tissue only, and was confirmed by 
histological staining. In one patient a truncation within the VP2 coding sequence was 
detected and several patients had only partial MCPyV sequence. However, MCPyV 
integration into the tumour cell genome could not be demonstrated.  
         
Conclusions: 
This study showed that the newly described human polyomaviruses were highly 
prevalent within the human respiratory tract, and were typically acquired early in life 
via the faecal-oral route, causing mild pathology in up to one-third of children. 
However, immunocompromised subjects were at greater risk of disease caused by 
polyomaviruses, particularly infections with KIPyV, and therefore should be seriously 
considered in the management of these patients. The most significant findings of this 
study were novel evidence that further strengthen the proposed involvement of human 
polyomaviruses in the development of human cancer, as demonstrated by the case of 
BKPyV-induced micropapillary urothelial bladder carcinoma, and the compelling data 
suggesting a potential role for MCPyV in lung carcinomas. 
It is important therefore that further studies be considered using appropriately 
controlled sample sets, to clearly delineate the role of the polyomaviruses in 
tumourgenesis. Once such a role is proven, appropriate vaccine development 
strategies may be devised, as successfully applied for the papillomaviruses, which 
genetically are closely related to the polyomaviruses. 
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CHAPTER ONE 
 
Review of the Literature 
 
  
1.1 The family Polyomaviridae  
 
The expanding family Polyomaviridae consists of more than 30 species which infect a 
variety of different hosts.[1] Generally avian polyomaviruses are highly pathogenic and 
have a wide host range, and mammalian polyomaviruses have a limited host range 
and are asymptomatic in the immunocompetent host.[2], [3] At present 13 of these 
species are linked to human infection, JC polyomavirus (JCPyV)[4], BK polyomavirus 
(BKPyV)[5], WU polyomavirus (WUPyV)[6], KI polyomavirus (KIPyV)[7], Merkel cell 
polyomavirus (MCPyV)[8], human polyomavirus 6 (HPyV6)[9], human polyomavirus 7 
(HPyV7), Trichodysplasia spinulosa-associated polyomavirus (TSPyV)[10] and 
human polyomavirus 9 (HPyV9)[11], Malawi polyomavirus (MWPyV)[12], St Louis 
polyomavirus (STLPyV),[13] human polyomavirus 12 (HPyV12)[14] and New Jersey 
polyomavirus (NJPyV)[15].   
 
In humans, polyomaviruses generally cause an initial asymptomatic infection in early 
childhood they then become dormant, only reactivating and causing severe disease in 
the immunocompromised host. Human polyomaviruses have widespread 
seroprevalence in the general population and can be oncogenic in animal models, but 
with the exception of MCPyV, evidence of human polyomaviruses involvement in the 
development of cancer is yet to be confirmed, and is the matter of extensive scientific 
debate. [16], [17]   
 
The family Polyomaviridae has recently been revised by the International Committee 
on Taxonomy of Viruses (ICTV) dividing the single genus into three genera; 
Orthopolyomavirus, Wukipolyomavirus and Avianpolyomavirus.  Essentially creating 
two mammalian genera and an avian genus the mammalian genus is further divided 
into two genera based on whole genomes sequence diversity of greater than 81-84%. 
[1]  
 
Figure 1.1 A radial phylogenetic tree generated using a Neighbour-Joining analyses of 
concatenated VP2, VP1 and LTAg gene sequences from a wide variety of mammalian, bird and 
fish polyomavirus species. All known human polyomaviruses are shown in red, with recognized 
polyomavirus subclades highlighted. Members of the Orthopolyomavirus, Wukipolyomavirus 
and Avianpolyomavirus genra are allow highlighted. 
 
The polyomavirus is a non-enveloped icosahedral particle containing a circular double 
stranded DNA genome of approximately 5000 base pairs.[18]  The genome is packed 
around the core host-cell nucleosomes (H2A, H2B, H3 and H4) and 24-26 of these 
nucleosomes forms a minichromosome. This minichromosome is structurally identical 
to the host cell chromatin. [3] The genome is divided into three functional regions the 
early and late coding region and the non-coding control region (NCCR) that contains 
the origin of replication. Generally the early coding region produces non-structural 
proteins including the small (STAg) and large tumour antigen (LTAg) and the late 
region encodes the three capsid proteins, VP1, VP2, and VP3. The origin of replication 
(ORI) separates these two coding regions, and replication commences bidirectionally 
from the ORI.[3], [18] Additional structural and non-structural proteins are encoded in 
some of the human polyomaviruses. For example JCPyV, BKPyV and SV40 encode 
an agnoprotein within the 5’end of the late coding region.  SV40 has an additional 
tumour antigen called 17KT and JCPyV has three additional tumour antigens, T’135, 
T’136 and T’165 all produced by alternatively spliced mRNA.[19], [20] 
 
The capsid consists of 72 pentamers of protein VP1, each pentamer is associated with 
a single copy of VP2 or VP3[18], [21] The virion is 40-45nm in diameter.  
 
 
 
 
 
 
 
 
 
 
Figure 1.2 Organisation of general features in the polyomavirus genome 
 
Large TAg 
1.2  Polyomavirus life cycle 
1.2.1 Cell entry 
 
The polyomavirus virion contains 72 pentamers of the protein VP1, each of these 
pentamers forms a barrel-like structure. VP2 and VP3 are contained within hollows of 
the VP1 pentamer. The VP1 proteins interacts via interlocking secondary structures to 
form a pentamer. This is strengthened by disulfide and calcium bonding, which is 
highly conserved throughout the polyomavirus family.[22] The VP1 protein provides 
most of the surface residues that interact with the host cell. Mutations in VP1 calcium 
binding residues produce many negative effects on the polyoma life cycle, including 
blocking entry into the host cell and nucleus and disruption of virion assembly.[23], 
[24] VP2 and VP3 appear to be important in nuclear entry. [25]  
 
The mechanisms of polyomavirus cell entry, transportation through the cytoplasm and 
entry into the nucleus still require further investigation. SV40 is the most intensively 
studied polyomavirus. Therefore much of the insights into the polyomavirus life cycle 
have been identified based on SV40 infections. SV40 uses the ganglioside GM1 as a 
receptor and enters the cell by caveolar-mediated endocytosis. However SV40 can 
also gain cellular entry independently of both clathrin or caveolin mediated 
endocytosis.[26], [27] After internalisation it is transported in a caveosome along 
microtubules to the endoplasmic reticulum (ER).[28], [29] The virus utilises the ER to 
initiate disassembly of the capsid and ER degradation pathways to enter the cytosol. 
Uncoating of the capsid is believed to be mediated through dissociation of the disulfide 
bonds, which are critical to the structure of the VP1 pentamers.[30] The virus is then 
believed to enter the nucleus through the nuclear pore complex (NPC).[25], [31]–[33]   
Transport to the nucleus through the NPC is signal and energy dependent; in SV40 
infection it requires interaction between the nuclear-targeting signals (NTS) and the 
importin α2/β heterodimer. NTSs are found on both the VP1 and VP3 proteins. 
However it appears that the VP3 NLS are essential for nuclear entry. Degradation 
pathways in the ER allow the exposure of VP3 proteins so interaction with NTS can 
occur.[34]–[36] Infectivity studies show related polyomaviruses use independent 
mechanisms for viral entry. In contrast to SV40, JCPyV uses a clathrin-dependent 
endocytosis pathway to gain entry to the host cell after binding to the 5HT2A serotonin 
receptor. [37], [38] BKPyV also utilizes caveolae mediated endocytosis but binds to 
ganglioside receptors GD1b and GT1b.[39], [40] 
 
Once the modified virion has entered the nucleus it is thought to interact with poly 
(ADP-ribose) polymerases -1 (PARP-1). Binding of PARP-1 to VP1 molecules 
dissociates the VP1 pentamers, allowing exposure of the viral enhancer region of the 
polyomavirus genome leading to early transcription.[41]  
1.2.2 Viral transcription 
 
Viral transcription is initiated through cellular RNA polymerase II, with early 
transcription being controlled by cis-acting sequences in the regulatory region, such 
as the TATA box and the 72 base pair repeat which are transcriptional enhancers. 
Binding sites for transcription factors are also coded for on the early promoter in a 
series of GC rich sequences.[3]  
 
Early transcription produces a single mRNA that is alternatively spliced into the STAg 
and LTAg. The coding regions for the T-antigens are overlapping resulting in the same 
N-terminal sequence but different C-terminal sequences. [18]  
 
Polyomaviruses do not process the necessary DNA synthesis machinery to replicate 
their DNA, they need to utilise the host cell replication machinery, and therefore they 
require a method of driving the cell into S-phase. [42] This is achieved largely through 
the interaction of the viral T-antigens with the host cell. The LTAg has an extensive 
array of effects on the host cells and its own replication; these include, driving the host 
cell into S phase, a transcription activator and suppressor, helicase activity and 
assistance in virion assembly.[3] 
1.2.3 The T-antigens 
 
The main mechanism polyomaviruses use to drive cells into S-phase is through the 
direct binding of LTAg to retinoblastoma suppressor proteins, namely pRb, p107 and 
p130.[43]–[45] These proteins form complexes with the transcription factor EF2, LTAg 
dissociates EF2 and pRb, enabling EF2 to bind its target sequence which promotes 
S-phase progression and DNA synthesis.[46], [47] The LTAg binds to Rb proteins 
using the conserved LxCxE motif, the EF2 protein is then displaced using the LTAg’s 
J domain to recruit Hsc70 and utilise its ATPase activity.[48], [49]  
 
Inappropriate entry of the host cell into S phase would normally signal a p53 apoptosis 
pathway, however binding of the LTAg to p53 allows the virus to escape p53 and 
continue viral replication.[3], [50] P53 is regulated by a negative feedback loop with 
the ubiquitous ligase Mdm2; when LTAg binds to p53, p53 is unable to bind to the 
Mdm2 promoter, cellular concentration of Mdm2 regulates cell cycling check 
points.[51]–[53] The discovery of p53, now identified as a critical tumour suppressor 
in humans was revealed during investigations into SV40 tumorgenesis.[54] The p53 
binding domain is found in the helicase domain within the variable C-terminal region 
of LTAg. 
 
LTAg also plays a more direct role in viral DNA syntheses; LTAg binding sites around 
the ORI promote DNA polymerase binding and also recruit replication protein A to the 
ORI, which is essential for efficient DNA replication. As LTAg binds around the ORI it 
forms a double hexamer complex, this complex has two roles; (1) the hexamer 
structure distorts the DNA and (2) the helicase function promotes unwinding of DNA 
at the replication fork both of which assist in initiation of DNA synthesis. [55], [56] 
Arrangement of LTAg binding sites around the ORI differ between all human 
polyomaviruses, however multiple repeats of the GAGGC pentanucleotide element or 
GCCTC its complement are found in all family members. [57]  
 
The STAg has an important role in promoting cell growth and therefore viral replication 
through its interaction with protein phosphatise 2A (PP2A).[58] PP2A regulates 
numerous cell cycling processes through phosphylation. STAg directly binds PP2A 
which disrupts its phosphatise ability.[59] The interaction with PP2A occurs through 
the binding of the CxxxPxC motif, a functional J domain is also required.[60], [61] STAg 
has also been observed to stimulate intercellular kinases to promoting cell growth 
pathways.[60], [62] 
 Figure 1.3 Schematic representation of both the mRNA and protein of the polyomavirus T-
antigens. Splicing of a single mRNA produces the STAg and LTAg which both share common 
regions at the 3’ end alternative splicing allows unique 5’ sequences in both proteins. On a 
protein level the conserved DnaJ domain that binds Hsc70 is found in both the LTAg and STAg 
in the common region. The common region of LTAg also contains a conserved Rb family binding 
domain. The unique region of the STAg encodes for the PP2A binding region. The unique region 
of the LTAg contains the origin binding domain and the helicase domain, the helicase/ATPase 
domain encodes for the conserved binding sites for p53 proteins. 
 
1.2.4 MicroRNA 
 
MiroRNA (miRNA) has also been shown to modulate SV40 gene expression, SV40 
miRNA accumulates in the late stage of infection and binds to the mRNA targeting it 
for cleavage. This effectively reduces the expression of T-antigens; however mutation 
experiments on miRNA encoding sequences do not reduce the production of infectious 
virions. It is thought that miRNA is used by the virus to reduce host cell lysis by 
cytotoxic t-cells. miRNA reduces the amount of T-antigen in the cell. Normally T-
antigen accumulation would signal degradation by cytotoxic t-cells, therefore miRNA 
ensures the virus can continue to replicate.[63] Recently miRNA from JCPyV and 
BKPyV was shown to target the stress induced ligand ULBP3, which is involved in 
activation of the natural killer (NK) T-cell receptor NKG2D. Down regulation of ULBP3 
results in a reduction in NKG2D mediated killing of virally infected cells by NK cells. It 
is hypothesised that this may be a method polyomaviruses use to remain latently 
infected without being eliminated by the host immune system.[64]   MCPyV and MPyV 
also encode miRNAs that regulate late viral gene expression; investigation into the 
presence and function of other human polyomaviruses miRNA is warranted. [65], [66]    
1.2.5 Structural proteins 
 
Once viral replication begins the infection enters late phase and again the LTAg 
promotes the transcription of the late genes which encode for structural proteins VP1, 
VP2 and VP3. At this stage LTAg beings to suppress early gene expression; the 
mechanism for this is poorly understood but thought to occur through high 
concentrations of LTAg binding around the ORI which causes conformational changes 
to the LTAg double hexamer promoting transcription of the late region.[56], [67] 
 
Transcription of the late genes produces a minimum of three proteins, VP1, VP2 and 
VP3 an agnoprotein is also encoded in JCPyV, BKPyV and SV40 but not in WUPyV, 
KIPyV and MCPyV.[6]–[8], [68] The three capsid proteins are encoded in an 
overlapping manner with VP3 completely encoded in the 3’ terminal sequence of VP2. 
Capsid proteins are transcribed after alternative splicing of late region mRNA. 
Translocation of transcribed proteins is not well understood but is thought to occur with 
interaction of the agnoprotein and VP1. As some polyomaviruses do not encode an 
agnoprotein, the NTS on VP1 and VP3 may also be involved[3], [69]. As VP1 can self-
assemble into capsid without the presence of VP2 or VP3 in baculovirus expression 
systems, it is thought that the low calcium concentration in the cytoplasm prevents 
assembly. This is supported by the relatively high concentration of calcium in the 
nucleus where virions may be seen by EM and confocal microscopy.[69]–[71]  After 
the late region proteins are translated and transported to the nucleus they assemble 
into virions. VP1 forms the major external protein with VP2 and VP3 extending 
internally and likely anchoring the minichromosome. Exit of fully assembled infectious 
polyomaviruses is thought to occur through a number of processes including host cell 
lysis, the agnoprotein increasing membrane permeability and VP3 lytic 
properties.[72]–[74] 
 
1.3 History of polyomaviruses 
 
The first polyomavirus to be isolated was the mouse polyoma virus (MPyV) by Ludwig 
Gross in 1953.[75] He observed the virus whilst studying murine leukaemia virus. 
When newborn mice were infected with this virus the mice not only developed 
leukaemia but also tumours in the parotid glands. Murine leukaemia virus can be heat 
inactivated. However Gross showed the development of tumours continued after heat 
inactivation of the inoculum and concluded that tumour growth was due to another 
infectious agent. After further experimentation Gross named the virus ‘polyoma’ due 
to its ability to generate tumours in various tissues throughout newborn mice. Since 
MPyVs discovery it has been studied intensively and has greatly enhanced the 
understanding of viral oncogenisis.[18]  
A summary of species within the family Polyomaviridae is listed in Table 1.1 However, 
this historical review of polyomavirus research is limited to those polyomaviruses 
believed to infect humans.  
 Table 1.1 The Family Polyomaviridae 
Name Abbreviation Year of 
discovery 
Host GenBank Pathogenicity 
Orthopolyomavurus 
Murine polyomavirus MPyV 1953 Mouse NC_001515 Tumours in various tissues of newborn mice 
Murine pneumotropic virus MPtV 1953 Mouse NC_001505.2 Intestinal pneumonia in newborn mice 
Simian virus 40 SV40 1960 Monkey NC_001669 Asymptomatic in natural hosts 
Baboon polyomavirus SA12 1963 Monkey NC_007611 Asymptomatic 
Hamster polyomavirus HaPyV 1967 Hamster NC_001663 Epitheliomas and skin lesions, secondary tumours 
in young naive hamsters  
JC polyomavirus JCPyV 1971 Human NC_001699 Asymptomatic/mild respiratory infection in healthy 
individuals, reactivation leading  to causes of PML 
in immunocompromised   
BK polyomavirus BKPyV 1971 Human NC_001538 Asymptomatic/mild respiratory infection in healthy 
individuals, reactivation in transplant patients can 
lead  to  nephropathy and risk of organ rejection   
Bovine polyomavirus BPyV 1974 Cow NC_001442 Asymptomatic 
B-lymphotropic polyomavirus LPyV 1979 Monkey NC_004763 Unknown in natural host, found in human PBMC’s  
Chimpanzee polyomavirus ChPyV 2005 Chimpanzee AY691168 Suspected diarrhoea 
Merkel cell polyomavirus MCPyV 2008 Human NC_010277 Merkel cell carcinoma, a rare neuroendocrinal 
tumour 
Squirrel monkey polyomavirus SqPyV 2008 Monkey NC_009951 Asymptomatic 
Bat Polyomavirus BatPyV 2009 Bat NC_011310 Asymptomatic 
Bornean orang-utan polyomavirus OraPyV1 2010 Orang-utan NC_013439 Unknown 
California sea lion polyomavirus SLPyV 2010 Sea lion NC_013796 Discovered in glossal mass on tongue. Sea lion 
diagnosed T-cell lymphoma but it is thought 
unlikely to be polyoma induced 
Sumatran orang-utan polyomavirus OraPyV2 2010 Orang-utan FN356901 Unknown 
Trichodysplasia spinulosa-
associated polyomavirus 
TSPyV 2010 Human NC_014361 Trichodysplasia spinulosa is a rare skin disease 
exclusively affecting the immunocomprimised 
Wukipolyomavirus 
KI polyomavirus KIPyV 2007 Human NC_009238 Unknown/? Respiratory 
WU polyomavirus WUPyV 2007 Human NC_009539 Unknown/? Respiratory 
Name 
 
Abbreviation Year of 
discovery 
Host GenBank Pathogenicity 
Human polyomavirus  6  HPyV6 2010 Human NC_014406 Found in epithelial proliferations in melanoma 
patients receiving BRAF inhibitors  
Human polyomavirus 7 HPyV7 2010 Human NC_014407 Detected in pruritic rashes in transplant recipients 
Avipolyomavirus 
Avian Polyomavirus APyV 1981 Birds NC_004764.2 Hepatitis and hydropericarduim, high mortality 
Goose hemorrhagic polyomavirus GHPyV 2000 Goose NC_004800 
 
Hemorrhagic nephritis, high mortality 
Crow polyomavirus CPyV 2006    Jackdaw crow NC_007922 Unknown, sudden death of bird 
Finch polyomavirus FPyV 2006 Bullfinch NC_007923 Unknown, sudden death of bird 
Canary Polyomavirus CaPyV 2010 Canary GU345044 Unknown, sudden death of bird 
Not yet assigned a species 
Athymic rat polyomavirus RatPyV 1984 Rat NA Inflammation of parotid gland 
Baboon polyomavirus 2 BPyV2 1989 Monkey NA Unknown 
Rabbit kidney vacuolating virus RKV 1966 Rabbit NA Asymptomatic 
Cynomolgus polyomavirus CyPV 1999 Monkey NA Unknown 
Human polyomavirus 9 HPyV9 2011 Human NC_015150.1 Unknown 
Malawi polyomavirus MWPyV 2012 Human NC_018102.1 Unknown 
St Louis polyomavirus STLPyV 2013 Human NC_020106.1 Unknown 
Human polyomavirus 12 HPyV12 2013 Human NC_020890.1 Unknown 
Raccoon polyomavirus RacPyV 2013 Raccoons NC_238451 Brain and olfactory tumours 
New Jersey polyomavirus NJPyV 2014 Human NC_024118 Unknown 
Bovine polyomavirus 2 BoPyV2 2014 Cow NC_025811 Unknown 
Bovine polyomavirus 3 BoPyV2 2015 Cow NC_025800 Unknown 
Black sea bass polyomavirus BSBPyV 2015 Fish NC_025790 Unknown 
Giant guitarfish polyomavirus GGPyV 2015 Fish NC_026244 Unknown 
 
 
 
 
 1.3.1 SV40 
 
SV40 was discovered in 1960 in a contaminated batch of Polio vaccine, which was 
generated in primary kidney cells from Rhesus monkeys.[76] This Polio vaccine was 
administered to approximately 100 million children and adults in the US between 1955 
and 1963 and the same vaccine production methods were used to generate Polio 
vaccine throughout the world. A vacuolating agent was seen during safety testing in 
some cultures leading to a cytopathic effect, and the agent was later named Simian 
virus 40 (SV40).[3], [76] Further investigations of SV40 infections in a variety of tissue 
culture systems showed the virus had the ability to form tumours in animals and many 
culture models.[77] This sparked years of detailed research dedicated to SV40 
infection and its oncogenic mechanisms. To date, SV40 infection has been linked to 
the development of mesothelioma, osteosarcoma, paediatric and adult brain tumours, 
and non-Hodgkin lymphoma. However other groups have not been able to replicate 
these initial findings.[78]–[88] Epidemiological studies have failed to find an increased 
risk of tumour development in populations exposed to the SV40 contaminated Polio 
vaccine.[88]–[92] Research into SV40 has greatly improved our understanding of the 
cell cycle and oncogenic pathways, leading to the discovery of tumour suppressor p53 
and cell cycle regulator pRb.[3], [18], [93] However, 50 years on, the question of SV40 
infection being a causal agent of human cancer is still, highly controversial.[16], [94], 
[95] 
 
 
 
 1.3.2 JC and BK polyomavirus 
 
The first two human polyomaviruses JC and BK were discovered in 1971, these 
discoveries were published in the same issue of Lancet. JCPyV and BKPyV were 
named after the initials of the two patients from whom the virus was isolated.[4], [5]  
JCPyV was isolated from the brain tissue of a patient with Hodgkin’s lymphoma who 
also had progressive multifocal leukoencephalopathy (PML). Isolated JCPyV agent 
was inoculated into a culture of human foetal brain tissue and found to be the causal 
agent of PML.[4] BKPyV virus was isolated in African green monkey kidney cells from 
the urine of a patient after renal transplantation.[5] 
 
BKPyV and JCPyV infection occurs during early childhood, resulting in a 
seroprevalence in the adult population of 50 -98%.[96] Mechanisms of transmission 
are not well understood but thought to be the fecal-oral or respiratory routes.[97]–[99] 
Primary infection is usually asymptomatic or with mild respiratory symptoms in healthy 
individuals.[98] After primary infection JCPyV and BKPyV establish a persistent 
infection, possibly in the lymphoid, neuronal, kidney, or haematopoietic tissues.[100]–
[102] Re-emergences of BKPyV and JCPyV in the host with the manifestation of 
severe disease may occur when the immune system is impaired or suppressed.  
 JCPyV is the causal agent of PML a fatal demyelinating disease that causes the lytic 
infection of oligodendrocytes of the central nervous system (CNS). Incidence of this 
once rare fatal disease has increased greatly with the 1980 pandemic of acquired 
immunodeficiency syndrome (AIDS).[103], [104] BKPyV is urotheliotrophic and 
generally reactivates in renal transplant patients leading to nephropathy which is 
associated with risk of organ rejection if not recognised early.[104]–[108] BKPyV can 
 also reactivate in bone marrow transplant (BMT) recipients leading to haemorrhagic 
cystitis (HC).[109], [110]  
Four main serological subtypes have been identified for both JCPyV and BKPyV. 
These subtypes are associated with geographical orientation. The possible clinical 
significance of these serotypes for either virus remains unclear.[111], [112]   
1.3.3 Lymphotrophic polyomavirus   
 
Lymphotrophic polyomavirus was isolated from a B-lymphoblastoid African green 
monkey cell line in 1979. The potential clinical impact of LPyV in humans has recently 
been investigated, showing that virus DNA may be detected in the peripheral blood of 
both healthy and immunocompromised subjects. [113] These investigations are 
ongoing. 
1.3.4 WU and KI polyomavirus 
 
The interest in human polyomaviruses was renewed in 2007 with the detection of two 
novel human Polyomaviridae members. Strangely similar to the initial reporting of 
JCPyV and BKPyV in 1971, these two novel polyomaviruses where reported within a 
month of each other.  Allander et al (2007) reported the detection of Karolinska 
Institutet (KI) polyomavirus by large scale molecular virus screening. Less than a 
month later Gaynor et al (2007) reported the detection of Washington University (WU) 
polyomavirus, again using high through-put molecular sequencing techniques. Both 
viruses were detected in respiratory secretions of children with acute respiratory 
illness. Phylogenetic analysis reveals that WUPyV and KIPyV are most closely related 
to each other and together with human polyomavirus 6 and 7 form a new genus 
Wukipolyomavirus.[1], [6], [114] The genome organisation of Wukipolyomavirus is 
 similar to other viruses in the family, which is not surprising as both viruses were 
identified based on sequence homology.  PCR detection rates for WUPyV and KIPyV 
in respiratory secretions are between 0.4 - 9% in studies conducted throughout the 
world.[6], [7], [115]–[132] Higher detection rates have been noted in 
immunocompromised populations. However most reports have been conducted using 
small cohorts and lack appropriate control populations. Clinical studies have identified 
that WUPyV and KIPyV are primarily detected in respiratory specimens collected from 
children. However they have also been found in blood, faeces and lymphoid 
tissues.[115], [120], [133]–[137] Co-detection with other respiratory pathogens is 
common making it difficult to determine an aetiological link between KIPyV and 
WUPyV infection and respiratory disease.[6], [7], [129], [131], [133], [138], [139] 
Different studies show that the seroprevalance of WUPyV and KIPyV range between 
54%-90% and 55%-93.3% in healthy adults respectively. This suggests that WUPyV 
and KIPyV infection is widespread.[96], [140], [141] In parallel with JCPyV and BKPyV 
it is hypothesised that WUPyV and KIPyV may persist in the host, and reactivate to 
cause disease in the immunocompromised population. To date studies show no 
statistically significant difference between detection rates of WUPyV or KIPyV in 
immunocompromised or immunocompetent populations. However increase incidence 
and high viral load of KIPyV have been noted in the immunocompromised host.[135], 
[142]–[154] Investigation of a possible causal role for WUPyV and KIPyV in a variety 
of different cancers types is underway.[155], [156]   
1.3.5 Merkel Cell polyomavirus 
 
In 2008 genome sequences of a fifth human polyomavirus were detected using a 
digital transcriptome subtraction technique of RNA extracted from a Merkel cell 
 carcinoma (MCC). This new virus was called Merkel cell polyomavirus (MCPyV).[8] 
MCC is a rare form of neuroectodermal tumour and is predominately found in the 
elderly, white and immunosuppressed populations. It is a very aggressive carcinoma 
with a host survival of only 9 months in 50% of advanced cases. This survival rate is 
greatly reduced in immunocompromised patients.[8], [157] The MCPyV genome, 
unlike other human polyomaviruses has high sequence homology with the LPyV and 
therefore it is more closely related to MPyV than SV40. Many of the conserved features 
of the polyomavirus T-antigen are found including: origin binding, a DnaJ binding 
domain, conserved Rb binding motif, and helicase/ATPase domain.[8] MCPyV has a 
seroprevalance of 25-42% in the healthy adult population.[96]  The initial MCPyV 
sequences found in MCC tumour biopsies were integrated into human receptor 
tyrosine phosphatise type G gene (PTPRG).[8] This viral integration has also been 
observed in polyomaviruses that cause tumours in cell culture models, but  has not 
been demonstrated in human tumours before the discovery of MCPyV.[8]  
1.3.6 Human polyomavirus 6 and 7 
 
In 2010 three new human polyomaviruses were discovered on adult skin. Human 
polyomavirus-6 and polyomavirus-7 were discovered on the forehead of volunteers 
using rolling circular amplification (RCA) to amplify circular DNA genomes.[9] HPyV6 
& HPyV7 are now placed in the genus Wukipolyomavirus. They show  a high sequence 
homology with WUPyV and KIPyV within the early regions of VP1 but are highly 
divergent in the late region of VP1/VP2.[1], [9] Small numbers of whole virions are 
shed from the skin of infected individuals. Shedding of virions is common with some 
initial investigations detecting 5/35 individuals positive for HPyV6 and 4/35 positive for 
HPyV7. Serological analyses using recombinant virus-like particles (VLP) shows a 
 seroprevalance of 69% for HPyV6 and 35% for HPyV7 in adults, confirming that 
exposure to these two polyomaviruses is common.[9] Early investigations of these 
viruses in cancer tissues have shown no association of HPyV6 and HPyV7 infection 
and  cancer development.[158]–[160]  
1.3.7 Trichodysplasia spinulosa-associated polyomavirus       
 
Trichodysplasia spinulosa-associated polyomavirus (TSPyV), was also discovered on 
human skin in 2010 using RCA amplification. Trichodysplasia spinulosa (TS) is a rare 
skin disease exclusively affecting immunocompromised patients. It has been 
speculated that the causal agent is papovavirus - like based on electron microscope 
images.[10], [161] The TSPyV virus has all the typical polyomavirus genomic features. 
It is grouped in the Orthopolyomavirus genus and shares the greatest sequence 
homology with Sumatran orang-utan polyomavirus (OrangPyV1).[1], [10] Clinically, TS 
develops as an eruption of erthematous papules many with follicular extensions 
localised to the central face, particularly the nose.[162]  Active infection with TSPyV in 
TS follicular biopsy’s has been demonstrated using quantitative PCR and visualised 
with electron microscopy, strongly suggesting that TSPyV is the causal agent of 
TS.[162]–[164] PCR methods have detected TSPyV in 4% of skin swabs from renal 
transplant patients without clinical TS, suggesting that TSPyV may be found on skin 
without apparent disease.[10] High seroprevalence (~70%) in the adult population 
supports the theory that TSPyV infection is usually asymptomatic and a causal agent 
of TS only in highly immunosuppressed individuals.[165], [166] 
 
 
 1.3.8 Human polyomavirus 9 
 
The use of degenerate primers lead to the discovery of another new human 
polyomavirus in 2011, Human polyomavirus 9 was detected in the serum of a renal 
transplant patient under immunosuppression. [167] Whole genome sequencing 
revealed HPyV9 is most closely related to LPyV and has all the typical genomic 
features of polyomaviruses.[167] It had long been postulated that a human 
polyomavirus simular to LPyV was in existence. LPyV sequences have been detected 
in peripheral blood of healthy and immunocompromised subjects, and serological 
studies have reported a prevalence of 30%.[96], [113], [168], [169] HPyV9 showed a 
seroprevalence of 47% in healthy adults, but cross reactivity of antibodies to HPyV9 
and LPyV was confirmed, and may account for previous serological evidence of LPyV 
infection in humans.[11] HPyV9 has also been detected on skin swabs of MCC 
patients, and infections with HPyV9 seem to be more common in MCC patient groups 
than aged matched controls.[170] 
1.3.9 Malawi polyomavirus 
 
This virus was identified in 2012, isolated in the stool sample of a healthy child from 
Malawi. Shotgun pyrosequencing was used to identify the initial six novel reads and 
subsequently the 4927bp whole genome was sequenced using walking primers.[12] 
A rtPCR assay was then designed and used to screen 514 stool samples from children 
with diarrhea in St.Louis, USA. MWPyV was detected in 12 of these samples, but the 
index strain of these samples differed by 5.3% at the nucleotide level compared to the 
Malawi index case. In parallel, a virus termed human polyomavirus 10 (HPyV10) was 
found in chondyloma specimens from a patient with warts with hypoglobulinemia 
 infections, and myeloathexis (WHIM).[171] Soon afterwards, a virus called MXPyV 
was described in the stools of Mexican children.[172] Both HPyV10 and MXPyV are 
genetically nearly identical to MWPyV, and can be considered strains of the virus. 
Studies on MWPyV conducted in Mexico also detected MWPyV in healthy and 
symptomatic fecal specimens and included a small number of respiratory specimens 
were a single case of MWPyV was also detected.  
1.3.10 St Louis polyomavirus  
 
Like MWPyV, St Louis polyomavirus was also uncovered in the stool specimen from 
a healthy child, using 454 pyrosequencing.[13] Not surprisingly this polyomavirus is 
phylogenetically, most simular to MWPyV. Interestingly this polyomavirus is believed 
to encode a unique protein through alternative splicing of the early coding region, 
called 229T. STLPyV had a prevalence of 1% in paediatric stool specimens, however 
no statistical association was found between symptomatic and non-symptomatic 
specimens. Recently a Chinese study confirmed the presence of STLPyV in stool 
specimens collected from children, this study also failed to find a statistical association 
between STLPyV and gastroenteritis.[173] In parallel to other member of the 
polyomavirus family the seroprevalence of STLPyV is high (68-77%) with age stratified 
data suggesting this polyomavirus is acquired in early childhood.[174] 
 
1.3.11 Human polyomavirus 12 
 
HPyV12 has been first identified in resected human liver tissue.[14] Investigation of 
organs, body fluids and excretions of diseased individuals and healthy subjects with 
both HPyV12-specific nested PCR and quantitative real-time PCR revealed additional 
 virus-positive samples of resected liver, cecum and rectum tissues and a positive fecal 
sample. Seroprevalences of 23% and 17%, respectively, were determined in sera from 
healthy adults and adolescents and a pediatric group of children. These data indicate 
that the virus naturally infects humans and that primary infection may already occur in 
childhood. No definitive association with disease is known to date. 
1.3.12 New Jersey polyomavirus 
 
New Jersey polyomavirus was discovered in endothelial cells in a pancreatic 
transplant recipient. This patient suffered multiple complications 11 months post-
transplantation; these symptoms included retinal blindness and necrotic plaques on 
multiple areas of the skin.[15] Specific rtPCR assays revealed a high load of NJPyV 
and virus particles were visualised using electron microscopy within the nuclei of 
vascular endothelial cells.  This patient’s weakness slowly subsided with reduction of 
immunosuppressive therapy, however her eye sight failed to return, and despite the 
improvement of her symptoms she still had NJPyV viremia 10 months after the onset 
of symptoms. NJPyV was not detected in the patient’s pre-transplant serum or in small 
numbers of sera collected from the general population. 
 
1.4 Human polyomaviruses and the immunocomproimised host  
 
Human polyomaviruses may cause significant disease in the immunocompromised 
host, with reactivation of latent to lytic infection resulting in viruria and viremia 
potentially leading to fatal disease.  
 
 1.4.1 Progressive multifocal leukoencephalopathy  
 
PML is a fatal demyelinating disease caused by JCPyV. It was once a rare clinical 
condition but has become more prevalent with the increased use of 
immunosuppressive therapy and the emergence of HIV infection.[107] PML develops 
in patients with impaired immunity, and has been associated with HIV/AIDS, solid 
organ transplant recipients, lymphoproliferative disorders, myeloproliferative disease, 
chemotherapy, autoimmune disorders, inherited immunodeficiencys and the 
elderly.[103], [175]–[180] PML is caused by a lytic infection of the oligodendrocytes 
which are the myelin producing cells of the CNS. Cell death leads to lesion formation 
in the cerebrum, cerebellum, brain stem and even the spinal cord.[181]–[183] The 
diagnostic hallmark for PML is the presence of oligodendrocytes with enlarged nuclei 
containing intranuclear inclusions. Clinical symptoms include impaired vision and 
speech, confusion and dementia, and degrees of paralysis. Disease progression is 
rapid with poor prognosis. Most patients die within 3 to 6 months.[103]   
 
The etiological agent of PML is JCPyV, yet the mechanism of how JCPyV develops 
from a chronic asymptomatic infection to the destructive demylination seen in PML is 
largely unknown. However, deletions, insertions and duplications are almost always 
found in the JCPyV NCCR of PML patients.[184]–[186] The rearrangement of JCPyV’s 
regulatory region occurs within the promoter/enhancer region, and analysis of this 
region maps sites for several transcription factors which are found in high 
concentration in neural cells. Rearrangements within this region often duplicate 
nuclear trans-activators such as SP1, YB1, sup2, NK-Κb, and Purα, leading to the 
increased expression of JCPyV in neural tissue.[103], [187], [188] The two classic 
states of the JCPyV regulatory region are referred to as the ‘archetype’ and 
 ‘neurotropic’ type. Archetype sequences are isolated from healthy patient urine and 
neurotropic sequences are found in brains with demyelisation. However, archetype 
sequences have also been reported in PML brains and neurotropic sequences found 
in biopsies of brain tissue of patients without a neurological disease.[189]–[191] Initial 
JCPyV infection is thought to occur through the respiratory system and then develop 
a persistent low level replication in the kidneys, but the question when and why 
archetype regulatory regions undergo rearrangement still remains largely 
unanswered. Lymphoid tissue, gastrointestinal tract, circulating peripheral blood 
lymphocytes, bone marrow and neural tissue have all been proposed as sites of re-
arrangement and viral persistence. However contradictory results in the detection of 
regulatory region rearrangement have been reported in these tissues.[191]–[200] It 
has also been suggested that specific mutations in the VP1 capsid, exclusively found 
in PML patients, lead to changes in cell receptor binding and may contribute to PML 
development.[201]   
1.4.2 Polyomavirus nephropathy 
 
Reactivation of BKPyV is a significant problem in kidney and bone marrow transplant 
patients and can lead to graft rejection. Rarely, BKPyV may also cause pneumonitis, 
hepatitis, retinitis and meningoencephalitis in immunocompromised populations.[202]  
BKPyV associated disease after renal transplantation is caused by lytic infection of the 
kidney epithelial cells resulting in necrosis and inflammation of the proximal 
tubules.[203] Reactivation of BKPyV is common after kidney transplantation with 
detection of BKPyV DNA in the blood or urine of 80% of transplant recipients. 
However, only 10% of recipients with an active BKPyV infection will develop 
polyomavirus nephropathy (PVN), and 90% of these patients will then reject their new 
 kidney.[106], [108]   Incidence of PVN is associated with increased immune 
suppression. However, other viral, patient and graft factors must contribute, as PVN 
is uncommon in other solid organ transplant recipients. Treatment options are limited, 
the most common being reduction of immunosupression which has a risk of acute graft 
rejection and is not effective in some patients.[108], [204]–[206] Some success has 
been seen with Cidofovir but this is also nephrotoxic at high concentrations.[207]  
1.4.3 Haemorrhagic cystitis 
 
Reactivation of BKPyV causes viruria in 50% of BMT patients and can lead to 
asymptomatic haematuria, haemorrhagic cystitis (HC), uretheral stenosis and 
interstitial nephritis.[208], [209] HC is the most common complication associated with 
BKPyV occurring in 10-25% of BMT patients, usually within 2 months of 
transplantation.[210]   
 
Patients experience urgency and frequency of urination, suprapubic pain and dysuria.  
Complications occur when bleeding becomes excessive and blood clots cause urinary 
tract obstruction.  High viral load of BKPyV correlates with development of HC, peak 
viral loads of 109 – 1010 copies/µl in urine and >104 copies/µl in plasma are observed 
in HC sufferers.[109], [211] First line treatment is to control haematuria which reduces 
clot formation and renal obstruction.[210] 
 
The sites of BKPyV persistence are the epithelial cells of the urogenital tract. However, 
considering the ubiquitous nature of BKPyV infection, it is still unknown why 
reactivation occurs for some transplant patients and not others. Unlike JCPyV, BKPyV 
reactivation in the immunosuppressed correlates with increasing levels of immune 
 impairment.[109], [206] Reactivation of BKPyV is more common in allogeneic 
transplant recipients and when deceased organs are used.[106], [212] This is also 
supported by findings that increased host production of BKPyV specific interferon γ 
correlates with resolution of PVN.  
 
Several viral factors have been investigated in BKPyV reactivation in the 
immunocompromised. Rearrangement of the NCCR region seems to be important, but 
have been commonly reported both within healthy organs and those associated with 
BKPyV disease.[213]–[215]  Polymorphisms within VP1, LTAg, and agnoprotein have 
also been suggested to increase tissue tropism and virulence but further investigation 
is required. [215]–[217]       
 
1.5 Human polyomaviruses and cancer 
 
Since the discovery of MuPyV in 1953, polyomaviruses have been suspected as 
etiological agents for human cancers. The role of SV40 as an aetiology agent of human 
cancer is a well debated issue. However, with the recent discovery of MCPyV and its 
integration into the host cell genome, interest in polyomaviruses as an agent of human 
cancer has once again been renewed. Infectious agents are considered to be 
important pathogenic elements in the complex multi-factorial process that leads to cell 
transformation. Currently it is believed that one fifth of human cancers are associated 
with an infectious agents, therefore it is important to investigate the potential role of 
newly described human polyomaviruses within human carcinomas. However currently 
only small, poorly controlled investigations into the oncogenic potential of WUPyV, 
 KIPyV, HPyV6, HPyV7, TSPyV and HPyV9 have been conducted. [155], [156], [158], 
[160], [165], [168], [218]  
1.5.1 Merkel cell carcinoma 
 
In 2008, Feng et al [8] used digital transcriptome subtraction to generate cDNA for 
pyrosequencing and then used bioinformatics to identify a unique integrated viral T 
antigen sequence within MCC tumour tissues. After sequencing the whole viral 
genome it was identified as a novel polyomavirus, 5387 base pairs in length, which 
was named merkel cell polyomavirus due to its association with MCC.  
MCC is a neuroectodermal tumour developing from the mechanoreceptor merkel cells 
in the dermis. MCC is one of the most aggressive forms of skin cancer; its incidence 
is rare but has tripled in the last 20 years.[219], [220] MCC has a high mortality rate 
with more than one-third of patients dying from this cancer; life expectancy is 
measured in months. Traditionally MCC is identified by staining with markers for 
cytokeratin 20 which is produced by the merkel cells.[221] The average age of MCC 
presentation is 70 years, and it is more common in white males. [222] An increased 
incidence of MCC is noted in areas of high UV radiation exposure, and it generally 
develops on the face and exposed extremities, suggesting UV radiation may also play 
a role in the development of MCC.[223] An interesting study, showed that MCPyV 
blocked the repair of DNA damage caused by UV-radiation,  supporting the link of UV 
radiation and MCC development.[224] Feng 2008 et al used Southern blotting 
techniques, with probes for both host and viral markers and restriction digestion to 
provide evidence that MCPyV integration occurred before clonal expansion of tumour 
cells, this integration site was also found in metastasised tissue from the same patient.  
 Southern blotting and PCR techniques demonstrated that 80% of MCC tumours had 
MCPyV sequences integrated into the host genome.   Low-level positives where found 
by Southern blot but not PCR for 8% of the 59 control tissue samples, these included 
9 skin tissue samples.  
 
Sequence analysis of the 10 MCPyV positive MCC tumours showed mutagenesis of 
the MCPyV genome. One of these initial MCPyV positive samples contained a 191bp 
deletion in the T-antigen sequence. This mutation was later found to translate into a 
premature stop codon in the LTAg. Translation of this truncated protein produces LTAg 
containing the DnaJ and RB binding domains but without the C-terminal helicase 
domain. An identical mutation was also found in MCC metastasises from the same 
patient, indicating that the integration of MCPyV sequence and mutation of this 
sequence occurred before cell transformation.[8] Further studies have shown that 
clonal integration and truncation of LTAg sequence was always found in MCPyV 
positive MCC’s[225] Mutated LTAg was replication incompetent as truncation occurs 
within or before the origin binding domain. If MCPyV active replication was to continue 
after clonal integration into the host genome it would lead to possible replication fork 
collisions and DNA damage due to the bidirectional polyoma promoter. Positive 
selection of these mutants is thought to occur through a simular mechanism as is used 
in papillomavirus transformation with loss of the E1 helicase protein gene seen after 
viral intergration.[225], [226] Clonal integration is not found in non-tumour MCPyV 
detections nor are mutations found in the LTAg sequence. Clonal integration into the 
host cells before tumour development is required not only in MCPyV positive MCC but 
also in animal models of polyomaviurses-induced tumorgenesis.[227] Interestingly in 
polyomavirus-induced tumour models, mutation in the LTAg that causes loss of the 
 origin binding and helicase region increases polyomaviruses transformation 
potential.[228]–[231]  
 
Several unique regions within the MCPyV early coding region differ from SV40 and 
are proposed to play a role in MCPyV induced cell transformation. A unique and highly 
conserved region of the MCPyV genome is encoded between the PP2A and the OBD 
(~1000bp – 1500bp).  This region, known as MUR (MCPyV unique region) encodes a 
hVam6p and nuclear localisation signal (NLS) which bind cellular proteins that 
facilitate the translocation of MCPyV LTAg into the nucleus.[232] Overexpression of 
cytoplasmic protein hVam6p, which is involved in lysosomal processing greatly 
reduces virion production and is proposed as a mechanism for MCPyV to develop a 
low level persistent infection.[233] The MUR region also encodes the MCPyV miRNA 
which in JCPyV and BKPyV has been shown to regulate the level of early transcription, 
and may have a role in minimising detection by the host immune system.[64], [66] A 
unique feature of MCPyV replication may also hold the key to understanding MCPyV 
induced cell transformation. MCPyV LTAg interacts with the chromatin-associated 
bromodomain containing protein 4 (Brd4), to recruit cellular replication factor C which 
promotes viral replication.[234] Inhibition of Brd4 also inhibits MCPyV replication in 
vitro and in vivo demonstrating the importance of Brd4 in viral replication.[235] The 
formation of MCPyV replication complexes also trigger DNA damage repair pathways, 
and both ataxia telangiectasia mutated (ATM) and ataxia telangiectasia and Rad3-
related protein (ATR) mediated pathways have been co-localised with MCPyV 
replication foci.[236]. An increasing number of studies have implicated the importance 
of MCPyV induced DNA damage or epigenetic mutations in the DNA damage 
response in MCC.[235], [237]–[239] Interestingly, human papillomavirus (HPV) 
 replication is also highly dependent on DNA damage responses and Brd4, which may 
provide further clues how MCPyV replication can induce cell transformation. [240] 
However not all MCC tumours harbour MCPyV virus, and virus sequences cannot be 
detected using a variety of sensitive measures. It is therefore suggested that MCPyV 
is a causal agent in most but not all MCC tumours. 
Extensive studies have shown that 24-100% of MCC tumours harbour MCPyV. 
(reviewed in[241]) Investigation into other forms of skin cancer found low levels of 
MCPyV DNA, however a strong association between cancer development and MCPyV 
infection was not found.[159], [241]–[244] MCPyV DNA has also been detected in non-
small-cell lung cancer and colorectal cancer by some groups but not others.[245]–
[249] No detection of  MCPyV DNA was found in prostate, central nervous system, 
and mesothelioma cancers.[218], [250], [251]  
The lymphatic system is proposed as a potential site of polyomavirus latency.[196], 
[252], [253] MCPyV also shows lymphotropism and has been detected by PCR in 
peripheral blood mononuclear cells (PBMC) of MCC patients. The lymphatic system 
is a common site for metastases and secondary malignancy in MCC sufferers. Results 
from Pantulu et al 2010 showed truncated LTAg sequences in chronic lymphocytic 
leukaemia (CLL) cells, however integration of MCPyV was not investigated and 
MCPyV DNA was detected at very low levels in CLL cohorts by others.[254]–[256] 
 A high prevalence of MCPyV was found in respiratory secretions with and without 
clinical symptoms suggesting it may, like other human polyomaviruses, have a 
respiratory route of infection.[257]–[259]  
 Confounding studies to date are the high levels of MCPyV DNA in the environment 
and from skin swabs.[159], [260] MCPyV DNA is detected in 75% of environmental 
swabs, and can still be detected after DNAse digestion, suggesting that like HPyV6,7 
& 9, MCPyV is shed as whole virions from healthy human skin.[9], [167], [260] 
Therefore contamination of samples with MCPyV from the environment and healthy 
skin is likely, and detection of MCPyV DNA from different sites, particularly the skin is 
likely to be overestimated.  
Investigations to date suggest that MCPyV is required for cell transformation and is 
not a passenger virus in the formation of MCC, but further investigation is require to 
determine why MCPyV cannot be detected in all MCC cancers. 
1.5.2 Other polyomaviruses and cancer 
 
No other polyomaviruses have been shown to have a causal relationship in human 
cancer.  However many studies have detected JCPyV, BKPyV and SV40 proteins and 
DNA in cancerous tissues.[89], [95], [261]–[264]  Human polyomaviruses have the 
ability to transform cells in vitro, largely through the oncogenic T-antigens. In vitro 
active replication of the T-antigens is not sufficient for transformation; viral integration 
appears to be a requirement for both in vivo and in vitro polyomavirus-induced 
malignancy. To date, MCPyV is the only polyomavirus found where viral integration 
into malignant cells has occurred.   
The JCPyV promoter is glial-cell specific and can transform human foetal glial cells 
and primary hamster brain cells.[265] Due to its tropism for neural cells it is most 
commonly associated with tumours of the CNS, particularly in brains of 
immunocompromised subjects. JCPyV has also been associated with tumour 
 development in colorectal cancer.[194], [195], [197], [266] In addition to the oncogenic 
T-antigens, the JCPyV agnoprotein is suspected to have a role in transformation. The 
agnoprotein is also thought to (1) modulate cell cycling by increasing the activity of 
p21/WAF-1 promoter. The p21 and WAF-1 proteins also bind to p53 therefore both 
LTAg and the agnoprotein are inactivating p53 cell cycle regulation. (2) Disrupts DNA 
damage repair and cell cycle arrest due to DNA damage through the agnoproteins 
effects on Ku70 DNA repair protein.[68], [261], [267]  
Despite the mounting biological evidence that demonstrates mechanisms by which 
JCPyV replication leads to cell transformation some reports fail to detect JCPyV in 
panels of human brain tumours.[268]–[272] However the techniques used to detect 
JCPyV proteins and DNA in these studies have been critically reviewed, the most 
common issue being the use of paraffin embedded tissue.[267] Paraffin embedded 
tissues can have highly fragmented DNA which is difficult to amplify and may lead to 
false negative results.  Studies into JCPyV detection in normal tissue have also 
confounded the potential role of JCPyV in human tumourgenesis, with reported 
detection rates varying widely in the same tissues types.[262], [265], [267] Simular 
discrepancies in studies also confound the debate of JCPyVs involvement in the 
development of colorectal cancers.[261], [266]  
BKPyV can also transform cells in newborn rats, mice and hamsters leading to 
tumours in a variety of tissues.[273], [274] To date BKPyV has been associated with 
a wide range of tumours particularly within the brain, pancreatic, renal and urogenital 
tissues.[273] BKPyV demonstrates tropism for the renal and urogenital tract and there 
is mounting evidence of its association with cancer of the prostate and bladder.[275] 
Unique BKPyV strains with duplications and a large deletion in the viral enhancer 
 region of the NCCR have been found in prostate cancer biopsies, but also in control 
tissues.[276] Further investigation into BKPyVs involvement in prostate cancer 
suggests it may have a role in early transformation but consistent production of T-
antigen is not required for tumourgenesis, somewhat explaining the sporadic detection 
of BKPyV DNA in prostate cancer tissues.[275], [277] BKPyV has also been detected 
in bladder cancers, particularly in immunocompromised patients. BKPyV  can be 
detected by PCR, various staining techniques and the visualisation of polyoma-like 
particles by EM in these bladder cancers.[278]–[281] However, the direct role of 
BKPyV in tumourgenesis has not been conclusively demonstrated. Like JCPyV, 
studies have been confounded by inconsistent detection of BKPyV in tumour and 
control tissues, and concerns surrounding the use of paraffin-embedded tissues.[275], 
[282], [283] 
In vitro evidence strongly suggests polyomaviruses contribute to the detrimental 
alternations in cell cycling that lead to tumourgensis. However defining the causal role 
of either BKPyV or JCPyV in the complex, multi-factorial process of cancer 
development is difficult and requires more well controlled investigations in fresh 
tumour tissue specimens. 
Initial studies into WUPyV, KIPyV, HPyV6, HPyV7, TSPyV and HPyV9 detection in 
cancer biopsies, particularly in skin cancers has commenced. [155], [156], [158], [160], 
[165], [168], [218] Given the difficulty in defining JCPyV or BKPyVs causal role in 
tumour development, further investigation is required and a comprehensive 
understanding of the biology and pathogenesis of the novel polyomaviruses is 
essential.    
 1.6 Specific Aims of this Study: 
 
At the commencement of this study, it became evident that many new polyomaviruses 
were circulating in the population globally. However, little was known about their 
biology, epidemiology or pathogenesis, in particular their role in oncogenesis. 
Considering that the polyomaviruses are closely related genetically to the papilloma 
viruses which cause cervical cancer, and that polyomaviruses have known oncogenic 
ability in other animals, it was important that the pathogenesis of the newly discovered 
polyomaviruses be investigated, not only in healthy subjects, but also in those 
populations most at risk, such as children and the immunocompromised. 
In this context, the following Chapters sought to address some of the outstanding 
issues relating to the role of the new polyomaviruses and their impact on human 
health: 
 
Chapter 2: Detection of Novel Polyomaviruses, TSPyV, HPyV6, HPyV7, HPyV9 
and MWPyV in Multiple Clinical Sites. 
Knowledge about the presence of the new polyomaviruses in different body 
compartments was virtually unknown at the time of commencement of this study. In 
this Chapter, an extensive clinical sample set collected from both healthy and 
symptomatic subjects will be examined for the presence of these viruses, with the 
specific aim to determine the most likely site of virus replication and their potential 
source for transmission. 
 Chapter 3: Acquisition and Clinical Associations of Novel Polyomaviruses 
WUPyV, KIPyV, MCPyV and MWPyV. 
Early results by others indicated that the new polyomaviruses were widely distributed 
in human populations, but there was no data regarding the acquisition of the new 
polyomaviruses early in life. The acquisition of these viruses will be examined in 
samples collected from a unique birth cohort of children between birth and 2 years of 
age. Presence of viral presence will be determined in the context of clinical 
presentation. 
Chapter 4: Prevalence and Pathology of Newly Described Polyomaviruses in 
Renal Transplant Recipients. 
Previous knowledge about the pathogenesis of BKPyV and JCPyV indicated that 
these viruses may cause serious disease in immunocompromised subjects. 
Therefore, following the examination of the distribution and acquisition of the new 
polyomaviruses in various populations in Chapters 2 and 3 of this study, this Chapter 
will address studies to determine if the new polyomaviruses posed an increased risk 
for adverse clinical outcomes in transplant recipients. 
Chapter 5: Detection and Characterisation of BKPyV in Bladder Cancer 
The studies conducted in this Chapter followed on from investigations in Chapter 4 
which examined the prevalence of human polyomaviruses in transplant recipients. 
These patients show a higher incidence of various cancers, and two cases of 
micropapillary urothelial carcinoma in renal transplant recipients were investigated for 
the suspected involvement of BKPyV as an agent of tumourgenesis.  
 
 Chapter 6: Presence of Polyomaviruses in Lung Carcinoma 
The research focus for this Chapter was aimed at examining a broader role of the 
novel polyomaviruses in cancer. Given that previous findings showed a strong 
association of these viruses with the respiratory tract, the presence of novel 
polyomaviruses was determined in a sample set of biopsy material from different lung 
carcinoma and their matched controls. 
Chapter 7: Characterising the Role of MCPyV in a Subset of Non Small Cell Lung 
Carcinoma  
Chapter 6 examined the association of new polyomaviruses with some lung 
carcinomas, with a particular emphasis on MCPyV. The study in this Chapter focussed 
on elucidating further evidence for the involvement of MCPyV in carcinogenesis. 
Chapter 8: General Discussion 
The implications of the findings described in Chapters 2-7 are discussed. 
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CHAPTER TWO 
 
Detection of Novel Polyomaviruses TSPyV, HPyV 6, HPyV 7, HPyV 
9 and MWPyV in Multiple Clinical Sites  
Published articles as a result of work presented in this chapter: 
 
• R. J. Rockett, T. P. Sloots, S. Bowes, N. O’Neill, S. Ye, J. Robson, D. M. Whiley, S. B. 
Lambert, D. Wang, M. D. Nissen, and S. Bialasiewicz, “Detection of novel polyomaviruses, TSPyV, 
HPyV6, HPyV7, HPyV9 and MWPyV in feces, urine, blood, respiratory swabs and cerebrospinal 
fluid.,” PLoS One, vol. 8, no. 5, p. e62764, Jan. 2013. 
      
 
 2.1 Introduction 
 
In the last chapter the discovery of new members of the expanding human polyomaviruses 
family have been extensively reviewed. The first two novel polyomaviruses, WU and KI were 
identified in children suffering from acute respiratory tract infections.[1], [2]. A year later, 
Merkel cell polyomavirus (MCPyV) was identified in Merkel cell carcinoma (MCC) tissue, 
with strong evidence suggesting MCPyV genome integration triggers cell transformation in 
MCC.[3] The discovery of MCPyV and its potential role in human carcinogenesis renewed 
research interest in novel polyomaviruses. As a result, WUPyV, KIPyV and MCPyV were 
characterized by numerous groups throughout the world examining each virus’s tissue 
tropism and potential pathogenesis.[4], [5] These studies demonstrated that these viruses 
can be detected in a variety of different tissues, however WUPyV and KIPyV are most 
commonly found in the respiratory tract and MCPyV is thought to be part of the normal skin 
flora.[6]–[10] Like BKPyV and JCPyV these three novel polyomaviruses can be detected in 
tonsillar tissues, which is speculated as the site for HPyV persistence.[11], [12] However, 
the pathogenesis of WUPyV and KIPyV in the respiratory tract in both healthy and 
immunocompromised patients is still being debated.[8], [13], [14] MCPyV can also be 
detected in the respiratory tract, although compared to WUPyV and KIPyV it is detected 
more commonly in adults than children. [15], [16] 
 
In 2010, human polyomaviruses 6 (HPyV 6) and 7 (HPyV 7) were discovered on the skin of 
foreheads of healthy volunteers.[17] In the same year another skin-associated 
polyomavirus, Trichodysplasia spinulosa-associated polyomavirus (TSPyV) was isolated 
from the face of an immunocompromised patient suffering from Tricodysplasia spinulosa. 
This condition is found exclusively in immunocompromised patients and leads to numerous 
follicular extensions around the face and nose.[18] In 2011, human polyomavirus 9 (HPyV 
 9) was amplified from the blood sample of a renal transplant patient using degenerative 
primers,[19] and in 2012 Malawi polyomavirus (MWPyV) was identified in a stool sample of 
a healthy child.[20]  
 
Few studies have investigated these novel human polyomaviruses and much of the HPyV 
research is still focused on MCPyV. Currently HPyV 6 and 7, like MCPyV are thought to 
naturally infect healthy human skin, yet studies have failed to detect HPyV 6 and HPyV 7 in 
MCC and other skin cancers.[21], [22] Recently HPyV 6 was found at high load in epithelial 
proliferations that develop after treatment of late stage melanomas with mutation-specific 
BRAF inhibitors.[23] HPyV7 was found at high load in two lung transplant patients that 
developed pruritic rashes. Immunohistochemical staining of the HPyV7 VP1 and electron 
microscopy confirmed presence of the virus in skin biopsies.[24]  
 
TSPyV has predominately been associated with cases of Trichodysplasia spinulosa in 
heavily immunosuppressed patients, and it is believed to also naturally infect the skin. It has 
been detected in 4% of eyebrow hairs, and in respiratory and fecal specimens from 
immunocompromised adults and children who do not have Trichodysplasia spinulosa. [14], 
[18] One study investigated TSPyV in pilomatricomas because of its suspected tropism for 
skin. However no TSPyV positive biopsies were found.[25]  
 
Two other polyomaviruses, MWPyV and HPyV10 were reported in stool specimens both 
from healthy children and adults and those suffering with gastroenteritis. [20], [26]  HPyV10 
was isolated from condylomas on the buttocks of patients suffering a rare genetic disorder 
known as warts, hypogammaglobulinemia, infections, and myelokathexis (WHIM) 
syndrome.[27]  
 
 The whole genome sequences reported for MWPyV, HPyV10 and MXPyV viruses share at 
least 94.6% sequence identity with the index MWPyV sequence (MA095). As the 
International Committee on Taxonomy of Viruses (ICTV) has determined that a new species 
of PyV must have less than 81% homology over the whole genome, these three viruses are 
considered the same species, and will be collectively referred to in this thesis as MWPyV. 
Numerous studies have investigated prevalence rates, basic epidemiology, genome 
diversity and the possible pathogenicity of WUPyV, KIPyV and MCPyV. [4], [12], [28]–[34] 
However, as yet, little similar data are available for HPyV 6,7,9, TSPyV and MWPyV 
infections.[14], [20], [26], [27] Given the potentially serious implications of polyomavirus 
infections in immunocompromised subjects, and the possible role of these viruses in cell 
transformation, it is important to further understand the biology and prevalence of HPyV 
6,7,9, TSPyV and MWPyV. In this study, real-time PCR and DNA sequencing were used to 
investigate the presence of these novel viruses in a variety of specimen types collected from 
different patient populations.  
2.2 Materials and methods 
 
2.2.1 Samples 
 
An overview of specimens tested and their associated basic demographic information is 
outlined in Table 2.1. Briefly, blood (n=161), urine (n=189), CSF (n=171), feces (n=263) and 
respiratory samples (n=1385) from a number of existing specimen banks were tested 
retrospectively. These included specimens obtained from healthy volunteers and 
symptomatic patients undergoing routine diagnostic testing at Pathology Queensland, 
Brisbane, Australia.  
 
 
 Table 2.1 Basic demographic information of specimen cohorts 
Sample type 
Number of 
specimens 
Disease state 
Age range 
(mean; median; age unknown) 
Respiratory 
 
n=1232 Symptomatic 0.02 – 92.4 years (16.6; 1.7; 36) 
Respiratory 
 
n=153 Healthy 0 – 17.2 years  (4.8; 2.1; 3) 
Blood 
 
n=161 Symptomatic 1.2 – 77.3 years (45.4; 49.97; 10) 
CSF 
 
n=171 Symptomatic 0 – 92.6 years (28.0; 23.17; 1) 
Urine 
 
n=189 Symptomatic 0.03 – 94.8 years (19.1; 16.3; 6) 
Feces 
 
n=185 Symptomatic 0.07 – 94.8 years (22.4; 4; 66) 
Feces 
 
n=78 Healthy 0 – 7.46 years (1.4; 1.2; 3) 
 
2.2.2 Respiratory samples 
 
The respiratory specimens (n=1232) examined in this study were obtained from 1143 
patients with acute respiratory symptoms who presented specimens for testing between 
October 2006 and December 2008. The majority of these samples were collected in 2008 
with approximately equal numbers of specimens from each month (at least 80 samples per 
month). The respiratory specimens consisted of 993 nasopharyngeal aspirates (NPA), 145 
bronchoalveolar lavage (BAL), 31 nose and throat swabs, 33 bronchial washing, 6 sputum, 
2 lung tissues and 22 respiratory specimens of unknown type. Specimens were from both 
immunocompetent and immunocompromised adult and pediatric patients (age range 0.02 - 
92.4 years, mean 16.6 years, median 1.7 years and 36 patients with ages not recorded). 
These patients presented with symptoms consistent with both upper and lower respiratory 
tract infection. The samples had previously been tested for common respiratory viruses by 
routine diagnostic PCR – influenza A and B (INF A & B), respiratory syncytial virus (RSV), 
parainfluenza viruses 1, 2, 3, & 4 (PIV 1, 2, 3 & 4), adenoviruses, human metapneumovirus 
(HMPV), human rhinoviruses (HRV) and human bocavirus (HBoV) as previously 
described.[35]–[39]. Available analytical sensitivities for these assay were determined as; 5 
 tissue culture infectious dose 50 (TCID50) per microliter of culture for RSV, 10 TCID50 for 
AdV, INF A and PIV1, 15 TCID50 for INF B, and PIV 3, 40 TCID50 for PIV 2, 0.01 TCID50 or 
10 copies/µl for HMPV, 50 copies/µl for HRV, and 10 copies/µl for PIV 4. Assay specificity 
was ensured by testing the nucleic acid extracts of 46 common respiratory pathogens and 
commensals. 
  
2.2.3 Blood samples 
 
Blood samples were obtained from 161 patients undergoing routine BKPyV, 
cytomegalovirus, or adenovirus testing, during October 2006 to December 2009. These 
patients were aged 1.2 - 77.3 years (mean 45.42 years, median 49.97 and 10 patients of 
unknown age), comprising 125 immunocompromised patients and 36 immunocompetent 
patients.  
2.2.4 CSF samples 
 
CSF samples were from 171 patients undergoing microbiological testing from March 2010 
until December 2010 for suspected neurological disease. These patients were aged 0 - 92.6 
years (mean 27.97, median 23.17, and 1 of unknown age). 
2.2.5 Urine samples  
 
Urine samples were from 189 patients undergoing routine testing for bacterial and viral 
infections from January 2009 until September 2012. These patients were aged between 
0.03 - 62.5 years (mean 19.08, median 16.33 and 6 of unknown age). 
 
 
 2.2.6 Fecal samples 
 
Fecal specimens were collected from 185 patients with gastrointestinal illness and tested by 
antigen-based assays for both rotavirus and adenovirus by Pathology Queensland or 
Sullivan and Nicolaides Pathology, Brisbane, Australia, during February 2011 until March 
2012. Patients were aged between 0.07 – 94.8 years (mean 22.4 years, median 4.4 years 
and 66 specimens were from patients of unknown age).  
2.2.7 Healthy control sample population 
 
Two separate healthy control sample populations were used in this study. The first, healthy 
control sample population A comprised nasopharyngeal aspirates from 75 healthy children 
without recent respiratory symptoms, undergoing endoscopy or colonoscopy. Specimens 
were collected between June 2007 and February 2011. The children ranged in age from 0.2 
- 17.2 years (mean 8.3 years, median 8.4 years).  
 
Healthy control sample population B consisted of paired throat swabs and fecal specimens 
from 78 otherwise healthy children recruited from the Emergency Department (with a non-
infectious presentation) or child care centers at the Royal Children’s Hospital, Brisbane. 
Specimens were collected from September 2007 until June 2010, with children’s ages 
ranging from 0 - 7.46 years (mean 1.4 years, median 1.2 years and 3 of unknown age). 
Both control populations excluded children with symptoms of respiratory or gastrointestinal 
infections in the seven days prior to collection. A follow-up phone call was made 
approximately 4 days after specimen collection to record any respiratory or gastroenteritis 
symptoms post-specimen collection (follow-up clinical information is not available for 17 
participants in healthy control population A and four participants in healthy control population 
B). If respiratory or gastrointestinal symptoms were recorded at follow-up, specimens where 
 excluded from the healthy control populations (six participants excluded from healthy control 
population A and seven participants excluded from healthy control population B).  
2.2.8 Sample processing 
 
Total nucleic acids were extracted from 0.2mL of blood, urine and CSF using the QIAxtractor 
instrument and DX viral nucleic acid reagents (Qiagen, Australia) according to 
manufacturer’s instructions. To monitor the efficiency and reproducibility of DNA extraction, 
samples were spiked with 104 copies of whole equine herpes virus (EHV) (expected PCR 
cycle threshold value (Ct) of 30 cycles) before DNA extraction.[40] Samples providing a 
crossing point within 3 cycles of 30 cycles were considered efficiently extracted and free of 
PCR inhibitors. Samples failing this criteria were re-extracted. 
 
Additional processing was required for respiratory swabs and fecal specimens before 
extraction. Briefly, 2.0 mL of phosphate buffered saline (PBS) was added to each collection 
tube containing the respiratory swab and vortexed vigorously before 0.2mL was removed 
for extraction. A 10µl loop was used to create a fecal suspension in 1mL of PBS, which was 
then vortexed and clarified by centrifugation at 6,000g before 0.2mL was removed for 
extraction. 
 
To reduce testing costs, nucleic acids from each specimen type were combined in 10 x 10 
pools for initial screening for each polyomavirus as previously described. [41] Pooling of 
specimens dilutes nueclic acid extracts by a factor of ten. Individual specimens in a positive 
pool were retested with a second assay specific for each polyomavirus. This second PCR 
assay targeted a different region of the polyomavirus genome. For specimens to be 
considered polyomavirus positive, both assays had to produce a positive amplification curve 
below 41 cycles. Limited sequence data is currently available for the novel polyomaviruses, 
 therefore some virus positive samples may potentially have been missed due to sequence 
variation within primer and probe targets. 
2.2.9 Virus detection 
 
Pooled sample extracts were screened by real-time polymerase chain reaction (rtPCR) 
assays for HPyV6,[42] HPyV7,[42] TSPyV [18] and HPyV9  in a duplex format  (Duplex 
format; HPyV6A + HPyV9B and HPyV7E + TSPyVA) using previously published assays, 
with primer and probes for each assay shown in Table 2.2.  
 
HPyV9 testing was performed using two novel rtPCR assays designed for this study. The 
HPyV9B assay was designed in the coding region for the large T-antigen, and was duplexed 
with the HPyV6A assay for sample pool testing. The HPyV9B assay was used as a 
confirmatory assay with oligonucleotides targeting the VP1 coding region of HPyV9.  
MWPyV testing was performed using two rtPCR assays. These comprised a previously 
described method by Siebrase (MW ES107) [20] and a newly designed assay (MW-E) 
developed as part of this study, targeting a conserved region of the MWPyV VP1 gene 
(Table 2.2). Primers and probes for MW ES107 and MW-E also have 100% homology to the 
VP1 sequences reported for HPyV10 and MXPyV.  
 
Briefly, the assay was designed using Primer Express 2.0 software and the two MWPyV 
whole genome sequences publicly available on Genebank (MWPyV accessions; MA095, 
NC_018102, WD976, JQ898292.1 accessed on 08 August 2012 and HPyV9 accession 
HQ696595 accessed on 06 November 2012). Whole genomes were aligned (Bioedit 7.0.5.3) 
and regions with 100% homology were selected. Sequence data were then inserted into 
Primer Express software to identify potential primer and probe targets that fit the TaqMan 
real-time design criteria. Two potential designs were selected for MWPyV and HPyV9, which 
 were further examined using Oligo Analyser (Integrated DNA Technologies, USA) to check 
the likelihood of secondary structures and self-dimers forming with all the potential primer 
and probe sequences in the rtPCR assays. The target regions were also subject to NCBI 
BLASTn searching to ensure sequences had no close sequence homology to other human 
or pathogen sequences.Analytical sensitivities for the three assays developed as part of this 
study (MW-E, HPyV9A and HPyV9B) were <10 copies/ul of extract. Primer and probes were 
assessed for specificity using a previously characterised panel (n=20) positive PyV clinical 
specimens and a panel of clinical samples positive for 20 different (unrelated) respiratory 
pathogens. 
A common reaction mix was used for all polyomavirus rtPCR assays. This consisted of 
12.5µl of Quantitect Probe PCR Mix (Qiagen, Australia), 10pmol of each primer, 4pmol of 
each probe and 5.0µl of template to make a 25.0µl final reaction volume. The rtPCR was 
performed on the Rotorgene 6000 or Rotorgene Q (Qiagen, Australia) under the following 
conditions: 15min incubation at 95°C, followed by 45 cycles of 95°C for 15sec and 60°C for 
1min. For a specimen to be considered rtPCR positive for a particular PyV it must have a 
positive amplification curve with a cycle threshold (Ct) value of less than 42 cycles for both 
assays.  
 
 
 
 
 
 
 
 
 
 Table 2.2 Primer and probes used in screening and confirmatory rtPCR assays 
Assay Target Primer (5’ – 3’) Reference 
MW-E forward 
MW-E reverse 
MW-E probe 
VP1 tcctggaagaggttctgttcctt 
tcctggaagaggttctgttcctt 
tgggactgataatcaagtacaggatgtaactgtgt 
[43] 
ES105 forward 
ES106 reverse 
ES107 probe 
LTag tgagaaggccccggttct  
gaggatgggatgaagatttaagttg 
cctcatcactgggagc 
[20] 
HPyV 6A forward 
HPyV 6A reverse 
HPyV 6A probe 
LTag accaggtgggtgatgaagaca 
cgcctgaatgttttaaaggagaa 
ttggtccctcagggtggcattca 
[42] 
HPyV 6D forward 
HPyV 6D reverse 
HPyV 6D probe 
LTAg ttgaggagctggacaaagagatt 
tctgggaagcttttgaattggt 
aggaagatgccttgtcacagaaaaggaaatg 
[42] 
HPyV 7E forward 
HPyV 7E reverse 
HPyV 7E probe 
LTAg aagacattcagtctttgcattttctg 
cccctcatacagcataaggttagatt 
ccacctttatctggatgatactttttgctggc 
[42] 
HPyV 7D forward 
HPyV 7D reverse 
HPyV 7D probe 
VP2/3 gaggaaggaaacactccccagta 
ttcacttctttttgtagctcctcaag 
actatacctcaatggatgctttttgt 
[42] 
TSPyV A forward 
TSPyV A reverse 
TSPyV A probe 
LTAg tgtgtttggaaaccagaatcatttg 
tgctaccttgctattaaatgtggag 
ttcttcttcctcctcatcctccacctcaat 
[18] 
TSPyV B forward 
TSPyV B reverse 
TSPyV B probe 
VP1 agtctaaggacaactatggttacag 
attacaggttaggtcctcattcaac 
acagcagtgaccaggacaagcctacttctg 
[18] 
HPyV 9 A forward 
HPyV 9 A reverse 
HPyV 9 A probe 
VP1 ctagggaacaatttgaatatcaggaa  
atagtgtccagatctaggctctgaac 
aagttaggctgaggcgggagataggg 
[43] 
HPyV 9 B forward 
HPyV 9 B reverse 
HPyV 9 B probe 
LTAg ctagggaacaatttgaatatcaggaa  
atagtgtccagatctaggctctgaac 
aagttaggctgaggcgggagataggg 
[43] 
 
 
2.2.10 Positive controls 
 
Synthetic control plasmids were used as positive controls for MWPyV, TSPyV, HPyV 6, 7, 
and 9. Detailed information on the design of these plasmids can be found in appendix A2.1. 
Water was used as a negative control on all rtPCR runs. 
2.2.11 DNA sequencing 
 
Whole genome sequencing was performed using a series of walking primers (Table 2.3). 
Sequence data were aligned and manipulated with Bioedit Sequence Alignment Editor 
version 7.0.9.0.[44] Phylogenetic analysis was performed using a neighbour-joining (NJ) 
 analysis with 1000 bootstrap and the Tamura-Nei substitution model in the (Mega 4.1) 
software package.[45] Whole genome sequences produced from this study were compared 
to the four published MWPyV whole genomes (accessions; MA095 NC_018102, WD976 
JQ898292.1, HPyV10 JX262162.1, UC-MXPyV JX259273.1 accessed on 20 November 
2012). 
Table 2.3 Primers used for MWPyV sequencing PCR 
Name Forward primer 5'-3’ Reverse primer 5'-3' 
Walk MW 1 agtttgcagacgcggtaaag gaataacagagattacagcacccata 
Walk MW 2 ctctaggcggagacggaag tcccaaaaagctctagaaactg 
Walk MW 3 gctcaattaattcaaactatttctgg tccacttgaacagaaggtcca 
Walk MW 4 caggccttactcctccacaa gtccggccctggaattat 
Walk MW 5 tgttccagatcttgcagaatg caactgcctcccacatatacaa 
Walk MW 6 tggtatggctacagtgatccaa  ggcatttgaaacactccaca 
Walk MW 7 agtacaacaaatgctgtttctacagt  ctgctggagcaactggtgt  
Walk MW 8 ctcttccaggagaccccact tttgttggtggcaacctgta  
Walk MW 9 ttcaatggatcttctccagattc ggcccaattaatagtggtaaaaca 
Walk MW 10 ccttttacatcttcaaaaacaacca  aaacagagtcaggaacatggttt 
Walk MW 11 gcttgctgacaaattgttttt  ggaaaaggggcaattcttgt  
Walk MW 12 agcacttactctatgttttccactta  gctttttgctttggtttgga  
Walk MW 13 accattgatcccattcagga  ttgaaaagcttagaagagaaggaga 
Walk MW 14 cagcaaacacagccacattt  ggttaagtagcaaaacaataagctaaa 
  
 
2.2.12 Data analyses and ethics approval 
 
Statistical comparisons were performed using the two-tailed fisher’s exact test.  
This study, including the use of specimens from a number of sources, was approved by the 
Queensland Children's Health Services Human Research Ethics Committee. Written 
informed consent was obtained from the guardians of the healthy control populations for 
extended virus testing. In accordance with National Guidelines [46], a waiver was obtained 
from the Ethics Committee for the need to obtain individual consent from patients whose 
stored specimens, originally submitted for routine diagnostic testing, were used in this study. 
 
  
2.3 Results 
 
2.3.1 Polyomavirus detections in different specimen types 
 
The results for HPyV 6, 7, 9, TSPyV and MWPyV screening in the various sample types are 
presented in Tables 2.4, 2.5 and 2.6. Polyomaviruses were only detected in respiratory and 
fecal specimens, with the most frequently detected polyomavirus being MWPyV. HPyV 9 
was not detected in any specimen.  
 
Table 2.4 Study sample population details and their associated MWPyV, HPyV 6, 7 &9 and TSPyV 
detections.  
Sample type Disease state 
MWPyV 
n (%) 
 
HPyV 6 
n (%) 
 
HPyV 7 
n (%) 
 
TSPyV 
n (%) 
 
HPyV 9 
n (%) 
 
Respiratory 
n=1232 
Symptomatic 18 (1.5) 2 (0.16) 3 (0.24) 1 (0.08) 0 
Respiratory 
n=153 
Healthy 14 (9.2) 0 0 0 0 
Blood 
n=161 
Symptomatic 0 0 0 0 0 
CSF 
n=171 
Symptomatic 0 0 0 0 0 
Urine 
n=189 
Symptomatic 0 0 0 0 0 
Feces 
n=185 
Symptomatic 9 (4.9)* 1 (0.5) 1 (0.5) 1 (0.5) 0 
Feces 
n=78 
Healthy 10 (12.8) 0 0 1 (1.2) 0 
*11 positive specimens collected, three from one patient tested three times over 5 days therefore only one 
positive specimen was used to calculate prevalence. 
 
2.3.2 Polyomavirus detections - Respiratory specimens  
 
In respiratory specimens, 18 (1.5%) samples from the symptomatic patients and 14 (9.2%) 
from the healthy control children were positive for MWPyV (Table 2.4). All MWPyV positive 
subjects were aged younger than 10 years. Nearly all of the MWPyV positive diagnostic 
 specimens (16/18) had at least one respiratory pathogen co-detected with MWPyV (Table 
2.4); 9/16 had one co-detection, 5/16 had two other viruses co-detected and 2/16 had three 
other viruses co-detected with MWPyV. Clinical symptoms were available for 11 of the 18 
MWPyV positive patients. These symptoms included fever, febrile convulsions, cough, 
wheeze, rhinorrhea, diarrhea, conjunctivitis and increased respiratory effort. Four MWPyV 
positive respiratory specimens were from immunocompromised children, all diagnosed with 
acute lymphoblastic leukaemia (ALL) (Table 2.5).  
 
For the remaining polyomaviruses, HPyV6, 7 and TSPyV were detected in 2 (0.16%), 3 
(0.24%), and 1 (0.08%) of the diagnostic respiratory samples, respectively. HPyV 6, 7 and 
TSPyV were not detected in any respiratory specimens from healthy children. The two 
respiratory specimens that were positive for HPyV6 were both from adults and comprised a 
BAL specimen from a male aged 48 years and a NPA from a female aged 61 years. Both 
HPyV6-positive patients were immunocompromised; the female patient was neutropaenic 
and pre-BMT and the male patient was HIV positive. In both of these patients HPyV6 was 
the only virus detected in each specimen.  
 
The three respiratory specimens that were positive for HPyV7 were from two symptomatic 
children and one immunocompromised adult male. The two samples from the symptomatic 
HPyV 7 positive children were BAL specimens, one from a 1 year old male with neutropaenic 
fevers, and one from a 13 year old female BMT recipient. The positive sample from the adult 
was an NPA collected from an immunocompromised male 67 years of age, suffering from 
acute myeloid leukaemia (AML). These samples were positive for HPyV7 only, except for 
the sample from the 1 year old male, in which adenovirus was also detected.  
 
 2.3.3 Polyomavirus detections - Fecal specimens  
 
MWPyV was detected in 11 (4.9%) of the fecal specimens from symptomatic patients and 
in 10 (12.8%) specimens from the healthy control group. Three of the symptomatic positive 
fecal specimens were collected from the same patient over a five day period; this was 
recorded as a single positive result for prevalence calculations. Of the MWPyV-positive 
patients, 1 child was aged between 0 and 1 years, 11 children where 1- 3 years of age, and 
6 patients of unknown age. In the symptomatic specimens, 8/11 (72.7%) reported a positive 
co-detection with either rotavirus or adenovirus (Table 2.5). 
 
A single positive specimen was detected for each of HPyV6, 7 and TSPyV in the 
symptomatic sample population. No clinical information was available for the HPyV6 positive 
patient. The HPyV7 positive patient was female, 63 years of age, and a renal transplant 
recipient. The TSPyV positive patient was female, aged 14 years, with ALL, and was a BMT 
recipient. One specimen was positive for TSPyV in the healthy control sample population; a 
one year old male (Table 2.4).  
  
Table 2.5 Individual polyomavirus detections for symptomatic patients, including available demographic information, PCR Ct values, viral co-detections 
and clinical information. 
Polyomavirus Sample Age (years) Sex Ct value Co-detections Clinical information 
Symptomatic respiratory specimens 
MWPyV NPA 4.21 M 28.87 HRV, HBoV ALL 
MWPyV NPA 1.22 F 29.1   
MWPyV NPA 3.80 M 29.27 PIV 3,HRV ALL 
MWPyV NPA 2.01 M 29.17 Adenovirus, HRV Conjunctivitis 
MWPyV NPA 0.54 F 30.81 HRV Gastroschisis, TPN dependent 
MWPyV NPA 1.35 F 30.94 RSV, HRV Cough, diarrhea 
MWPyV NPA 6.64 F 30.59 hMPV ALL 
MWPyV NPA 0.60 F 31.5 hMPV, HRV Yellow rhinorhea 
MWPyV NPA 1.71 M 33.13 HRV  
MWPyV NPA 4.38 F 32.75 HRV ALL 
MWPyV NPA 1.36 M 34.65 Adenovirus 
Febrile, cough, increased respiratory 
effort 
MWPyV Aspirate 1.81 M 34.8 PIV 1, HRV, HBoV 2 days post unexplained seizures 
MWPyV NPA 2.85 F 35.89 hMPV Febrile for 2+ days 
MWPyV NPA 1.09 M 38.09 HRV Febrile convulsions 
MWPyV NPA 0.14 M 35.19 PIV 3 Bronchiolitis 
MWPyV NPA 1.77 M 37.11 PIV 3 & 4, Adenovirus PUO Febrile 
MWPyV NPA 1.39 M 38.8 HRV 
CP, recurrent RTIs, respiratory 
distress, wheeze, rhinorrea 
MWPyV NPA 5.03 M 35.57  Sotos syndrome, cough 
TSPyV NPA 0.57 M 37.86 hMPV  
HPyV6 
Lavage 
Bronchus/RLL 
48.2 M 39.17  Pre-BMT, Neutropenic 
HPyV6 NPA 61.4 F 28.92  HIV 
HPyV7 NPA 1.04 M 36.84 Adenovirus Neutropenic, fevers 
HPyV7 NPA 67.2 M 35.9  AML 
 HPyV7 BAL 13.6 F 32.83  BMT 
Symptomatic fecal specimens 
MWPyV Fecal 1.01 M 29.52 Rotavirus Diarrhea, cough 
MWPyV Fecal 1.46 F 25.65 Rotavirus Chronic diarrhea 
MWPyV Fecal n/a n/a 33.67 Rotavirus n/a 
MWPyV Fecal n/a n/a 33.76 Rotavirus n/a 
MWPyV Fecal n/a n/a 30.25 Adenovirus n/a 
MWPyV Fecal n/a n/a 32.13 Adenovirus n/a 
MWPyV Fecal n/a n/a 35.76 Adenovirus n/a 
MWPyV Fecal n/a n/a 33.44 Rotavirus n/a 
*MWPyV Fecal 1.21 M 29.58  ALL 
*MWPyV Fecal 1.21 M 30.71  ALL 
*MWPyV Fecal 1.20 M 28.99  ALL 
TSPyV Fecal 14.4 F 31.77  BMT/ALL 
HPyV6 Fecal n/a  36.68 Rotavirus n/a 
HPyV7 Fecal 63.8 F 36  Renal transplant 
*Same patient collected over 5 days,HRV – human rhinovirus, HBoV – human bocavirus, PIV 3 – parainfluenza 3, hMPV – human metapneumovirus, RSV – human 
respiratory syncytial virus, ALL – acute lymphoblastic leukaemia, AML – acute myeloid leukaemia, BMT – bone marrow transplant, TPN – total parenteral nutrition, CP 
– cerebral palsy, PUO – pyrexia of unknown origin , URTI – upper respiratory tract infection, HIV – human immunodeficiency virus. 
  
2.3.4 MWPyV detection in symptomatic versus control populations  
 
A total of 26 MWPyV positive specimens were detected in 217 respiratory and fecal 
specimens collected from the healthy control populations. This proportion was significantly 
higher than the 29 detections in 1417 symptomatic specimens using a two-tailed Fishers 
exact test (p=0.0001).  
MWPyV detection was significantly (p=0.0001) more common in children younger than five 
years (34/1017) than in children aged five years and older (4/425)  
2.3.3 Healthy control population B - Paired respiratory and fecal specimens 
The control population B contained paired fecal and respiratory specimens from 78 healthy 
children. MWPyV was detected in both the fecal and respiratory specimens of 4 participants. 
In addition, MWPyV was detected in 4 participants' respiratory swabs, but not in the paired 
fecal specimens, and in the fecal specimen but not the respiratory specimen of 7 participants 
(Table 2.6).  
 
 
 
 
 
 
 
 
 
 Table 2.6. Individual polyomavirus detections for healthy control populations, including match fecal 
and respiratory specimens. 
Polyomavirus Sample 
Age 
(years) 
Sex 
Ct value 
respiratory 
Ct value 
Fecal 
Healthy control population A 
 
MWPyV NPA 0.9 F 30.61 n/a 
MWPyV NPA 9.7 M 34.03 n/a 
MWPyV NPA 9.5 F 35.28 n/a 
MWPyV NPA 1.1 M 35.98 n/a 
MWPyV NPA 1 M 36.87 n/a 
Healthy control population B 
 
MWPyV Nose and throat swab / fecal 2.09 M 30.54 34.77 
MWPyV Nose and throat swab / fecal 1.76 M 29.99 30.95 
MWPyV Nose and throat swab / fecal 1.2 M 31.96 33.33 
MWPyV Nose and throat swab / fecal 1.76 M 34.6 ND 
MWPyV Nose and throat swab / fecal 1.03 F 33.88 ND 
MWPyV Nose and throat swab / fecal 1.48 M 35.64 33.72 
MWPyV Nose and throat swab / fecal 0.84 M 35.83 ND 
MWPyV Nose and throat swab / fecal 1.45 M 34.31 ND 
MWPyV Nose and throat swab / fecal 1.31 M ND 32.58 
MWPyV Nose and throat swab / fecal 0.64 M ND 32.68 
MWPyV Nose and throat swab / fecal 1.17 F ND 33.62 
MWPyV Nose and throat swab / fecal 1.62 F ND 31.01 
MWPyV Nose and throat swab / fecal 1.71 M ND 33.34 
MWPyV Nose and throat swab / fecal 1.21 F ND 32.62 
TSPyV Nose and throat swab / fecal 1.32 M ND 36.35 
ND – Not detected 
 
2.3.5 MWPyV whole genome sequencing 
 
Although a total of 51 MWPyV positives samples were detected in this study, whole genome 
sequence data were generated for only nine of these samples  (GenBank accession 
numbers: KC549586, KC549587, KC549588, KC549589, KC549590, KC549591, 
KC549592, KC549593, KC549594). The cycle threshold values for the majority of the 
positive results were high (average Ct value of 33, range 24.91 – 40.37), which is consistent 
with low viral loads. These were therefore difficult to sequence reliably, and quality sequence 
data over the entire viral genome was not obtained.  A phylogenetic tree, including the four 
previously published MWPyV whole genome sequences, is shown in Figure 2.1. Overall 
homology between all 13 MWPyV genome sequences ranged from 95.6 to 100%. Sequence 
homology of greater than 99.6% was seen between all sequences except the index case 
 (MA095) from Malawi (95.6%). Notably, an 11 base pair insertion (nucleotide position 171-
181) within the non-coding control region was noted in all sequences except the index case 
MA095.  
 
Figure 2.1. Neighbour-Joining phylogeneic analysis of 13 MWPyV whole genome sequences 
  
(GenBank accession numbers: MA095 NC_018102, WD976 JQ898292.1, HPyV10 JX262162.1, UC-MXPyV 
JX259273.1 QLD02 KC549586, QLD03 KC549587, QLD04 KC549588, QLD05 KC549589, QLD09 
KC549590, QLD10 KC549591, QLD11 KC549592, QLD12 KC549593, QLD13 KC549594) 
 
2.4 Discussion 
 
Real–time PCR was used to measure the prevalence of five novel human polyomaviruses, 
HPyV 6, 7, 9, TSPyV and MWPyV in blood, urine, CSF, respiratory and fecal specimens 
from both healthy and symptomatic populations. Unlike JCPyV and BKPyV, no evidence 
was found of these novel polyomaviruses in blood, urine or CSF. [4]  
The MWPyV prevalence rate in respiratory samples from symptomatic subjects differed from 
that reported in a previous study  for MXPyV, which genetically is highly homologous to 
 MWPyV, showing a low detection rate (0.74%) in nasal washes from children suffering 
respiratory infections.[26]. Similarly, in subjects with symptoms of gastrointestinal infection, 
the prevalence rate in this study (4.4%) was higher than previously reported rates in children 
with diarrhea in St Louis, Missouri, USA (2.3%) [20], California (3.3%) and Chile (0%). [26]  
In contrast to our findings however, Yu et al (2012) reported a high detection rate for MXPyV 
(12.5%) in children suffering diarrhea in Mexico.  These observed differences may be due 
to the population tested in different geographic locations, or perhaps the sensitivity of the 
assays employed in the different studies.  
 
Detection of MWPyV was significantly higher in the fecal and respiratory specimens of 
healthy children compared to the symptomatic sample populations. This trend was also 
reported in age matched control populations from children in the study from Chile. (Yu et al., 
2012).  Therefore evidence for MWPyV as the causal agent of gastrointestinal disease is 
not established, and it appears likely that infection with MWPyV in young children, when it 
occurs, is asymptomatic.  
 
In this study, another confounding factor was that the majority (16/18) of MWPyV-positive 
results in respiratory specimens from symptomatic patients were co-detected with a least 
one other respiratory pathogen. Likewise, 8/11 MWPyV-positive fecal specimens were co-
detected with either adenovirus or rotavirus. This is similar to the high co-detection rates 
reported for WUPyV and KIPyV infections in respiratory samples, and raises questions 
about the clinical significance of these viruses in acute childhood disease.[47]. 
The results of MWPyV in matched fecal and respiratory specimens from healthy children 
were important in potentially answering questions about the transmission of this virus. 
Presence of MWPyV in either respiratory, or feces, or both suggests a fecal-oral mode of 
transmission for MWPyV, with first acquisition orally, dissemination to the lower respiratory 
 and gastrointestinal tract, followed by fecal shedding. Similar mechanisms of transmission 
have been proposed for other human polyomaviruses.[48]   
 
Detection of MWPyV exclusively occurred in children younger than 10 years of age, which 
follows the generally accepted paradigm of polyomavirus infection occurring early in life. It 
is therefore not surprising that children younger than five years of age had significantly 
higher MWPyV detection rates than children older than five years. These findings are 
supported by previous serological data that show acquisition of MWPyV occurs with an age 
related increase in seroprevalence in children aged 3 and over. [49] 
 
Currently there is very little known about sequence variation of MWPyV globally. The 
Australian isolates from this study clustered with the three reported isolates from the United 
States and Mexico. The isolate from the index case originating in Malawi was divergent from 
the Australian, US, and Mexican isolates. Notably, sequence variation between the index 
case and the Australian isolates was 5.3%, whereas only 0.4% variation was observed 
between the Australian and North American isolates. While these data are limited, they are 
suggestive of a geographical distribution for MWPyV similar to that of BKPyV. Previous 
studies have shown that associations between BKPyV genotypes and geographical 
locations (America, Asia, and Europe) are sufficiently consistent and can be used to trace 
human migration.[50] It is likely that the high sequence homology observed for MWPyV 
strains from Australia and the US may be because the samples were from individuals of 
European descent having a common ancestry.[50], [51] The 11bp insertion detected in 
samples examined in this study, were also observed in the non-coding control region of the 
North American MWPyV positive isolates.[20], [26] While the significance of this insertion is 
yet to be determined, it is similar to insertions reported within the KIPyV non-coding control 
 region and it is postulated that these may have some effect on transcription factor binding 
sites.[52]  
 
In this study, HPyV6, 7 and TSPyV were also detected in respiratory and fecal specimens, 
but at low prevalence (<1%), confirming the findings in other recent publications. [14] HPyV9 
has previously been reported in the blood of transplant recipients, but was not detected in 
the specimens studied here. [19], [53] The inability to detect HPyV9 in this study may reflect 
the relatively small number of blood samples examined from immunocompromised subjects 
(n=125). A novel variant of HPyV9 was recently reported, containing deletions in the NCCR. 
However this would not affect these rtPCR test results, as the assays designed for this study 
target the LTAg and VP1 region. [54] 
 
HPyV6, 7 and TSPyV were detected in both children and adults, but all detections in adults 
were from immunocompromised patients. Interestingly, a recent study of 
immunocompromised children also found a low prevalence of HPyV6, 7, 9 and TSPyV in 
respiratory, fecal and urine specimens collected longitudinally.[14]  
An increased detection of WUPyV and KIPyV in immunocompromised populations has also 
been suggested previously, but most studies have failed to demonstrate either an increased 
incidence or more severe clinical symptoms for this patient group.[8], [13], [55], [56] An 
important factor to note is that HPyV 6, 7 and TSPyV have also been detected on human 
skin of healthy subjects, and that the possibility of contamination from the skin through 
natural shedding and during collection of the respiratory and fecal samples must be 
considered. 
 
In summary, these results show that MWPyV, HPyV 6, 7, 9, and TSPyV, may be detected 
in various samples collected from different population groups. MWPyV is the most frequently 
 detected in respiratory and fecal specimens, suggesting a mode of fecal-oral transmission, 
but its role in human disease remains unclear and requires further well-controlled studies. 
However, viral infections in the immunocompromised are of particular concern, and 
therefore the observation in this study that the novel polyomaviruses may be detected in this 
patient group, warrants further research. 
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CHAPTER THREE 
 
Acquisition and Clinical Associations of Novel Polyomaviruses 
WUPyV, KIPyV, MCPyV and MWPyV 
 
Peer-reviewed publication resulting from work presented in this chapter: 
 R. J. Rockett, S. Bialasiewicz, L. Mhango, J. Gaydon, R. Holding, D. M. Whiley, S. 
B. Lambert, R. S. Ware, M. D. Nissen, K. Grimwood, and T. P. Sloots, “Acquisition 
of Human Polyomaviruses in the First 18 Months of Life,” Emerg. Infect. Dis., vol. 
21, no. 2, pp. 365–367, Feb. 2015. 
 
 3.1 Introduction 
 
The advent of very sensitive molecular techniques has led to the discovery of many new 
viruses causing respiratory tract infection. However even with the use of these sensitive 
laboratory methods, causal agents are still only detected in 40-60% of all cases. [1] 
Therefore many respiratory tract infections still have an unknown aetiology. When the 
polyomaviruses KIPyV and WUPyV were discovered in the respiratory tracts of children with 
acute respiratory tract infections, it suggested that these viruses could have a pathogenic 
role in respiratory disease. [2], [3] To this end, many groups throughout the world have 
studied the incidence of WUPyV and KIPyV in a variety of different respiratory specimens, 
and have reported rates between 0 to 15%. [4]–[21] However, these studies have largely 
been conducted on hospital-derived samples where disease burden is high, and therefore 
may not truly represent the incidence of novel polyomaviruses in the respiratory system from 
healthy or infected individuals with low viral load. Efforts to associate clinical symptoms with 
PyV detection have also been hampered by a high co-detection rate of PyV with other known 
respiratory pathogens. To date, the novel PyVs have not been isolated in cell culture, and 
hence Koch’s postulates could not be demonstrated, making it difficult to prove a definitive 
link between respiratory symptoms and detection of the novel PyV. [22]  
 
Previous prevalence studies have generally been conducted on samples from children 2 
years of age and older, and serological data suggested that, similar to JCPyV and BKPyV, 
antibodies to novel polyomaviruses were rapidly acquired after the loss of maternal 
antibodies. [23]–[27]  
 
Whilst WUPyV and KIPyV were initially discovered in respiratory samples, MCPyV was first 
identified in Merkel cell carcinoma (MCC) tissue, with evidence suggesting that MCPyV 
genome integration triggers cell transformation [28]. However, MCPyV has also been 
 reported in respiratory samples and skin, and therefore potential skin or environmental 
contamination of respiratory samples must be considered [29]–[31]. MWPyV was first 
discovered in a fecal specimen from a healthy child, however in the previous chapter it was 
shown  that MWPyV was frequently present in respiratory secretions, particularly in children 
aged under five years of age [32]. MWPyV, like MCPyV, HPyV 6 and 7 could also be a 
cutaneous polyomavirus as it has been detected in anal warts. [33]  Therefore, 
contamination from cutaneous MWPyV in respiratory and gastrointestinal samples should 
also be considered. Despite clear evidence that polyomaviruses, particularly WUPyV, 
KIPyV, MCPyV and MWPyV, can be detected in respiratory secretions, no clear pathogenic 
role for these viruses in respiratory tract infections has been established. [34] 
 
Several studies have also detected these viruses in stool specimens.[35], [36] including 
MCPyV which is often detected in several tissue types including stool specimens, and is 
generally considered to naturally infect cutaneous epithelial cells.[37] MWPyV has also been 
detected in stool samples from both healthy individuals and from patients suffering 
gastrointestinal illness.[32], [38], [39]. This is consistent with evidence that PyVs may be 
detected in both respiratory and gastrointestinal specimens because they have a fecal-oral 
route of infection. However, some evidence exists that MWPyV is a potential gastrointestinal 
pathogen. [37], [40]  
 
Therefore, based on the frequent detection of novel polyomaviruses, particularly WUPyV, 
KIPyV, MCPyV and MWPyV, in both the respiratory and gastrointestinal tracks, this study 
sought to investigate the prevalence of these viruses and their potential role in pathogenesis, 
using matched respiratory and stool samples collected as part of a separate study, the 
Observation Research in Childhood Infectious Diseases (ORChID). 
 3.2 Specimens and Laboratory Methods  
 
3.2.1 The ORChiD study samples  
 
The ORCHiD project is a unique Brisbane-based community observational birth-cohort 
study which was designed to investigate the burden of acute respiratory and gastrointestinal 
illness within the first two years of life in a healthy paediatric population.[41] This well 
controlled cohort presented a unique opportunity to study the acquisition and potential 
pathology of the polyomaviruses associated with the respiratory and gastrointestinal tracts 
in a community setting.  
 
The mothers of study participants were recruited from neonatal clinics in Brisbane before 
the birth of their child. Families were then visited in hospital shortly after birth for initial 
respiratory and fecal swab collection and training on correct methods of respiratory and 
nappy swab collection. At this visit a baseline nasal swab was also collected from each 
parent. Regular contact by phone calls, text messages and emails was maintained with the 
families throughout the two year study period. Anterior nasal swabs and fecal swabs taken 
from soiled diapers (“nappy swabs”) were collected weekly by the parents until the child’s 
second birthday. Parents also recorded daily information regarding clinical symptoms, as 
well as other clinical and social information, such as duration of breast feeding, immunisation 
status, medical treatments and day-care attendance. Recruitment into the study was 
conducted over a 3 year period, and ceased after respiratory and stool samples were 
collected weekly from 165 healthy full-term babies.    
 
 
 3.2.2 Study ethics 
 
The Human Research Ethics Committees of the Children’s Health Queensland Hospital and 
Health Service, the Royal Brisbane and Women’s Hospital and the University of Queensland 
approved the ORChID study. Parents/caregivers of each baby provided written, informed 
consent at the time of enrolment into the study. 
3.2.3 Sample collection 
 
Regular supplies of sterile rayon swabs (Virocult, MW950, Medical Wire & Equipment, 
England) were provided to each parent. For sample collection, the respiratory swabs were 
rotated against the internal anterior walls of both nostrils and then placed in a transport tube 
that contained a viral transport media-soaked foam pad in the base. To collect nappy 
specimens a separate swab was inserted into the fecal material in a soiled nappy. Parents 
were then instructed to squeeze the foam pad to release the fluid and bathe the top of the 
swab. The swabs were sent, ideally within 24-hours of collection, by regular postal mail (in 
accordance with Australia Post regulations) at ambient temperature to the research 
laboratory where they were stored at -80°C until analysis. On the first visit by the study 
nurse, a respiratory and fecal swab were collected from the newborn, as well as nasal swabs 
from both parents. 
3.2.4 Swab preparation 
 
Nasal swabs were thawed and 2 ml of phosphate buffered saline was added to each tube, 
and thoroughly vortexed. Liquid was decanted from the original swab tube into 2ml, 48 well 
storage racks (Matrix, Thermo Scientific, Australia).  
 
 For nappy swabs, 2.5ml of STAR buffer (Roche, Australia) was added to the nappy swab 
tube and mixed thoroughly by vortexing. Liquid was decanted into a 10ml conical tube and 
clarified by centrifugation at 3900g for 5 minutes.  2ml of the clarified supernatant was then 
added into dedicated storage tubes and stored in 48 well racks (Matrix, Thermo Scientific, 
Australia).  
3.2.5 DNA extraction  
 
Nasal and nappy swab samples were thawed and vortexed before 200 μl of sample was 
removed and spiked with 5 μl of equid herpesvirus 1 (EHV-1) culture supernatant. EHV-1 
served as an extraction and inhibition control (see section 3.2.6). Nucleic acids were 
extracted using the QIAxtractor automated system (Qiagen-Australia) using the DX 
extraction reagents, according to the manufacturer’s instructions. The final volumes of 
specimen extracts were 150 μl/specimen eluted into 96 well racks (Matrix, Thermo Scientific, 
Australia).  
3.2.6 Quality control  
 
For each run (96 extracts/run), extracts were tested using a duplex real-time PCR assay for 
EHV-1 and ERV3 in the following reaction compositions; 10pmoles of each primer, 4pmoles 
of each probe (Table 1), 10 μl of SensiMix II Probe PCR Mix (Bioline, Australia) and 2 μl of 
extract in a 20 μl final reaction. Cycling conditions used for amplification were: initial hold at 
10 min at 95°C; followed by 45 cycles of 30 sec at 95°C and 60 sec at 60°C. EHV1 was 
added to each swab sample at known cycle threshold value (generally around 30 cycles). 
Changes to the cycle threshold (ct) values for EHV-1 were monitored throughout the study. 
Samples were considered to have failed the EHV-1 component (i.e. failed extraction or 
possessed PCR inhibitors) if the EHV-1 real-time PCR cycle threshold (Ct) results for 
individual samples were more than two standard deviations from the mean value of all 
 samples in the extraction plate. Samples where EHV-1 individual sample Ct values were 
greater than 2 standard deviations away from the mean cycle threshold value for that PCR 
run were recorded as inhibited.  
 
The levels of endogenous retrovirus 3 (ERV3) were measured in all extracts to monitor 
specimen collection efficiency, and ensure adequate numbers of epithelial cells were 
collected. ERV 3 is an integrated retrovirus, two copies of the ERV3 genome can be found 
in all human diploid cells. Therefore ERV3 levels can be monitored by semi-quantitatively 
Ct values to measure cellular DNA levels in ORCHiD swabs.[42] Levels of cellular DNA as 
measured by the ERV3 loads, are indicative of respiratory cells being obtained during the 
anterior nasal swab collection. Although the fecal extracts were also tested for ERV3 as part 
of the duplex assay, the ERV3 data was not considered, as levels of ERV3 DNA are 
generally very low in fecal samples. This is because human faeces consists primarily of 
bacterial waste and human cells are normally not present in abundant quantities within fecal 
material, hence the ERV3 data were of limited value for the monitoring of fecal specimen 
collection (unpublished data).   
3.2.7 Extract pools 
 
To improve the efficiency of high-throuput PCR testing, rtPCR was performed on pools of 
10 nucleic acid extracts per pool. DNA extracts for each swab sample were pooled using 
the CAS-1200 liquid handling system (Qiagen-Australia).[43] These pools consisted of 
sample extracts in a 10 x 10 pool format. For positive pools, individual sample extracts were 
then tested to confirm positivity. Rhinovirus screening was performed on individual sample 
extracts, and not on the pooled extracts, as the number of expected positive samples (>10%) 
was considered too high for there to be cost benefits from pooling. 
 3.2.8 Design of the polyomavirus rtPCR assays 
 
A specific and sensitive rtPCR assay was designed to simultaneously detect WUPyV and 
KIPyV. This assay adopted a triplex format with two specific and highly conserved targets 
for KIPyV and a single conserved target for WUPyV. The triplex format was designed to 
reduce costs and the amount of extract used in the assays, particularly in the ORChID study 
where >25 viral and bacterial rtPCR assays would ultimately be used for pathogen detection. 
Two targets were used for KIPyV to avoid potential false-negative results caused by 
sequence variation, as only limited sequence data was publically available, including only 
14 whole genomes on GeneBank (accessed 08/18/2014) at the time of writing this thesis. 
In contrast, considerable sequence information was available for WUPyV, including 80 
whole genomes available on GeneBank (accessed 08/18/2014). Hence, given the 
substantial sequence information for WUPyV which showed a high level of homology across 
the viral genome, it was deemed that a single genetic target for WUPyV detection was 
sufficient. Primer and probe targets were designed using standard TaqMan design 
parameters in Primer Express 3.0.1 software (Applied Biosystems Pty Ltd, Australia). Whole 
genomes available for WUPyV and KIPyV were aligned (Bioedit 7.0.5.3) and regions with 
100% homology were selected.[44] Sequence data were then inserted into Primer Express 
software to identify potential primer and probe targets that fit the TaqMan real-time design 
criteria. Three potential designs were selected for KIPyV and two for WUPyV, which were 
further examined using Oligo Analyser (Integrated DNA Technologies, USA) to check the 
likelihood of secondary structures and self-dimers forming with all the potential primer and 
probe sequences in the WUPyV and KIPyV triplex rtPCR. The target regions were also 
subject to NCBI BLASTn searching to ensure sequences had no close sequence homology 
to other human or pathogen sequences. Two final designs were selected for KIPyV in the 
NCCR (246 – 341bp) and STAg (4524-4635bp) regions and a single target for WUPyV in 
 the NCCR (529-600bp) sequence. Primer and probe sequences are shown in Table 3.1. 
Primer and probes were assessed for sensitivity and specificity using a previously 
characterised panel of 10 WUPyV and 10 KIPyV positive clinical specimens and a panel of 
clinical samples positive for 20 different (unrelated) respiratory pathogens. The sensitivity of 
the assays was evaluated in the singleplex, duplex and triplex PCR assay formats to ensure 
competitive inhibition and other factors did not affect the sensitivity of the rtPCR assays in 
the triplex form.  
 
Testing for MWPyV and MCPyV was performed using previously described rtPCR methods, 
in a duplex assay format (detailed methods, and assay design for MWPyV are described in 
Chapter 2).[30], [32], [45] As above, the MWPyV/MCPyV duplex assay was evaluated for 
sensitivity compared to the singleplex format with no significant reduction in sensitivity 
observed in the duplex form.  
 
Extract pools positive for WUPyV and KIPyV were confirmed using the same triplex assay, 
whereas MWPyV and MCPyV were confirmed using a second assay targeting a different 
region of the viral genome. (Table 3.1) For a swab to be considered rtPCR positive for a 
particular PyV it must have a positive amplification curve with a cycle threshold (Ct) value of 
less than 42 cycles for both assays.  
 
A common reaction mix was used for all PyV rtPCR assays. This consisted of 10µl of Bioline 
SensiMix II Probe (Bioline, Australia), 10pmol of each primer, 4pmol of each probe and 2µl 
of template to make a 20µl final reaction volume. The rtPCR was performed on the 
Rotorgene 6000 or Rotorgene Q (Qiagen, Australia) under the following conditions: 10min 
incubation at 95°C, followed by 45 cycles of 95°C for 15sec and 60°C for 1min. 
 
 Table 3.1 Oligonucleotide sequences for rtPCR assays used to screen ORChID respiratory and nappy 
swabs for WUPyV, KIPyV, MCPyV and MWPyV.  
Assay 
Name 
Oligo Name Sequence 5’ to 3’ Virus Region  
WUPyV & 
KIPyV 
triplex 
WU-F forward gccgacagccgttggatata 
WUPyV NCCR WU-F reverse tttcaggcacagcaagcaat 
WU-F probe fam-agggtcaccatttttatttcagatgggca-bhq 
KI-D forward cacaggtggttttctataaattttgtactt 
KIPyV STAg KI-D reverse gaagcagtgggatgtatgcattc 
KI-D probe tgcattggcattcgtgattgtagcca 
KI-E forward gaacttctactgtccttgacacaggta 
KIPyV NCCR KI-E reverse ggattagaacttacagtcttagcatttcag 
KI-E probe  accctttgtaggccaaaggagagtgaagg 
MWPyV & 
MCPyV 
duplex 
ES105 forward tgagaaggccccggttct 
MWPyV LTAg ES106 reverse gaggatgggatgaagatttaagttg 
ES107 probe mgb-cctcatcactgggagc 
MCV1.1 forward agctcagaagtgacttctctatgtttga 
MCPyV LTAg MCV1.1 reverse acaatgctggcgagacaact 
MCV1.1 probe tttgcagaggtcctgggtgcatg 
MCPyV 
confirm 
MCV2.0 forward ggcagcatcccggctta 
MCPyV VP1 MCV2.0 reverse ccaaaaagaaaagcatcatcca 
MCV2.0 probe atacattgccttttgggtgtttt 
MWPyV 
confirm 
MW-E forward tcctggaagaggttctgttcctt 
MWPyV VP1 MW-E reverse tcctggaagaggttctgttcctt 
MW-E probe -tgggactgataatcaagtacaggatgtaactgtgt 
 
3.2.9 Additional respiratory virus screening of the ORCHiD respiratory swabs 
 
Samples were also screened for an extended spectrum of respiratory viruses using 
previously optimized and described PCR and reverse transcriptase PCR assays. Virus 
testing assays included: rhinovirus (HRV) [46], influenza viruses (A and B) [47], respiratory 
syncytial viruses (A and B) [48], parainfluenza viruses (1–3) [49], human adenoviruses [41], 
human metapneumovirus [50], human coronaviruses (OC43, HKU1, 229E, and NL63) [51] 
and human bocavirus [52].  
3.2.10 Positive controls 
 
Synthetic control plasmids were used as positive controls for MCPyV and MWPyV, more 
detailed information of on the design of these plasmids can be found in appendix A2.1. 
Clinical positive specimen’s previously proven positive for WUPyV, KIPyV and repiratory 
 viruses listed in section 3.2.9 were used to control rtPCRs. Water was used as a negative 
controls were included on all rtPCR runs. 
3.2.11 Data analysis  
 
Overall prevalence in the ORChID population was determined using descriptive statistics, 
including overall and individual prevalences compared to other common respiratory 
pathogens, co-detection rates with other viruses, and semi-quantitative viral loads. 
3.3 Specific aims of this study: 
 
The samples of the ORChID cohort were used to conduct the four studies described below. 
These were: 
 
1. Primary studies investigating the prevalence of WUPyV, KIPyV, MCPyV and MWPyV  
(section (3.3.1)  
2. Investigating the clinical association of these viruses (section 3.3.2).  
3. Examining the prevalence of the PyVs in a subset of fecal specimens collected 
simultaneously with ORChID nasal swabs (section 3.3.3)  
4. Examining evidence of active replication of WUPyV and KIPyV in positive nasal 
swabs by specifically targeting LTAg expression (section 3.3.4) 
 
3.3.1 Study 1- Prevalence of WUPyV, KIPyV, MCPyV and MWPyV   
 
In total 8833 respiratory swabs were screened using rtPCR protocols specific for WUPyV, 
KIPyV, MCPyV and MWPyV to assess the overall prevalence of these viruses in a healthy 
community-based study. This included the baseline parent respiratory swab collected at the 
 commencement of the study. The ORChID study sample collection was still ongoing at the 
time of this investigation, and study swabs were tested as they were received into the 
laboratory. Therefore this analysis contains samples from the participants at various age 
intervals. i.e. not all participants had provided samples through to the age of two years. 
 
3.3.2 Study 2 - Clinical associations of WUPyV, KIPyV, MCPyV and MWPyV infection 
 
3.3.2.1 Subset of ORChID respiratory swabs tested for PyV 
 
As described above, the respiratory swab testing was conducted as samples were received 
in the laboratory, and so sampling was not completed for all participants. Therefore, to 
investigate the age of acquisition, length of viral shedding and associated symptoms a 
subset of 2851 swab results were analysed. This subset represented the first 56 children to 
complete 18-months (censored at swabs collected after 530 study days) of the ORChID 
study. They provided 3851 nasal swab specimens (mean 69 (range 41-77) swabs per 
subject) and 29678 person-days of observation (mean 530 person-days of observation per 
participant (range 384 -560). Swab return rate varied between families, generally (mean 69) 
return rate was high however during some periods participants may not collect a swab for 
several weeks.  Therefore the first swab collected after 530 study days was not collected 
until 560 days for a limited number of participants. 
3.3.2.2 Clinical data collection 
 
As part of the ORChID study, parents completed a daily symptom diary from birth until their 
infant’s second birthday. This diary consisted of a tick box system under the following criteria 
of symptoms; ear infection, runny nose, cough, sore throat, muscle aches, wheezing, 
shortness of breath, pulmonary congestion, pneumonia, fever, chills, headaches, irritability, 
 decreased activity, number of loose stools and number of vomits per 24 hours. Parents also 
recorded any temperature associated with fever, with a digital thermometer provided at the 
start of the study. An example of the ORChID symptom diary can be found in Appendix A3.1.  
3.3.2.3 Sole detection of polyomavirus 
 
To limit the potential for mixed infections to confound clinical associations, these 
investigations focused on PyV ‘sole detection’. A sole detection was defined as an individual 
swab which was positive for only a single PyV and for which no other virus was detected. 
Sole PyV detections were analysed for the PyV ORChID subset, and used to generate Odds 
Ratios (OR) for PyV sole detection corresponding to reported clinical symptom/s. Odds 
ratios were also calculated for the known pathogenic respiratory viruses RSV A & B, hMPV 
and hADV as a comparator to the PyV ORs. This analysis determined the likely odds of any 
symptom being recorded by parents. In this analysis, symptom information was only 
collected for the day of PyV sole detection. Reported symptoms were segregated using the 
broad categories described below in section 3.3.2.5. Calculation of odds ratios was 
performed using STATA 13 software (Texas, USA). 
3.3.2.4 Sole detection episode 
 
The complex overlapping nature of infections with respiratory viruses in children in this age 
group can confound any analysis of associating clinical symptoms with a particular viral 
detection. Therefore PyV sole detections were determined and further analysed for viruses 
detected for 7 days prior or after the PyV positive swab detection. Episodes where an 
individual PyV was the only virus detected in this 14-day period were designated as sole 
detection episodes. Symptoms detected within this period were considered highly likely to 
be associated with the PyV detection rather than being the result of a previous virus 
detection or a new, yet undiagnosed, virus infection. A sole detection episode was defined 
 as one or more consecutive swabs where an individual PyV was the only virus detected, 
and no other viruses were reported seven days prior to or after the PyV detection. Detection 
of a different PyV or the same PyV after 30-days and at least two intervening negative 
samples was considered a new infection episode.  
3.3.2.5 Symptom classification 
 
During the period of sole detection, clinical data was broadly categorized as upper 
respiratory (ear infection, runny nose, cough, sore throat and muscle aches), lower 
respiratory (wheezing, shortness of breath, pulmonary congestion and pneumonia), non-
specific (fever, chills, headaches, irritability and decreased activity) and gastrointestinal 
(more than 2 lose stools in 24hours and any number of vomits). Non-specific symptoms 
generally occurred with reports of other upper or lower respiratory symptoms, however if no 
other symptoms were reported they were separately characterised as non-specific 
symptoms. Gastrointestinal symptoms were recorded in the presence or absence of 
respiratory symptoms. 
 
3.3.3 Study 3 - Prevalence of WUPyV, KIPyV, MCPyV and MWPyV in simultaneously 
collected nappy swabs.  
 
A selection of the fecal samples were tested. A total of 1398 nappy swabs were prepared, 
extracted and screened for WUPyV, KIPyV, MCPyV and MWPyV. These swabs represented 
all nappy swabs received for the first 15 patients (mean 93.2 (range 50-109) swabs per 
subject) in the PyV respiratory swab ORChID subset (described above 3.3.2.1). Specimen 
preparation, nucleic acid extraction, quality control, extract pooling and polyomavirus rtPCR 
were conducted as previously described in sections 3.2. 4 to 3.2.8. Nappy swab results were 
compared to the corresponding respiratory swab results for each patient: 1113 nappy swabs 
had matched respiratory results [a total of 285 nappy results were omitted; 16 of these swabs 
 had no corresponding respiratory sample collected and 269 swabs were collected after the 
censor date of 530 days.] These nappy samples were not tested for all other recognised 
gastrointestinal pathogens. This prevented the adequate assessment of clinical associations 
with symptoms and contributing these to the detection of PyVs. 
3.3.4 Study 4 - Examining evidence of active replication of WUPyV and KIPyV in positive 
nasal swabs by specifically targeting LTAg expression 
 
In this study, evidence of active replication was investigated for WUPyV and KIPyV in 
positive nasal swabs by specifically examining the presence of mRNA associated with LTAg 
expression. 
3.3.4.1 RNA extraction on a subset of high load WUPyV and KIPyV positive nasal swabs. 
 
A total of 26 WUPyV DNA positive and 6 KIPyV DNA positive respiratory specimens were 
selected to examine if mRNA from WUPyV and KIPyV could be detected. The samples were 
selected on the basis of having high WUPyV or KIPyV viral loads. Attempts to determine the 
expression of MWPyV and MCPyV were not conducted due to the low viral load of these 
viruses in nasal specimens. 
 
For RNA experiments, the original specimens were thawed and 200μl of sample was 
extracted using an RNAeasy extraction protocol as per manufactures instructions (Qiagen, 
Australia). An additional on-column DNA digestion step was included in the extraction 
protocol to eliminate contaminating genomic viral DNA. Total RNA was eluted in 50μl of 
Qiagen elution buffer (Qiagen, Australia) and stored at -80°C until RTPCR assays were 
performed.  
 
 3.3.4.2 Design of reverse transcriptase (RT) PCR assays for WUPyV and KIPyV  
 
Three different methodologies were developed to determine the presence of WUPyV or 
KIPyV LTAg mRNA. The first methodology converted an rtPCR assay for WUPyV LTAg into 
a standard reverse transcription rtPCR assay to measure expression of WUPyV LTAg. The 
method relies on the ability of the RNA extraction to remove contaminating PyV DNA. The 
other two methods utilised the intron sequence contained in the STAg/LTAg coding region 
to selectively amplify RNA rather than DNA. An intron spanning assay was designed that 
would produce a product of ~125bp if amplifying RNA from the LTAg or a ~500bp product if 
amplifying the DNA sequence containing the intron. This product size difference could be 
visualised using SYBRGreen melting peak analysis or on an electrophoresis gel after PCR 
amplification. Predicted salt adjusted melting temperatures (Tm) were calculated at 76°C for 
LTAG RNA products whereas DNA products would produce a predicted melting peak at 
90°C. 
 
In addition, an exon-exon RTPCR was designed, whereby the reverse primer was designed 
over the exon junction such that it was homologous with mRNA sequences only and would 
not amplify PyV DNA. Expression of β-actin in nasal extracts was used as a control for total 
RNA extracted in the original sample.[53] Detailed assay designs for the exon-exon 
RTPCRs can be found in appendix A3.2. 
Oligonucleotide sequences used in the study can be found in Table 3.2 for each assay 
including the RNA and DNA product sizes.  
 
Expression of the WUPyV LTAg (WUPyV LTAg assay) was measured using One-step 
RTPCR reagents (Qiagen, Australia); 5μl of Qiagen One-Step RT-PCR 5x PCR mix, 10pmol 
of each primer, 4pmol probe, 1μl of enzyme, 1μl of 25mM dNTPs and 2μl of extract in a final 
 reaction volume of 25μl. The conditions used in this reaction were as follows; reverse 
transcriptase incubation of 30 min incubation at 50°C, followed by DNA polymerase 
activation of 15 min at 95°C, followed by 45 cycles of 95°C for 15 sec and 60°C for 1 min.  
 
Intron spanning and exon junction RTPCRs used the QuantiTect SYBR Green RTPCR kit 
(Qiagen, Australia). The final reaction volume of 25μl was made up of 12.5 μl of QuantiTect 
SYBR Green RTPCR master mix, 10pmol of each primer, 0.25μl of QuantiTect RT Mix, and 
5μl of RNA extract. Cycling conditions used in this reaction were as follows; reverse 
transcriptase incubation of 30min incubation at 50°C, followed by DNA polymerase 
activation of 15min at 95°C, followed by 45 cycles of 94°C for 15sec, 52°C for 30sec and 
72°C for 30sec, melting conditions; ramping from 40°C to 99°C raising 1°C each step. All 
themocycling was performed on the RotorGene instruments (Qiagen Australia). 
 
With each RTPCR assay a negative reverse transcriptase control step was also included. 
This measures the Ct values of contaminating PyV DNA amplified in the RNA extracts. 
Conditions for the negative reverse transcriptase reaction were as follows: incubation of the 
one-step master mix at 95°C for 5min to inactivate the reverse transcriptase enzyme. 
Extracted RNA was then added to the inactivated RT master mix and cycled as above with 
the following exceptions, no reverse transcriptase incubation and reduction of the DNA 
polymerase activation step to 10 minutes and 95°C.  
 
 
 
 
 
 Table 3.2 Oligonucleotide sequences designed for RTPCR assays to detected messenger WUPyV and 
KIPyV LTAg sequences in high load nasal swabs   
Assay Name Oligo Name Sequence 5’ to 3’ 
Product 
size 
DNA 
Product 
size 
RNA 
WUPyV LTAg 
WU-E-for tttctccaggagatttaggcatttc 
109 109 WU-E-rev atacccacatatggtaccccagact 
WU-E-probe tcttcccagtaggaattaaactgagaccaccagt 
WUPyV Intron 
spanning 
WU-intron F ttagtacagtgcaccaactaaatgaagaa 
508 125 
WU-Intron R gaattaaactgagaccaccagtaatcc 
KIPyV Intron spanning 
KI-Intron F atttaaatgaagaagaagataatatatggcaa 
498 73 
KI-Intron R tcatcccagtcaggtgtaccg 
WUPyV 
Exon-exon 
WU-Exon F1 agagtgtgttagtacagtgcaccaactaa 
N/A 88 WU-Exon R1 ctggggtaccatatgtgggtattctac 
WU-Exon R2 ggggtaccatatgtgggtgttctac 
KIPyV 
Exon-exon 
 
KI – Exon F1 aatatcatccagataaaggaggaaatga 
N/A N/A KI – Exon R1 caggtgtaccgtatgtaggtactgagaa 
KI – Exon R2 ggtgtaccgtatgtaggtactgggaa 
β-actin 
β -actin F ggcatccacgaaactacctt 
90 90 β -actin R agcactgtgttggcgtacag 
β -actin probe atcatgaagtgtgacgtggacatccg 
 
 
3.4 Results  
 
3.4.1 Prevalence of WUPyV, KIPyV, MCPyV and MWPyV in nasal swabs collected in the 
ORChID study (Study 1) 
 
In total, 8833 respiratory swabs were screened for WUPyV, KIPyV, MCPyV and MWPyV. 
Table 3.3 below provides an overall summary of the results. On average 53.7 (range 2 – 
109) swabs were analysed per patient with the average age of swabs collected for the cohort 
being 10.4 months (range 0 – 736 days).  
 
All four PyVs were commonly detected in these samples, with 44 – 267 positive swabs for 
each virus (Table 3.3). MWPyV was the most prevalent of the PyVs, and was the second 
most frequently detected virus overall after rhinoviruses. Next most frequent was KIPyV 
(third most detected virus overall), followed by WUPyV (the 7th overall) and MCPyV (9th 
overall) (Fig 3.1).  Co-detection of other respiratory pathogens with PyVs was common and 
 ranged from 30- 69%. WUPyVs, KIPyV and MWPyV were detected on average in 2-3 (range 
1-24) swabs per participant, however MCPyV was only detected once per participant. A 
single positive MCPyV respiratory swab was collected from the parent of one participant.   A 
wide range of Ct values were observed for WUPyV and KIPyV. Interestingly, overall Ct 
values for WUPyV and KIPyV were significantly lower than Ct values for MCPyV and 
MWPyV. (Pairwise Mann-Whitney p<0.001 two-tailed test n1=310, n2=186).  
 
 
 
 Figure 3.1 Overall ORChID results for respiratory virus detection. Figure A represents the overall 
detection of respiratory viruses, particularly the high incidence of RHV. A collection the more common 
respiratory pathogens makes up 26% of all detections and is illustrated in Figure B, including overall 
numbers of detections for the polyomaviruses.  
 
Total number of swab tested 8833. Figure A represents the overall number of detections for each respiratory 
virus, each segment is labelled with the virus, overall incidence and number of detection (n=). Figure B 
represents the segment labelled other 26% and illustrates seven of the most common respiratory viruses 
detected, after RHV, including the polyomaviruses. Abbreviations as follows; respiratory syncytial virus A and 
B (hRSV A and B), parainfluenza viruses 1, 2 and 3 (Para 1, 2 and 3), adenoviruses (AdV), metapneumovirus 
(MPV) and human rhinoviruses (HRV). 
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 Table 3.3 Overall screening results PyV detection in all 8833 respiratory swabs  
 WUPyV KIPyV MCPyV MWPyV 
No. of detections 55 131 44 267 
% Co-detected with 
other respiratory 
pathogen 
68.2% 
30/44 
42% 
55/131 
30% 
13/44 
35.6% 
95/267 
Median no. of 
detections per 
participant (range) 
2.1 
(1-7) 
3 
(1-6) 
1 
(1 – 2) 
3 
(1 – 24) 
Median Ct Values 
(range) 
30.61 
(14.9 – 37.3) 
32 
(18.36 - 40.2) 
40.2 
(32.9 – 44.4) 
35.6 
(29.74 - 40.74) 
*Cycle threshold values (Ct) are approximately inversely related to viral load 
 
3.4.2 Comparative prevalence of WUPyV, KIPyV, MCPyV and MWPyV in nasal swabs 
collected in from 56 children followed from birth to 18 months of age. (Study 1 and 2)  
 
All four novel PyV viruses were detected within this subpopulation of the ORChID study 
cohort and between 23% (13/56) and 56% (31/56) of children provided at least one positive 
result for one of the polyomaviruses. MWPyV was the predominant (n=157) PyV detected 
(Table 3.4). First detection of WUPyV, KIPyV and MWPyV occurred around the children’s 
first birthday, with each virus detected for an average of two consecutive weeks after primary 
detection. Detection of MCPyV was less frequent, with primary detections occurring around 
seven months of age which was earlier than that observed for WUPyV, KIPyV and MWPyV 
(Mann-Whitney p= <0.001 two-tailed test; pair-wise comparison of age). MCPyV was not 
detected in any consecutive swab collections. WUPyV (50%, 18/36) and KIPyV (49%, 31/63) 
were commonly detected with other respiratory viruses, with rates similar to those observed 
for the overall ORChID cohort (Table 3.1). Again, MWPyV (33%, 52/157) and MCPyV (21%, 
3/13) had lower semi-quantitative viral loads (Mann-Whitney p= <0.001 two-tailed test; pair-
 wise comparison of Ct values), and were less frequently detected with other respiratory 
viruses (Table 3.4).  
 
Table 3.4 Summary of PyV detections in the PyV ORChID cohort of 56 children in the first 18 months 
of life. A total of 3851 nasal swabs were analysed. 
 
 
 
WUPyV KIPyV MCPyV MWPyV 
Total number of 
detections 
(n=3851 nasal swabs) 
36 63 13 157 
% of PyV detection per 
participant 
25% 
(14/56) 
45% 
(26/56) 
23% 
(13/56) 
56% 
(31/56) 
Median age at primary 
detection 
(range) 
11 months 
(5.2-16.6) 
10 months 
(5.6-18.6) 
7 months 
(0.07-18.8) 
13 months 
(0.9-13.1) 
Median length of viral 
shedding 
(range) 
2 weeks 
(1-4) 
2 weeks 
(1-5) 
1 week 
(1) 
1.2 weeks 
(1-3) 
% Co-detected with other 
respiratory viruses 
50% 
(18/36) 
49% 
(31/63) 
21% 
(3/13) 
33% 
(52/157) 
Median cycle threshold 
(Ct) values* 
(range) 
29.45 
(18-37) 
30.91 
(18-40) 
38.58 
(34-40) 
35.15 
(30-40) 
*Cycle threshold values (Ct) are approximately inversely related to viral load 
 
3.4.3 Clinical associations of WUPyV, KIPyV, MCPyV and MWPyV characterised during 
sole detection episodes (Study 2) 
 
Clinical associations of PyV infection were investigated in swabs from 56 children, (n=2851) 
collected weekly from birth and censored at 530 study days (Study 2). 
 
Clinical symptoms were observed during PyVs sole detection episodes for WUPyV, KIPyV 
and MWPyV, but not MCPyV episodes (Table 3.4). During symptomatic episodes numerous 
overlapping respiratory virus detections were commonly observed, making PyV sole 
detection episodes too rare to undertake meaningful formal statistical analyses. An example 
of the complex nature of virus detections in the ORChID cohort is illustrated in Figure 3.2, 
which shows one participant’s longitudinal swab collections (between 71 to 82 weeks of age) 
 with virus detections and reported clinical symptoms. This participant had positive swabs for 
KIPyV and MWPyV during this period, with both viruses being detected for 4 consecutive 
weeks. Sole detections for MWPyV were seen at week 75 and 76 and corresponded to 
parental reporting of upper respiratory tract symptoms. At week 79 a sole detection of KIPyV 
was observed at the same time of parental reporting of upper and lower respiratory 
symptoms. However for this participant, no period during these PyV detections could be 
classified as a PyV ‘sole detection episode’. This was due to preceding and subsequent 
rhinovirus detections for the MWPyV sole detections and coronavirus detection before and 
after the KIPyV sole detection.  
 
Figure 3.2 Demonstrations the complexity of one participant’s serial respiratory virus detections 12 
weeks in the study period (71 to 82 weeks of age). No period during PyV detection contributed to a PyV 
sole detection episode due to frequent co-infections proceeding or following PyV sole detection 
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Each vertical line represents a weekly swab collection. Unfilled circles represent a week where no symptoms 
were recorded, black dots represent a week with upper respiratory tract symptoms, black solid fill represents 
upper and lower respiratory tract symptoms recorded. Viruses are represented with the following symbols, 
rhinovirus +, KIPyV ǂ, MWPyV ø, coronavirus HKU1 ¤, coronavirus 0C43 Θ.    
 
 The sole detection episodes did however correspond to parental reporting of clinical 
symptoms for 57% (5/9) of WUPyV and 36% of both KIPyV (5/14) and MWPyV (13/36) 
episodes (Table 3.5). The clinical symptoms associated with PyV sole detection episodes 
were predominately characterized as upper respiratory in nature (Table 3.5). However single 
sole detection episodes from WUPyV, KIPyV and MWPyV also had gastrointestinal 
symptoms reported. No lower respiratory tract symptoms were reported for WUPyV and 
KIPyV whereas 2 episodes reported a combination of upper and lower respiratory tract 
symptoms during MWPyV presence. Only non-specific symptoms were reported during 1 
sole detection episode for KIPyV and two episodes for MWPyV.  
 
Table 3.5 Sole PyV detection episodes and reported clinical symptoms 
 
 
 
 WUPyV KIPyV MWPyV 
No. of sole detection 
episodes 
9 14 36 
% of sole detection 
episodes with 
symptoms 
57% 
5/9 
36% 
5/14 
36% 
13/36 
No. of sole detected 
episodes without 
symptoms 
3 9 23 
Symptoms indicate 
LRTI 
0 0 0 
Symptoms indicate 
URTI 
4 3 9 
Both URT and LRT 
symptoms reported 
0 0 2 
Nonspecific symptoms 
reported only 
0 1 2 
Diarrhea/vomiting 
reported 
1 1 1 
No symptom information 
available 
2 0 0 
 3.4.4 Odds ratios of clinical symptoms corresponding to the sole detection of WUPyV, KIPyV 
and MWPyV (Study 2)  
 
PyV sole detection episodes were rare (n=36 for MWPyV), therefore a formal statistical 
analysis of symptom associations was unable to be conducted due to low numbers. 
However PyV sole detections (where an individual PyV was the only virus present in that 
swab collection) were used to calculate Odds ratios for the likelihood of PyV sole detection 
being associated with symptoms.  
 
Odds ratios were not calculated for MCPyV as no clinical symptoms were recorded for 
MCPyV sole detections. Between 14 and 106 PyV sole detections were analysed, and were 
found to be actually higher than other ‘traditional’ respiratory pathogens with between 6 and 
26 sole detections for RSV A & B, hMPV and hADV. (Table 3.6) Clinical symptoms were 
reported for 36% (5/14) WUPyV, 30% (10/33) KIPyV and 31% (36/106) MWPyV sole 
detections, compared with 41% (9/22) RSV A, 83% (5/6) RSV B, 78% (7/9) hMPV and 62% 
(16/27) for hAdV. PyV sole detection corresponded to a 2.07 to 2.67 times greater likelihood 
of a parental report of clinical symptoms than symptoms reported with no virus detected. 
Odds ratio calculations were only statistically significant for MWPyV sole detections. Higher 
odds of 7.61 – 23.77 were calculated for RSV B, hMPV and hADV with all of these 
calculations reaching statistical significance.  
 
 
 
 
 
 
 
 Table 3.6 Odds ratio calculations for PyV sole detections and reported clinical symptoms 
 WUPyV KIPyV MWPyV RSV A RSV B hMPV hADV 
No. of sole 
detections 
14 33 106 22 6 9 26 
% of sole detection 
episodes with 
symptoms 
36% 
5/14 
30% 
10/33 
31% 
36/106 
41% 
9/22 
83% 
5/6 
78% 
7/9 
62% 
16/27 
No. virus detected 
without symptoms 
9 22 70 13 1 2 10 
Symptoms indicate 
LRTI 
0 1 2 3 1 4 2 
Symptoms indicate 
URTI 
5 9 34 9 5 7 11 
Both URT and LRT 
symptoms reported 
0 1 2 3 1 4 2 
Nonspecific 
symptoms reported 
only 
0 1 3 0 0 0 0 
Diarrhea/vomiting 
reported 
1 1 2 1 0 1 3 
No symptom 
information 
available 
4 0 2 1 0 1 0 
Odds ratio 
(95%CI) 
2.64 
(0.88-
7.91) 
P=0.0824 
2.07 
(0.98-
4.37) 
P=0.574 
2.16 
(1.46-
3.19) 
*P=0.0001 
3.29 
(1.4-
7.74) 
*P=0.00
6 
23.77 
(2.77-
203.7) 
*P=0.004 
16.64 
(3.45-
80.32) 
*P=0.000
5 
7.61 
(3.43-
16.86) 
*P=<0.000
1 
* Statistically significant  
 
3.4.5 Prevalence of WUPyV, KIPyV, MCPyV and MWPyV in simultaneously collected nappy 
swabs. (Study 3) 
 
In the 15 participants tested, WUPyV, KIPyV, MCPyV or MWPyV could be detected in at 
least one nappy swab for 1 to 6 participants (Table 3.7). Total numbers of positive results 
for WUPyV, KIPyV and MCPyV were higher for respiratory swabs than in corresponding 
nappy samples. Two participants had positive detections for WUPyV and KIPyV in nappy 
swabs, and in both cases the PyV detection occurred simultaneously or following PyV 
detection in the respiratory swabs (1 week before).  
 
Data for the detection of WUPyV and KIPyV in nappy swabs showed that the percentage 
detection per participant, the total number of detections, length of viral shedding and viral 
 load (measured by median Ct values) were all lower than the corresponding respiratory 
results (Table 3.7). In contrast, for MWPyV, more positive results were obtained in fecal 
swabs (n=55) than in respiratory swabs (n=32). However the overall detection per participant 
for MWPyV (40%) was the same in both fecal and respiratory specimens.  MWPyV was 
typically detected in the nappy swabs before the respiratory swabs (Table 3.7) with a 
younger median age of primary detection; 7.7 months in nappy swabs compared to 11.1 
months in respiratory samples. Viral shedding was on average slightly longer in nappy 
swabs (1.5 weeks compared to 1 week in respiratory swabs) however median Ct values 
were slightly higher in nappy swabs suggesting a lower viral load than in respiratory swabs. 
MCPyV was only detected in one participant’s nappy swabs in 5 non-consecutive collections 
(6.25% 1/15). However 6 participants had a positive MCPyV detection in their respiratory 
specimens (40% 6/15).  
 
 Table 3.7 Summary of PyV fecal detections in the first 18 months of life for 15 ORChID participants 
with matching PyV respiratory swab results.  
 
 
 
WUPyV 
fecal 
WUPyV 
Resp 
KIPyV 
Fecal 
KIPyV 
Resp 
MWPyV 
fecal 
MWPyV 
Resp 
MCPyV 
Fecal 
MCPyV 
resp 
% of PyV 
detection per 
participant 
13.3% 
(2/15) 
20% 
(3/15) 
13.3% 
(2/15) 
33.3% 
(5/15) 
40% 
(6/15) 
40% 
(6/15) 
6.25% 
(1/15) 
40% 
(6/15) 
Total no. of 
detections 4 9 3 11 55 32 5 6 
Median age at 
primary 
detection 
(range) 
10.4 
months 
(6.1-6.5) 
9.7 
months 
(5.6-
10.2) 
7.4 
months 
(5.4-9.5) 
15.6 
months 
(9.0-
18.6) 
7.7 
months 
(2.3-9.4) 
11.1 
months 
(3.5-
12.9) 
1.4 
months 
 
5.2 
months 
(1.3-
14.8) 
Median length 
of viral 
shedding 
(range) 
1.5 
weeks 
(1-2) 
2 weeks 
(1-4) 
1.5 
weeks 
(1-2) 
2 weeks 
(1-2) 
1.5 weeks 
(1-3) 
1 weeks 
(1-2) 
1 week 
 
1 week 
 
Median cycle 
threshold (Ct) 
values* 
(range) 
38.2 
(35-43) 
30.55 
(23-39) 
33.3 
(31-34) 
31.31 
(21-43) 
35.15 
(30-40) 
34.37 
(31-40) 
37.36 
(37-38) 
40.18 
(37-41) 
*Cycle threshold values (Ct) are approximately inversely related to viral load 
 
 3.4.6 Examining evidence of active replication of WUPyV and KIPyV in positive nasal swabs 
by specifically targeting LTAg expression (Study 4) 
3.4.6.1. Expression of WUPyV LTag  
 
Presence of WUPyV LTAg mRNA was found in 22 of the 26 WUPyV DNA-positive nasal 
specimens (Table 3.8). However contaminating WUPyV DNA was also present despite 
additional DNase digestion procedures during the RNA extraction, and could be confounding 
WUPyV LTAg RNA results. On average an 8.3 cycle drop in Ct values was seen between 
RNA and DNA levels of β–actin compared to an average of 2.4 cycle drop in Ct between 
RNA and DNA levels of WUPyV LTAg. This suggests that the stable circular double stranded 
DNA PyV genome is resistant to DNase digestion compared to human genomic DNA, here 
measure through digestion of β–actin. Therefore additional RNA specific amplification 
methods were developed to confirm WUPyV and KIPyV LTAg expression.  
 
 
 
 
 
 
 
 
 
 
 
 
 Table 3.8 Expression of WUPyV LTag and β-actin using rtRTPCR assays 
ORChID ID 
WUPyV 
DNA Ct 
β-ACTIN 
RNA Ct 
 
β-ACTIN 
contaminating 
DNA 
 
WUPyV 
LTAg 
RNA 
WUPyV 
contaminating 
DNA 
Swab 
transit 
time 
3 31.32 28.59 ND 37.07 ND 2 
4 31.55 35.76 41.44 37.28 37.81 2 
4 27.19 33.22 ND 34.34 36 5 
10 24.29 27.3 34.54 31.37 33.4 1 
10 31.43 29.21 37.26 37.49 ND 2 
15 32.49 33.07 36.54 38.01 ND 5 
15 17.93 29.4 33.93 25.46 28 5 
15 27.02 27.1 32.91 35.44 37.25 3 
19 34.54 31.38 34.47 ND ND 3 
19 31.49 28.55 33.98 36.2 39.38 3 
19 29.99 32.77 38.54 34.9 38.3 16 
19 27.72 32.77 ND 36 37.5 9 
25 23 33.42 ND 31.7 35 2 
25 29.21 30.75 ND 36.87 42.5 3 
27 29.72 29.91 ND 41.36 ND 1 
27 23.49 30.1 ND 32.21 34.19 1 
27 23 29.4 ND 32.58 37.98 2 
27 33 30.88 ND ND ND 2 
27 37.25 29.66 ND 39.13 ND 2 
27 32.87 30.88 ND 40.09 ND 2 
27 32.53 31.2 ND 39.34 ND 1 
29 22.87 31.87 ND 27.98 30.5 1 
39 34.02 30.72 ND ND ND 2 
39 18.24 29.64 ND 28.4 30.7 2 
39 34.43 42.93 ND 39.2 ND 4 
41 18.96 40.76 ND ND ND 3 
* ND = not detected, Cycle threshold values (Ct) are approximately inversely related to viral load 
 
3.4.6.2 Expression of WUPyV and KIPyV LTAg using intron spanning and exon-exon RT-
PCR 
 
An RT-PCR targeting the intron containing STAg and LTAg coding region was used to 
measure expression of WUPyV (Table 3.9) and KIPyV (Table 3.10) LTAg. RNA levels for 
both WUPyV and KIPyV LTAg could be detected at low levels for each of the PyV-DNA 
positive nasal specimens. Melting peaks corresponded to predicted salt adjusted Tm 
temperatures for RNA. RNA Ct values were on average 10 cycles lower than Ct values 
obtained with PyV DNA control PCR assays. Attempts to visualise RT-PCR product size by 
gel electrophoresis failed due to low PCR product levels. Insufficient extracted RNA for some 
samples did not allow confirmation of PyV RNA using the exon-exon junction assay.  
  
Table 3.9 Expression of WUPyV LTAg in high load WUPyV positive nasal swabs using RNA specific 
assays 
ORChID ID WUPyV DNA Ct 
Intron spanning 
Ct 
Intron spanning 
Tm 
Exon-exon Ct 
4 27.2 35.8 73°C N/A 
10 24.3 34.9 73°C N/A 
15 18 32.9 78°C 38.1 
27 23 34.6 73°C 36.4 
39 18.2 43.7 78°C 36.8 
43 26.1 33.4 73°C N/A 
56 18.1 39.7 78°C N/A 
* ND = not detected, N/A not available due to insufficient RNA extract, Cycle threshold values (Ct) are 
approximately inversely related to viral load 
 
Table 3.10 Expression of KIPyV LTAg in KIPyV positive nasal swabs using RNA specific assays 
ORChID ID KIPyV DNA Ct 
Intron spanning 
Ct 
Intron spanning 
Tm 
Exon-exon Ct 
3 30.6 35.5 72°C 33.23 
4 29.1 37.6 72°C N/A 
30 26.9 36.6 72°C N/A 
31 30 36.7 72°C N/A 
34 27.4 45 72°C N/A 
48 28.9 40.3 72°C 33.8 
* ND = not detected, N/A not available due to insufficient RNA extract, Cycle threshold values (Ct) are 
approximately inversely related to viral load 
 
3.5 Discussion  
 
A subset of samples collected in the ORChID birth cohort study provided a unique sample 
set for this study to investigate the acquisition, prevalence and clinical significance of the 
novel polyomaviruses, WUPyV, KIPyV, MWPyV and MCPyV, within the respiratory and 
gastrointestinal tracts. These polyomaviruses were studied in contrast to the full spectrum 
of novel polyomaviruses, because evidence suggested they play a role in respiratory tract 
infections. To date, the majority of similar studies have used retrospective samples collected 
from high disease burden patients, generally in a hospital-based environment. Similar to our 
findings, a number of these studies had noted that PyV detections are more common in 
young children. However in these studies, only small numbers of specimens were included 
 from patients under 2 years of age, [12] and it is therefore likely that the prevalence of PyV 
was underestimated. Previous retrospective studies have also been unable to define the 
clinical characteristics of a PyV infection within the respiratory tract.  
3.5.1 Prevalence of the novel polyomaviruses, WUPyV, KIPyV, MWPyV and MCPyV 
 
This is the first comprehensive study to examine the acquisition and clinical associations of 
the novel human polyomaviruses WUPyV, KIPyV, MCPyV and MWPyV during the first 18 
months of life in a community based population. All viruses were frequently detected in this 
subject group, with MWPyV the second most common virus after rhinoviruses (Figure 3.1). 
This result was somewhat surprising, as MWPyV was initially found in the fecal specimen of 
a healthy child and subsequently from children with diarrhoea.[38], [39]. The only other study 
examining MWPyV in respiratory samples was conducted in Mexico. This study examined, 
136 nasal washings from children with respiratory tract infections, and detected only one 
MWPyV positive sample.[39] However the age ranges of these children were not reported 
and therefore the difference in observed prevalence could be due to a potentially older 
paediatric patient set in the Mexico study.  
 
The prevalence of MWPyV in respiratory samples from the ORChID birth cohort was much 
higher than in respiratory samples from a hospital based population (see Chapter 2).   This 
difference is almost certainly the result of the sampling populations, namely the age of the 
ORChID population when PyVs are thought to be acquired compared to a broader age range 
of a retrospective sample collection.     
 
There is only one other longitudinal study of respiratory samples examining PyVs by PCR. 
[16] This study followed 18 children 1-7 years of age, with the participants collecting nasal 
swabs fortnightly for 6 months and recording daily clinical respiratory symptoms. Testing 
 was only conducted for WUPyV and KIPyV showing a prevalence of 44% and 17% 
respectively for the 18 children studied. These results were quite different from the results 
in this study (25% for WUPyV and 45% for KIPyV), but this difference may have been due 
to age difference and the small case numbers in the Netherlands study. However this study 
also showed that the presence of KIPyV and WUPyV occurred primarily in younger children. 
Both this study and the Netherlands study showed evidence of prolonged virus shedding (4-
8 weeks) for both WUPyV and KIPyV.  This viral shedding pattern is similar if not more 
prolonged than for other DNA viruses, and has been previously described for bocavirus 
infections.[54]      
 
Result for the detection of MCPyV (23% -13/56) was markedly different to those from 
WUPyV, KIPyV and MWPyV, as MCPyV was not detected in any consecutive swabs. Also, 
some of the MCPyV detections occurred in the first months of life, and on average, primary 
detection occurred at the significantly younger age (7months compared to around 12months 
for WUPyV, KIPyV and MWPyV). Seroepidemiology studies of PyV show that maternal 
antibodies are present for all polyomaviruses, including MCPyV. [24] In addition, other 
retrospective studies have noted that MCPyV is more often found in the respiratory 
secretions of adults rather than children, and that MCPyV can be shed from healthy human 
skin and is readily found on 60 - 70% of environmental surfaces.[29], [31], [55] Therefore, 
as it seems unlikely that primary infection occurs before the waning of maternal antibodies 
at around 6 months of age, the results obtained in this study may reflect contamination from 
skin or environmental sources, rather than a true indication of MCPyV present in the 
respiratory tract of the participating child. Interestingly parents were asked to contribute one 
nasal swab at the initial visit by study staff after the birth of the participant. One of these 
parental swabs was positive for MCPyV and their child had a number of positive MCPyV 
swab collections during the study period. Therefore the MCPyV detections from this 
 participant could have been contamination from the MCPyV-positive parent collecting the 
swabs.  
3.5.2 First acquisition of the novel polyomaviruses  
 
On average, primary acquisition of WUPyV, KIPyV and MWPyV occurred around 12 months 
of age. This was consistent with seroprevalence data for these viruses showing PyV 
antibody prevalence quickly rises after 6 months of age and reach adult levels at 5 years of 
age.[26], [56]  This data, together with the finding that WUPyV and KIPyV earliest detection 
in some subjects occurred at month five after birth, suggesting that primary infection occurs 
after maternal antibodies diminish around 6 months of age.  
Primary detection for MWPyV in the ORChID samples was at 13 months, which is similar to 
that reported in a recent Italian study which reported that 27% of 1-2 year old children had 
MWPyV antibodies, increasing rapidly to 68% in 2-3 year olds. Interestingly in the Italian 
study, adult seroprevalence of MWPyV only reached 42% which is much lower than the 64-
87% seropositivity reported for MCPyV, HPyV6, 7 and TSPyV. [27] Perhaps once MWPyV 
infection is cleared, reactivation with age does not occur, which would explain the absence 
of MWPyV in respiratory samples from adults, described in Chapter 2 of this study. [32] In 
support of this hypothesis, increasing antibody titres with age were not reported for TSPyV 
suggesting that persistent life-long low level infection with asymptomatic reactivation may 
not occur for some of the novel human polyomaviruses.    
3.5.3 Viral load estimates and evidence of viral replication 
 
When analysing the WUPyV, KIPyV and MWPyV positive samples for semi-quantitative viral 
load, it was observed that WUPyV and KIPyV had statistically significant higher viral loads 
 than MWPyV and MCPyV. This suggests that WUPyV and KIPyV actively infects cells within 
the respiratory tract, but that MWPyV and MCPyV are simply passengers. Additionally, the 
demonstration of presence of mRNA for the LTAg of WUPyV and KIPyV, albeit at low levels, 
implies active replication of these two PyV in cells within the respiratory tract. This is 
supported by previous reports that high levels of bocavirus mRNA correlate with clinical 
symptoms.  
A number of methodological problems may have prevented the accurate estimation of 
mRNA in the samples. Firstly, ORChID swabs were collected by parents and posted into the 
laboratory with on average 3 days in transit. RNA integrity would likely have been affected 
by this prolong period at room temperature. Secondly, difficulties removing contaminating 
genomic PyV DNA also occurred, probably because PyVs possess a very stable double 
stranded circular genome. Despite an additional DNAase digestion step in the RNA 
extraction methodology only a 2 Ct cycle drop in sensitivity was observed when amplifying 
PyV DNA compared to RNA, showing that DNase digestion was not effective. In 
comparison, an average decrease of 8 cycles of sensitivity was noted for the housekeeping 
gene β-actin when amplifying DNA compared to RNA, confirming cellular DNA was digested. 
For this reason, the intron spanning and exon-exon RT-PCR was applied, and confirmed 
the presence of WUPyV and KIPyV LTAg RNA at low levels. Unfortunately additional original 
samples which were collected and stored appropriately were not available to further confirm 
these initial findings.  However, recent evidence has demonstrated the presence of KIPyV 
in the lung and spleen of immunocompromised patients by immunohistochemistry, and 
multiple lines of evidence strongly suggest WUPyV and KIPyV actively replicate within the 
respiratory tract.[57] Due to the low DNA load of MCPyV and MWPyV in ORChID nasal 
swabs, conducting expression assays was not possible for these PyVs. 
 
 3.5.4 Transmission of the new polyomaviruses WUPyV, KIPyV, MCPyV and MWPyV 
 
It has been broadly postulated that polyomaviruses may have a fecal-oral route of 
transmission. Previous reports have shown that MWPyV is largely found in the 
gastrointestinal tract of individuals both symptomatic and asymptomatic of disease, and 
therefore it seems plausible that the low loads of MWPyV in the respiratory tract reflect a 
passenger status. MWPyV was therefore of particular interest when examining the presence 
of WUPyV, KIPyV, MCPyV and MWPyV in nappy swabs from a subset of 15 ORChID study 
participants.  
The presence of these PyVs in samples from the respiratory and gastrointestinal tract 
collected from the same patient at the one time was investigated. Although all four PyVs 
could be detected in the nappy swabs (prevalence 6 - 40% of samples), MWPyV was 
detected more frequently in nappy swabs than the respiratory specimens. However the 
percentage of participants positive for MWPyV at any time was 40% in both the respiratory 
and gastrointestinal tracts.  
First detection of MWPyV also occurred earlier in nappy swabs than in nasal swabs (7.7 
months in the gastrointestinal samples compared to 11.1 months for respiratory specimens), 
which was different for that found for WUPyV, KIPyV and MCPyV where detection in the 
respiratory samples proceeded or was simultaneous with detection in nappy swabs. Semi-
quantitative viral loads were also lower in nappy swabs for WUPyV, KIPyV and MCPyV than 
in respiratory samples. However viral loads between the two sample types were comparable 
for MWPyV. The comparison of viral loads between these samples types should be 
interpreted with caution however, as cellular material (when comparing ERV3 Ct values) 
was higher in respiratory swabs than fecal swabs. 
 Taken together the paired respiratory and nappy PyV detections results suggest that 
WUPyV, KIPyV and MWPyV are acquired through a fecal-oral route, although WUPyV and 
KIPyV appear to actively replicate in the respiratory tract, whereas MWPyV may have 
tropism for the gastrointestinal tract.  
3.5.5 Association of the new polyomaviruses with clinical presentation. 
 
 It is difficult to interpret the role of MCPyV as a pathogen from the results obtained in this 
study. This is exemplified by the results from one participant who showed multiple sporadic 
MCPyV detections. This, together with lack of evidence of this virus in the respiratory tract, 
may be indicative of environmental or cutaneous contamination during sampling by the 
parent. It is therefore important that this possibility is addressed in the design of any future 
similar investigations. Testing for other gastrointestinal pathogens in nappy swabs was not 
performed and was outside the scope of this study, therefore clinical associations could not 
be determined.   
High co-detection rates of WUPyV and KIPyV with other respiratory viruses (>70%) reported 
in previous studies, have prevented the establishment of meaningful associations of virus 
with clinical symptoms [34], [58]. However, here a definition for “sole detection” was 
established which allowed us to examine the association of PyV with clinical symptoms. This 
was aided by the low prevalence rate for all viruses in the ORChID samples. Even so, some 
limitations must be still considered. Firstly, when examining single swabs positive for an 
individual PyV and their associated clinical symptoms this does not account for other viral 
infections proceeding or following the PyV sole detection. Also it does not account for clinical 
symptoms that may be reported before or after the PyV sole detection. Secondly, other 
studies have suggested that peak viral load usually occurs 3 days before clinical symptoms 
appear.[59] This study was based on swabs collected weekly, and therefore did not have 
 the capacity to evaluate the daily dynamics of a PyV infection. Importantly no positive 
MCPyV sole detections were associated with parental reports of clinical symptoms, 
suggesting this virus is was not associated with respiratory symptoms in healthy children. 
The analysis of “sole detection” episodes however has allowed the calculation of the odds 
of PyV causing respiratory symptoms compared to the odds of clinical symptoms being 
recorded without virus. This analysis was also performed to compare PyV odds ratios to 
other well characterised respiratory pathogens such as RSV A and B, but applied a more 
stringent approach examining the clinical symptoms associated with PyV sole detection. 
However, due to the complex nature of respiratory pathogen acquisition during this study, 
only a limited number of PyV sole detection episodes for each individual PyV could be 
defined, and prevented a more extensive robust statistical analysis from being performed   
Although this second method of analysis is more rigorous at excluding other respiratory 
pathogens potentially causing clinical symptoms recorded during a PyV sole detection, it 
does not completely exclude this possibility. A limitation of both methods is that the clinical 
symptoms reported may be due to a pathogen not tested for in this study or as yet 
undiscovered. It has previously been reported that symptoms may continue for up to 30 days 
after a virus is undetectable by PCR.[60] Interestingly, both methods showed similar results 
with around 30% of PyV sole detections and sole detection episodes having clinical 
symptoms reported.   
This is the first report that shows statistical evidence of an association of sole presence of 
PyV associated with clinical symptoms. In both sole detections and sole detection episodes 
analysis, WUPyV gave the highest odds ratio and overall percentage of symptomatic sole 
detection episodes. This is consistent with previous findings in the longitudinal study from 
the Netherlands that reported a strong association of  symptoms with presence of WUPyV 
but not KIPyV.[16] However reports of KIPyV PCR detection and immunohistochemical 
 staining in the lung of a child who died of respiratory failure provides evidence that KIPyV 
can also infect cells and cause significant pathology in the respiratory tract.[57]  
RSV is considered to be a significant respiratory pathogen in young children, it was therefore 
surprising that the odds ratios for RSV A (OD 3.29) and WUPyV (OD 2.64) were very similar. 
However, this may simply reflect the small number of RSV A sole detections in the ORChID 
cohort samples. Also, no community-based studies on RSV A infections have been reported 
previously, and therefore it is possible that asymptomatic RSV A infections may occur 
commonly in this age group.   
3.5.6 Conclusions 
This subset of specimens from a “healthy” community cohort provided a unique opportunity 
to examine the prevalence, age of acquisition and clinical associations of the novel human 
polyomaviruses in infants under 2 years of age. Strong evidence was found that MWPyV 
may be acquired through the fecal-oral route, and that viral replication of WUPyV and KIPyV 
occurs in the respiratory tract. 
Also, although limited, statistical analysis shows that the odds of WUPyV, KIPyV, and 
MWPyV causing mild clinical infection are high, and for WUPyV is similar to the known 
respiratory pathogen, RSV. However, clear evidence that these new polyomaviruses are a 
significant cause of disease in healthy children still needs to be proven, 
Taking these findings together with previous knowledge that the known human 
polyomaviruses JCPyV and BKPyV are serious pathogens of immunocompromised 
subjects, it would seem prudent that the presence of the new polyomaviruses in 
immunocompromised populations be further examined to establish a potential pathogenic 
role for these viruses.   
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 4.1 Introduction 
 
In this thesis it was shown that PyV can be detected in respiratory secretions collected from 
immunocompromised patients and children under two years of age. Evidence presented in 
Chapter 3 indicated that primary infection of WUPyV, KIPyV and MWPyV can cause mild 
respiratory symptoms in otherwise healthy unselected children. However, other reports into 
the potential pathogenicity of WUPyV, KIPyV and MWPyV in healthy patients have been 
contradictory.[1]–[4]  
 
Clinical studies into the well characterized polyomaviruses JC and BK demonstrated that 
primary infection with these viruses was asymptomatic or mild, but that reactivation of virus, 
when the immune system was impaired, can lead to severe disease. [5]. After primary 
infection JCPyV and BKPyV are thought to continue a low load persistent infection, possibly 
in the lymphoid, neuronal, kidney or hematopoietic tissues.[6]–[8] This persistent infection 
can reactivate in immunocompromised patients causing, in some cases, a high load lytic 
infection in specific cell types which results in severe clinical symptoms. Progressive 
Multifocal Leukoencephalopathy (PML) occurs when JCPyV reactivates in 
immunocompromised patients, causing a lytic infection of the oligodendrocytes leading to 
demyelization within the brain that rapidly progresses to a fatal outcome.[9], [10] In bone 
marrow (BMT) and renal transplant patients, reactivation of BKPyV in urogenital tissues may 
cause hemorrhagic cystitis (HC) and nephropathy, which can lead to graft rejection in up to 
10% of kidney transplant recipients.[11], [12] BKPyV and JCPyV are considered to be 
ubiquitous viruses in the general population, however only a small percentage of patients 
will have severe clinical manifestations after immune suppression. Although there are 
suggestions that sequence changes either within the NCCR region or the sequences coding 
for viral proteins may increase the pathogenicity and infectivity of JCPyV and BKPyV, it 
 seems likely that the host humoral immune response also plays a major role in viral 
clearance.[13], [14]  This is supported by the fact that the best current treatment option for 
transplant recipients who develop PyV viremia or viruria is to lower the patient’s level of 
immunosuppression to allow humoral immune response to control viral replication.[15]  
 
BKPyV and JCPyV have a tropism towards the urogenital tract and can be detected in the 
urine of healthy adults. However the reactivation of BKPyV, and in rare cases JCPyV in 
kidney transplant recipients can lead to nephropathy. [16]–[18] Asymptomatic BKPyV and 
JCPyV viruria is often seen in immunocompromised populations, but BKPyV infection that 
leads to polyomavirus-associated nephropathy (PVAN) and kidney rejection, only develops 
in 8-12% of kidney transplant recipients, and rarely in other immunocompromised 
populations.[17], [19] PVAN is generally found in individuals with high plasma and urine 
BKPyV loads, although PVAN has also been reported in patients with no BKPyV viremia, 
but high load viruria.[20] The most effective method to prevent PVAN is to prospectively 
monitor patients for BKPyV viremia using quantitative PCR, which then allows for the 
reduction of immunosuppression and subsequent clearance of the virus by the reconstituted 
immune system. [17] Although JCPyV has been associated with rare cases of nephropathy 
and can be detected in 25% of kidney transplant recipients, it is rarely detected in 
corresponding blood specimens and is thought to be largely asymptomatic.[18] 
 
JCPyV and BKPyV have ubiquitous seroprevalence in the population, and initial infection 
continues as a low level persistent infection in potentially multiple tissues, with each 
polyomavirus having a tropism for different cell types. Despite being largely asymptomatic 
in immunocompetent hosts, reactivation of low level persistence infection in 
immunocompromised patients can have severe clinical impacts. Pathology caused by 
 JCPyV and BKPyV is associated with a high viral load causing a lytic infection in particular 
cell types.  
 
Given that WUPyV, KIPyV and MWPyV but not MCPyV can cause mild respiratory 
symptoms in healthy immunocompetent children, it may be inferred that these viruses could 
also have greater clinical effects in immunocompromised patients.[21] Early studies into 
WUPyV, KIPyV, and MWPyV detection in immunocompromised populations suggested that 
these viruses could be readily detected in multiple specimen types. However a pathogenic 
role for these viruses has not been clearly identified.[1], [4], [22]–[26] A recent study 
demonstrated the ability for KIPyV to replicate in respiratory epithelial and immune cells in 
the lung and spleen of immunocompromised patients who developed fatal 
complications.[27] Similarly WUPyV has also been detected in respiratory epithelial cells 
within the lung of a lung transplant recipient with Jobs syndrome.[28] These cases strongly 
implicated both KIPyV and WUPyV in having a pathogenic role in the respiratory tract of 
these patients.   
 
Reports of MCPyV discovery showed that viral sequence was integrated into the host cell in 
80 – 100% of cases of Merkel cell carcinoma (MCC), a rare but aggressive skin cancer.[29] 
A major risk factor for the development of MCC is advancing age and 
immunosuppression.[30] Therefore reactivation of Merkel cell polyomavirus has been 
investigated in numerous immunocompromised patient cohorts and attempts have been 
made to link its detection to other forms of cancer, particularly skin cancers.[23], [31]–[39] 
MCPyV can be found in many tissue types throughout the body, although it has also been 
detected as whole virions on healthy human skin. It is also detectable in environmental 
specimens, therefore potentially, many low level detections of this virus may be due to 
contamination of specimens during collection.[40]–[42] When detected in patients without 
 MCC, MCPyV is typically found at much lower viral load than in patients with MCC, and thus 
far, low level detection has not been strongly linked to any pathology and may be part of 
normal skin flora.[43], [44]    
 
Another cutaneous polyomavirus, TSPyV, has been strongly linked to the development of 
trichodysplasia spinulosa (TS) a rare follicular skin condition that exclusively affects 
immunocompromised individuals.[45] TSPyV can be found in high viral load in skin biopsies 
from TS patients and viral capsids have been visualized using electron microscopy.[46] 
TSPyV is also found in other specimen types at much lower viral load, both in healthy 
patients and those under immunosuppressive therapy. It has not thus far been linked to 
other skin conditions, with TS patients generally clearing the virus after reduction of 
immunosuppression or topical application of anti-viral medications. [47] 
 
Similarly, newly described polyomaviruses HPyV 6 & 7 were also discovered in skin swabs, 
originally from healthy patients.[43] HPyV 6 has been detected in non-melanoma skin 
proliferations that develop in patients undergoing mutation-specific BRAF inhibitor therapy 
for end-stage melanomas.[48], and recently, HPyV 7 has been detected at high viral loads 
in swabs from pruritic skin rashes in immunocompromised patients.[49] HPyV 6 & 7 have 
also been detected in respiratory swabs, urine and fecal specimens collected from 
immunocompromised patients, although these detections are generally at low viral loads 
and have not been strongly linked to any pathology.[4], [50]  
 
HPyV 9 was detected in the serum of a renal transplant recipient, and has been 
subsequently identified in a number of renal transplant patient study cohorts.[51], [52] 
Detections of HPyV 9 were reported at low viral loads and were not associated with any 
symptoms.[50], [53]    
  
Newly described polyomaviruses MWPyV and STLPyV were discovered in fecal specimens 
collected from healthy children.[54], [55] However MWPyV has also been detected in 
respiratory specimens and anal warts from immunocompromised patients. [56]–[58] So far, 
studies into both viruses have only included screening of a limited number of specimens 
from immunocompromised patients.    
 
The most recently discovered members of the Polyomaviridae, HPyV 12 and NJPyV, have 
investigations limited to the early reports of their discoveries. HPyV 12 was detected in 
organs of the gastrointestinal tract and was also detected in feces but not in detected in 
small numbers of respiratory, urine, blood or cerebrospinal fluids.[59] NJPyV was discovered 
in endothelial cells in a pancreatic transplant recipient. This patient suffered multiple 
complications 11 months post-transplantation; these symptoms included retinal blindness 
and necrotic plaques on multiple areas of the skin. NJPyV was not detected in the patient’s 
pre-transplant serum or in small numbers of sera collected from the general population. [60]  
 
The studies in this chapter will examine the presence of newly described polyomaviruses in 
renal transplant recipients in a longitudinal study, and their prevalence and potential 
pathology will be compared to BKPyV and JCPyV reactivation.   
 
4.2 Methods 
 
4.2.1 Longitudinal Renal Transplant Study 
 
Patients were recruited into a longitudinal kidney transplant study at the Department of 
Nephrology, Princess Alexander Hospital, Brisbane, Australia. A total of 167 patients were 
 recruited into the study and had blood, urine and combined nose and throat swabs collected 
at baseline (pre-transplant), and on day 4, one month and three, and six months post-
transplant. If BKPyV carriage was detected the patients were further monitored out to 12 
months or until BKPyV was not detected in whole blood specimens. Basic demographic 
information was recorded including, age, sex, and type of kidney transplanted (live donor or 
cadaver). If patients recorded a positive BKPyV rtPCR result, their attendance to out-patient 
clinics was increased to a fortnightly visit; during these visits blood, urine and combined 
nose and throat specimens were collected. Increased specimen collection was continued 
until BKPyV viremia was cleared (negative by rtPCR).  Clinical symptoms and other co-
morbidity data were collected throughout the study. Retrospective clinical observations were 
noted 7 days either side of the detection of a newly described polyomavirus.    
4.2.2 Specimen preparation for nucleic acid extraction 
 
Combined nose and throat flocked swabs (NTS) (Copan Diagnostics, Italy) were collected 
from patients and directly inserted into 1ml of PBS. Whole blood specimens were collected 
in 5ml EDTA vacutanors (BD, Australia), while urine was collected in standard 50ml 
collection vessels. All specimens were immediately frozen at -80°C and stored for extraction 
in batches of 96 specimens.  
4.2.3 Nucleic acid extraction 
 
After specimens were thawed and thoroughly vortexed, 200µl of whole blood, urine or 
combined nose and throat PBS fluid was spiked with 5 μL of equid herpesvirus 1 (EHV1) 
culture supernatant. EHV1 served as an extraction and inhibition control. Nucleic acid was 
extracted using the CAS1820 XtractorGene automated system with the DX extraction 
reagents, according to the manufacturer’s instructions (Qiagen, Australia). The final volumes 
 of specimen extracts were 100 μL per specimen eluted into 96 well racks (Matrix, Thermo 
Scientific, Australia). 
4.2.4 Nucleic acid extraction quality control 
 
For each run (96 extracts/run), extracts were tested using a rtPCR assay for EHV-1 in the 
following reaction compositions; 10pmoles of each primer, 4pmoles of each probe, 10 μL of 
Quantitect Probe PCR Mix (Qiagen, Australia) and 2 μL of extract in a 20 μL final reaction. 
Cycling conditions used for amplification were: initial hold at 15 min at 95°C; followed by 45 
cycles of 30 sec at 95°C and 60 sec at 60°C. The expected cycle threshold (Ct) for the added 
volume of EHV1 was 30 cycles. Changes to the Ct values for EHV1 were monitored 
throughout the study. Samples were considered to have failed the EHV1 component (ie. 
failed extraction or possessed PCR inhibitors) if the EHV1 real-time PCR Ct results for 
individual samples were more than two standard deviations from the mean value of all 
samples. Samples where an EHV1 individual sample Ct value was greater than 2 standard 
deviations away from the mean cycle threshold value were re-extracted [61]. 
4.2.5 Monitoring polyomaviruses by rtPCR 
 
Initially extracts were screened with the following duplex rtPCR assays; BKPyV (Va3) 
/JCPyV (JL1), MWPyV-ES/MWPyV-VP, STLPyV-LT/STLPyV-VP, MCV1.1-LT/HPyV6-LT, 
MCV2.0-VP-HPyV7D-LT, TSPyV-LT/HPyV6-VP, TSPyV-VP/HPyV9-LT, HPyV9-VP/HPyV-
VP.A triplex assay was used to screen for WUPyV (WU-REG)/KIPyV (KI-D & KI-E) and a 
singleplex was used to screen for HPyV12 (VP). Extracts with positive results were 
confirmed with a second rtPCR assay that targeted a different conserved region of each 
PyV genome. Oligonucleotide sequences for screening and confirmatory assays are shown 
in Table 4.1. Positive extracts for BKPyV, JCPyV and WUPyV were reconfirmed with the 
screening assays because of the sequence stability of the target used in the screening 
 assays. An extract was considered positive for a particular PyV when both screening and 
confirmatory assays produced an amplification curve before a cycle threshold value of 42. 
All assays utilized a common PCR mix consisting of either Qiagen Quantitect Probe (EHV, 
WUPyV, KIPyV) (Qiagen, Australia), or Bioline SensiMix II Probe (MCPyV, HPyV6,7,9,12, 
TSPyV, MWPyV, and STLPyV) (Bioline, Australia) mix, along with 8pmol of each primer, 
3.2pmol of probe, and 2µL of template in a final reaction volume of 20µL.  Cycling was 
performed with either a Rotorgene 6000 (Qiagen, Australia), or a LightCycler 480 (Roche 
Diagnostics, Australia). Cycling conditions used for amplification were: initial hold at 15 min 
at 95°C; followed by 45 cycles of 30 sec at 95°C and 60 sec at 60°C. All rtPCRs were 
conducted on the RotorGene 3000, 6000 or Q (Qiagen, Australia).  
Table 4.1 Primer and probe sequences, in 5’ to 3’ orientation, used to screen for polyomaviruses in the 
kidney transplant cohort 
Virus Oligo Name Sequence (5'-3') Role Study 
BKPyV V3a- F agcaggcaagggttctattactaaat 
Screening and 
confirmatory 
[62] 
 V3a- R gaagcaacagcagattctcaaca  
 V3a- Probe aagaccctaaagactttccctctgatctacaccagttt  
JCPyV JL1 - F aagggagggaacctatatttcttttg 
Screening and 
confirmatory 
[63] 
 JL1 - R tctagcctttgggtaacttcttgaa  
 JL1 - Probe ctcatacacccaaagtatagatgatgcagacagca  
WUPyV Reg-F   gccgacagccgttggatata Screening [32] 
 Reg-R  tttcaggcacagcaagcaat   
 Reg-Prb  agggtcaccatttttatttcagatgggca   
KIPyV LT-F   cacaggtggttttctataaattttgtactt Screening [32] 
 LT-R  gaagcagtgggatgtatgcattc    
 LT-Prb  tgcattggcattcgtgattgtagcca   
 Reg-F   gaacttctactgtccttgacacaggta Confirmatory [32] 
 Reg-R  ggattagaacttacagtcttagcatttcag   
 Reg-Prb  accctttgtaggccaaaggagagtgaagg   
MCPyV LT1.1-F   agctcagaagtgacttctctatgtttga Screening [32] 
 LT1.1-R  acaatgctggcgagacaact   
 LT1.1-Prb  tttgcagaggtcctgggtgcatg   
 2.0-F ggcagcatcccggctta Confirmatory [64] 
 2.0-R ccaaaaagaaaagcatcatcca   
 2.0-Prb atacattgccttttgggtgtttt   
HPyV6 VP2-F  ttgaggagctggacaaagagatt  Screening [32] 
 VP2-R  tctgggaagcttttgaattggt   
 VP2-Prb  aggaagatgccttgtcacagaaaaggaaatg   
 LT-F  accaggtgggtgatgaagaca Confirmatory [32] 
 LT-R  cgcctgaatgttttaaaggagaa   
 LT-Prb  ttggtccctcagggtggcattca   
HPyV7 VP2-F   gaggaaggaaacactccccagta Screening [32] 
 VP2-R  ttcacttctttttgtagctcctcaag   
 VP2-Prb  actatacctcaatggatgctttttgt   
 LT-F   aagacattcagtctttgcattttctg Confirmatory [32] 
 LT-R  cccctcatacagcataaggttagatt   
 LT-Prb  ccacctttatctggatgatactttttgctggc   
 TSPyV VP1-F agtctaaggacaactatggttacag Screening  
 VP1-R attacaggttaggtcctcattcaac   
 VP1-Prb acagcagtgaccaggacaagcctacttctg  [45] 
 LT-F tgtgtttggaaaccagaatcatttg Confirmatory  
 LT-R tgctaccttgctattaaatgtggag   
 LT-Prb ttcttcttcctcctcatcctccacctcaat   
HPyV9 VP1-F ctagggaacaatttgaatatcaggaa Screening [4] 
 VP1-R atagtgtccagatctaggctctgaac    
 VP1-Prb aagttaggctgaggcgggagataggg   
 LT-F caaactccctccaccatttacc Confirmatory [32] 
 LT-R tctccatactttactgaaactccatttt    
 LT-Prb ccccccttctggatcttcattttttctttc   
MWPyV ES-F tgagaaggccccggttct Screening [54] 
 ES-R gaggatgggatgaagatttaagttg   
 ES-Prb cctcatcactgggagc   
STLPyV VP1-F gaagttgaaaatggctccaaaaa Screening [21] 
 VP1-R atcatattcacatcttctcctcctagga    
 VP1-Prb tagatgcacctcacagacatgtccaatgg    
 LT-F tgcagaggtcccttcatcatc Confirmatory This study 
 LT-R ttttctttttagggcggacaatat    
 LT-Prb ccaccattgctcccaagcaggagtac   
HPyV12 VP-F gtgggaagctgtcagtgtga Screening [59] 
 VP-R ccacctactgcaaacatgtg    
 VP-Prb actacaggatggcctaccccattgtcagtc    
EHV F gatgacactagcgacttcga n/a [61] 
 R cagggcagaaaccatagaca   
  EHV-Prb tttcgcgtgcctcctccag     
LTAg = Large T Antigen, NCCR = Non Coding Control Region, STAg= Small T Anigen, VP1= Viral protein 1, 
VP3= Viral protein 3 
 
4.2.6 Calculations of novel PyV viral load 
 
Polyomavirus extracts confirmed positive for PyV were quantified to determine the genome 
copies per mL of sample. A serial dilution of the synthetic control plasmids (see Appendix 
A2.1) containing the PCR targets for the  HPyV6A, HPyV7D, TSPyV VP, STLPyV VP, 
WUPyV F, KIPyV D and MCPyV1.1 assays were used to create standard curves for 
quantification purposes. Whilst the quantification of viral load in homogeneous specimen 
types such as blood and urine allow accurate comparison of carriage of virus, 
standardization of respiratory specimens is difficult due to the variability of specimen 
collection methods. Therefore additionally quantification of virus load in all specimen types 
was recorded semi-quantitatively based on Ct values. Ct values were inversely proportional 
to the viral load in the specimen collected, and were grouped into three categories (high, 
 medium and low). Approximate viral load was determined by Ct value cutoffs as previously 
described[65]; values lower than Ct 28 were considered to be indicative of a high viral load, 
Ct values between 28 and 35 a medium viral load, and Ct values higher then Ct 35 a low 
viral load. 
4.2.7 Positive controls 
 
Synthetic control plasmids were used as positive controls for MCPyV, MWPyV, TSPyV, 
HPyV 6, 7 & 9, STLPyV, and HPyV12: more detailed information of on the design of these 
plasmids can be found in appendix A2.1. Clinical positive specimens previously proven 
positive for JCPyV, BKPyV, WUPyV, and KIPyV. Water was used as a negative controls 
were included on all rtPCR runs. 
4.2.8 KIPyV whole genome sequencing 
 
Selected extracts from KIPyV-positive respiratory swabs were sequenced using walking 
primers (Table 4.2). Primers were designed using Primer Express 2.0 software and KIPyV 
sequences that were publicly available on Genebank (accession numbers NC_009238.1, 
EF127906.1, EF520287.1, EF520288.1, EF520289.1, EU358766.1, EU358767.1 and 
KC571691.1).  
 
Conventional PCR was performed using a HotStar Taq Master mix (Qiagen, Australia), 5 μl 
of 10x PCR buffer, 10 μl of Buffer Q, 1.5 μl of 10mM dNTPs, 1.25μl of 25mM MgCl, 10pmol 
of each KIPyV walking primer pair, 0.75μl of HotStar Taq (5 units/μl) and 4μl of extract in a 
final reaction volume of 50μl. Themocycling was performed on the BioRad DNA Engine 
Peltier Thermal Cycler ( BioRad, Australia) under the following conditions: incubation at 
95°C for 15min, followed by 35 cycles of 94°C for 45sec, 55°C for 60sec and 72°C for 60sec, 
and a final extension 7min at 72°C. PCR products were sent for Sanger sequencing at the 
 Australian Genome Research Facility (Brisbane, Australia) Sequence data was aligned and 
manipulated with Bioedit Sequence Alignment Editor version 7.0.9.0.[66]  
 
Table 4.2 KIPyV walking primers designed to amplify the whole genome of KIPyV 
Oligo name Primer (5’ – 3’) 
KI-seq-ONE-323F gagtgaagggtaactgaaatgc 
KI-seq-ONE-926R aggttgaagagccagtctgg 
KI-seq-TWO-881F ctcaggaatggcattggt 
KI-seq-TWO-1535R ttgacttcttggccttgttag 
KI-seq-THREE-1457F gtatgtgctagaacaactaaatgct 
KI-seq-THREE-2003R acaccaactacatcaagtggct 
KI-seq-FOUR-1860F  cctgatataccaaatcaagttagtg 
KI-seq-FOUR-2484R catagtcacctctgttacaccaac 
KI-seq-FIVE-2467F  aagtgtttaacagacccacagaa 
KI-seq-FIVE-3129R tgtgtttgaagatgtcaaaggtc 
KI-seq-SIX-3077F ccatcaaggtagtctcttaagttatc 
KI-seq-SIX-3714R  ctaactttgctctggaatttgac 
KI-seq-SEVEN-3672F  acactcttcaggcttagtagcaa 
KI-seq-SEVEN-4329R tttgttgtatagatacctacatacgg 
KI-seq-EIGHT-4313F tgaactgtgaccaccactcat 
KI-seq-EIGHT-4938R gcaaagcagctaatgcaac 
KI-seq-NINE-4910F  cttctcattagtggtaaattgcc 
KI-seq-NINE-372R caggttcgagacgatggc 
 
4.2.9 Respiratory virus rtPCR 
 
Respiratory specimens positive for KIPyV from patients 43 (Baseline and month 1) and 68 
(baseline, month 1 and 3) were also screen for 13 common viral respiratory pathogens as 
previous described in Chapter 3 (section 3.2.11). With the addition of an rtPCR assay to 
detect cytomegalovirus, reaction mix and cycling conditions were as described in Chapter 
3, section 3.4.11. Oligonucleotide sequences are shown in Table 4.3.  
 
Table 4.3 Oligonucleotide sequences for CMV rtPCR assay 
Virus Oligo Name Sequence (5'-3') Target Reference 
CMV CMV -F aac tca gcc ttc cct aag acc a MIE [67] 
 CMV -R ggg agc act gag gca agt tc   
 CMV - probe caa tgg ctg cag tca ggc cat gg   
 
 
 
 4.2.10 Skin cancer or skin pathology reported in patients with a polyomavirus detection  
 
Several of the newly described polyomaviruses have pathology associated with the skin. 
Therefore, in this study, patients who developed skin pathologies were investigated after a 
detection of TSPyV, MCPyV, HPyV 6 or HPyV 7. Report of skin cancer or skin pathology 
was censored at the five year post transplantation follow-up.   
4.2.11 Directed Rolling Circle amplification of low load PyV clinical specimens 
 
Rolling circle replication (RCA) is a process of unidirectional nucleic acid replication that can 
rapidly synthesize multiple copies of circular molecules of DNA, such as plasmids, 
bacteriophages, and circular viral DNA genomes (eg: polyomaviruses). 
 
In general PyVs were detected at low viral load in the kidney transplant specimens, therefore 
the RCA method was modified to increase sensitivity by the use of specific primers for each 
PyV. The two terminal 3’ bases of each primer were phosphorothioate modified to avoid the 
strong endonuclease activity of the Phi29 DNA polymerase. The Phi29 enzyme is isothermic 
and amplifies at 30°C, therefore a pool of 3 primers were used for each PyV, designed to 
operate at Tm’s of 15°C, 30°C and 50°C. Each primer set targeted opposite ends of its 
respective PyV genome. Primer target conservation was ensured through alignment of 
available respective PyV genomes using Bioedit 7.0.5.3. Primer specificity was assessed 
using NCBI blastn with default parameters.  
 
Specimens confirmed positive for TSPyV, HPyV6 and STLPyV were amplified using a 
specific directed RCA (dRCA) for each PyV (Table 4.4). This increased viral template to 
allow more coverage of the whole PyV genome sequencing reads using the Ion Torrent 
sequencer (Life Technologies, Australia).    
  
The PyV dRCA protocol used was a modification of previously published RCA methods, and 
was specifically designed for this study.  [68], [69] The protocol used a two-step pre-
amplification and amplification procedure, where the pre-amplification served to initially 
prime the template to facilitate the downstream dRCA reaction. For the pre-amplification 
step, 0.4µM of each primer, 1x phi29 Buffer (Thermo Scientific, Australia) and dH2O was 
made up to 10 µl, followed by addition of 2µl of template, with the final 12µl mix being 
incubated at 95°C for 3 minutes, 50°C for 1 minute, 30°C for 1 minute, and 4°C for 30 sec. 
The amplification mix contained 0.4µM of each primer, 1x phi29 Buffer, 2ng/µl of Bovine 
Serum Albumin, 15mM dNTPs, 2U/µl of phi29 DNA polymerase (Thermo Scientific, 
Australia), and dH2O to a final reaction volume of 10µl. Both the primed pre-amplification 
and amplification mixes were then combined into a final 22µl volume and incubated at 30°C 
for 24 hours, followed by phi29 inactivation at 65°C for 10 minutes and cooling to 4°C. The 
dRCA products were diluted in 40µl of dH2O prior to downstream PCR or sequencing. To 
determine the increase in PyV template after dRCA reactions, specific rtPCR reactions were 
conducted on dRCA products as per methods in section 4.2.5 and 4.2.6.  
Table 4.4 Oligonucleotide sequences for specific dRCA amplification for TSPyV, HPyV 6 and STLPyV 
positive extracts.   
Oliog Name Sequence 5'-3' Tm (C) 
HPyV6-Drca-1F tcttgaggagctggac*a*a 51 
HPyV6-dRCA-1R gtgacacagacctaactgat*t*g 51 
HPyV6-dRCA-2F attcttgtataacag*t*a 29 
HPyV6-dRCA-2R ctttgatcattat*t*t 29 
HPyV6-dRCA-3F actacctgg*a*c 14 
HPyV6-dRCA-3R tctctgtg*g*g 14 
TSPyV-dRCA-F1 ccgcccggctt*t*a 51 
TSPyV-dRCA-R1 gcttgaaataccatccagat*a*a 53 
TSPyV-dRCA-F2 aggccctga*c*a 31 
TSPyV-dRCA-R2 ttaagctactgg*a*g 31 
TSPyV-dRCA-F3 ggccct*g*a 14 
TSPyV-dRCA-R3 taagctact*g*g 14 
STLPyV-dRCA-1F caaactgtggaaaatgttag*a*c 50 
STLPyV-dRCA-1R aaacgctgtgtcagc*a*g 50 
STLPyV-dRCA-2F tggactctctga*a*a 31 
STLPyV-dRCA-2R ttgttggct*c*g 30 
STLPyV-dRCA-3F tgatttatct*c*c 18 
STLPyV-dRCA-3R gagttcatg*g*t 14 
 
 4.2.12 Ion Torrent PyV sequencing 
 
Amplicons from positive dRCA reactions were sequenced using the Ion Torrent Personal 
Genome Machine (PGM) (Life Technologies, Australia). dRCA products were ethanol 
precipitated, fragmented and ligated with multiplex adapters using standard library 
preparation kit protocols. Adapter-ligated fragments were then clonally amplified onto Ion 
Sphere Particles (ISPs) by emulsion PCR using the Ion One Touch 2 system (Life 
Technologies, Australia) and enriched using the Ion ES system. Enriched ISPs were loaded 
onto an Ion 318 chip and sequenced using Ion 400 sequencing chemistry on the Ion Torrent. 
Read quality trimming, mapping and contiguous assembly were conducted using CLC Bio 
Genomics Workbench 6.5. Phylogenetic analysis was performed using a neighbor-joining 
(NJ) analysis with 1000 bootstrap and the Tamura-Nei substitution model using the 
Geneious 8.0.5 software. 
 
4.3 Results 
 
4.3.1 Basic demographic details of kidney transplant cohort 
 
In total 1169 specimens were collected; 495 whole bloods from 167 participants (mean 
bloods per patient 3, range 1-11), 313 urines from 164 participants (mean urines per patient 
1.9, range 1-10) and 361 combined nose and throat swabs from 162 participants (mean 
swabs per patient 2.2, range 1-10). Participant retention proved difficult after patients were 
no longer required to attend outpatient clinics, and as such, only 42 patients submitting 
specimens for all time-points within the 6 month study duration. In particular, the collection 
of combined nose and throat swabs was poor as the samples were not a clinical requirement 
to monitor BKPyV carriage. Only 17 participants submitted the five scheduled respiratory 
 samples for 6 months of the study period.  Basic demographic information including the age 
at date of transplantation, sex and donor type of the patients recruited in the kidney 
transplant study are outlined in Table 4.5.  
 
Table 4.5 Demographic information of patients recruited into the kidney transplant study 
  Number % 
Total  167  
Age transplant obtained Mean (SD and range)  48.5 (12.7, 18.1 – 74.8)  
Sex male 113 67.7% 
 female 54 32.3% 
Transplant type Live 52 31.1% 
 Cadaver 115 68.9% 
 
4.3.2 Monitoring of BKPyV and JCPyV carriage in longitudinal kidney transplant study 
 
Carriage of JCPyV and BKPyV in longitudinal blood, urine and respiratory samples collected 
for 12 months after kidney transplantation is summarized in Table 4.6. Both viruses were 
present in all specimen types, and were most commonly detected, and at highest viral load, 
in the urine specimens. More than two consecutive time point’s positive for a PyV was 
termed persistent shedding. Around half of the viremic and viruric participants that were 
BKPyV-positive consistently shed virus both in blood and urine specimens. Consistent 
shedding is noted for BKPyV in urine, blood and respiratory specimens but only in urine and 
blood for JCPyV. Clinically no patients in this cohort developed PVAN, and no respiratory 
illness were reported that corresponded to the detection of BKPyV or JCPyV in respiratory 
swabs.   
 
 
 
 
 Table 4.6 Demographic information of patients recruited into the kidney transplant study 
 BKPyV JCPyV 
Prevalence per participant in blood (%) 28/167 (16.8) 9/167 (5.4) 
No. of patients consistently shedding virus in blood (%) 14/167 (8.4) 3/167 (1.8) 
Viral load - Average Ct values – viremia 
(Ct range) 
Medium - 33.2 
(26.3 – 39.1) 
Low - 37.3 
(30.7 – 40.8) 
Prevalence per participant in urine (%) 69/162 (42.6) 24/162 (14.8) 
No. of patients consistently shedding virus in urine (%) 23/162 (14.2) 9/162 (5.6) 
Viral load - Average Ct values – viruria 
(Ct range) 
High - 25.7 
(9.75 – 41.9) 
Medium - 28.8 
(20.2 – 38.7) 
Prevalence per participant in respiratory specimens (%) 15/164 (9.2) 1/164 (0.6) 
No. of patients consistently shedding virus in respiratory tract (%) 1/164 (0.6) N/A 
Viral load - Average Ct values – respiratory 
(Ct range) 
Low - 36.9 
(33.3 – 39.9) 
N/A 
 
4.3.3 Monitoring of novel PyV in blood, urine and respiratory specimens 
 
No positive samples were detected for HPyV 9, MWPyV, or HPyV 12 in any specimen types. 
The overall incidence of BKPyV and JCPyV in blood, urine and respiratory specimens is 
listed in Table 4.7. On average, low viral loads were detected in blood specimens for 
MCPyV, WUPyV and HPyV6. However TSPyV recorded a medium viral load in the blood of 
one patient that consistently shed TSPyV over 1 month with an average of 29.8 cycles 
(medium load). Sporadic low viral load detection of newly described PyVs was also found in 
urine samples for MCPyV, WUPyV, HPyV6 and 7. Novel PyVs were most commonly 
detected in nose/throat swabs, with KIPyV and STLPyV only detected in this sample type. 
Most detections were sporadic and at low or medium viral loads. Cycle threshold values 
were significantly lower for the KIPyV positive specimens when compared to Ct values 
recorded for WUPyV or when compared to all other newly described PyV detected in the 
respiratory tract (Pairwise Mann-Whitney p<0.001 two-tailed test ( WUPyV n1=10, KIPyV 
n2=10) (all newly described PyV n1 =20, KIPyV n2=10).  
  
Table 4.7 Newly described polyomavirus detections in blood, urine and respiratory swabs collected over 12 months post kidney transplant. 
 MCPyV WUPyV KIPyV HPyV6 HPyV7 TSPyV STLPyV 
% Prevalence blood (no.) 
1.8% 
3/167 
1.2% 
2/167 
0% 
0.6% 
1/167 
0% 
0.6% 
1/167 
0% 
Viral load - Average Ct Values 
in blood 
(range) 
Low - 36.3 
(35.4-38.6) 
Low -38.5 
(37.9 – 39.0) 
 
Low -37.8 
(n/a) 
 
Medium -29.8 
(29.7 – 29.9) 
 
% Prevalence Urine (no.) 
1.2% 
2/162 
1.9% 
3/162 
0% 
0.6% 
1/162 
0.6% 
1/162 
0% 0% 
Viral load - Average Ct Values 
in urine (range) 
Low -38.4 
(37.7 – 39.7) 
Low -39.0 
(37.8 – 40) 
 
Low -  38 
(n/a) 
Low -40.9 
(n/a) 
  
% Prevalence respiratory 
swabs (no.) 
9% 
15/164 
6.1% 
10/164 
4.3% 
6/164 
3% 
5/164 
1.2% 
2/164 
0.6% 
1/164 
0.6% 
1/164 
Viral load - Average Ct Values 
in respiratory swabs (range) 
Low -36.7 
(30.7 – 40.7) 
Low -37.5 
(35.6 – 39.1) 
Medium -29.5* 
(19.8 – 37.1) 
Low -35.9 
(34.5 – 38.3) 
Low -39.3 
(37.9 – 40.7) 
Low -37.8 
(n/a) 
Low -35.2 
(36.9 – 33.5) 
* Ct Values were significantly higher for KIPyV respiratory positives than all other newly described PyV.  
 4.3.4 Detection of KIPyV in respiratory specimens from renal transplant patients 
 
Five patients had at least one detection of KIPyV in respiratory samples. Two patients, 43 
and 68 had persistent detections over 31 days and 85 days respectively. Of the three 
remaining patients where KIPyV was detected at single time points, only one (patient 41) 
had respiratory samples collected subsequent to the virus detection, and did not exhibit 
further virus positivity.  Patient 76 had both KIPyV and HPyV 7 detected in the respiratory 
swab taken at day 27, the KIPyV copy number was 100 fold higher than the HPyV 7 
detected.  
 
Table 4.8 KIPyV positive detections in respiratory specimens longitudinal collected from kidney 
transplant recipients.  
Patient 
ID 
Specimen 
type 
Time 
elapsed 
since Tx 
(days) 
KIPyV Ct 
values 
Viral load 
(copies/ml) 
Clinical observations 
41 Respiratory 
85 Medium (31.0) 5.7x102 
None reported 
43 Respiratory 0 Medium (33.0) 3.9x102 None reported 
43 Respiratory 31 High (28.0) 
 
5.8x103 
URTI 
66 Respiratory 37 
Low 
(37.1) 
>70 Dry rash 
68 Respiratory 0 Medium (30.9) 1.2x103 None reported 
68 Respiratory 29 High (26.5) 5.8x103 
URTI, severe ATN, delayed 
graft function 
68 Respiratory 85 High (19.2) 9.3x104 
URTI, sore throat cough, 
wheeze 
69 Respiratory 76 Medium (34.8) 1x102 pneumonia 
76 Respiratory 27 High (28.0) 
 
4.8x103 
 
None recorded 
*URTI is upper respiratory tract infection, ATN is acute tubular necrosis, ⋆ co-detected with HPyV 7 (HPyV 7 
viral load = >100cpy/ml) 
 
 
 
Two patients (subject 43 and 68) had KIPyV virus detected at all available time points in 
their respiratory swabs. Subject 43 was positive for KIPyV at baseline and month 1 (no other 
respiratory swabs were collected) and subject 68 was positive for KIPyV at baseline, month 
 1 and month 3 (no other respiratory swabs were collected). Subject 43’s baseline swab had 
a Ct value of 33, decreasing to a Ct value of 28 at month 1, suggestive of increasing KIPyV 
viral load. Subject 68 had a baseline Ct value of 31, decreasing to 27 at month 1 and 
decreasing further to 19 at month 3. Both patients reported upper respiratory symptoms at 
month 1 and 3. Bacterial cultures were performed as part of routine follow-up but no 
organisms were isolated. Subsequent testing by rtPCR for 14 common respiratory 
pathogens was conducted, with no other respiratory pathogens detected. 
   
Clinically both patients (subject 43 and 68) were highly immunosuppressed for an extended 
period leading up to their kidney transplant. Subject 43 had systemic lupus erthematosis 
which required immunosuppressive treatment for 6 months prior to transplantation. The 
subject was found to have a positive B cell cross match which puts them at very high risk 
for organ rejection, and therefore thymoglobulin immunosuppressive therapy was 
administered.  
 
Subject 68 had been immunosuppressed for >25 years, and was the recipient of a second 
kidney transplant, and had a history of thyroid and multiple skin cancers. This subject was 
also treated with thymoglobulin post-transplant.  
4.3.5 KIPyV whole genome sequencing 
 
The KIPyV DNA isolated from both patients at each positive time point was sequenced using 
the walking primers and Sanger sequencing. Overall, the 5 whole KIPyV genomes amplified 
were 100% homologous with the first published KIPyV sequence (NC_009238.1).  No 
coding changes were seen between the whole genome sequences of patient 43 and the 
KIPyV index sequence in the baseline or month 1 respiratory swab samples. No coding 
 changes were noted between the KIPyV index sequence and the Baseline, month1, and 3 
specimens from Subject 68.  
4.3.6 Detection of MCPyV in longitudinally collected specimens from kidney transplant 
recipients   
 
Six patients demonstrated persistent MCPyV shedding, with all but one case involving the 
respiratory tract (patient 40) (Table 4.9). In all cases, MCPyV was present at the time of 
transplantation, and persisted in some cases for ten months post-transplant. MCPyV 
persistence shedding was most notable in the respiratory specimens, however one patient 
(patient 40) showed persistent viremia for 30 days post-transplantation.  Subject 33 had 
MCPyV detected in respiratory specimens pre-transplantation and MCPyV persisted in 
respiratory and sporadically in urine specimens for 6 months post-transplant. MCPyV viral 
load varied from high to low within this 6 month period but was highest in the respiratory 
tract.No organisms were isolated from urine or blood cultures one month post-
transplantation.  
 
Patient 34, 55, 63 and 79 had MCPyV persistently detected in respiratory specimens for 
between 30 days and ten months post-transplantation. Generally MCPyV was detected at 
low to medium viral load. No consistent type of clinical symptoms were noted during MCPyV 
detections (Table 4.9). Low viral load and insufficient original sample prevented further 
characterization of MCPyV positive specimens.  
 Table 4.9 MCPyV detections in blood, urine and respiratory specimens longitudinally collected in kidney transplant recipient 
Patient 
ID 
Specimen type 
 
Time elapsed 
since Tx (days) 
Ct value 
Viral load 
(copies/ml) 
Clinical observations 
09 Respiratory 83 Low (38.5) >70 None recorded 
13 Respiratory 27 Low (37.0) >70 Coryza, URTI, scalp cyst, subsequent skin cancers 
27 Respiratory 0 Medium (33.6) 8.1x101 Pityrosporum folliculitis 
33 Respiratory 0 High (27.9) 2x103 None recorded 
33 
Urine 
27 
Medium (32.5) >70 
Unwell, URTI, febrile, no urine of blood culture growth 
Respiratory Medium (33.7) 6.2x101 
33 Respiratory 95 Low (36.2) 1x102 Skin cancers 
33 
Urine 
182 
Low (35.6) >70 
Skin cancers 
Respiratory Medium (34.2) >70 
34 Respiratory 0 Low (36.6) >70 None recorded 
34 Respiratory 33 Medium (30.4) 8x102 None recorded 
38 Blood 4 Low (37.6) >70 Abdominal pain 
40 Blood 4 Medium (34.8) 1.9x102 None recorded 
40 Blood 29 Medium (32.5) >70 None recorded 
48 Respiratory 105 Low (36.5) >70 None recorded 
55 Respiratory 0 Low (35.6) >70 Acute cellular rejection 
55 Respiratory 26 Low (35.6) 9.7x101 None recorded 
55 Respiratory 57 Low (36.5) >70 Diarrhoea, gastro panel negative, diabetes 
62 Urine* 28 Low (36.8) >70 None recorded 
63 Respiratory 0 Medium (29.5) 1.2x103 None recorded 
63 Respiratory 31 Medium (32.7) 1.5x102 
Type 1 cellular rejection, febrile, blood and urine culture negative, 
skin cancers, wheeze, COPD and decrease exercise tolerance 
65 Respiratory 22 Medium (33.3) 1.5x102 None recorded 
79 Respiratory 0 Medium (29.3) 4.3x102 None recorded 
79 Respiratory 28 Medium (30.7) 9.1x102 None recorded 
79 Respiratory 220 Low (35.7) >70 Epigastric pain 
85 Respiratory 0 Low (36.2) >70 None recorded 
88 Respiratory 0 Low (35.6) >70 None recorded 
96 Blood 30 Low (36) >70 folliculitis 
119 Respiratory 0 Low (37.6) >70 Subsequent skin cancers 
158 Respiratory 0 Low (36.2) >70 None recorded 
⋇ Samples co-detected with JCPyV. Upper respiratory tract infection (URTI), urinary tract infection (UTI) chronic obstructive pulmonary disease (CPOD) 
 4.3.7 Detection of WUPyV in longitudinally collected specimens from kidney transplant 
recipients 
 
None of the patients demonstrated persistent shedding of WUPyV in longitudinal collections. 
(Table 4.10) However two patients (Patient 15 and 37) had WUPyV detected in 
corresponding urine and respiratory swabs collected at the same time point. In these 
samples WUPyV was detected at low viral load with less than 70 copies of WUPyV per 
milliliter of specimen. Three patients, 9, 44 and 97 recorded respiratory symptoms 
corresponding with WUPyV detection in their respiratory tract. Due to the low load detected, 
these samples were not screened for additional respiratory pathogens. One patient, 21 also 
had gastric bleeding corresponding to a time point where WUPyV was detected in their 
blood.  
 
Co-detection with another polyomavirus was noted in three patients, 30, 37 and 44. In 
patient 30 WUPyV was co-detected with low load BKPyV in the respiratory swab sample, 
and in patient 37 with high load BKPyV in the urine sample. WUPyV was also detected with 
low load TSPyV in the respiratory specimens collected from patient 44.  
 
 
 
 
 
 
 
 
 
 Table 4.10 WUPyV detections in blood, urine and respiratory specimens longitudinally collected in 
kidney transplant recipient 
Patient ID Specimen 
type 
Time elapsed 
since Tx 
(days) 
WUPyV Ct 
value 
Viral load 
(copies/ml) 
Clinical 
observations 
09 Respiratory 174 Low (37.8) >70 URTI 
15 
Respiratory 
172 
Low (36.0) >70 
None recorded 
Urine  Low  >70 
21 Blood 25 Low (37.9) >70 Gastric bleeding 
30⋈ Respiratory 66 Low (39.1) >70 None recorded 
37 
Respiratory 
106 
Low (35.6) >70 
None recorded 
Urine⋈ Low (37.8) >70 
44 ¥ Respiratory 84 Low (38.3) >70 Flu like illness 
59 Respiratory 28 Low (36.0) >70 None recorded 
62 Respiratory 28 Low (37.9) >70 None recorded 
64 Respiratory 22 Low (37.4) >70 None recorded 
65 Blood 4 Low (39.0) >70 None recorded 
70 Respiratory 22 Low (38.3) >70 None recorded 
72 Urine 23 Low (39.3) >70 None recorded 
82 Respiratory 0 Low (38.3) >70 None recorded 
97⋈ Urine 189 Low (40.1) 
>70 Nephropathy, chesty 
productive cough 
⋈ Sample co-detected with BKPyV, ¥ sample co-detected with TSPyV, Upper respiratory tract infection (URTI) 
 
4.3.8 Detection of TSPyV in longitudinally collected blood and urine specimens from kidney 
transplant recipients 
 
Persistent shedding of TSPyV was noted in two blood samples collected at day 4 and month 
1 from patient 127 (Table 4.11). Both samples contained a TSPyV at medium viral load and 
also had BKPyV detected at low viral load. No clinical symptoms were observed during the 
first month post-transplantation. Patient 44 also had TSPyV detected in their respiratory tract 
3 months post-transplant (Table 4.11). Due to the low viral load of the PyV detected in patient 
44’s respiratory specimens further testing for other respiratory pathogens was not 
performed.  
  
 
 
 Table 4.11 TSPyV detections in blood and respiratory specimens longitudinally collected in kidney 
transplant recipient 
Patient ID Specimen type 
Time elapsed 
since Tx (days) 
Ct value 
Viral load 
(copies/ml) 
Clinical 
observations 
127⋈ Blood 4 Medium (30.4) 4x103 
None 
recorded 
127⋈ Blood 25 Medium (30.8) 2.9x103 
None 
recorded 
44⌀ Respiratory 84 Low (39.4) >70 Flu like illness 
⋈ Sample co-detected with BKPyV, ⌀ sample co-detected with WUPyV. 
 
4.3.9 Detection of STLPyV in longitudinal collected respiratory samples from kidney 
transplant recipients 
 
STLPyV was detected in two respiratory specimens from the same patient (patient 13). 
(Table 4.12) One month post-transplantation STLPyV and MCPyV were co-detected both at 
low viral loads. During this time the patient recorded rhinitis and symptoms consistent with 
an upper respiratory tract infection. This patient also reported a scalp cyst and more than a 
week later required the removal of skin cancers. No polyomaviruses were detected in the 
specimen collected at 3 months post-transplant, however at the month 6 post-transplant 
STLPyV was again detected in the respiratory sample. Despite the viral load increasing by 
at least 100 fold, no clinical observations were recorded during the time of STLPyV positivity. 
No additional respiratory bacterial or viral pathogen investigations were undertaken. No 
follow-up respiratory specimens were collected from patient 13 therefore the persistence of 
STLPyV could not be ascertained.  
 
 
 
 
 Table 4.12 STLPyV detections in blood and respiratory specimens longitudinally collected in kidney 
transplant recipient 
Patient ID Specimen 
type 
Time elapsed 
since Tx (days) 
STLPyV Ct 
value 
Viral load 
(copies/ml) 
Clinical observations 
13 ˠ Respiratory 27 Low (38.9) >70 
Coryza, URTI, scalp cyst, 
subsequent skin cancers 
13 Respiratory 167 
Medium 
(33.5) 
1.4x103 None recorded 
ˠ Samples co-detected with MCPyV, Upper respiratory tract infection (URTI) 
 
4.3.10 Detection of HPyV6 in longitudinally collected respiratory, urine and blood samples 
from kidney transplant recipients 
 
None of the 7 patients that had HPyV6 detected in blood, urine or respiratory specimens 
showed persistent HPyV 6 shedding (Table 4.13). Five patients had HPyV 6 copy numbers 
under the limit of quantification. HPyV6 was predominately detected in the respiratory tract, 
however the virus was not detected in any subsequent respiratory samples, with the 
exception of patient 108, for whom no additional samples were available. Patient 49 
exhibited one of the higher viral loads in the study, and presented with pneumonia 2 weeks 
prior to transplantation, however no clinical observations were recorded corresponding with 
the actual date of HPyV 6 detection.  
 
Table 4.13 HPyV 6 detections in blood and respiratory specimens longitudinally collected in kidney 
transplant recipient 
Patient ID 
Specimen 
type 
Time 
elapsed 
since Tx 
(days) 
HPyV 6 Ct 
value 
Viral load 
(copies/ml) 
Clinical observations 
16 Respiratory 0 Low (35.8) >70 None recorded 
37⋈ Urine 232 Low (36.6) >70 None recorded 
49 Respiratory 0 Medium (33.7) 6.6x101 
Pneumonia 2 weeks 
prior to KTx 
61 Respiratory 0 Low (35.4) >70 None recorded 
104 Blood 28 Low (37.3) >70 None recorded 
108 Respiratory 30 Medium (34.7) >70 SOB, weight loss 
131 Respiratory 0 Medium (32.8) 3.7x102 None recorded 
Shortness of breath (SOB) 
 4.3.11 Detection of HPyV7 in longitudinally collected respiratory, urine and blood samples 
from kidney transplant recipients 
 
Three patients had positive HPyV7 detections (Table 4.14), all at low viral load. Patient 68 
had HPyV7 detected at 1 month post-transplantation which corresponded to a urinary tract 
infection. Patient 76 had a co-detection of HPyV7 at low load and KIPyV at high viral load 
but no clinical observations were recorded. Patient 68 and 89 had follow-up specimens in 
which HPyV7 was not detected; no follow-up respiratory specimen was taken for patient 76. 
 
Table 4.14 HPyV7 detections in urine and respiratory specimens longitudinally collected in kidney 
transplant recipient 
Patient ID Specimen 
type 
Time 
elapsed 
since Tx 
(days) 
HPyV7 Ct 
value 
Viral load 
(copies/ml) 
Clinical observations 
68 Urine 29 Low (37.7) >70 UTI 
76⎈ Respiratory 27 Low (39.9) >70 None recorded 
89 Respiratory 0 Low (40.0) >70 None recorded 
⎈ Co-detected with KIPyV, Urinary tract infection (UTI) 
 
4.3.12 Skin pathology associated with MCPyV, TSPyV, HPyV6 or HPyV7 detection at five-
year post-transplant follow-up. 
 
MCPyV was detected in 18 patients, five of which developed skin cancer at an average of 
29 months post-transplantation (range 16-47 months). These patients developed a range of 
histological presentations including Basal cell carcinoma (BCC), Squamous cell carcinoma 
(SCC) and Intra-epidermal carcinoma (IEC). One patient had a history of skin cancers prior 
to kidney transplantation, and one patient developed hyperkeratotic follicucentruc eruptions 
7 months after kidney transplantation. Clinically this was suggestive of trichodysplasia 
spinulosa (TS), however HPyV6 was the only polyomavirus detected in this patients’ 
specimens. Another patient who had HPyV7 detected had a history of skin carcinoma prior 
to kidney transplantation (Table 4.15).    
  
Table 4.15 Case of skin cancer or other skin pathology and detection of skin topic polyomaviruses at 
five year post-transplant follow-up.  Time frame indicates time to first instance of skin cancer/skin 
pathology. 
 
Months post-Tx 
development 
Virus 
5 year 
rate 
Skin pathologies Range Mean 
MCPyV 
5/18 
(27.7%) 
BCC, SCC IEC 16-47* 29 
HPyV6 
1/7 
(14.3%) 
Hyperkeratotic follicucentric eruption, suggestive of 
TS 
7 7 
HPyV7 
1/3 
(33.3%) 
BCC, SCC, IEC -* - 
TSPyV 0/2 - - - 
BCC = Basal cell carcinoma, SCC = Squamous cell carcinoma, IEC = Intraepidermal carcinoma, TS = 
Trichodysplasia spinulosa.* BCC, SCC, and IEC occurances prior to transplantation (singular case in MCPyV 
positive population) 
 
4.3.13 Directed rolling circle amplification (dRCA) and whole genome sequencing of TSPyV, 
HPyV6 and STLPyV. 
 
The results of dRCA amplification for TSPyV, HPyV6 and STLPyV are shown in Table 4.16. 
Successful dRCA amplification was obtained from two TSPyV positive extracts, two HPyV 
6 positive extracts and a single STLPyV extract. However, five of seven dRCA reactions 
failed to amplify HPyV 6 in previously positive extracts. These were the baseline respiratory 
swabs of patients 16, 108 and 131, the respiratory swab taken at 1 month of patient 108, 
and urine at 8 months post-transplant from patient 37. Also, STLPyV could not be amplified 
by dRCA from the respiratory swab collected at 6 months post transplantation for 1 of 2 
patients positive for this virus (patient 13) Consequently Ion Torrent sequencing could not 
be conducted on any of these samples. 
 
 
 
 
 Table 4.16 Increases in viral template after dRCA amplification for TSPyV, HPyV6 and STLPyV and 
resulting PyV specific read number and coverage after next generation sequencing.  
Specimen ID 
Day post 
KTx 
Specimen 
type 
rtPCR 
Ct 
rtPCR Ct 
after RCA 
Mapped reads 
MCPyV reads/total 
reads (%) 
Range of 
read 
coverage 
TSPyV Positives 
127  4 Blood 36.7 5.0 151/50745 (0.3%) 0-18 
127 
25 Blood 
38.7 4.4 
21388/641876 
(3.3%) 
348-3084 
HPyV6 Positives 
49 
0 Respiratory 
swab 
35.4 8.4 
2613/533782 
(0.45%) 
57-343 
61 
0 Respiratory 
swab 
33.7 7.4 6836/68377 (1%) 166-878 
STLPyV Positives 
13 
167 Respiratory 
swab 
36 7.3 10255/503310 (2%) 367-1321 
 
4.3.13.1 TSPyV whole genome sequences 
Sequences from both TSPyV-positive samples shared 100% homology between the viruses 
isolated on days 4 and 25 (month 1), and contained no non-synonymous changes when 
compared to the index sequence (accession NC_014361.1). Mutations in the NCCR were 
detected at nucleotide position 159. This mutation was previously shown in 13 of the 15 
whole genomes that were publically available. A second mutation at nucleotide position 
2458 was also within a non-coding region of the genome. A single non-synonymous 
mutation at position 3106 was also detected in the genome sequence coding for the LTAg. 
(accessions NC_014361, GU989205.1, JQ723730.1, AB873001.1,  KMOO7161.1, 
KF444091, KF444092, KF444093, KF444094, KF444095, KF444096, KF444097, 
KF444098, KF444099, KF444100, and KF444101).  The TSPyV genome sequence 
characterized from the sample collected at day 25 (month 1) was submitted to Genbank as 
isolate QLD-127M1b (Accession # KM655816). 
 4.3.13.2 STLPyV whole genome sequences 
STLPyV has not previously been detected in respiratory specimens; therefore the sequence 
information generated in this study was unique. The whole viral genome was sequenced 
from the nose/throat swab collected from patient 13 at 6 months post-transplant. This 
STLPyV genome showed 94.1% pairwise identity with the prototype sequence 
NC_020106.1 and up to 99.7% identity with the five other publically available STLPyV 
genomes. (Genbank accession numbers NC_020106.1, KF651951.1, JX463184.1, 
KF525270.1, and KF530304.1) Coding changes in the NCCR and non-synonymous 
changes compared to the STLPyV index case in viral encoded proteins are listed in Table 
4.17. If these changes are noted in the five other STLPyV genomes listed on Genbank the 
changes are labelled as common. Phylogenetic analysis of the whole STLPyV genomes and 
the respiratory positive specimen sequenced in the kidney transplant study is demonstrated 
in Figure 4.1. The STLPyV genome was submitted to Genbank as isolate QLD-13M6r 
(accession # KR090570) 
 
 
 
 
 
 
 
 
 Table 4.17 STLPyV coding changes in NCCR and viral proteins in respiratory isolated from patient 13 
compared to the STLPyV index case (accession no. NC_020106.1)    
Nucleotide 
position 
Nucleotide change Amino acid change Virus region 
Common or 
unique 
82 C to G n/a NCCR Common 
85 Single base deletion n/a NCCR Common 
160 A to C n/a NCCR Unique 
276 A to G n/a NCCR Common 
285 A to C n/a NCCR Common 
287 CAT to ATA n/a NCCR Common 
641 A to T I to L VP2 Common 
644 CAG to AGT Q to S VP2 Common 
845 CA to AG Q to R VP2/3 Common 
1056 G to A S to N VP2/3 Common 
1073 G to A V to I VP2/3 Common 
1089 T to C V to A VP2/3 Common 
1130 A to T T to S VP2/3 Common 
1344 G to C V to L VP1 Common 
1377 A to T T to S VP1 Unique 
1729 G to C G to A VP1 Common 
1732 C to A T to N VP1 Common 
2013 GCT to TCC A to S VP1 Common 
2569 C to T M to I LTAg Common 
2611 T to A E to D LTAg Common 
3321 C to T V to I LTAg Unique 
3444 A to G Y to H LTAg Common 
3464 C to T S to N LTAg Common 
3675 C to A A to S LTAg Common 
4281 C to T A to T STAg Common 
4411 CTG to TTT Q to K STAg Common 
4753 TTG to TGC Q to A LTAg/STAg Common 
 
  
Figure 4.1 Neighbor-joining phylogenetic analysis of publically available whole genome sequences of 
STLPyV polyomavirus. Previous detections of this virus have only been demonstrated in urine and 
fecal specimens. (Genbank accession numbers NC_020106 fecal specimen Malawi, KF651951.1 X 
specimen, China, JX463184.1, KF525270.1, KF530304.1) 
 
4.3.13.3 HPyV6 whole genome sequences 
 
Whole genome sequences generated from the two positive HPyV 6 baseline respiratory 
swab specimens in this study (patient 49 and 61) revealed a  99.8% pairwise identity 
between these sequences and the 8 other HPyV6 genomes publically available 
(NC_014406, HM011558, HM011559, HM011560, HM011561, HM011562, HM011563, and 
 KM387421).  Synonymous changes for both genomes are shown in table 4.18, and both 
these genome sequences were submitted to Genbank as isolates QLD-49Br (accession # 
KR090570) and QLD-61Br (accession # KM655817), respectively. 
 
Table 4.18 Non-synonymous changes in HPyV 6 coding changes proteins in respiratory isolated from 
patient 49 and 61 compared to the HPyV 6 index case (accession no. NC_014406)    
Specimen ID 
Nucleotide 
position 
Nucleotide 
change 
Amino acid change 
Virus 
region 
Common or 
unique 
Patient &49 61 1220 A to G S to G VP2/3 Common 
Patient 49 1329 C to T P to S VP2/3 Unique 
Patient 49 1362 A to T M to L VP2/3 Unique 
Patient 61 1362 A to C M to L VP2/3 Unique 
Patient 49 2227 C to T T to I VP1 Unique 
Patient 49 2722 C to T D to E VP1 Unique 
Patient 49 & 61 2910 T to C I to V LTAg common 
Patient 49 & 61 2914 G to C D to E LTAg Common 
Patient 49 & 61 3389 G to T T to K LTAg Common 
Patient 49 & 61 3743 C to T R to K LTAg Common 
Patient 61 4074 A to C S to A LTAg Unique 
Patient 49 4602 G to A R to C STAg Unique 
Patient 49 4884 C to T D to N STAg/LTAg Unique 
Patient 49 & 61 4895 C to T R to K STAg/LTAg Common 
 
 
4.4 Discussion 
With the exception of HPyV 9, MWPyV, and HPyV 12, the newly described human 
polyomaviruses can be readily detected in kidney transplant recipients’ blood, urine and 
respiratory swabs collected up to 10 months post-transplant. Detection of novel 
polyomaviruses was most frequent in respiratory specimens, whereas the detection of 
JCPyV and BKPyV was generally in blood and urine specimens. 
4.4.1 Detection of BKPyV and JCPyV in renal transplant recipients 
BKPyV prevalence and detection in this cohort is comparable to many other studies of 
kidney transplant populations and will be used here as a comparator with the findings 
described in this study for the newly described polyomaviruses. BKPyV had a prevalence of 
 16.8% (28/167) in blood and 42.6% (69/162) in urine from subjects who recorded at least 
one BKPyV positive result from each specimen type. Persistent BKPyV viremia was noted 
for 8.4% (14/167) of patients and persistent viruria in 14.2% (23/162) of patients. A 
comprehensive review of PVAN reported between 8-12% of kidney transplant recipients 
have persistent post-transplant viremia.[17] This is comparable to the detection rates 
reported in this study, but no patients in this kidney transplant cohort subsequently 
developed PVAN. This may be due to the strict BKPyV monitoring resulting in responsive 
reductions in immunosuppressive therapy. Active monitoring of BKPyV and rapid reduction 
of immunosuppression after reactivation of BKPyV has been shown to be the most effective 
strategy in preventing PVAN in kidney transplant recipients.[17] Only a few studies have 
monitored the prevalence of BKPyV in respiratory samples. In this cohort it was 
demonstrated that 9.2% (15/164) of patients had BKPyV detection in respiratory swabs 
however only one patient in this cohort had persistent BKPyV shedding at low viral loads. 
Rare cases of fatal BKPyV pneumonitis have been reported, however these cases have 
mostly occurred in bone marrow transplant recipients with high load BKPyV viraemia and 
viruria and immunohostochemical evidence of BKPyV within the lung. [70], [71] In the patient 
with persistent BKPyV detection, the viral load remained low in the respiratory specimen, 
but at high load in urine and blood samples at corresponding time points, suggesting a 
BKPyV spill-over event rather than pneumonitis. Especially as no respiratory symptoms 
were reported during the relevant time period.  
In contrast to BKPyV, JCPyV reactivation in this kidney transplant cohort was detected with 
a prevalence of >6% in the blood, urine and respiratory swabs at significantly lower viral 
load than BKPyV (in blood and urine specimens). This finding supports other studies that 
suggest that JCPyV can be detected in the blood and urine of kidney transplant recipients 
but is usually asymptomatic and in this cohort was not associated with nephropathy. 
However here we report the detection of JCPyV within the respiratory tract one renal 
 transplant patient, to our knowledge this is a novel finding and have not been previously 
reported. However this detection was not associated with the report of any clinical 
symptoms.    
4.4.2 Detection of WUPyV and KIPyV in renal transplant recipients 
WUPyV and KIPyV have been previously detected sporadically in blood and urine 
specimens from immunocompromised patients [72]. In this study WUPyV was detected at 
low viral load predominately in respiratory specimens, and no persistent shedding was noted 
in any patients. WUPyV has been associated with respiratory disease, however in this study, 
only three of the ten patients with WUPyV detected in their respiratory tract samples had 
reports of corresponding respiratory symptoms. Of the patients that recorded respiratory 
symptoms two had another polyomavirus co-detected. The low viral load of WUPyV 
detected in this renal transplant cohort and low incidence of clinical symptoms suggested 
that WUPyV is not commonly associated with respiratory disease in kidney transplant 
patients. In contrast, two subjects displayed persistent shedding of KIPyV in their respiratory 
swabs, with average Ct values 5 cycles lower than the reported Ct values of all other newly 
described polyomaviruses detected in respiratory specimens. These differences were 
statistically significant. Both of the subjects with persistent KIPyV, had detectable KIPyV pre-
transplantation, and demonstrated decreasing Ct values over several months suggesting 
increasing viral replication. In one of the subjects, the Ct values decreased by more than 10 
cycles over a 3 month period, which roughly equates to a 1000 fold increase in viral load. 
Both subjects also reported respiratory symptoms during this period with no other viral or 
bacterial pathogens being detected by culture or PCR. A recent study reported the detection 
of high load KIPyV in the respiratory samples of a paediatric bone marrow transplant patient 
who died of respiratory failure. [50] Similar to our results, no other bacterial or viral pathogen 
was detected, and furthermore, KIPyV capsid protein presence was demonstrated in the 
patient’s lung epithelial cells and avelour macrophages, [27] which strongly suggested 
 KIPyV’s causal association with the respiratory disease in this particular patient. The KIPyV 
detection in the transplant lung, along with evidence of KIPyV RNA within respiratory 
samples (presented in Chapter 3) suggested that KIPyV can actively infect cells within the 
lung. Therefore it was highly likely that KIPyV was responsible for the respiratory symptoms 
experienced by the two patients in this study. Both of our subjects had significant 
immunosuppressive therapy before their transplantation, which may explain the detection of 
KIPyV in the pre-transplant specimens. It seemed likely that the high level of 
immunosuppressive therapy both patients were receiving contributed to the reactivation and 
active replication of KIPyV. Interestingly, no substantial sequence variation was noted in 
KIPyV genomes isolated from either patient during KIPyV infections, this suggests a single 
ongoing KIPyV infection, although a new exogenous KIPyV infection cannot be ruled out. 
Sequence variation in the NCCR or VP1 region of BKPyV was thought to increase immune 
escape and urogenital tropism during BKPyV reactivation in immunocompromised 
patients.[73]–[75] Increases in KIPyV load did not seem to increase the KIPyV mutation rate 
in the KIPyV infections presented here, and therefore reactivation might be linked to the 
level or type of immunosuppression rather than increases in KIPyV virulence.  High level 
immunosuppression is also a risk factor in developing PVAN in kidney transplant patients, 
and suggests that KIPyV, like BKPyV, could be highly immune-modulated. Based on this 
study it seemed likely that KIPyV might cause respiratory tract illness in a subset of highly 
immunosuppressed kidney transplant patients, however this requires further investigation in 
larger cohorts of renal transplant recipients.  
4.4.3 MCPyV detection in renal transplant recipients 
MCPyV had the highest prevalence (9%) in respiratory specimens of any of the newly 
described polyomaviruses. Six subjects persistently shed MCPyV at low viral loads in the 
respiratory tract for one to ten months post transplantation. Previous studies have 
investigated the presence of MCPyV in oral fluid from both immunocompetent and 
 immunocompromised patients with and without oral lesions.[39] Baez et al [39]reported 
MCPyV could be detected at a similar prevalence between the immunocompetent and 
compromised samples however, and an association was noted between non-cancerous oral 
lesions and MCPyV detection. In Chapter 3 of this thesis, no association between the report 
of respiratory symptoms and MCPyV DNA detection was found in healthy children. However, 
others have reported increased MCPyV DNA detection in elderly and immunosuppressed 
patients with respiratory tract illnesses.[36] In this cohort we found two patients with 
persistent, low load, MCPyV-positive respiratory samples who also reported symptoms of 
respiratory tract infection. No further characterization of these samples could be conducted 
due to the limited volume of primary specimens available.  Therefore it cannot be ruled out 
that the respiratory symptoms were caused by other undetected pathogens.  
 
MCPyV was also detected at a prevalence >2% in urine and blood specimens. With only 
one patient demonstrating sporadic detection of MCPyV in urine samples collected at 1 and 
then at 6 months. At 1 month this patient reported symptoms of fever with suspected UTI. 
However no pathogens were identified by routine microbiological screening. The results of 
this study contrast with a recent report of high prevalence of MCPyV in urine specimens 
from immunocompetent (46%) and immunocompromised (16%) adults with no reported 
symptoms. [38], [76] Potentially this discrepancy in MCPyV prevalence in urine could be due 
to MCPyV contamination during urine or respiratory sample collection. As MCPyV can be 
actively shed from healthy human skin and is found in the environment, therefore 
endogenous MCPyV could contaminate specimens during collection or processing this 
scenario seems likely, particularly in cases were MCPyV DNA was detected at low viral 
loads. [41], [42]  MCPyV viremia has also previously been reported in healthy and 
immunocompromised cohorts without the presence of MCC or clinical symptoms. 
 
 This data taken together with other reports seem to correlate with the suggestion that 
MCPyV has multi organ dissemination which appears to be rarely symptomatic and is readily 
found in patients without MCC.[40], [77] However, why MCPyV only causes such a rare 
cancer despite its ubiquity requires further examination. These investigations will be 
especially important in immunocompromised populations, which are at an increased risk of 
developing MCC.  
4.4.4 HPyV6 & 7 detection in renal transplant recipients 
Generally, polyomaviruses 6 and 7 are suspected of having a tropism for the skin. However, 
they were detected in blood, urine and respiratory specimens in the kidney transplant cohort 
examined in this study. HPyV6 was detected in all three specimen types whilst HPyV7 was 
only detected in urine and respiratory specimens. All positive HPyV6 and HPyV7 specimens 
were detected at high Ct values, which suggested a low viral load. No subject was positive 
in multiple sample types concurrently, and no consistent shedding was detected. The low 
HPyV6 and 7 viral loads detected in this study suggested it was unlikely these viruses 
contribute to clinical symptoms using a similar mechanism to BKPyV, in which high viral 
loads were associated with disease. However further investigations of HPyV6 and 7 in skin 
swabs from immunocompromised patients are warranted, especially since high viral load 
infections have been detected in skin rashes in highly immunocompromised patients, and 
their detection in this study at low loads in body fluids may be indicative of active infections 
elsewhere in the body, such as the skin. However in parallel to MCPyV, HPyV 6 and 7 have 
been detected on healthy human skin, therefore the potential for sample contamination 
should be considered. [43]  
4.4.5 TSPyV detection in renal transplant recipients 
A single subject in this study was viremic for TSPyV, and continued to shed this virus in the 
follow-up blood specimen taken a month later. A second participant also had a single 
 detection of TSPyV at low viral load in their respiratory specimen. TSPyV has previously 
been detected in respiratory samples, faeces, kidney biopsies, and urine collected from 
different cohorts of immunocompromised patients, but viral loads were generally low in the 
absence of TS. However, TSPyV has not previously been detected in blood or serum from 
immunocompromised patients nor in the serum cohort screened in Chapter 2. [47], [50], 
[52], [56] Therefore, the detection of TSPyV viremia in a kidney transplant patient in this 
study was a novel finding, even though it was not associated with any recognized skin 
conditions. Whole genome sequencing detected no sequence changes between specimens 
collected on day 4 and month 1 post-transplant. The comparison of the genome sequences 
identified in this patient and other whole TSPyV genomes available on Genbank suggested 
that the TSPyV genomes were highly conserved and that sequence variation may not play 
a role in increasing the virulence or pathogenicity of this virus. Unfortunately follow-up blood 
specimens were not available for this subject and therefore it could not be determined if the 
patient continued to have a viremic TSPyV infection. Information about the level of 
immunosuppressive therapy received by this patient was not available, and the level of the 
subject’s immunosuppressive therapy may be a risk factor in the development of 
polyomavirus associated skin conditions.  High level immunosuppression has often been 
reported in TS cases. Future studies into newly described polyomaviruses should include 
skin swab collection as both TSPyV and HPyV7 have been associated with skin conditions 
in immunocompromised cohorts where PyVs can be detected at high viral copy number.   
4.4.6 STLPyV detection in renal transplant recipients 
Interestingly, STLPyV was detected at low viral load in two respiratory swabs collected five 
months apart from the same patient. The presence of STLPyV in respiratory specimens has 
not previously been reported. In this study one STLPyV positive respiratory swab was 
successfully sequenced and revealed a sequence with >5% sequence variation to the index 
case from Malawi. However it was highly homologous with other STLPyV genomes 
 available, with less than 1% variability to some viruses isolated from China and the USA. In 
total, the comparison of available genomes suggests that sequence variation is most likely 
due to geographical location of the virus isolated, with Australian isolates highly homologous 
with specimens collected from the USA, but showing >5% variation from specimens 
originating from Malawi cases. This geographical clustering was also seen in our 
phylogenetic analysis of the MWPyV genomes in Chapter two and has been observed for 
other polyomaviruses.[4], [78], [79]  
 
Our analyses of STLPyV phylogeny may lack resolution due to the paucity of available 
STLPyV sequences, with only 5 STLPyV whole genome sequences being publically 
available. Also, apart from the genomes detected in respiratory samples in this study, all 
published genome sequences originated from fecal samples. Unfortunately in this study no 
fecal specimens were collected which would have allowed the investigation of viral presence 
in this specimen type. Such data would give further information on tissue tropism and the 
possible route of transmission.  
4.4.7 Lack of HPyV 9, HPyV 12 and MWPyV detection in renal transplant recipients 
In this cohort of kidney transplant recipients the newly described polyomaviruses HPyV 9, 
12 and MWPyV were not detected. This is surprising for HPyV 9, as the virus was discovered 
in the serum and urine of kidney transplant patients and has been subsequently detected in 
another kidney transplant cohort.[51], [53]  A possible reason may be due to differences in 
assay sensitivities, as very low level viremia of HPyV 9 was reported in previous studies. 
The report first identifying HPyV 9 used a nested PCR methodology to screen clinical 
specimens, but provided no information on the sensitivity of the PCR methods used. The 
study described by van der Meijden 2014 et al, [53] reported an analytical sensitivity of 10 
copies/µl for the HPyV 9 rtPCR assay used which was the calculated sensitivity of the assay 
used in this study. However, van der Meijden used serum instead of whole blood, and a 5 
 times greater amount of input DNA extract, which may have potentially increased the overall 
sensitivity of the assay.  
A variant of the HPyV 9 genome has been identified recently with sequence variation in the 
NCCR. However, this would not affect the sensitivity of the rtPCR used in this study, as 
these assays targeted regions in the LTAg and VP1 which are highly homologous. Therefore 
it is possible that very low level HPyV 9 viraemia may be present in the subjects examined 
in this study population. Therefore, the clinical relevance of HPyV 9 infection would be 
questionable in the absence of high viral loads.  
Newly described human polyomavirus MWPyV was detected in high prevalence in the 
pediatric cohorts presented in Chapter 2 and 3 of this thesis. However this polyomavirus 
was not detected within the adult population, with or without immunosuppression. MWPyV 
was discovered and has been frequently detected in fecal specimens and therefore may 
have a tropism toward this specimen type. It has also been reported in anal wart biopsies 
which may suggest it can be detected in skin. Further investigations into the detection of this 
polyomavirus in fecal and skin specimens from adult and pediatric immunocompromised 
cohorts is warranted to elucidate the pathogenic role, if any, of this virus.  
HPyV 12 has only been reported in organs of the gastrointestinal tract. It was not detected 
in the cohort of patients studied here, and therefore information about its biology, 
epidemiology and pathogenicity remain to be elucidated in other studies.  
4.4.8 Skin tropic newly described polyomaviruses and the development of skin cancer or 
skin pathologies 
Kidney transplantation has greatly increased the survival rates of patients with acute kidney 
dysfunction, however the immunosuppressive therapy required has also greatly increased 
the risk of cancer development in transplant recipients.[80], [81] Skin cancer in kidney 
transplant recipients contributes to poor 10-year survival rates, and it has been suggested 
 that a viral agent, such as MCPyV might be involved in cell transformation in these 
cancers.[37] Indeed, a number of the subjects who persistently shed MCPyV in this study 
went on to develop skin cancer. However a five year follow-up of patients found no 
correlation between the detection of MCPyV, or other suspected cutaneous tropic 
polyomaviruses (TSPyV, HPyV 6 and 7) and the development of skin cancer. 
4.4.9 Conclusions 
In summary, the newly described human polyomaviruses WUPyV, KIPyV, MCPyV, HPyV 6 
and 7, and STLPyV can be detected in multiple specimen types from kidney transplant 
patients. Predominately these viruses were detected at low viral load in the respiratory tract. 
Here the first case of STLPyV and TSPyV in respiratory specimens was reported. Although 
some patients with persistent shedding of MCPyV were detected, no association with the 
development of skin cancers was noted up to 5 years after transplantation. Viremia or viruria 
with high viral loads were not noted with any of the newly described polyomaviruses in this 
cohort. However persistent detection with increasing viral load was noted for KIPyV in the 
respiratory tract of two kidney transplant patients who required high levels of 
immunosuppressive therapy. These detections also correspond to the report of respiratory 
tract symptoms in both patients, suggesting KIPyV may play a role in respiratory disease in 
patients under long-term immunosuppression.   
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Detection and Characterisation of BKPyV in Bladder Carcinoma 
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carcinoma of the bladder and BK viruria in kidney transplant recipients.,” Transpl. 
Infect. Dis., vol. 15, no. 3, pp. 283–9, Jun. 2013. 
  
5.1 Introduction 
 
In this Chapter biopsy specimens from two cases of micropapillary urothelial carcinomas 
(MPUC) of the bladder that developed after long-term immunosuppression following renal 
transplantation were examined, and the presence of BKPyV within tumour tissues was 
investigated.  
5.1.1. Are polyomaviruses carcinogens? 
 
Polyomaviruses were first discovered by Lugwig Gross who in 1953 noted an external agent 
that caused multiple tumours to develop in neonate mice.[1] Polyomaviruses themselves 
were named after their ability to cause cell transformation. However, most efforts before 
2008 to find a causal role for polyomaviruses in cancer were contradictory or 
unsuccessful.[2], [3] In 2008 Merkel cell polyomavirus was discovered in merkel cell 
carcinoma.[4]  
 
The key to the oncogenic potential of polyomaviruses is their multifunctional viral T-antigens. 
These diverse non-structural proteins have many roles in the polyomavirus life cycle, but 
most importantly they provide the virus with a method of replicating, as the virus itself does 
not encode any of its own replication machinery. Both the small and large T-antigens (STAg 
and LTAg, respectively) impact upon numerous cell cycling and proliferation pathways. In 
fact, intensive study of these proteins has given us most of our knowledge of cell cycling 
pathways and human oncogenes. The LTAg has binding sites for the retinoblast suppressor 
family (Rb) and the p53 pathway and direct binding of the LTAg to these ligands can both 
stimulate the Rb proteins and suppress p53’s apoptotic signalling.[5], [6] The STAg impacts 
on cell proliferation, predominately through the PP2A proliferation signalling pathway; all 
 PyVs encode a conserved PP2A binding region.[7], [8] In both SV40 and MCPyV induced 
cell transformation, viral integration into the host genome is required. This facilitates the 
over-expression of PyV ocogenic proteins, LTAg and STAg,[9] in MCPyV, both an 
integration and viral mutation event is often detected. This is thought to render the virus 
incompetent of generating a productive infection that would cause cell lysis.[10] In contrast, 
recently a novel polyomavirus has been detected at high load in the brain tumours of 
raccoons (RacPyV). In this cancer RacPyV was required to maintain the transformed 
phenotype, but the virus is only detected in an episomal state.[11]  
 
Merkel cell polyomavirus currently is the only member of the human polyomavirus family 
that has strong evidence for a causal role in a human carcinoma. Almost all the other human 
polyomaviruses have been observed in various cancer tissues, but a causative role in 
human carcinomas remains unconfirmed.[2], [3], [12]–[25] In this respect, there are several 
factors that appear to have divided the literature and led many researchers to be sceptical 
of polyomavirus and human cancer associations;  
 
(1) The first confounder is that polyomaviruses are known to persist at very low levels 
in the respective tissues for which they have individual tropism [For example, BKPyV has a 
strong tropism for the urogenital tract tissues, JCPyV for neural cells, whereas the tropisms 
of the more recently discovered PyVs is still in question]; Polyomaviruses are also thought 
to persistently infect lymphocytes. When lymphocytes are recruited to tumour tissue sites 
the increased number of lymphocytes persistently infected with PyV in tissue samples may 
contribute to the detection of PyVs in tumour tissue. This is similar to EBV, which has been 
shown to harbour in lymphocytes and can be often detected at low viral load in various 
tumour tissues.[26] For these reasons, when screening using sensitive PCR methods 
 polyomavirus DNA can readily be found without necessarily any involvement in cell 
transformation; ie. false-positive results. 
(2) The second confounding factor is methodological issues which can lead to false-
negative results: Many studies use archival FFPE tissue specimens, and molecular methods 
used for the detection of polyomaviruses can have widely different sensitivities. The process 
of formalin fixation has cross-linking effects on DNA, and this cross-linked DNA can become 
damaged if the fixation process is prolonged. This leads to fragmentation of cellular and viral 
DNA, therefore making detection using PCR and sequencing difficult. Generally archival 
FFPE samples are collected over long time periods; therefore the fixation methodology has 
likely evolved over time. When using molecular methods the researcher is generally blinded 
to the processes of this fixation, and therefore, has limited control over the loss of viral or 
host cellular DNA integrity. This has led to conflicting study results, where for example 
JCPyV was not found in FFPE brain tissue by molecular assays, but was found in a different 
cohort of fresh frozen brain tissues.[27], [28] ie. false-negative results. For these reasons, 
where possible it is important to use fresh frozen tissue extracts in investigations of 
infectious agents in carcinoma tissues. 
(3) SV40 LTAg sequences are utilised in almost all commercially available plasmids 
and therefore laboratory contamination of tumour extracts with plasmid DNA is always a 
possibility. Removing plasmid DNA from laboratory workspaces and equipment is almost 
impossible and is a likely to be an ongoing source of SV40 PCR contamination. In addition 
SV40 antibodies have cross-reactivity with other closely related polyomaviruses; JCPyV and 
BKPyV which has led to an overestimation of immunoreactivity to SV40 in many studies.[3] 
ie. false-positive results.  
 
These experimental consideration make it difficult to definitively link any infectious agent to 
the development of human carcinogenesis. However, the transformation potential of 
 polyomaviruses in animal models is well established and has greatly assisted in the 
understanding of the molecular mechanisms that occur in human carcinogenesis. In 
addition, the causal role of papillomaviruses in cervical cancer has led to the development 
of successful papilloma vaccines that will prevent cervical cancers in millions of women. This 
success has evoked interest in determining if the closely related polyomaviruses could also 
be involved in the development of more than one human cancer.   
5.1.2 Micropapillary urothelial carcinoma  
 
The overall risk of cancer in transplant recipients is higher than in the general population; in 
renal transplant recipients the risk is 3-4 fold higher.[29] BKPyV has a tropism for the 
urogenital tract and can be commonly detected asymptomatically in healthy patients, 
however its reactivation in renal transplant recipients can lead to graft loss.[30] BKPyV 
involvement is suspected in MPUC and other rare urothelial carcinomas in transplant 
recipients due to long term BKPyV viruria and abundant staining of LTAg in neoplastic 
tumour cells, but not in normal tissue.[16], [31], [32] Further evidence is the ability of BKPyV 
to produce high-grade papillary urothelial bladder carcinoma in a transgenic mouse model, 
and BKPyV can also readily transform cells in vitro and animal models.[33], [34] MPUC is 
an aggressive urinary bladder urothelial carcinoma with a micropapillary differentiation; it 
represents <1% of all urothelial carcinomas. Most studies have shown that MPUC has a 
poor response to chemotherapy; beam radiotherapy and intravesical therapy with 
cystectomy is the recommended treatment strategy. Prognosis is generally poor with 54% 
survival rates at five years and 27% ten years post-diagnosis.[35]  
5.1.3 Study overview 
 
In this Chapter the potential involvement of BKPyV in two cases of MPUC was investigated. 
Both patients were renal transplant recipients for whom clinical staff approached the 
 laboratory after noting strong LTAg staining in their MPUC neoplastic cells. Both PCR and 
sequencing methods were used to characterise the presence of BKPyV and to determine if 
BKPyV integration into the host genome had occurred. 
 
5.2 Materials and Methods 
 
5.2.1 Micropapillary urothelial carcinoma. 
 
In collaboration with the Renal Transplant Unit at the Princess Alexander Hospital, Brisbane, 
tissues from micropapillary urothelial carcinomas, which developed in two kidney transplant 
recipients were investigated for the presence of BKPyV. The study was initiated after 
evidence of extensive immunohistochemical staining, using a monoclonal antibody to the 
LTAg of SV40, in the neoplastic cells, but not in surrounding normal tissue of these patients 
5.2.2 DNA and RNA extraction 
 
Formalin-fixed paraffin-embedded tumour tissue sections from both patients (patients 1 and 
2) were extracted using the QIAamp DNA FFPE kit and the RNeasy FFPE kit (both 
manufactured by Qiagen, Australia) as per the manufactures instructions.   
5.2.3 BKPyV Quantification using rtPCR 
 
Quantification of BKPyV was conducted using a previously published BKPyV primer and 
probe set called V3a (Chapter 4 section 4.2.5) [36]. This targeted the major capsid or VP1 
protein of BKPyV. Endogenous retrovirus 3 was used as a cellular marker; this rtPCR has 
also been previously published, and described in Chapter 3, section 3.2.6 [37]. Serial 
dilutions of BKPyV viral culture (ATCC 45024) and A549 tissue culture cell lines were used 
to generate a standard curve for quantification. Quantification was expressed as viral 
 genome to human genome equivalent ratios.  A common rtPCR master mix was used for 
each assay containing 12.5μl of QuantiTect Probe (Qiagen, Australia), 10pmol of each 
primer, 4pmol probe, and 2μl of extract in a final reaction volume of 25μl. Themocycling was 
performed on the RotorGene 6000 (Qiagen Australia) under the following conditions: 
incubation at 95°C for 15min, followed by 45 cycles of 95°C for 15s and 60°C for 60s.  
5.2.4 BKPyV RNA Quantitation 
 
Semi-quantitation of mRNA expression of BKPyV VP1 (V3a) and LTAg was achieved using 
the same oligonucleotides as above [36], [38] except here an RT-PCR protocol was used 
for RNA detection. A common master mix was used for both sets of oligonucleotides that 
included; 5μl of Qiagen One-Step RT-PCR 5x PCR mix, 10pmol of each primer, 4pmol 
probe, 1μl of enzyme, 1μl of 25mM dNTPs and 2μl of extract in a final reaction volume of 
25μl. Themocycling was performed on the RotorGene 6000 (Qiagen Australia) under the 
following conditions; incubation at 50°C for 20min; incubation at 95°C for 15min, followed by 
45 cycles of 95°C for 15s and 60°C for 60s.  To control for contaminating BKPyV DNA in the 
tissues a negative RT-step was performed in conjunction with all RT-PCR assays. This 
consisted of the addition of total nucleic acid extract to the DNA quantification master mix 
and cycling conditions defined in section 5.2.4, which allowed us to quantify the amount of 
residual DNA contributing to the quantitation of VP1 and LTAg mRNA. 
5.2.5 BKV Genotyping 
 
BKV genotyping was conducted using the sequence data from two concatenated short 
fragments of the VP1 and LTAg. These BKPyV targets were amplified using nested PCR 
primers with the oligonucleotide sequences found in Table 5.1 for both reactions.  BKPyV 
genotyping was performed using the methodology previously described for KIPyV which can 
be shown in Chapter 4 section 4.2.8. Phylogenetic relationships were assessed using MEGA 
 software (Neighbor-Joining analyses with 1000 bootstraps) and compared to representative 
strains of each BKPyV sub-type; Representative strains of each BKV sub-type are; UT-Ia 
(DQ305492), KOM-1-Ib1 (AB211373), LAB-22-Ib2 (AB301093) TW-7-Ic (AB211384), PHL-
8-IVa1 (AB269859), MMR-1-IVa2 (AB269841), TW-3-IVb1 (AB211391), KOM-7-IVb2 
(AB211388), MON-6-IVc1; (AB269850), GRC-5-IVc2; (AB269831), ETH-3-II (AB263916), 
KOM-3-III (AB211386). 
 
Table 5.1 Oligonucleotide sequences for BKPyV genotyping 
Oligo name Primer (5’ – 3’) 
BKV-LTAg-Seq-F1 ttattccatgtcctgaaggcaaat 
BKV-LTAg-Seq-R1 tggagctcatggaaatgctg 
BKV-LTAg-Seq-F2 tcttcaaaaacaaccatgtactgatc 
BKV-LTAg-Seq-R2 cactgtttgctacctaaaatggattc 
BKV-VP1-Seq-F1 gctcccaaaaagccaaagg 
BKV-VP1-Seq-R1 tgtgttggtcacatgaagtactgg 
BKV-VP1-Seq-F2 ccgtgcaagtgccaaaact 
BKV-VP1-Seq-R2 ctggataagcattgtttttgtcca 
 
5.2.6 Non-coding control region (NCCR) amplification 
 
Non-coding control region mutations are thought to be involved in altering PyV tropism for 
different tissue types. Therefore any sequence changes in the NCCR of patient 1 and 2 were 
also examined. A nested PCR approach was used and oligonucleotide primer sequences 
for assays to amplify the BKPyV NCCR can be found in Table 5.2. Outer primer sequences 
were desgined for this study, however inner primer sequences have been previously 
published.[39] A common amplification mix and cycling conditions were used and can be 
found in Chapter 4 section 4.2.8.  
  
Table 5.2 Oligonucleotide sequences for NCCR sequencing 
Oligo name Primer (5’ – 3’) 
BKV NCCR Outer F cctttgtcagggtgaaattcct 
BKTT5 F gagctccatggattcttc 
BKV NCCR Outer R aaattccagcaaaagctctaaaataaa 
BKTT6 R ccagtccaggttttacca 
 
 5.2.7 BKPyV integration 
 
To investigate the possible integration of BKPyV sequence into the hosts genome a 
methodology previously used for investigating Hepatitis B integration was modified [40][41].  
Eight primer pairs were designed to overlap and walk the BKPyV whole genome. In addition 
internal primers were designed so a second amplification could be performed for each PCR 
(oligonucleotide sequences are shown in Table 5.3). Initial PCR reactions were performed 
using a sense or anti-sense BKPyV specific primer and a degenerate primer was also 
added. This degenerate primer would theoretically bind approximately every 1000bp in the 
human genome. Therefore an amplification reaction was created which could amplify 
human/BKPyV junctions if there were present in the two bladder cancer cases. (Figure 5.1)  
First round amplification used HotStar Taq Master mix (Qiagen, Australia), 5 μl OF 10x PCR 
buffer, 1μl of 10mM dNTPs, 2μl of 25mM MgCl, 10pmol of each BKPyV specific primer, 
20pmol of the degenerate human primer, 0.25μl of HotStar Taq (5 units/μl) and 2μl of extract 
in a final reaction volume of 50μl. Themocycling was performed under the following 
conditions: incubation at 95°C for 15min, followed by 35 cycles of 94°C for 45s, 55°C for 60s 
and 72°C for 60s, and a final extension 7min at 72°C. To remove residual PCR reagents 
samples were cleaned up after first round amplification using the QIAQuick columns 
(Qiagen, Australia) and eluted into 30μl. Second round amplification used the above 
conditions with the exception of 10pmol of the degenerative primer and 1-pmol of the internal 
specific BKPyV primer amplification used the same conditions, however reduced the number 
of PCR cycles to 25. PCR products were visualised on a 1.5% agarose gel, with unique 
bands excised and purified using the QIAQuick gel purification kits (Qiagen, Australia). 
Purified products were cloned into pGEM-T Easy vectors (Promega, Australia) at the 
University of Queensland Protein Expression Facility, with five clones for each product being 
sequenced. Sequences were analysed using NCBI BLASTn to identify possible viral/human 
 sequences. Human sequence locations were determined using the UCSC Blat Genome 
Browser. 
 
 
 
Figure 5.1 Illustration of method used to detect BKPyV integration in bladder carcinomas.  
 
 
 
 
 
 
 Table 5.3 Oligonucleotide sequences used in BK integration PCRs  
Oligo name Primer (5’ – 3’) 
Primary generic human primer gcttgcgtgcatgtcgactgttcannnnnnncgcgt 
Secondary generic human Primer: gcttgcgtgcatgtcgactgttca 
BK-Int-F1-outer-391 gttctgcgccagctgtca 
BK-Int-F1-inner-417 ttcagtgaaagttggtaaaacctgg 
BK-Int-F2-outer-1064 caataccttgatcctaggcattgg 
BK-Int-F2-inner-1116 tcccaggctttgtggcat 
BK-Int-F3-outer-VP1 gctcccaaaaagccaaagg 
BK-Int-F3-inner-VP1 ccgtgcaagtgccaaaact 
BK-Int-F4-outer-2336 atagcctgtatgtttcagctgctgat 
BK-Int-F4-inner-2371 ctgtttactaacagctctggaacacaac 
BK-Int-F5-outer-2857 tgattgggattcagtgcttgatc 
BK-Int-F5-inner-2891 tcttcagtttctgaatcctcttctctt 
BK-Int-F6-outer-3330 ttattccatgtcctgaaggcaaat 
BK-Int-F6-inner-3383 tcttcaaaaacaaccatgtactgatc 
BK-Int-F7-outer-3795 aaatacttttttgatttttactttctgcaa 
BK-Int-F7-inner-3886 ctgacactttttacactcctctacattgta 
BK-Int-F8-outer-4316 gtatacacagcaaagcaggcaag 
BK-Int-F8-inner-4359 cttgactaagaaactggtgtagatcagag 
BK-Int-R1-outer-1117 aaagcctgggaaatagtagcaaac 
BK-Int-R1-inner-1092 aagaaggaccccaatgcctag 
BK-Int-R2-outer-1812 tctctctgggctatcactgctaaagt 
BK-Int-R2-inner-1766 agactaaagcccctaaggttttcatc 
BK-Int-R3-outer-2480 agcaaaaaggaaattgggtaagg 
BK-Int-R3-inner-2376 aaacaggccacaaatatcagcag 
BK-Int-R4-outer-3065 tttggtttaggcctgtagctgatt 
BK-Int-R4-inner-3022 caatctagaattgttgaatggaaggaa 
BK-int-R5-outer-LTAg cagcatttccatgagctcca 
BK-int-R5-outer-LTAg gaatccattttaggtagcaaacagtg 
BK-Int-R6-outer-4186 tgcaattaataatttctgtcaaaagctg 
BK-Int-R6-inner-4144 tttaatttgtaagggtgttaataaggaatacttactata 
BK-Int-R7-outer-4945 atcagcctgattttggaacctg 
BK-Int-R7-inner-4909 tttgtgctgattttcctctttgc 
N = generic nucleotide base that will bind all bases with equal affinity 
 
5.2.8 Verification of human/BKPyV integration sites.  
 
Primers were designed external to the human/BKPyV sequences generated by the 
integration PCR. These primers were used to amplify and sequence verify the presence of 
the BKPyV/human integration site from the original FFPE extracts (see appendix 1 for 
oligonucleotides). 
 
 
 
 Table 5.4 Oligonucleotide sequences used for PCR verification of potential BKPyV integration sites. 
Oligo name Primer (5’ – 3’) 
First candidate site BKPyV VP1 
HGD1-Integ-F1 ccaacatggtgaaaccctatctcta 
HGD1-Integ-F2 aaaaattagccgggcatggt 
BK-Int-R3-inner-2376 aaacaggccacaaatatcagcag 
BKV-VP1-Integ-R ttacagatctttttctcaggcgaat 
BKV-V3aR atacataggctgcccatccac 
Second candidate site BKPyV LTAg/NCCR  
BKV-LT-Integ-F1 tcgccccctttgtcagg 
HGD2-Integ-R1 ccaaaataaaaaaaacaatgactttcaa 
HGD2-Integ-R2 caatgtccaacattttaccacttaataatt 
 
5.2.9 Ethics 
 
Written informed consent was collected for both patients and the collection of these cancer 
tissues was approved by the Princess Alexander Hospital Human Research Ethics 
Committee (PAH 2007/057). 
 
5.3 Results 
  
5.3.1 Micropapillary urothelial carcinoma case studies  
 
5.3.1.1. Clinical information - Patient 1 
 
Patient 1 was a 55 year-old Caucasian male with a history of end stage renal failure due to 
diabetic nephropathy. He received a kidney-pancreas transplant in 2001 with standard 
maintenance immunsupression of tacrolimus, mycophenolate mofetil (MMF) and 
prednisolone, but he did not require T-lymphocyte-depleting therapy. He continued with an 
uncomplicated post-transplant course until 2005 when his creatinine levels reached 
130μmol/L (he had stabilised post-transplant creatinine levels 80-100μmol/L). Renal biopsy 
confirmed interstitial nephritis with evidence of viral cytopathic effect.  BKPyV rtPCR 
 confirmed he had viremia and virurea and positive immunohistochemical biopsy staining for 
cross-reactive SV40 LTAg (this monoclonal antibody is routinely used to detect BKPyV 
LTAg). Immunosupressive treatment was reduced and the patient’s renal function stabilised, 
however BKPyV viremia and viruria persisted (ranged between 1100 to 44000 copies/ml).  
Due to the persistent BKPyV levels in the urine and blood his immunosuppressive treatment 
was again reduced in 2007 with only a minimal effect on BKPyV viral load (540 to 3600 
copies/ml), however it was decided based on his stable graft function and concern over graft 
rejection to not attempt further reduction in his immunosuppression.  
 
In 2010, despite being clinically well, urine cytology showed cells suspicious for urothelial 
malignancy. Further cystoscopy and biopsy results were consistent with an urothelial 
carcinoma involving the bladder.   Histopathologyed showed the carcinoma to be an in situ 
high-grade invasive urothelial carcinoma, micropapillary variant, with extra-vesical spread. 
At the time of tumour diagnosis the patient had a persisting BKPyV viral load in both his 
serum and urine of 2100 copies/ml. Immunohistochemical staining for BKPyV LTAg in the 
bladder carcinoma showed nuclei were strongly positive in the carcinoma cell, but negative 
in the surrounding tissue (Calbiochem, catalog no. DP02, 1:200 dilution, cross-reactive with 
the BKPyV LTAg). (Fig 5.1) Electron microscopy showed no evidence of viral particles in the 
carcinoma. (Fig 5.2) Despite a further reduction in immunosuppression and treatment with 
cidofovir (0.3mg/kg) the patient’s disease progressed rapidly and he died 6 months after 
bladder cancer diagnosis. Patient 1 had a number of risk factors for urothelial cancer 
including being a heavy smoker for 20 years, male gender and occupational exposure to 
aromatic amines without respiratory protection.  
  
 
Figure 5.2 Patient 1 - SV40 LTAg immunoperoxidase staining of bladder cancer. Polyoma positive 
staining extensive in nuclei of neoplastic cells but not surrounding normal tissue (100x 
magnificantion) 
 
 
 
 
Figure 5.3 Patient 1 – Negative stained electron microscopy of tumour biopsy showing no noticeable 
polyoma virus particles.  
 
 
 5.3.1.2 Clinical information - Patient 2 
 
Patient 2 was a 75 year-old male who received a deceased donor kidney transplant in 2003 
due to hypertensive nephrosclerosis. He received standard immunosuppressive therapy of 
tacrolimus, MMF and prednisolone) and reached a stable post-transplant serum creatinine 
of 120μmol/L. Less than 2 years after his transplant his serum creatinine levels reached 
160μmol/L and tissue biopsy showed immunoreactivity to polyomavirus LTAg antibodies. 
He had BKPyV detectable in both urine and serum (sera BKPyV load 1.7x106 copies/ml). 
His immunosuppression was reduced however his BKPyV viremia and viruria remained and 
further reduction of his immunosuppression was required, before his BKPyV viral load 
became undetectable in 2007 and his serum creatintine stabilised to 190μmol/L. In 2010, 
urine cytology noted malignant cells and his BKPyV viral load was detectable in urine but 
not serum. Histological staining showed urothelial carcinoma in situ with diffuse 
polyomavirus immunohistochemical staining (Fig 5.3) and MPUC involving the lamina 
propria without muscularis invasion. Electron Microscopy of this patient’s urothelial 
carcinoma was not performed. His prostate was also abnormal and a biopsy confirmed an 
adenocarcinoma, however cells in this tumour were not reactive to polyomavirus antibodies. 
A cystoprostatectomy was performed and the patient remained well at a 20-month follow up.  
Patient 2 had a past history of smoking, but apart from his male gender had no other risk 
factors for urothelial cancer.  
 
  
Figure 5.4 Patient 2 - SV40 LTAg immunoperoxidase staining of bladder cancer. Polyoma positive 
staining in nuclei of neoplastic cells but not surrounding normal tissue, however staining is not as 
intensive compared to Patient 1 (100x magnificantion) 
 
5.3.1.3 BKPyV quantification using rtPCR and RTPCR 
 
A summary of results of rtPCR and RTPCR assays for BKPyV viral load are provided in 
Table 5.6 and expression levels of the BKPyV viral proteins LTAg and VP1 in Table 5.7. 
Both BKPyV viral markers were readily detectable by rtPCR and both gene targets were 
detected at simular cycle threshold values. However expression of the two different viral 
proteins was relatively consistent for patient 1 but a three-fold increase in expression of 
LTAg was seen when compared to VP1 in patient 2.  Low level contaminating BKPyV DNA 
was detected by ‘negative RT’ assays, however detection of BKPyV RNA was 2 to 3 logs 
higher than levels of contaminating DNA.  
 
 
 
 Table 5.5 Quantitation of BKPyV viral load using rtPCR assays targeting the LTAg and VP1 region of 
the genome. BKPyV copy numbers per diploid cell were much higher in Patient 1 than Patient 2. 
Patient number 
BKPyV LTAg  
Cycle threshold (Ct) 
BKPyV VP1  
Cycle threshold (Ct) 
BKPyV copies /Diploid cell 
Patient 1. 33.01 31.28 14.8 
Patient 2. 32.56 33.3 1.4 
 
 
Table 5.6 Expression levels of BKPyV LTAg and VP1 using RTPCR assays targeting LTAg and VP1 
mRNA. Patient 1 have demonstrates only a slight increase in expression of LTAg compared to VP1 
whereas Patient 2. Has a threefold increase in expression of LTAg compared to VP1.  
Patient number 
BKPyV mRNA LTAg     
Cycle threshold (Ct) 
BKPyV mRNA VP1            
Cycle threshold (Ct) 
Ct shift in expression of 
LTAg v VP1 
Patient 1. 24.92 24.3 0.62 
Patient 2. 24.23 27.51 3.28 
 
5.3.1.4 BKPyV Genotyping 
 
Small concatenated sequence fragments from VP1 and LTAg were used to analyse the 
phylogenetic relationships between the BKPyV isolated from Patient 1 (Genebank 
accession; JN157645) and patient 2 (JN157644) (Figure 5.4).  Patient 1 had BKPyV subtype 
Ib1, while Patient 2 had BKPyV subtype Ib2. 
 
  
Figure 5.5 Phylogenetic relationship of BKPyV isolated from Patient 1 and 2 compared to 
representative strains of each BKPyV subtype. BKPyV isolated from Patient 1 was subtype Ib1, while 
Patient 2 had BKPyV subtype Ib2. Representative strains of each BKV sub-type are; UT-Ia (DQ305492), 
KOM-1-Ib1 (AB211373), LAB-22-Ib2 (AB301093) TW-7-Ic (AB211384), PHL-8-IVa1 (AB269859), MMR-1-
IVa2 (AB269841), TW-3-IVb1 (AB211391), KOM-7-IVb2 (AB211388), MON-6-IVc1; (AB269850), GRC-5-
IVc2; (AB269831), ETH-3-II (AB263916), KOM-3-III (AB211386). 
 
5.3.1.5 BKPyV Non-coding control region sequencing 
 
Specific BKPyV primers were used to amplify the NCCR region from virus in both Patient 1 
and 2. Both patients had BKPyV that showed several polymorphisms, including single base 
pair changes, point insertions and deletions. The Patient 1 NCCR sequence showed a 49bp 
deletion in part of the Q and R block. However no polymorphisms in either patient were 
predicted to affect the BKPyV LTAg binding sites. (Figure 5.5) 
 
 
 
  
 
 
 
Figure 5.6 Schematic of BKV non-coding control regions (NCCR) sequenced from tumour biopsies of 
Patient 1 (JN157645) & 2 (JN157644). Sequence changes, such as point insertions (triangle), single 
nucleotide polymorphisms (bars), and deletions (dashes) are referenced against the wild-type WW 
NCCR (AB211371.1), and its sequence block configuration. Canonical pentanucleotide LTAg binding 
sites are represented as black arrows.  
 
5.3.1.6 BKPyV integration in micropapillary urothelial carcinoma tissues 
 
Potential BKPyV integration sites were examined using a random human primer and 8 sets 
of nested specific primers in both forward and reverse orientation that would allow walking 
amplification of the whole BKPyV genome at approximately every 800bp of sequence. This 
technique was a modification of a published protocol investigating Hepatises B integration. 
[40] No potential integration sites were detected for patient two. However two potential sites 
were found for Patient 1. Bands of interest (the selection of which is described in figure 5.6) 
were selected and removed from an electrophoresis agarose gel before purification, cloning 
and sequencing. 
 
Based on the above cloning and sequencing, the first candidate integration site for patient 
1 was located between the C-terminal end of the BKV VP1 gene (position 2161). It followed 
a human sequence from the human DPY19L2 gene (chromosome 12 q14.2, position 
63,975,410). The second candidate integration site was located at the LTAg side of the 
 origin of replication in the NCCR (position 5116), and with the human RAB8B gene 
(chromosome 15 q22.2, position 63,533,395). (Figure 5.7) 
 
 
Figure 5.6 Gel image of bands removed for BKPyV/human cloning and sequencing. Second round 
products were run on a 2% agarose gel and bands of interest were cut out for cloning and sequencing. 
Band were removed based on the fact they were stronger and of a different size than common 
background amplification products. Bands encircled with red boxes were removed and sequence in 
lanes 3 and 13. 100 base pair ladders were used to determine product size (Genworks, Australia) 
 
5.3.1.7 Verification of human/BKPyV integration sites.  
 
External primers to the putative BKPyV and human sequences for both potential integration 
sites were designed. Only the VP1/DPY19L2 confirmatory assay produced the expected 
product size on an electrophoresis gel. This gel band was purified and sequenced and 
returned a homologous sequence to the original cloned hybrid sequence. However the 
NCCR/RAB8B specific PCR did not amplify, therefore we cannot confirm the hybrid 
sequence in the original sample.  
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Figure 5.7 Potential BKV integration sites in Patient 1 tumour tissue as determined by PCR, cloning 
and sequencing. Bold & underlined nucleotides in A) are shared between human and viral sequence. 
Non-bold or underlined nucleotides in B) are unidentified sequence.  
 
5.4 Discussion  
 
This study investigated the presence of BKPyV in two case studies of the aggressive form 
of bladder cancer called micropapillary urothelial carcinoma (MPUC) found in renal 
transplant recipients. MPUC is a rare form of cancer found with an incidence rate of >1% in 
the general population. Numerous studies have suggested that long-term low levels of 
BKPyV viremia and viruria may contribute to cell transformation in rare forms of bladder 
cancer in renal and pancreatic transplant recipients.[16], [17], [24], [32], [42], [43] However 
the possible molecular mechanisms of BKPyV involvement had not been thoroughly 
examined.  
 
 5.4.1 Integration of BKPyV confirmed in one case of Micropapillary urothelial bladder 
carcinoma 
 
In this chapter it was shown that BKPyV was integrated into the host genome in one case, 
with the host junction located in the VP1 coding sequence. In this patient expression of both 
LTAg and VP1 viral proteins could be detected by RTPCR but virions could not be visualised 
by electron microscopy (Fig 5.2). This strongly suggested active expression of BKPyV viral 
proteins, including both the LTAg and STAg, which have several mechanisms to promote 
cell cycling. However, whole virus particles that would cause host cell lysis were not being 
produced. This scenario is similar to that thought to occur in MCPyV-associated Merkel cell 
carcinoma. In MCC cases, MCPyV is almost always found to be integrated into the host 
genome, and a second mutation is usually found in the MCPyV genome rendering it 
replication incompetent.[10] Generally the mutations found in the viral genome occur in the 
carboxy-terminus of the LTAg coding sequence and produce premature stop codons before 
the origin binding and helicase domain. This allows production of an LTAg protein that 
contains PP2A, pRb and p53 binding domains and therefore can still stimulate cell cycling. 
However the LTAg also promotes viral replication, containing binding sites around the origin 
binding domain. LTAg binding to these sites recruits host cell replication machinery and the 
helicase domain is thought to start unwinding viral DNA to assist in viral DNA replication. In 
MCC it is speculated that truncation of the viral LTAg protein before the origin binding and 
helicase domain prevents development of DNA replication forks in the integrated viral/host 
sequence.[10] Replication forks cause extensive DNA damage and rapid cell lysis, therefore 
it is suggested that selective pressure eliminates replication of full length MCPyV LTAg. In 
case 1 of our MPUC investigation we found a confirmed integration site in the VP1 protein, 
although we did not sequence the full length BKPyV LTAg, therefore we do not know if a 
second mutation prematurely truncating the LTAg was present. MCPyV has also been 
detected in MCC tumours with an integration site within the VP1 protein, with MCPyV 
 sequences retaining a full-length LTAg. [10], [44] Truncations in the VP1 region can inhibit 
the formation of polyomavirus virion or reduce viral infectivity, however it is unknown how 
the integration of the intact LTAg escapes replication fork errors from developing.  
 
To our knowledge this is the first confirmation of BKPyV integration into a bladder carcinoma. 
However Monini et al [43] had previously shown Southern blotting with evidence for clonal 
integrated forms of BKPyV associated with urogenital carcinomas from immunocompetent 
patients. Clonal integration is an important factor in determining if BKPyV had an active role 
in the initial transformation event, or if viral integration occurred after uncontrolled cell 
replication commenced. Due to insufficient specimen we were unable to determine if the 
BKPyV integration in patient 1 was a clonal event. Given the multiple risk factors that both 
patients in these case studies presented, and the fact that another unconfirmed integration 
site was found in case study 1, we cannot rule out the possibility that polyclonal integration 
had occurred.   
 
Several mutations and deletions were also noted in the BKPyV NCCR of both cases, 
although these changes did not affect LTAg binding sites. Polymorphism in the NCCR have 
been noted by other researchers in both cancer and healthy tissues, and it has been 
suggested that these mutations may be geographically distributed in nature, with different 
genotypes circulating in different geographical locations and not affect BKPyV virulence or 
potential oncogenesis.[43], [45] Conducting investigations of PyV involvement in human 
cancers is difficult in retrospective studies where samples have not been appropriately 
stored. It also demonstrates the difficulty of teasing out the underlying viral mechanisms 
involved in cell transformation within a potentially complex multifactorial biological process. 
However, if PyVs are ultimately shown to have a role in human cancer, particularly in 
specialised immunocompromised and high-risk populations such as those investigated 
 here, then pre-transplant vaccination against particular PyV could be effective in preventing 
cancer development in solid organ transplant recipients.  
5.4.2 Limitations to MPUC case studies 
 
Further investigation of the BKPyV LTAg coding sequence in the two MPUC bladder cancer 
cases was not possible due to the small sample received. Also the virus host junction could 
not be further characterised by Southern blotting to determine if the integration event was 
clonal and if this occurred before cell transformation. Only FFPE tissue was available to 
conduct BKPyV characterisation experiments, and the DNA quality was compromised 
through fragmentation or cross-linking. The limitation in using FFPE tissues have also been 
noted in studies conducting characterisation of MCPyV integration in MCC tissues, which 
are often unsuccessful compared to investigations using fresh frozen tissues.[10], [46] The 
use of FFPE tissues in this study, may have affected the sensitivity of the PCR methods 
used to determine a host/virus junction in case study 2.  
 
Overall the case studies presented in this Chapter highlight that BKPyV can become 
integrated into the host genome in renal transplant recipients suggesting It can have a role 
in cell transformation, Further investigations into the development of bladder cancer in renal 
transplant recipients is warranted. However the analysis of fresh tissue is important if further 
molecular characterisation of possible BKPyV integration events is to yield meaningful 
results. 
5.4.3 Conclusion and further experiments  
 
In this Chapter, methods were developed that provide evidence of BKPyV integration into 
one case of of MPUC after renal transplantation was shown in this study, although 
demonstrating the role of polyomaviruses, if any, in cell transformation is experimentally 
 difficult. Successful viral characterisation requires adequately stored fresh frozen cancer 
tissue, with a well-matched control group. Also, within tissue cohorts it is imperative that 
accurate virus detection, molecular characterisation and expression of viral proteins is 
performed. In parallel to molecular methods, histological studies confirming viral presence 
in tumour cells are also critical. The results presented in this Chapter highlight evidence that 
supports a possible role for polyomaviruses carcinogenesis, which warrants further 
investigation. 
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CHAPTER SIX 
Presence of Polyomaviruses in Lung Carcinoma 
 
  
 6.1 Introduction 
 
6.1.1 Infectious agents and cancer  
 
It is estimated that infectious agents may have a role in up to 20% of all human carcinomas. 
These agents include bacteria and parasitic worms, but the most common oncogenic 
infectious agents are viruses.[1] Currently there are seven viruses recognized as causing 
human cancer; Epstein- Barr virus (EBV), Hepatitis B (HBV), Human lymphotrophic virus-1 
(HTLV-1), human papillomaviruses (particularly high risk HPV 16 and  18), Hepatitis C 
(HCV) and Merkel cell polyomavirus (MCPyV).[2] Vaccine strategies have been highly 
successful at reducing cancer incidence, particularly for HBV and HPV.[3], [4] Infectious 
agents that cause cancer can be divided into two categories; direct agents which express 
oncogenes that directly contribute to cell transformation and indirect carcinogens that cause 
cell transformation presumably through chronic infection and inflammation which leads to 
the gradual acquisition of mutations that lead to oncogenesis in the host cell.  Currently the 
majority of the viral agents (HPV, MCPyV, and EBV) known to transform cells use a direct 
carcinogenic pathway, but in most cases elements of direct and indirect mechanisms 
apply.[1] 
6.1.2 Animal polyomaviruses and cell transformation 
 
Polyomaviruses have the ability to cause cell transformation in both animal models and in 
humans, but generally in rare forms of cancer only. The mechanisms involved in 
polyomavirus induced cell transformation have been intensively studied in SV40 and murine 
polyomavirus (MPyV).[5] Unlike the human polyomaviruses, the animal SV40 and MPyV 
can be grown in cell culture systems, which has greatly enhanced our understanding of the 
role of the LTAg and STAg on cell cycling and proliferation. Both SV40 and MPyV can readily 
 produce tumours in animals, such as newborn hamsters, but can also transforms human 
cell lines. [6]–[10]  In SV40 models, the early coding region produces three non-structural 
proteins from a single transcript; LTAg, STAg and 17KT.[11] Mutagenesis studies show that 
the transforming ability of SV40 is largely dependent on the LTAg and transformation can 
occur when only the LTAg is present. [12] SV40 and all human polyomaviruses have 
conserved binding regions for two essential tumour suppressors, the rRb and p53; much of 
our current understanding of these important pathways has been discovered from studying 
SV40.[13]–[18] In addition to the cell cycling and proliferation effects of SV40 LTAg, viral 
genome integration into the host cells is almost always required for cellular 
transformation.[19]  This integration allows high level constitutive expression of the early 
coding region. Again, this integration event is also essential for the cellular transformation 
of other oncogenic viruses, such as human papillomaviruses. The ability of SV40 to 
transform cells also seems to be enhanced by mutations in the NCCR that reduce the ability 
to replicate viral DNA. [20] 
6.1.3 Human polyomaviruses as a cause of cell transformation 
 
The role of human polyomaviruses in cell transformation has been controversial for many 
years. However the discovery of MCPyV involvement in transformation of MCC and 
numerous publications by leading researchers (eg. Zur Hausen, 2009 [21]) postulating a 
role of other PyVs in oncogeneis, fuels continual interest in this field. The current evidence 
to suggest MCPyV is the causal agent in MCC is high, the detection of MCPyV proteins and 
DNA can be found in the majority of tumour tissues. In addition MCC patients demonstrate 
significant increased sero-reactivity to MCPyV T-antigens than non-MCC control 
populations.[22] MCPyV antibody reactivity to a common region in the STAg/LTAg protein 
is almost exclusively seen in MCC patients, and these decrease rapidly after excision of the 
MCC tumour. Such antibody response also correlates with MCPyV DNA load detected in 
 MCC tissues. [23] The re-emergence of the seroresponse to STAg/LTAg antigens in MCC 
patients has also been successfully used as a diagnostic pre-curser to the development of 
metastatic disease.[23], [24]  
 
In the previous Chapter integration of BKPyV in one patient with an aggressive type of 
bladder cancer was observed. However an integration event could not be found for the 
second case study. Immunohistochemistry also revealed strong staining to LTAg antibodies 
in neoplastic cells in both cases.  Unfortunately, the limited availability of specimens for each 
patient and the fact that no fresh frozen tissue from the bladder was stored, also made it 
impossible to further characterize the BKPyV detected in either of the carcinoma tissues. 
Therefore, we could not fully explore the possibility of viral integration in the second case, 
and were also prevented from conducting Southern blotting experiments to determine if the 
integration event in the first case was clonal and occurred before cell expansions.   
6.1.4 Human polyomaviruses – a potential cause of lung cancer 
 
Given the identification of integrated BKPyV in rare forms of bladder cancer in the previous 
Chapter, a more comprehensive study was designed to determine if PyVs may have a role 
in lung carcinoma. Earlier studies have shown that most of the novel PyVs can be detected 
in respiratory swabs.[25]–[30] Certainly, it was shown in Chapter 3 of this thesis that WUPyV, 
KIPyV, MCPyV and MWPyV can be readily detected in nasal swabs from children younger 
than 2 years of age and therefore are resident in the lung. Several studies have also 
successfully propagated MCPyV synthetic clones, which are generally fastidious in lung cell 
lines.[31], [32] There is also increasing speculation in the literature about the potential role 
of infectious agents in lung cancer, particularly given 20% of sufferers have never smoked. 
Environmental pollutants are the major causal agents in lung carcinoma; the most prevalent 
risk factor is tobacco smoke. Public health efforts across the world have helped to drop rates 
 of smoking and have also removed tobacco smoke from work places. Despite these 
campaigns and subsequent decreased rates of smoking and exposure to smoking, there 
has not been an equivalent decrease in lung carcinoma. This suggests there are other 
factors involved in the development of lung carcinoma.  
 
Only a handful of publications have investigated human PyVs in lung carcinoma tissue. Initial 
research focused on the presence of MCPyV in small cell lung carcinoma (SCLC), as this 
cancer type is both histologically indistinguishable from, and shares a neuroendocrine origin 
with MCC. Three studies showed contradictory results when investigating MCPyV in SCLC 
with Helmbold et al.[33] finding 39% and Wetzel et al.[34] finding 6.5% of SCLC cases 
positive for MCPyV, whereas Karimi et al.[35] found no MCPyV in SCLC. Low sample 
numbers could potentially explain the discrepant results of these studies given less than 50 
tumour specimens were investigated in each study. In addition, all three studies used 
formalin fixed paraffin embedded archival lung tissue. Formalin fixation can cause 
fragmentation and cross-linking of DNA and therefore can lead to false negative PCR 
results.[36] Others studies have investigated the role of PyVs in other forms of lung 
carcinoma and found between 4.7% and 16.9% of samples were MCPyV positive, all of 
which were non-small cell lung carcinoma (NSCLC).[37]–[40] In one of these studies, an 
integration site for MCPyV was detected in two cases of adenocarcinoma.[38] To date, only 
one small study examining 30 lung neoplasia has investigated the newly described 
polyomaviruses, and only involved WUPyV and KIPyV. The authors reported a singular, 
KIPyV detection in an adenocarcinoma. [41]  
In this study, a well-characterized bank of lung carcinoma tissues uncompromised by fixation 
was comprehensively investigated for the presence of all human polyomaviruses.  
 
 6.2 Methods 
 
6.2.1 Lung cancer cohort  
 
Lung tissue was obtained from one hundred lung cancer patients through an application to 
the Australasian Biospecimens Network (ABN) biobank. All tumour specimens were 
confirmed to be primary lung cancers by histology, and comprised tumours of varying 
histological type and grade. Clinical pathological parameters were collected including sex, 
age at diagnosis, histological classification, grade, smoking status (defined as a current, 
previous or never smoker at diagnosis), date of death, and cause of death, metastasis at 
diagnosis, family and personal history of cancer, immune status, and co-morbidities. 
Immune status was defined as immunocompetent or immunocompromised based on 
treatment with immunosuppressive agents or history of immunosuppression through the use 
of the following medications; Ciclosporin, Tacrolimus, Sirolimus, Mycophenolate, 
Methotrexate, Azathioprine, Mercaptopurine. Participants were also considered 
immunocompromised if they suffered from the following co-morbidities that require 
immunosuppressant use; Solid organ transplant recipient (bone marrow, heart, liver, kidney 
or lung), Rheumatoid arthritis, Multiple sclerosis, Myasthenia gravis, Systematic lupus 
erythematosis, Focal segmental glomerulosclerosis, Crohn’s disease, Behcet’s disease, 
Pemphigus, and Ulcerative colitis.  
 
Clinical details are summarized in Table 6.1. Information on date of death and cause of 
death was only available for 34 patients therefore these parameters were not analysed. One 
patient only had basic demographic information available (age at diagnosis, date of 
diagnosis and sex)  
 
 Table 6.1 Summary of clinical information for the lung cancer cohort 
Parameter  Number 
Total  N=100 
Age at Diagnosis (Mean and range) 63.5 (29-93) 
Sex   
 Female 55 
 Male 45 
Smoking status Smoker at Dx 35 
 Previous smoker 38 
 Never smoker 19 
 Unknown 8 
Cancer type Adenocarcinoma 43 
 Squamous cell carcinoma 20 
 Large cell carcinoma 19 
 Carcinoid (typical or atypical) 9 
 Small cell carcinoma 1 
 Mixed 5 
 Other 3 
Grade 1 5 
 2 24 
 3 37 
 4 13 
 Variable 2 
 Not described 19 
Immune status Immunocompetent 90 
 Immunocompromised 5 
 Unknown 5 
Previous history of cancer Yes 33 
 No 61 
 Unknown 6 
Metastatic disease at diagnosis Yes 31 
 No 68 
 Unknown 1 
 
6.2.2 Specimens used in this study  
 
6.2.2.1 Fresh frozen lung tissue  
 
One hundred freshly frozen lung cancer tissues were obtained from the Australasian 
Biospecimens Network (ABN). For each tumour tissue, a corresponding normal tissue 
specimen from outside the tumour margins was also obtained. Therefore, two tissue 
samples were received for each patient with a minimum of 25mg of tissue for each 
specimen.  
 6.2.2.2 Formalin-fixed paraffin embedded tissue 
 
Five sections of FFPE tissue was obtained from both normal and tumour tissue blocks for 
each MCPyV, HPyV 6 and 7 PCR positive lung tissue (4µM in thickness). A section stained 
for Hematoxylin and eosin (H&E) stain was also obtained from the biospecimen bank to 
demonstrate tissue morphology. 
6.2.2.3 Serum from lung cancer patients 
 
Sera was also obtained from 19 patients within the cohort, including 10 of the MCPyV PCR 
positive patients. No sera was available for MCPyV PCR positive patient, LC1. Serum 
samples were collected at the time of each patient’s lobectomy. 
6.2.3 Ethics 
 
The project was approved by the Human Research Ethics Committee of the Children’s 
Health Queensland Hospital and Health Service.  
6.2.4 Fresh frozen tissue DNA extraction 
 
Each 25mg section of tissue was defrosted on ice and diced on a slide glass slide with a 
disposable razor blade. The diced tissue sample was split into to two tubes; approximately 
20mg of tissue was stored for DNA extraction and 5mg of tissue was frozen at -80°C for 
RNA extraction. DNA samples were spiked with 5μl of a known concentration of equine 
herpes virus (EHV), and then digested in 200μl of ALT buffer and 20μl of proteinase K 
(Qiagen, Australia) at 56°C overnight. Additional (20 - 40 μl) proteinase K was added if 
tissues didn’t digest after 12hours. After digestion samples were extracted using the DNeasy 
Blood and Tissue Kit (Qiagen, Australia) according to the manufactures instructions. Nucleic 
acid was eluted off the purification column by two consecutive volumes of elution buffer, to 
 produce two nucleic extracts with a final volume of 100 μl for each sample. The primary 
extract was used for virus screening, whereas the second elution was stored for sequencing 
and virus characterisation if required. Extracts were stored at -20°C.  
6.2.5 Extraction quality control 
 
Extraction quality and presence of PCR inhibitors were monitored through EHV spiking and 
EHV/ERV3 duplex testing, as previously described in Chapter 3 section 3.2.6. 
6.2.6 Screening using rtPCR for infectious agents 
 
Duplex rtPCR methods were used to screen lung tissue extracts for BKPyV(Va3) / JCPyV 
(JL1), WUPyV (WU-REG)/KIPyV (KI-D and KI-E), MCPyV(MCV1.1) / MWPyV(ES107), 
TSPyV(VP1)/HPyV7(7e), HPyV6 (HPyV6A)/ HPyV9(HPyV9LT) and STLPyV (VP1)/ 
HPyV12 (VP1). [30], [42]–[48] Previously published singleplex assays were used to detect 
adenovirus, bocavirus, CMV, EBV and HHV6 (primers modified for TaqMan chemistry) 
.[49]–[52] A conventional degenerate-HPV PCR (FAP) assay were used to screen for human 
papillomaviruses .[53] Oligonucleotide sequences for all primers and probes used to screen 
for infectious agents in lung tissue can be found in Table 6.2. 
 
A generic master mix was used for all screening and confirmatory rtPCRs. It consisted of 
10pmoles of each primer, 4pmoles of each probe (Table 6.1), 10 μl of QuantiTect Probe Mix 
(Qiagen, Australia) and 2 μl of extract in a 20 μl final reaction. Cycling conditions used for 
amplification were: initial hold at 15 min at 95°C; followed by 45 cycles of 30 sec at 95°C 
and 60 sec at 60°C. The conventional PCR used to screen for human papillomaviruses used 
the following master mix; 2 μl of lung tissue extract, 0.75μM of each primer, 200μM of each 
dNTP, 3.5mM of MgCl2 , 3.75 units of HotStarTaq DNA polymerase, 5μl 10x PCR buffer and 
10μl of Q-solution (Qiagen, Australia) made up to a final 50μl reaction mix. Thermocycling 
 was conducted on the BioRad DNA Engine Peltier Thermal Cycler ( BioRad, Australia) and 
consisted of an initial hold at 15 min at 95°C; followed by 45 cycles of 90 sec at 94°C, 90 sec 
at 50°C and 90 sec at 72°C, followed by a final extension of 10min at 72°C. Visualization of 
PCR product was conducted using 10ul of reaction mix on a 1.5% agarose gel run at 90 
volts for 1 hour. 
 Table 6.2 Primer and probe sequences, in 5’ to 3’ orientation, used for rtPCR screening. 
Assay Oligo name Primer (5’ – 3’) Target Reference 
BK/JC DUPLEX 
BK - V3a- F agcaggcaagggttctattactaaat 
VP3 [42] BK - V3a- R gaagcaacagcagattctcaaca 
BK - V3a- Probe aagaccctaaagactttccctctgatctacaccagttt 
JC - JL1 - F aagggagggaacctatatttcttttg 
LTAg [43] JC - JL1 - R tctagcctttgggtaacttcttgaa 
JC - JL1 - Probe ctcatacacccaaagtatagatgatgcagacagca 
WU/KI DUPLEX 
WU-F-REG for gccgacagccgttggatata 
NCCR [44] WU-F-REG rev tttcaggcacagcaagcaat 
WU-F-REG Probe agggtcaccatttttatttcagatgggca 
KI-D StAg F cacaggtggttttctataaattttgtactt 
STAg [44] KI-D StAg R gaagcagtgggatgtatgcattc 
KI-D StAg probe tgcattggcattcgtgattgtagcca 
KI-E-REG-F gaacttctactgtccttgacacaggta 
NCCR [44] KI-E-REG-R ggattagaacttacagtcttagcatttcag 
KI-E-REG probe accctttgtaggccaaaggagagtgaagg 
MCV/MW Duplex 
MCV-LT1.1-F agctcagaagtgacttctctatgtttga   
LTAg [44] MCV-LT1.1-R acaatgctggcgagacaact  
MCV-LT1.1-Prb tttgcagaggtcctgggtgcatg 
ES105-F tgagaaggccccggttct 
LTag [45] ES106-R gaggatgggatgaagatttaagttg 
ES107-probe cctcatcactgggagc 
TSV/HPyV7 Duplex 
TSPyV B forward agtctaaggacaactatggttacag 
VP1 [46] TSPyV B reverse attacaggttaggtcctcattcaac 
TSPyV B probe acagcagtgaccaggacaagcctacttctg 
HPyV 7E forward aagacattcagtctttgcattttctg 
LTAg [44] HPyV 7E reverse cccctcatacagcataaggttagatt 
HPyV 7E probe ccacctttatctggatgatactttttgctggc 
HPyV6/HPyV9 
Duplex 
HPyV 6A forward accaggtgggtgatgaagaca 
LTag [44] HPyV 6A reverse cgcctgaatgttttaaaggagaa 
HPyV 6A probe ttggtccctcagggtggcattca 
HPyV 9 B forward ctagggaacaatttgaatatcaggaa 
LTAg [30] HPyV 9 B reverse atagtgtccagatctaggctctgaac 
HPyV 9 B probe aagttaggctgaggcgggagataggg 
HPyV12/STLPyV 
DUPLEX 
HPyV12 forward gtgggaagctgtcagtgtga 
VP1 [47] HPyV12 reverse ccacctactgcaaacatgtg 
HPyV12 probe actacaggatggcctaccccattgtcagtc 
 STL-VP-F gaagttgaaaatggctccaaaaa 
VP1 [48] STL-VP-R atcatattcacatcttctcctcctagga 
STL-VP -Probe tagatgcacctcacagacatgtccaatgg 
CMV 
CMV -F aac tca gcc ttc cct aag acc a 
MIE protein [49] CMV -R ggg agc act gag gca agt tc 
CMV - probe caa tgg ctg cag tca ggc cat gg 
EBV 
EBV - F cggaagccctctggacttc 
BALF5 [50] EBV - R ccctgtttatccgatggaatg 
EBV - Probe tgtacacgcacgagaaatgcgcc 
ADENOVIRUS 
AdenoHeim-F gccacggtggggtttctaaactt 
Hexon 
gene  
[51] AdenoHeim-R gccccagtggtcttacatgcacatc 
AdenoHeim-Probe tgcaccagacccgggctcaggtactccga 
HHV6 
HHV6-pol-F  tgctcggactgcatcttgga 
DNA 
polymerase 
modified from [52] HHV6-pol -R ttattgccgtgtgttgcgatt 
HHV6-pol ttaacataatccaccgtggaacaaagcatct 
HPV - FAP 
FAP59_F taacwgtiggicayccwtatt 
L1 [53] 
FAP62_R ccwatatcwvhcatitciccatc 
LTAg = Large T Antigen, NCCR = Non Coding Control Region, STAg= Small T Anigen, VP1= Viral protein 1, VP3= Viral protein 3, BALF5= Encode EBV DNA 
polymerase, L1= Papillomavirus major capsid protein, MIE protein= the major immediate-early promoter of cytomegalovirus, wobble bases encoded by letters; I = 
inosine, W= T,A, Y= C,T, D= A,G,T, B= G,C,T, H= A,C,T and V= A,C,G 
  
 6.2.7 Confirmatory PCR Assays  
 
Where possible, a second rtPCR assay was used to confirm any lung cancer extracts that 
provided positive results for an infectious agent. Confirmatory screening was also performed 
on negative specimens, where only a normal or tumour, but not both tissues types were 
positive for an individual patient. These assays typically targeted an alternative conserved 
region of the viral genomes to that used for the screening. Oligonucleotide sequences for 
confirmatory singleplex rtPCR assays for MWPyV, TSPyV, HPyV 6, 7 & 9, STLPyV, CMV, 
adenovirus and HPV (conventional PCR assay) are listed in Table 6.3. An additional test 
was not required to confirm positivity for KIPyV as the screening assay already contained 
two KIPyV targets. Confirmatory tests were not available for HHV6 and EBV at the time of 
thesis writing. Confirmatory rtPCR reactions were run using the reagents and equipment 
outlined in section 6.2.6. The confirmatory HPV conventional PCR was conducted using the 
following mastermix and cycling conditions; 2 μl of lung tissue extract, a concentration of 
20μM each  forward and reverse primer, 200μM of each dNTP, 3.125mM of MgCl2 , 3.75 
units of HotStarTaq DNA polymerase, 5μl 10x PCR buffer and 10μl of Q-solution (Qiagen, 
Austalia) made up to a final 50μl reaction mix. Thermocycling was conducted on the BioRad 
DNA Engine Peltier Thermal Cycler ( BioRad, Australia)  and consisted of an initial hold at 
15 min at 95°C; followed by 45 cycles of 60 sec at 94°C, 60 sec at 58°C and 60 sec at 72°C, 
followed by a final extension of 10min at 72°C. Visualisation of PCR product was conducted 
using 10ul of reaction mix on a 1.5% agarose gel run at 90 volts for 1 hour. 
 Table 6.3 Oligonucleotide sequences for confirmatory PCR assays.    
Assay Oligo name Primer (5’ – 3’) Virus Target 
MWPyV  E Singleplex 
MW-E forward tcctggaagaggttctgttcctt 
VP1 [30] MW-E reverse tcctggaagaggttctgttcctt 
MW-E probe tgggactgataatcaagtacaggatgtaactgtgt 
TSPyV A singleplex 
TSPyV A forward tgtgtttggaaaccagaatcatttg 
LTAg [46] TSPyV A reverse tgctaccttgctattaaatgtggag 
TSPyV A probe ttcttcttcctcctcatcctccacctcaat 
HPyV6D singleplex 
HPyV 6D forward ttgaggagctggacaaagagatt 
LTAg [44] HPyV 6D reverse tctgggaagcttttgaattggt 
HPyV 6D probe aggaagatgccttgtcacagaaaaggaaatg 
HPyV7E singleplex 
HPyV 7D forward gaggaaggaaacactccccagta 
VP2/3 [44] HPyV 7D reverse ttcacttctttttgtagctcctcaag 
HPyV 7D probe actatacctcaatggatgctttttgt 
HPyV9 A singleplex 
HPyV 9 A forward ctagggaacaatttgaatatcaggaa 
VP1 [30] HPyV 9 A reverse atagtgtccagatctaggctctgaac 
HPyV 9 A probe aagttaggctgaggcgggagataggg 
STLPyV LT singleplex 
STL-LT-F tgcagaggtcccttcatcatc 
LTAg [47] STL-LT-R ttttctttttagggcggacaatat 
STL-LT-FAM ccaccattgctcccaagcaggagtac 
CMV BOP singleplex 
CMV BOP F aggtcttcaaggaactcagcaaga 
Major envelope 
glycoprotein  
[54] CMV BOP R cggcaatcggtttgttgtaaa 
CMV BOP Pr accccgtcagccattctctcggc 
HPV PGMY ASSAY 
PGMY11-A gcacagggacataacaatgg  
L1 [55] 
PGMY11-B gcgcagggccacaataatgg 
PGMY11-C gcacagggacataataatgg 
PGMY11-D gcccagggccacaacaatgg 
PGMY11-E gctcagggtttaaacaatgg 
PGMY09-F cgtcccaaaggaaactgatc 
PGMY09-G cgacctaaaggaaactgatc 
PGMY09-H cgtccaaaaggaaactgatc 
PGMY09-Ia  gccaaggggaaactgatc 
PGMY09-J cgtcccaaaggatactgatc 
PGMY09-K cgtccaaggggatactgatc 
PGMY09-L cgacctaaagggaattgatc 
PGMY09-M cgacctagtggaaattgatc 
PGMY09-N cgaccaaggggatattgatc 
 PGMY09-Pa  gcccaacggaaactgatc 
PGMY09-Q cgacccaagggaaactggtc 
PGMY09-R cgtcctaaaggaaactggtc 
HMB01b  gcgacccaatgcaaattggt 
AdenoHeim multiplex 
AdenoHeim-F1  gccscartgggcatacatgcacatc 
VP1 [56] 
AdenoHeim-R1  gccactgtggggtttctaaaytt 
AdenoHeim-F2  gccgcagtggkcktacatgcacatc 
AdenoHeim-R2  gccacsgtggggttyctaaactt 
AdenoHeim-F3  gccccagtggkcktacatgcacatc 
AdenoHeim-R3  gctacggtrggatttctaaactt 
AdenoHeim-TM1  tcggrgtacctsagtccgggtctggtgca 
AdenoHeim-TM2 tcggagtacctgagcccsggkctggtgca 
 
 6.2.8 Positive controls 
 
Synthetic control plasmids were used as a positive controls for MCPyV, MWPyV, TSPyV, 
HPyV 6, 7 and 9, STLPyV, HPyV12; more detailed information of the design of these 
plasmids can be found in appendix A2.1. DNA extracted from previously characterized 
clinical specimens were used as positive controls for the JCPyV, BKPyV, WUPyV, KIPyV, 
CMV, EBV, adenovirus, bocavirus, and HHV6 assays. Water negative controls were 
included on all rtPCR runs. A confluent 75cm flask of HeLa cells, which has an integrated 
copy of HPV 16, was extracted and acted as positive control for the HPV assay. In addition, 
a confluent 75cm flask of A549 cells was extracted and used as a negative control. A plasmid 
containing portions of the HPV 18 sequence, primed by the FAB assays, was also used as 
a HPV positive control (kindly provided by Dr Annika Antonsson, QIMR Berghofer, Brisbane, 
Australia).  
6.2.9 Polyomavirus quantification 
 
Polyomavirus extracts confirmed positive for PyV were quantified to determine the genome 
copies per cell. A serial dilution of the synthetic control plasmid containing the PCR targets 
for the EVR3 (2 copies per diploid cell), HPyV6D, HPyV7E and MCPyV2.0 assay was used 
to generate copy numbers of PyV genomes per cell in lung tissue extracts.  
6.2.10 Directed Rolling Circle amplification of PyV genomes 
 
Confirmed positive specimens for MCPyV, HPyV6 and HPyV7 were amplified using a 
specific directed rolling circle amplification for each PyV (Table 6.4). This increased the viral 
template to allow increased coverage of the whole PyV genome through Ion Torrent PGM 
sequencing.  Detailed methods and oligonucleotide sequences to amplify HPyV 6 are 
described in Chapter 4 Section 4.2.12 
 6.2.11 Additional optimization methods for MCPyV Directed Rolling Circle amplification  
 
Three additional MCPyV primers (primers pairs MCPyV dRCA 4, 5 and 6) were designed in 
a highly conserved region of the STAg due to the limited success of this technique for 
MCPyV positive lung tissues (Table 6.4). In addition, increased Phi29 (4U/ µl) concentrations 
were used in MCPyV dRCA reactions to increase assay sensitivity. 
 
Table 6.4 Oligonucleotide sequences for specific dRCA amplification for HPyV 6, 7 and MCPyV positive 
lung tissues.   
Oligo Name Sequence 5'-3' Tm (C) 
HPyV7-dRCA-1F ggaaactagggctctc*c*t 49 
HPyV7-dRCA-1R aatgcctgtctgagtttt*t*a 49 
HPyV7-dRCA-2F agaacaggaaga*g*a 29 
HPyV7-dRCA-2R ttttttattagtg*g*a 30 
HPyV7-dRCA-3F aactatacttc*t*g 16 
HPyV7-dRCA-3R gaggtcagt*t*t 16 
MCPyV-dRCA-1F ttgctcctaattgttatg*g*c  52 
MCPyV-dRCA-1R atcctatagaagtatggtgtc*c*t   50 
MCPyV-dRCA-2F actccttagtga*g*g 29 
MCPyV-dRCA-2R tactgtcctttta*g*a 29 
MCPyV-dRCA-3F catatagacaa*g*a  15 
MCPyV-dRCA-3R catatgttt*g*c 15 
MCPyV-dRCA-4F gaaatcctgttat*a*a  29 
MCPyV-dRCA-4R cctattacaattg*a*a 30 
MCPyV-dRCA-5F atttcctcctac*t*t 29 
MCPyV-dRCA-5R ggctctctaataa*c*t  31 
MCPyV-dRCA-6F actgactactgctt*a*c  30.5 
MCPyV-dRCA-6R cttttattgct*g*c  30 
* Represent phosphorothioate primer modifications 
 
6.2.12 Ion Torrent PyV sequencing 
 
Was performed as outlined in Chapter 4 Section 4.2.13  
 
6.2.13 Antibody staining of MCPyV LTAg  
 
Immunohistochemistry was performed on formalin-fixed paraffin-embedded tissue sections 
from MCPyV PCR positive lung cancer tissues, using two monoclonal antibodies, CM2B4 
 (Santa Cruz Biotechnology, USA) and AB3 (gift from the DeCaprio Laboratory, Harvard 
University). CM2B4 is a mouse monoclonal antibody, raised against exon 2 (peptides 116-
129) of the MCPyV LT antigen.[57] The mouse monocloncal antibody AB3 was also raised 
against exon 2 of the MCPyV LTAg (260 residues from the N-terminal end). (Rodig 2012) 
Normal and tumour FFPE tissue sections of 4μm were obtained for all MCPyV, HPyV6 and 
7 positive patients. Histology was performed by the HistoTechnology facility, QIMR 
Berghofer. Slide preparation and staining with CM2B4 was as follows; slides were de-
paraffinised and rehydrated through xylol and descending grades of alcohols to water. 
Endogenous peroxidase activity was blocked with 3% hydrogen peroxide for 10mintues. 
Epitope retrieval was performed using Dako Target Retrieval Solution pH6.0 for 30min at 
95°C using the Biocare Medical decloaking chamber. Slides were allowed to cool for 
20mintues before washing in TBS +0.05% Triton X-100 for 2 minutes, then three changes 
of TBS for 2 minutes each. Biocare Background Sniper plus 2.0% BSA was applied for 30 
minutes to stop non-specific binding. Primary antibody CM2B4 was diluted 1:40 and applied 
overnight in Da Vinici Green at room temperature. Sections were washed in three changes 
of TBS the first with 0.05% Triton X-100 each for 5 minutes. Biocare Medical MACH1 Probe 
was applied for 45 minutes and sections washed in three changes of TBS for 5 minutes 
each. Biocare Medical MACH1 Universal Polymer HRP was applied for 45 minutes and 
sections washed in three changes of TBS for 5 minutes each. Signal was developed with 
Vector NovaRed for 5 to 8 minutes. Sections were washed in water for 5 minutes each then 
counterstained and coverslipped using the Leica XL stainer. The specificity of staining with 
CM2B4 was controlled by testing an isotype-matched control mouse IgG2b in parallel.  
Slide preparation for AB3 staining was as follows; slides were soaked in xylene, passed 
through graded alcohols, and placed in distilled water. Slides were then pretreated with 1.0 
mM EDTA, pH 8.0 (Zymed), in a steam pressure cooker (Decloaking Chamber, Biocare 
Medical) as per the manufacturer’s instructions, followed by washing in distilled water. All 
 further steps were performed at room temperature in a hydrated chamber. Slides were 
pretreated with Peroxidase Block (Dako) for 5 minutes to quench endogenous peroxidase 
activity. Mouse monoclonal antibodies Ab3 were applied at the indicated final concentration 
of 0.6 μg/ml in Dako diluent for 1 hour. Slides were washed in 50 mM Tris-HCl, pH 6.4, and 
detected with anti-mouse Envision+ kit (DAKO) as per the manufacturer’s instructions. After 
further washing, immunoperoxidase staining was developed using a DAB chromogen 
(Dako) and counterstained with hematoxylin. All slides images were acquired using an 
Aperio ScanScope Digital Slide Scanner and ImageScope Viewer. 
6.2.14 Immunohistochemical staining of HPyV6 and 7  
 
Specific and pan-monoclonal antibodies to HPyV 6 and 7 were obtained from the Buck 
Laboratory (NIH, Bethesda, USA). A description of the three antibodies, their viral target and 
cross-reactivity can be found in Table 6.5. Staining was performed using the protocol 
outlined in section 6.2.13 for AB3. 
 
Table 6.5 Monoclonal antibodies used to stain FFPE lung tissue positive for HPyV 6 and 7, including 
their cross-reactivity with other PyVs.  
Anibody name Immunogen Cross reactivity 
Xt7  Pan PyV - STAg MCPyV, SV40, HPyV6 and  7 
2t10 HPyV 7 STAg Weak HPyV6 
1t1 HPyV 6 STAg HPyV7, MCPyV, weak MWPyV 
  
6.2.15 Immunohistochemistry positive controls 
 
Positive controls for MCPyV were obtained from Sullivan and Nicolaides Pathology 
(Brisbane, Australia) and consisted of tissue from a patient with histologically confirmed 
MCC FFPE sections were then stained with both MCPyV LTAg antibodies as outlined in 
section 6.2.14. Positive control material for HPyV 6 and 7 was obtained through the 
 transfection of expression plasmids for MCPyV, HPyV 6 and 7, kindly provided by the Buck 
Laboratory (NIH, Bethesda, USA). 
6.2.16 Cloning and purification of PyV expression plasmids 
 
Two expression plasmids were obtained for the different PyV viral proteins. Plasmid details 
are outlined in Table 6.6. Expression plasmids were used as a positive control for 
immunohistochemical staining. This approach was adopted because it is difficult to obtain 
known positive tissue samples for HPyV 6 and 7. Plasmids were re-cloned to produce 
sufficient concentrations for transfection into DH5alpha cells, using Bioline silver competent 
cells (Bioline, Australia). Briefly, cells were thawed on ice and approximately 10ng of plasmid 
was added to 50 µl of competent cells and mixed gently. Cells were incubated on ice for 
30min. Tubes were then heat shocked in a 42°C water bath for 30 sec after which 950µL of 
SOC media (Bioline, Australia) was added. Tubes were incubated with shaking (200rpm) at 
37°C for 1 hour. Either 50 µL or 100 µL of cell transformation mixture was diluted with SOC 
media and spread onto LB agar plates with 5µg/ml Zeocin (Integrated Sciences, Australia). 
Plates were incubated overnight at 37°C. Positive colonies were inoculated into 5ml of Luria 
broth (LB) containing 5µg/ml Zeocin and loosely covered, with the culture was incubated at 
37°C for 12 – 18 hours in a shaking incubator (200rpm).  Cultures were purified using the 
UltraClean 6 minute mini plasmid purification kit (MO BIO Laboratories Inc, Canda) as per 
the manufactures instructions. Purified plasmid was quantified by the NanoDrop 1000 
spectrophotometer (Thermo Scientific, Australia). Confirmation of plasmid and insert was 
verified by size on a 1.5% agarose gel (insert containing plasmids ~5kb whereas plasmid 
only 3.5kb) and rtPCR for HPyV 6 and 7 LTAg using boiled colonies and purified plasmid. 
(rtPCR methods are described in more detail in section 6.2.4).  
 
 Table 6.6 Summary of the expression plasmids used for production of MCPyV, HPyV 6 and 7 and viral 
proteins. 
Plasmid name Ng/ul 280/260 260/230 Insert 
P7T 796.8 1.85 1.98 HPyV 7 LTAg 
P6T 154.3 1.77 1.76 HPyV 6 LTAg 
 
6.2.17 Transfection of HeLa cells with PyV expression plasmids 
 
Only a few studies have investigated the presence of HPyV 6 and 7 in human tissues, 
therefore we transfected HeLa cells with transfection plasmids to produce STAg protein. Cell 
pellets were then stained with three antibodies, xt7 a nonspecific PyV STAg antibody that 
binds to the STAg of human polyomaviruses, 2t10 which specifically binds to the STAg of 
HPyV 7 and has no cross-reactivity and 1t1 which was designed to bind to the STAg of 
HPyV6 but has cross-reactivity with the STAg of HPyV7, MCPyV and weak reactivity to 
MWPyV. Staining of expression plasmids can be found in appendix A6.1. 
 
HeLa cells were grown in standard media of Eagle’s Minimum Essential Medium 
supplemented with 10% fetal bovine serum and 50units/ml of penicillin-Streptomycin (Life 
Technologies, Australia) at 37°C humidified and 5% CO2. HeLa cell cultures were passaged 
twice to obtain normal growth before transfection. Five million Hela cells were seeded into 
a T75 flask one day prior to transfection. Plasmids (36.5µg) were mixed with lipofectamine 
2000 (Life Technologies, Australia) in serum free media as per manufactures instructions. 
HeLa cells were approximately 80% confluent before transfection, monolayers were washed 
with PBS twice before the addition of Liopfectanmine/plasmid mix and incubated for 1hour 
at  37°C humidified and 5% CO2.  Transfection mix was removed and growth media was 
added to monolayers. Cells were monitored for 1-3 days at normal conditions and then 
harvested by centrifugation at 2500rpm. Pelleted cells were fixed for 20min with Neutral 
 buffered Formalin (obtained from HistoTechnology facility, QIMR Berghofer Medical 
Research Institute). After fixation pellets were re-suspended in PBS 50% ethanol mix and 
paraffin embedded.  Cell pellets were embedded and sectioned and then stained with 
appropriate antibodies at the HistoTechnology facility, QIMR Berghofer Medical Research 
Institute (please see section 6.2.14). 
6.2.18 Sero-reactivity to MCPyV proteins 
 
A total of 250 μl of this sera was sent to collaborators at The Fred Hutchinson Cancer 
Research, Seattle WA, USA, who had previously described that sero-reactivity to antibodies 
recognizing MCPyV STAg and LTAg was significantly elevated in patients with MCC. 
Multiplex antibody binding assays were used to detect the sero-reactivity to the MCPyV VP1, 
STAg and LTAg, and BKPyV VP1 reactivity was used as a comparator. Detailed methods 
for these assays have been previous described. [24]   
 
Matching serum samples from 10 MCPyV positive lung cancer patients ( LC 4, 5, 7, 9, 10, 
44, 48, 61, 65 and 69) and 9 MCPyV negative lung cancer patients (LC 11, 12, 13, 15, 16, 
18, 53, 56, and 58) were obtained from the Australasian Biospecimens Network (ABN).  Sera 
were investigated for reactivity to BKPyV VP1 and MCPyV VP1 and STAg. Sero-reactivity 
was compared to sera from 8 MCC patients, which were selected to have a range of antibody 
titres to STAg with one MCC STAg negative serum. Experiments were conducted using 
three dilutions of sera (100, 1000 and 10000). The sero-response was compared between 
groups (MCC v lung cancer) using the Fisher’s exact test performed with STATA software 
(StatCorp, College Station, Texas). MFI signal intensity was also compared between 
MCPyV positive and negative lung cancer patients using Mann-Whitney two-tailed T-test.   
 
 6.3 Results 
 
6.3.1 Extraction quality control  
 
Both normal and tumour extracts were monitored for extraction efficiency and levels of 
cellular DNA (Table 6.7). To ensure sufficient extract, total nucleic acid was eluted from the 
purification column twice. The second eluate produced on average a 2 cycle decrease in 
cycle threshold value, however levels of cellular DNA were on average comparable. An EHV 
Ct value which was 2 standard deviations from the EHV Ct mean for the 200 extracted 
specimens was used to investigate extraction efficiency. Using this criteria 7 samples 
showed signs of poor extraction efficiency and fell outside the normal range of EHV Ct 
values. These samples could not be re-extracted due to lack of available sample.  
 
 
Table 6.7 Monitoring of cellular DNA levels and extraction efficiency in total nucleic extractions from 
lung cancer cohort tissues 
 
First elution 
EHV Ct 
Second elution 
EHV Ct 
First elution 
ERV3 Ct 
Second elution 
ERV3 Ct 
Average 26.4 28.4 19.8 20.5 
Range 22 - 36 23.6 - 34.8 15.9 - 23.8 16.5 - 25.1 
*Extraction efficiency and levels of cellular DNA were monitored for all lung cancer extracts. Cycle threshold 
values (Ct values) are inversely proportional to viral load allow the standardization of nucleic acid extraction 
and levels of cellular DNA in lung cancer specimens. 
 
6.3.2 PCR results for infectious agents in normal and tumour tissue from the lung cancer 
cohort 
 
Screening and confirmatory PCR reactions found no positive tissues for JCPyV, BKPyV, 
WUPyV, KIPyV, TSPyV, HPyV9, MWPyV, STLPyV, and HPyV12. Lung tissue extracts that 
were positive for an infectious agent are summarized in Table 6.8. A large number of non-
 PyV viral detections were observed, but were not further characterized as this falls outside 
the scope of this thesis. The most prevalent PyV detected was MCPyV, followed by HPyV 
7 and 6. MCPyV and HPyV6 were more prevalent in normal tissue than tumour tissue. 
HPyV6 detections had on average the highest estimated viral loads based on Ct values, 
while HPyV7 was more commonly detected in tumour tissues than in normal tissue. Both 
MCPyV and HPyV7 could be detected in both the tumour and normal tissues of 3 and 2 
patients respectively. 
 
Table 6.8 Detection of an infectious agent detection in fresh frozen lung tissue  
Virus 
% positive 
per patient 
%positive 
tumour tissue 
% positive 
normal tissue 
% both tissues 
types positive 
average Ct values 
 n=100 n=100 n=100 n=100 (range) 
MCPyV 11 8 11 8 
34 
(29-36) 
HPyV6 3 1 2 0 
31.72 
(31-32) 
HPyV7 3 3 2 2 
34.93 
(32-36) 
EBV 69 48 53 29 
35.21 
(26.3-38.6) 
CMV 4 2 4 2 
35.85 
(33-42) 
HHV6 86 50 71 38 
36.39 
(23-44) 
HPV 1 1 0 0 
n/a 
 
AdV 6 3 3 0 
41.28 
(39-43) 
 
6.3.3 PCR Detection of novel polyomaviruses lung cancer tissues 
 
6.3.3.1 MCPyV Detections 
 
Eleven patients had a positive MCPyV detection, making this virus the most prevalent 
polyomavirus with PCR detections summarized in Table 6.9. The PCR results show 
detection can be roughly separated into three categories: 
 
 A) MCPyV was only detected in normal tissues, with no or very low viral load detected in 
paired tumour tissues. The majority (5/11) of patients fall into this category with MCPyV 
only detected in the normal lung tissue of patients LC5, 9 and 44. Patients LC65 and 
LC69 harbored much higher MCPyV viral loads in the normal tissue than corresponding 
tumour tissue.  Interestingly the normal lung tissue from patient LC5 had MCPyV 
detected at Ct values of 32 using the LTAg but MCPyV could not be detected by the 
VP2 assay in the same specimen.  
B) MCPyV was primarily detected in tumour lung tissue with very low viral load detected in 
corresponding normal tumour tissue. Two patients fall into this category, LC7 and LC61 
(2/11), both patients had very low load MCPyV in normal lung tissue, that was only 
detected with one rtPCR assay.  
C) Equivalent MCPyV loads in corresponding normal and tumour tissue. Four patients, LC1, 
4, 10 and 48 fall into this category (4/11). Patients LC4, 10 and 48 had virus detected in 
both normal and tumour tissues with both MCPyV screening and confirmatory assays, 
whereas patient LC1 only had low level virus detected in both tissues, this detection was 
only seen with the screening assay (LTAg rtPCR) and could not be confirmed with the 
confirmatory assay.  
 
Overall Ct values, which is inversely proportion to viral load were compared for MCPyV 
detected in the normal and tumour tissues, finding no significant difference between the viral 
loads of MCPyV. (Pairwise Mann-Whitney p=0.2.77 two-tailed test (normal tissue=11), 
(tumour tissue=8). Patients LC44 and  65 had dual detections of both MCPyV and HPyV 7, 
with HPyV 7 being found at low Ct values in patient 65 and MCPyV detected at lower Ct 
values in patient LC44. 
 
 Table 6.9 Cycle threshold values (Ct values) of MCPyV positive lung cancer tissue.   
Specimen ID MCPyV 1.1 Ct values MCPyV 2.0 Ct Values 
MCPyV copy no. per 
cell (x10-3) 
Category A 
LC 5 Normal  32.1 ND 0.5 
LC 5 Tumour  ND ND ND 
LC 9 Normal  34.6 35.1 0.04 
LC 9 Tumour  ND ND ND 
LC 44 Normal ф  31.9 32.9 0.3 
LC 44 Tumour  ND ND ND 
LC 65 Normal ф  35.3 35.5 0.1 
LC 65 Tumour ф ND 38 ND 
LC 69 Normal  34.3 35.6 0.05 
LC 69 Tumour  ND 35.55 0.05 
LC 9 Normal  34.6 35.1 0.04 
LC 9 Tumour  ND ND ND 
Category B 
LC 7 Normal  ND 38.6 ND 
LC 7 Tumour  33.4 34 0.1 
LC 61 Normal  ND 36.1 0.04 
LC 61 Tumour  31.6 38.53 0.5 
Category C 
LC 1 Normal  35.9 ND 0.04 
LC 1 Tumour  35.8 ND 0.03 
LC 4 Normal 29.2 28.1 0.5 
LC 4 Tumour  29.1 28.7 0.5 
LC 10 Normal  35.7 35.2 0.04 
LC 10 Tumour  35.2 34.3 0.03 
LC 48 Normal  33.2 38.53 0.1 
LC 48 Tumour  32.4 34.3 0.1 
ф Specimens also positive for HPyV 7 
 
6.3.3.2 HPyV 6 Detections 
 
Three patients had positive HPyV 6 detections (Table 6.10). Two patients were positive for 
HPyV6 in normal tissue only and one patient had virus detected in tumour tissue only. No 
patients had HPyV 6 detected in both tumour and normal tissue. Patient 73 had a co-
detection of HPyV 6 and 7 in normal lung tissue, with the number of HPyV 6 copies per cell 
being 10 times higher than the copy numbers of HPyV 7.  
 
 Table 6.10 Cycle threshold values (Ct values) of HPyV 6 positive lung cancer tissue. 
  HPyV 6-A assay Ct Values HPyV 6-E assay Ct Values 
HPyV 6 copy number per 
cell (x10-3) 
LC 29 Normal ND ND ND 
LC 29 Tumour 30.9 32 3  
LC 66 Normal 29.3 30.7 10.5 
LC 66 Tumour ND ND ND 
LC 73 Normal * 31.6 32.4 0.5 
LC 73 Tumour * ND ND ND 
* Specimens also positive for HPyV 6 
 
6.3.3.3 HPyV 7 Detections 
 
A total of four patients had HPyV 7 detected in their tissue samples. Two patients had HPyV 
7 detected in both normal and tumour tissues whereas the other two patients only had 
detections in normal tissue. A number of dual detections were noted with patients LC44 and 
65 both positive for MCPyV and HPyV 7 (Table 6.11) and LC73 positive for both HPyV 6 
and 6.    
 
Table 6.11 Cycle threshold values (Ct values) of HPyV 7 positive lung cancer tissue. 
  HPyV 7-E assay Ct Values HPyV 7-D assay Ct Values 
HPyV 6 copy number 
per cell (x10-3) 
LC 65 Normal ф 30.14 32.28 2.7 
LC 65 Tumour ф 36.5 36 0.05 
LC 73 Normal * 36.5 36 0.0036 
LC 73 Tumour * 34.6 34.8 0.045 
LC 74 Normal 35.9 35.2 0.032 
LC 74 Tumour ND ND ND 
Ф Specimen also positive for MCPyV, * specimen also positive for HPyV 6. 
 
6.3.4 Clinical details of patients with novel polyomaviruses detected in lung tissues 
 
Clinical details of patients with PyV detections can be found in Table 6.12. All patients who 
had a PyV detection were immunocompetent. Fisher’s exact tests found no statistical 
 correlation between age (>65 years or <65 years), sex, morphology, smoking status, or 
immune status and MCPyV, HPyV6 or 7 detection.  
 
Table 6.12 Clinical parameters of PyV positive lung cancer patients.  
Study 
ID 
Age 
at Dx 
Sex Morphology Grade 
Cancer 
history 
Smoking 
status 
Metastatic at 
Dx 
MCPyV Positives 
LC1 60 M Adenocarcinoma 3 No Previous No 
LC4 68 M Adenocarcinoma 1 No Smoker yes 
LC5 62 M Squamous cell 
carcinoma 
3 No Previous Yes 
LC7 75 F Adenocarcinoma Variable No Never No 
LC9 60 F Large cell 
(neuroendocrine) 
3 No Previous Yes 
LC10 56 F Adenocarcinoma 1 No  Previous No 
LC44 53 F Adenocarcinoma 3 Yes Smoker Yes 
LC48 62 M Large cell 
carcinoma 
4 No Smoker Yes 
LC61 61 M Squamous cell 
carcinoma 
2 No Previous Yes 
LC65 79 F Adenocarcinoma 3 No Never No 
LC69 75 F Large cell 
carcinoma 
4 No Smoker No 
HPyV6 Positives 
LC29 61 F Large cell 
carcinoma 
n/a No Smoker No 
LC66 74 M Carcinoid n/a Yes n/a No 
LC73 71 M Squamous cell 
carcinoma 
3 No Smoker Yes 
HPyV7 Positives 
LC44 53 F Adenocarcinoma 3 Yes Smoker Yes 
LC65 79 F Adenocarcinoma 3 No Never No 
LC73 71 M Squamous cell 
carcinoma 
3 No Smoker Yes 
LC74 58 M Adenocarcinoma 2 No Previous No 
 
 
6.3.5 Directed Rolling Circle amplification of HPyV6 and 7  
 
All HPyV6 positives tissues (n = 3) and 3 out of the five positive HPyV7 tissues showed 
significant increases in viral template after dRCA amplification (Table 6.13). Extracts showed 
increases in viral load of between 3 and 8 logs (as evidenced by deceases in Ct values of 
between 10 and 25 cycles when tested by real-time PCR).  
  
Table 6.13 Increases in viral template after dRCA amplification for HPyV6 and 7 and resulting PyV 
specific read number and coverage after next generation sequencing.  
Specimen ID rtPCR Ct 
rtPCR Ct after 
RCA 
Mapped reads MCPyV 
reads/total reads (%) 
Range of 
read 
coverage 
HPyV6 Positives 
LC29 Tumour 30.9 6.5 1931/632396 (0.3%) 24-233 
LC66 Normal 29.3 6.5 7517/645782 (1.2%) 214-563 
LC73 Normal 31.7 21.3 51393/476178 (10.8%) 238-573 
HPyV7 Positives 
LC65 Normal 30.1 4.5 13837/593951 (2.3%) 444-988 
LC65 Tumour 36.2 12.7 517/643210 (0.8%) 11-150 
LC74 Normal 35.8 13.3 247/609314 (0.04%) 5-149 
 
6.3.6 Ion torrent whole genome sequencing for HPyV 6 and 7 positive lung tissues 
 
Ion torrent sequencing produced whole genome sequences with good coverage across the 
whole genome for 5 out of the 6 positive specimens (mapped to reference sequences 
NC_014407; HPyV7 and NC_014406; HPyV6). The exception, LC73 normal extract, had no 
coverage in several areas of the whole genome. These segments were re-sequenced using 
standard Sanger sequencing methods however only partial coverage of the whole HPyV 7 
genome could be obtained.  
When compared to the publically available HPyV6 and 7 sequences, less than 1% 
nucleotide variability was observed across the whole genomes (CLC Bio Genomics 
Workbench 6.5). Nucleotide changes that lead to non-synonymous amino acid changes are 
outlined for HPyV 6 and 7 positive lung tissues in Table 6.14. Non-synonymous changes did 
not affect any of the conserved predicted binding regions within the LTAg (CR1, DnaJ or Rb 
binding domains). No non-synonymous changes were detected in the VP1 protein of the 
HPyV 6 genomes, however 3 unique non-synonymous changes were detected in the HPyV 
7 VP1 coding regions form patients 74 and 65. 
 
 Table 6.14 Synonymous mutations in HPyV 6 and 7 positive lung cancer tissues.  
Specimen ID 
Nucleotide 
change 
Nucleotide 
position 
Amino 
acid 
change 
Virus 
region 
Common 
or unique 
HPyV6 Positives 
LC29 Tumour, LC66 Normal, LC73 
Normal 
910 A to G Q to G VP2/3 Common 
LC29 Tumour, LC66 Normal, LC73 
Normal 
2910 T to C I to V LTAg Common 
LC29 Tumour, LC66 Normal, LC73 
Normal 
2914 G to C D to E LTAg Common 
LC73 Normal 3200 A to C L to V LTAg Unique 
LC29 Tumour, LC66 Normal, LC73 
Normal 
3389 G to T F to K LTAg Common 
LC29 Tumour 3467 G to A A to V LTAg Unique 
LC29 Tumour 3583 C to T M to I LTAg Unique 
LC66 Normal 3735 C to A E to D LTAg Unique 
LC29 Tumour 3740 G to T A to D LTAg Common 
LC29 Tumour, LC66 Normal, LC73 
Normal 
3742 G to T R to K LTAg Common 
LC29 Tumour 3767 T to C E to G LTAg Unique 
LC29 Tumour 3769 A to T D to E LTAg Unique 
HPyV7 Positives 
LC65 Normal & Tumour 1352 CA to TC H to S VP3/1 Common 
LC65 Normal & Tumour, LC74 
Tumour 
1424 A to C E to D VP1 Common 
LC65 Normal & Tumour 1512 C to A P to T VP1 Common 
LC65 Normal & Tumour 1708 C to A T to I VP1 Common 
LC65 Normal & Tumour 1717 G to C S to T VP1 Common 
LC65 Normal & Tumour 1825 G to C T to S VP1 Common 
LC74 Tumour 2301 G to C A to P VP1 Unique 
LC65 Normal & Tumour 2305 G to C T to S VP1 Unique 
LC65 Normal & Tumour 2361 A to C I to L VP1 Common 
LC74 Tumour 3031 T to C N to S VP1 Unique 
LC65 Normal & Tumour 3440 T to G K to Q LTAg Common 
LC65 Normal & Tumour 4282 G to T Q to K LTAg Common 
LC65 Normal & Tumour 4501 C to T D to N 
LTAg/
STAg 
Common 
LC65 Normal & Tumour 4537 A to G L to S 
LTAg/
STAg 
Common 
LC65 Normal & Tumour 4550 G to T H to Q 
LTAg/
STAg 
Common 
LC65 Normal & Tumour 4786 G to C Q to E 
LTAg/
STAg 
Common 
Reference genomes HPyV 6; NC_014406 and HPyV 7; NC_014407 also aligned with other publically available 
sequence for HPyV 6 (HM011564, HM011565, HM011566, HM011567, HM011568 and HM011569) and HPyV 
7 (HM011558, HM011559, HM011560, HM011561, HM011562 and HM011563) to access if synonymous 
amino acid changes occur in other genomes. 
 
 
 
 6.3.7 Directed Rolling Circle amplification of MCPyV positive lung tissues 
 
Initially the MCPyV positive lung tissues were amplified using the standard dRCA conditions 
outlined in section 5.2.6. This initial reaction showed on average a decrease in Ct value of 
2.1 cycles (0.6 logs)  (Table 6.15)  A MCPyV positive respiratory samples was then included 
and the dRCA was repeated with increased phi29 concentration. This only resulted in an 
increase of average viral template increase of 0.6 cycles in the lung samples, despite the 
respiratory positive specimen showing an increase in viral template of 12 cycles.    
 
Table 6.15 Viral template increases after dRCA amplification in MCPyV positive lung tissues, using 
standard conditions and increasing phi29 concentrations.  
MCPyV ID MCPyV 
Ct 
Ct after 
RCA 
Ct  after dRCA increased 
enzyme primer pool 1 
Ct change after 
dRCA 
LC 4N 29.19 34.99 31.63 Decrease 2.4 
LC 4T 29.1 35.02 31.24 Decrease 2.1 
LC 5N 32.09* ND 35.89 Decrease 3.8 
LC 7T 33.38 40.69 36.92 Decrease 4.5 
LC 10N 35.7 38.77 ND Decrease 6.3 
LC 10T 35.24 ND ND Decrease 6.8 
LC 44N 31.85 33.74 29.83 Increase 2.0 
LC 48N 33.23 34.99 32.93 Increase 0.3 
LC 48T 32.36 36.85 35.00 Decrease 2.6 
LC 61T 31.59 40.37 34.99 Decrease 3.4 
LC 65N 35.27 41.61 30.75 Increase 4.5 
LC 69N 34.32 39.70 34.21 Decrease 0.11 
MCPyV respiratory positive 1 28.74 NT 16.73 Increase 12.0 
MCPyV respiratory positive  2 34.6 NT ND Decrease 6.4 
* Sample only positive with MCPyV LTAg assay. Ct change after dRCA calculated by subtracting MCPyV Ct 
value from the Ct value recorded after dRCA with increased enzyme using primer pool 1. 42 cycles was used 
to calculate Ct change in Not detected (ND) extracts. NT indicates specimens that were not tested in an 
experiment. 
 6.3.8 MCPyV immunohistochemistry staining using Merkel cell carcinoma tissue 
 
A block of FFPE MCC control tissue was obtained from Sullivan Nicolaides Pathology 
(Brisbane, Australia). Images of this MCC tissue are shown in Figure 6.1 stained with 
hematoxylin and eosin and stained with the MCPyV LTAg specific antibodies CM2B4 
(Appendix A6.1) and AB3 (Fig 6.2), including corresponding isotype negative control staining 
for each antibody. Strong nuclear staining with MCPyV LTAg antibodies was present in both 
the low and high magnification in this MCC tissue, however AB3 staining was only present 
in tumour cells, whereas staining with CM2B4 was less confined to the tumour tissue. This 
suggested that CM2B4 was less specific than AB3 and could stain lymphocytes without the 
presence of MCPyV LTAg. Experiments to determine this potential artefact were conducted, 
and confirmed that AB3 had superior specificity over CM2B4 (presented in Appendix A6.1).  
 
Figure 6.1 Hematoxylin and eosin staining of MCC control tissue demonstrating morphology of the 
MCC tissue. A) 20x B) insert box at 200x magnification 
A) B) 
 
 
 
 Figure 6.2 AB3 staining for MCPyV LTAg in MCC control tissue. A) 20x B) insert box at 200x 
magnification. Black arrow indicates margin of tumour and normal tissue with tumour tissue staining 
strongly with AB3 antibodies, however no staining was seen in stromal tissue (red arrow) AB3 isotype 
negative MCC control tissue. C) 20x D) insert box at 200x magnification  
    
A) B) 
 
 
C) D) 
 
 
 
 
  
 6.3.9 Immunohistochemistry staining MCPyV positive lung tissues 
 
Eleven lung cancer patients had MCPyV detected in their lung tissues. 
Immunohistochemical staining was conducted on the normal and tumour FFPE tissue using 
two specific MCPyV LTAg antibodies, CM2B4 and AB3. Optimization of 
immunohistochemical staining demonstrated that MCPyV LTAg AB3 antibody had 
increased specificity over CM2B4. Therefore, antibody AB3 was selected to be used in the 
downstream analyses of all lung tissue staining. MCPyV LTAg immunohistochemistry 
confirmed all but one patient’s MCPyV positive lung tissue results. Staining of slides from 
patient LC1 had no evidence of MCPyV LTAg nuclear staining.  
 
A selection of MCPyV LTAg and corresponding H&E staining is presented in Figures 6.3 to 
6. and represents an example of each of the MCPyV PCR positive categories. Staining from 
patient LC5 represents category A) where patients had MCPyV PCR positive normal lung 
tissue with no, or low load MCPyV DNA detection in corresponding tumour tissue. Patient 
LC7 represents category B) where MCPyV PCR positivity was found predominately in 
tumour lung tissue. Patients LC4 and LC48 represent examples from category C) where 
equivalent MCPyV DNA load was detected in both normal and tumour tissues. Staining 
results for the remaining MCPyV positive lung tissues can be found in appendix A6.2. For 
each tissue, staining intensity was classified in figure legends as; +1 few cells positive, ++ 
more than 30% of all cells positive, +++ more than 50% of cells positive. 
 
6.3.9.1 MCPyV Immunohistochistry stain for Category A) MCPyV PCR results – Patients 
predominately MCPyV positive in normal lung tissue.  
 
Patient LC5 normal and tumour tissue is used as an example of cases were MCPyV LTAg 
staining is isolated to respiratory epithelial cells within normal lung tissue (Figure 6.3). 
 However artefactual blush can be seen in the cytoplasm in tumour tissue staining (Figure 
6.4).   
 
Figure 6.3 MCPyV Category A LC5 Normal H&E. A) Normal lung morphology 20x B) insert box at 200x 
magnification, C) LC5 Normal AB3 20x D) Number of cells stained ++. Black arrow indicates strong 
nuclear staining in sporadic respiratory epithelium cells with AB3. Insert box at 200x magnification. 
A) B) 
 
 
C) D) 
 
 
 
 
 
 
 Figure 6.4 MCPyV Category A LC5 Tumour H&E. A) Grade 3 squamous cell carcinoma 20x B) insert 
box at 200x magnification, black arrow indicates nest of tumuor cells.C) LC5 Tumour AB3 20x D) 
Number of cells stained Nil. No clear nuclear staining seen of MCPyV LTAg antibody, although arrows 
indicated a staining blush within the cytoplasm, potentially to be artefact. Insert box at 200x 
magnification. 
A) B) 
 
 
C) D) 
 
 
 
 
 
 6.3.9.2 MCPyV Immunohistochistry stain for Category B) MCPyV PCR results – Patients 
predominately MCPyV positive in Tumour lung tissue.  
 
Patient 7 is an example where MCPyV DNA is predominately detected in tumour tissue, very 
low load MCPyV was detected in corresponding normal lung tissue. Immunohistochemical 
staining confirms PCR findings with + sparse staining of respiratory epithelial cells in normal 
lung tissue (Figure 6.5). However extensive staining (+++) of MCPyV LTAg is seen in the 
nucleus of almost all tumour cells, with only sparse staining in surrounding stromal tissue 
(Figure 6.6).   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 Figure 6.5 MCPyV Category B LC7 Normal H&E. A) Normal lung morphology 20x B) insert box at 200x 
magnification, C) LC7 Normal AB3 20x D) Number of cells stained +. Black arrow indicate sparse 
nuclear staining of AB3 in respiratory epithelial cells. Insert box at 200x magnification. 
A) B) 
 
 
 
C) D) 
 
 
 
 
 
 Figure 6.6 MCPyV Category B LC7 Tumour H&E. A) Variable grade adenocarcinoma 20x B) insert box 
at 200x magnification. C) LC7 Tumour AB3 20x D) Number of cells stained +++. Black arrows indicate 
nests of tumour cells with strong nuclear staining for AB3. Insert box at 200x magnification. 
A) B) 
 
 
 
C) D) 
 
 
 
 
 
 
 6.3.9.3 MCPyV Immunohistochistry stain for Category C) MCPyV PCR results – Patients 
MCPyV positive in both normal and tumour lung tissue. 
 
Two examples are illustrated from patients with equivalent MCPyV viral load in normal and 
corresponding tumour tissue. PCR results demonstrated Patient 4 had 5 MCPyV copies per 
1000 cells in normal and lung tissue. This is confirmed by MCPyV LTAg 
immunohistochemical staining with +++ staining in the nucleus in both lung tissues. Within 
normal tissue staining is predominately found in respiratory epithelial cells (Figure 6.7). 
Nests of adenocarcinoma were MCPyV LTAg positive in the corresponding tumour slide 
with limited staining in surrounding stromal cells (Figure 6.8). MCPyV DNA was detected in 
both Patient 48’s normal and tumour tissue with a viral load of 1 MCPyV copy per 1000 cells. 
Immunohistochemical staining showed cells have strong nuclear reactivity in both tumour 
and normal tissues, confirming PCR results. Again MCPyV positive cells were predominately 
respiratory epithelial cells in normal lung tissue (Figure 6.9). In large cell carcinoma tissue 
MCPyV LTAg positive tumour nests can be clearly seen surrounded by largely MCPyV LTAg 
negative cells (Figure 6.10).   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 Figure 6.7 MCPyV Category C LC4 Normal H&E staining. A)  shows normal lung morphology 20x B) 
insert box at 200x magnification, C) LC1 Normal stained with AB3 20x D) Staining intensity +++. Black 
arrow indicates strong nuclear staining of MCPyV LTAg in respiratory epithelium cells. Insert box at 
200x magnification. 
 
 
 
 
 
 
 
 
 
 
 
 
 
A) B) 
 
 
C) D) 
 
 
 Figure 6.8 MCPyV Category C LC4 Tumour H&E. A) Grade 3 Adenocarcinoma of 20x B) insert box at 
200x magnification, C) LC4 Tumour AB3 staining 20x D) Number of cells stained +++. Black arrows 
show nests of tumour cells all with strong nuclear staining positive for ab3. Insert box at 200x 
magnification. 
 
 
 
 
A) B) 
 
 
C) D) 
 
 
 Figure 6.9 MCPyV Category C LC48 Normal H&E. A) Normal lung morphology. 20x B) insert box at 200x 
magnification, C) LC48 Normal AB3 20x D) Number of cells stained ++. Black arrows show strong 
nuclear staining in all respiratory epithelial cells but limited staining in surrounding stromal tissue. 
Insert box at 200x magnification. 
A) B) 
 
 
C) D) 
 
 
 
 
 
 Figure 6.10 MCPyV Category C LC48 Tumour H&E. A) Grade 4 large cell carcinoma. 20x B) insert box 
at 200x magnification, C) LC48 Tumour AB3 20x D) Number of cells stained ++. Black arrows indicate 
nuclear staining of all tumour cells in tumour nests but no staining of surrounding immune and stromal 
cells. Insert box at 200x magnification. 
A) B) 
 
 
 
C) D) 
 
 
 
 
 
 
 6.3.10 Immunohistochemical staining for HPyV 6 and 7 positive lung tissues 
 
Immunohistochemical staining was performed on three HPyV 6 PCR positive patients, 
LC29, 66 and 73 well as three HPyV 7 PCR positive patients LC65, 73 and 74. Although 
PyVs were predominately detected in normal tissue, staining was performed on both 
matched specimens for each patient. Two patients with the highest HPyV 6 viral load, LC29 
and LC66, were selected to serve as examples to be illustrated in this Chapter, however 
immunohistochemical staining for all rtPCR positive HPyV6 and 7 patients can be found in 
Appendix A6.3. Patient LC29 showed staining in tumour cells in a distinctive dot-like pattern, 
with this staining pattern being found in nests of tumour cells (Figure 6.12). No staining for 
HPyV 6 was noted in the normal lung tissue from patient LC29, which corresponded to the 
HPyV 6 PCR results which only detected HPyV 6 in the tumour tissues of this patient (Figure 
6.11). Staining in normal lung tissue from patient LC66 demonstrated low level staining in 
respiratory epithelial cells (Figure 6.13). No HPyV 6 staining was noted in the tumour tissue 
from patient LC66, which again supported PCR detection of HPyV 6 only in the normal tissue 
for this patient (Figure 6.14). Immunohistochemical staining for all HPyV 7 PCR positive was 
inconclusive due to faint low level staining.  
 
For each tissue staining intensity is classified in figure legends as; +1 few cells positive, ++ 
more than 30% of all cells positive, +++ more than 50% of cells positive. 
  
 Figure 6.11 Lung HPyV 6 positive tissue; LC29 Normal H&E. A) Normal lung morphology. 20x B) insert 
box at 200x magnification, C) LC29 Normal 1t1 20x D) Number of cells stained – Nil. Insert box at 200x 
magnification. 
A) B) 
 
 
C) D) 
 
 
 
 
 
 
 Figure 6.12 Lung HPyV 6 positive tissue; LC29 Tumour H&E. A) Large cell carcinoma, grade 
unclassified. 20x B) insert box at 200x magnification, C) LC29 Tumour 1t1 20x D) Number of cells 
stained +++. Black arrows indicate staining which appears on be on the nuclear membrane within nests 
of tumour cells. Insert box at 200x magnification. 
A) B) 
 
 
C) D) 
 
 
 
 
 
 Figure 6.13 Lung HPyV 6 positive tissue; LC66 Normal H&E. A) Normal lung morphology. 20x B) insert 
box at 200x magnification, C) LC66 Normal 1t1 20x D) Number of cells stained +. Faint staining 
indicated by arrows in the nuclei of respiratory epithelial cells. Insert box at 200x magnification. 
A) B) 
 
 
C) D) 
 
 
 
 
 
 
 Figure 6.14 Lung HPyV 6 positive tissue; LC66 Tumour H&E. A) Carcinoid of unclassified grade. 20x 
B) insert box at 200x magnification, C) LC66 Tumour 1t1 20x D) Number of cells stained- Nil. Insert box 
at 200x magnification. 
A) B) 
 
 
C) D) 
 
 
 
 
 
 
 6.3.11 Summary of clinical details, polyomavirus PCR and histology results in lung tissues  
 
This section combines molecular and immunohistochemical data for PyV positive patients 
in both matched normal and tumour tissue (MCPyV positives Table 6.16, HPyV6 positives 
Table 6.17 and HPyV7 positives Table 6.18). Staining intensity is classified as; +1 few cells 
positive, ++ more than 30% of all cells positive, +++ more than 50% of cells positive. Staining 
intensity and cell type is summarized for AB3 antibody immunohistochemistry and is 
presented with the PCR determined polyomavirus copy number per cell.   
 
Table 6.16. Summary of clinical, histological and PCR copy number results for MCPyV positive lung 
specimens 
Specimen ID Histological Type 
MCPyV genome 
copy number per 
cell (1x10-3 cells) 
Staining 
intensity – 
AB3 
MCPyV LTAg 
positive cell type 
LC1 Normal  0.04 Nil n/a 
LC1 Tumour Adenocarcinoma 0.03 Nil n/a 
LC4 Normal  3.7 +++ Respiratory epithelial 
LC4 Tumour Adenocarcinoma 0.5 +++ Tumour cells 
LC5 Normal  0.5 + Respiratory epithelial 
LC5 Tumour 
Squamous cell 
carcinoma 
ND Nil n/a 
LC7 Normal  ND + Respiratory epithelial 
LC7 Tumour Adenocarcinoma 0.1 ++ Tumour cells 
LC9 Normal  0.04 + Respiratory epithelial 
LC9 Tumour Large cell carcinoma ND Nil n/a 
LC10 Normal  0.04 + Respiratory epithelial 
LC10 Tumour Adenocarcinoma 0.03 ++ Tumour cells 
LC44 Normal  0.3 + Respiratory epithelial 
LC44 Tumour Adenocarcinoma ND Nil n/a 
LC48 Normal  0.1 ++ Respiratory epithelial 
LC48 Tumour Large cell carcinoma 0.1 +++ Tumour cells 
LC61 Normal  0.04 + Respiratory epithelial 
LC61 Tumour 
Squamous cell 
carcinoma 
0.5 +++ Tumour cells 
LC65 Normal *  0.1 ++ Respiratory epithelial 
LC65 Tumour* Adenocarcinoma ND + Tumour cells 
LC69 Normal  0.05 ++ Respiratory epithelial 
LC69 Tumour Large cell carcinoma 0.05 + Tumour cells 
 
 
 
 Table 6.17 Summary of clinical, molecular and histology results for HPyV 6 positive lung tissues 
Specimen ID Histological Type 
HPyV6 copy 
number per cell 
(1x10-3 cells) 
Staining 
intensity – 
Staining cell type 
LC29 Normal  ND Nil n/a 
LC29 Tumour Large cell carcinoma 3 +++ Tumour cells 
LC 66 Normal  10.5 + Respiratory epithelial 
LC 66  Tumour Carcinoid ND Nil n/a 
LC 73 Normal*  0.5 Nil n/a 
LC 73 Tumour* 
Squamous cell 
carcinoma 
ND Nil n/a 
*LC73 is positive for both HPyV 6 and 7 in normal tissue. 1t1 and 2t10 antibodies have cross-reactivity 
therefore could be staining for both or either virus. The viral load is 1 log higher for HPyV 6 in this tissue 
therefore we believe it is most likely staining HPyV6. 
 
 
Table 6.18 Summary of clinical, molecular and histology results for HPyV 7 positive lung tissue  
Specimen ID Histological Type 
HPyV 7 copy 
number per cell 
(1x10-3 cells) 
Staining 
intensity – 
2t10 
Staining cell type 
LC44 Normal  ND 
Not 
preformed 
n/a 
LC44 Tumour Adenocarcinoma ND 
Not 
preformed 
n/a 
LC65 Normal  0.0026 Nil n/a 
LC65  Tumour Adenocarcinoma 5.5 + Respiratory epithelial 
LC73 Normal*  0.0036 + Respiratory epithelial 
LC73 Tumour* 
Squamous cell 
carcinoma 
0.045 + Respiratory epithelial 
LC74 Normal  0.032 + 
Respiratory epithelial 
cells 
LC74 Tumour Adenocarcinoma ND Nil n/a 
*LC73 was positive for both HPyV 6 and 7 in normal tissue. 1t1 and 2t10 antibodies have cross-reactivity 
therefore could be staining for both or either virus. The viral load is 1 log higher for HPyV 6 in this tissue 
therefore we believe it is most likely staining HPyV6. 
 
 
 
6.3.12 Sero-reactivity of MCPyV positive lung cancer patients to MCPyV antigens 
 
Serology results obtained from collaborators at the Fred Hutchinson Cancer Research, 
Seattle WA, USA showed there was little to no detectable reactivity to MCPyV STAg in the 
sera from lung cancer patients. The experiment illustrated in Figure 7.5, shows borderline 
MCPyV STAg positive sera from lung cancer patients 4 and 7. However reactivity was lower 
than the lowest MCC MCPyV STAg positive serum tested, and sera were not positive upon 
 retesting (data not shown, personal communication). MCPyV VP1 titres were significantly 
higher in sera from MCC patients compared to lung cancer patients (dilution 100 p=0.4, 
dilution 1000 p>0.01, dilution p>0.01). Although two populations of MFI titres were apparent 
for MCPyV VP1, no significant difference in sero-reactivity was found between MCPyV 
positive lung cancers compared to MCPyV negative lung cancers (Mann-Whitney two-tailed 
t-test p>0.05 for all dilutions).  Sero-reactivity to BKPyV VP1 was somewhat lower in lung 
cancer sera compared to MCC sera, however this was not statistically significant (dilution 
100 p=0.2, dilution 1000 p=0.13, dilution p=0.08). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 Figure 6.15 Multiplex fluorescent immunoassay titres (MFI) for sero-reactivity to BKPyV VP1, MCPyV 
VP1 and STAg. MFI was calculated for three dilution of sera 100, 1000 and 10000. Serum from 20 lung 
cancer patients (10 MCPyV positive and 9 MCPyV negative lung tissues) was compared to sera from 8 
MCC patients.  Sero-reactivity for was significantly higher for MCPyV VP1 in MCC patients compared 
to Lung cancer patients. Sero-reactivity was not detected from MCPyV STAg in lung cancer patients. 
Sero-responses for BKPyV VP1 were higher in MCC patients than lung cancer patients although this 
was not significant. Two populations of MCPyV VP1 sero-responses are observed for Lung cancer 
patients, although no significant difference is seen when MFI was compared between MCPyV positive 
and MCPyV negative lung cancer serum. 
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6.4 Discussion 
 
Here the detection of human polyomaviruses, MCPyV, HPyV 6 and 7 in lung carcinomas 
and paired normal lung tissue was described. MCPyV had an overall prevalence of 11%, 
however in only 6/11 patients was the presence of MCPyV detected predominately in tumour 
 specimens or at equivalent loads in both normal and tumour tissues. Similarly, HPyV 6 and 
7 were both detected with an overall prevalence of 3%, but with the majority of detections 
(2/3 patients for each virus) being found in only normal lung tissue. 
   
These results confirmed earlier reports of 5 to 18% MCPyV prevalence rates in NSCLC 
tissues, and were the first to describe the presence of HPyV6 and 7 in lung cancer.[37], [38], 
[40], [58] In most cases, the detection of MCPyV, HPyV 6 and 7 by PCR could be confirmed 
with monoclonal antibody staining of FFPE tissue.  
6.4.1 MCPyV detection and small cell lung cancer 
 
SCLC is a rare and aggressive form of lung cancer which is strongly associated with 
smoking. SCLC has histological and immunohistochemical similarities to MCC and was one 
of the first pulmonary tumours to be investigated for the presence of MCPyV.[59] Other 
studies have detected a prevalence of MCPyV in SCLC of between 0 and 39%.[59], [35], 
[39], [60] The Brisbane cohort only contained one patient with histologically confirmed SCLC 
and MCPyV was not detected in either normal or tumour tissue. Due to the limited number 
of confirmed SCLC samples in this cohort, any further conclusions regarding MCPyV 
prevalence in SCLC could not be made.     
6.4.2 MCPyV detection and non-small cell lung carcinoma 
 
The detection of MCPyV in the Brisbane cohort of lung cancer specimens was exclusively 
found in NSCLC, with a prevalence of 11%.  These results were broadly similar to five other 
studies which investigated the presence of MCPyV DNA in NSCLC. The first study in North 
America examined a cohort of 30 fresh frozen lung carcinomas with an overall prevalence 
16.7% (n=7). [39] Other larger studies have examined NCSLC from FFPE archival 
specimens finding MCPyV DNA prevalence of 4.7% in Chile (n=86) [37], 9.1% (n=110) in 
 Greece [40], and 16.9% (n=189) in China [61]. Low sample number, the method of nucleic 
acid extraction from FFPE samples, and geographical differences of MCPyV seroprevalence 
may account for the difference in MCPyV prevalence in NSCLC observed between different 
countries. [62], [63]. In a similar study to the Brisbane study, a Japanese cohort of fresh 
frozen NSCLC tissues (n=117) showed that 16.8% of lung carcinomas had MCPyV DNA 
detected.[38]  
 
An advantage of the Brisbane cohort design was the collection of patient matched 
macroscopically normal lung tissue for each tumour sample. All five previous studies 
investigating MCPyVs involvement in NSCLC had limited specimens (<20) or no control lung 
tissues, and subsequently MCPyV was only found in a small number of control 
specimens.[37]–[40], [61]  
 
In the Brisbane cohort, MCPyV prevalence was higher in normal lung tissue than tumour 
tissues. MCPyV DNA has previously been reported in numerous tissues in the absence of 
neoplasia, including normal lung tissue from autopsy specimens.[64] The greater 
prevalence of MCPyV in normal lung tissue compared to tumour tissue in this study, may 
indicate that opportunistic reactivation of MCPyV can occur within the lung, and the 
presence of the virus may not be associated with cell transformation. However in some of 
the cases examined, MCPyV was present in tumour specimens, but absent in normal tissue. 
These results potentially demonstrate multiple roles for MCPyV within the lung as either an 
opportunistic virus or as an infectious agent contributing to cell transformation. 
6.4.3 MCPyV viral load in NCSLC  
    
In this study, the MCPyV load detected in the samples examined was relatively low, ranging 
between 0.01 – 3.7 copies per 1000 cells. Only the Japanese study quantified the MCPyV 
 load within NSCLC and reported a similar MCPyV load between 0.1 – 26 copies per 1000 
cells.[38] MCPyV load within MCC tumours has been reported between 0.01 - 95.3 per cell 
in fresh-frozen tissues, which is 1000-fold higher than the MCPyV load detected in the 
NSCLC in this study. [65]. The difference between MCPyV load in MCC and NSCLC may 
be due to technical differences in load calculations. However if MCPyV were clonally 
integrated in NSCLS and the virus was directly involved in cell transformation, the majority 
of cancer cells would be expected to contain a copy of MCPyV. Thus, it seems unlikely that 
MCPyV is clonally integrated because of the low copy number of MCPyV observed per cell, 
and therefore the virus may contribute to cell transformation in a different mechanism than 
that proposed for MCC.   
6.4.4 Identification of MCPyV LTAg proteins in NSCLC 
 
The presence of MCPyV in the tissues studied was confirmed in all but one patient by the 
presence of MCPyV LTAg using immunohistochemical staining in MCPyV positive normal 
and tumour tissues. In normal lung tissues MCPyV LTAg was predominately detected in the 
nucleus of respiratory epithelial cells, whilst in tumour tissues, extensive nuclear staining in 
transformed cells was observed. These findings were supported by previous results from 
studies in Japan and China, which also demonstrated MCPyV LTAg staining within the 
majority of tumour cells in MCPyV positive lung carcinomas.[38], [61] To our knowledge this 
study is the first to demonstrate MCPyV LTAg expression in macroscopically normal lung 
tissue and demonstrates that MCPyV, like KIPyV and WUPyV may replicate in lung 
respiratory epithelial cells. [66], [67] In some cases where MCPyV DNA is only detected in 
normal tissue, it seems likely that this is a reactivation of MCPyV within the lung, possibly 
linked to the patient’s impaired immune system due to the development of lung carcinoma. 
However LTAg staining in some patients is present in the majority of tumour cells, and is 
comparable to the staining pattern seen in cases of MCC. Interestingly almost all tumor cells 
 showed expression of MCPyV proteins although the MCPyV DNA load was only detected 
at around 1 MCPyV copy per 1000 cells. This suggests that either copy number calculations 
were an underestimate of the actual load of MCPyV DNA in tumour tissues or that non-
specific binding occurred with the MCPyV LTAg antibody.  
 
The detection of MCPyV in tumour tissue was intriguing as MCPyV LTAg was clearly evident 
in cancer cells but not surrounding normal stromal tissue, similar to LTAg staining described 
in MCC. This may indicate that MCPyV was not extensively present in lymphocytes within 
the tumour tissues, and suggests that MCPyV may have a role in NSCLC development. If 
MCPyV was transforming cells utilizing a similar mechanism to the one proposed in MCC, 
viral integration must occur, generally accompanied with mutations truncating the coding 
sequences for MCPyV proteins. 
6.4.5 MCPyV whole genome sequencing 
 
The role of MCPyV in the development of MCC, is thought to be through the direct 
stimulation of viral T-antigens on cell cycling and proliferation pathways. It is proposed that 
the over-expression of viral proteins in MCC occurs after two mutation events; integration 
into the host genome and viral mutation that renders the virus replication incompetent. To 
investigate MCPyV sequence changes, whole genome amplification using rolling circle 
amplification was conducted. The whole MCPyV genome could not be amplified in any of 
the MCPyV positive lung cancer specimens using a modified direct rolling circle amplification 
(dRCA) technique, yet the whole genomes of a MCPyV positive respiratory specimen and 
HPyV 6 and 7 positive lung cancer specimens were able to be amplified. Considering that 
dRCA preferentially amplifies circular DNA (eg: the PyV genome), the inability to amplify 
MCPyV by dRCA, in addition to the extensive staining of MCPyV in lung tumour tissues, 
suggested that the MCPyV genome in the cells of lung carcinoma tissues may be linearized 
 or integrated. However, failure to amplify MCPyV by dRCA may also be due to sequence 
variation in the relatively small dRCA oligonucleotide sequence. To account for this 
possibility, six different sets of primers were used targeting conserved regions of the MCPyV 
STAg or VP2, as well as random hexamers. Even so, the random hexamers and the new 
primer sets produced genome amplification only in the MCPyV positive respiratory sample. 
6.4.6 MCPyV sero-response in NSCLC patients 
 
Increased sero-response to MCPyV tumour antigen is considered to be a prognostic factor 
in the majority of MCC patients, however no significant increases were found in MCPyV T-
antigen sero-reactivity in MCPyV-positive NSCLC patients compared to a subset of MCPyV 
negative NSCLC. It was suspected that the majority of cases may be opportunistic 
reactivation of viable MCPyV, rather than MCPyV integration that leads to overproduction of 
the MCPyV early region proteins, as demonstrated in MCC. The serological data would 
suggest that MCPyV did not have a role in the formation of NSCLC in the majority of these 
patients. However in a small number of cases (2/11) increased sero-reactivity to MCPyV 
early proteins was demonstrated. Interestingly the patients that had the highest MCPyV 
early protein sero-responses; LC4 and LC7 were also those who harboured MCPyV at the 
highest viral load in tumour tissue. Therefore these patients were of particular interest in 
MCPyV whole genome sequencing and integration experiments that were conducted in 
Chapter seven.  
6.4.7 Clinical parameters and MCPyV detection  
 
Histologically MCPyV DNA and LTAg proteins were predominately detected in 
adenocarcinoma tissues (n=6), but were also present in squamous cell (n= 2) and large cell 
carcinomas (n=3). This mirrors the results of previous studies demonstrating the highest 
rates of MCPyV detection in adenocarcinoma.[37]–[40], [61] However, these studies lacked 
 statistical significance most likely reflecting that adenocarcinoma was the most common 
histological type of lung carcinoma. Statistically, in this study, no significant association 
could be demonstrated between MCPyV detection and age (>65 years or <65 years), sex, 
morphology, smoking status, or immune status.  Interestingly, the Japanese study reported 
a trend towards a higher prevalence of MCPyV detection in patients who had never 
smoked.[38] This trend was not observed in the North American, Greek or Brisbane 
cohorts.[39], [40]   
 
The demographics of lung cancer sufferers in Asian were quite different to those reported in 
the USA and Europe. Up to 60 -80% of women diagnosed with lung cancer in Asian had no 
smoking history compared to 15-20% of women with no smoking history developing lung 
cancer in the USA and Europe. [68] 19% of patients examined in this study (Brisbane cohort) 
had never smoked, of which 2 had a positive MCPyV detection. The study in Greece 
reported 9% of patients had never smoked with only a single MCPyV detection in that 
population.[40] In contrast the Japanese study reported 24% of the cohort did not have a 
smoking history, of which 8 out of 20 (40%) of the MCPyV positive specimens came from 
subjects who had never smoked.[38] The Chinese and Japanese study results suggested 
that the difference reported in smoking rates and the detection of MCPyV were most likely 
due to differences in the genetic susceptibilities of lung cancer in Asia. [38], [58], [61] Host 
genetic factors have been statistically associated with the detection of MCPyV in 
NSCLC.[40], [61] The Chinese study found a correlation between EGRF mutation and 
MCPyV detection were as the Greek study found changes in BRAF and bcl-2 expression in 
MCPyV positive lung carcinomas. BRAF and bcl-2 have anti-apitopic affects and are 
downstream targets of EGRF. Although investigating the genetic profile of host oncogenes 
in the Brisbane lung cohort is outside the scope of this virology based thesis, it is suspected 
that particular host genetic susceptibility and MCPyV detection may be linked.  
 6.4.8 The detection of HPyV 6 and 7 in NSCLC 
 
HPyV 6 and 7 were detected in both normal and lung carcinoma extracts in this cohort, 
which, to our knowledge, is the first report of these polyomaviruses in lung carcinoma. HPyV 
6 and 7 were discovered in healthy human skin and, like MCPyV, appear to be cutaneous 
and potentially part of the healthy skin flora.[69] In this thesis HPyV 6 and 7 have been 
detected in respiratory swabs, generally in immunocompromised adults (Chapter 2 and  
6).[30] Others have reported these viruses in normal and cancerous skin lesions and skin 
rashes of lung transplant recipients.[70]–[72]  
 
In this study, HPyV 6 was detected in three patients, all with different histological cancer 
types. The virus was readily amplified by dRCA methods, suggesting it was present in a 
circular episomal form within tumour tissue. Subsequent whole genome sequencing 
revealed low genome diversity and no predicted functional mutations, which supported the 
notion that these viruses were present as part of a viral reactivation or “normal” infection. 
Immunohistological staining was only successful for two patients, one a normal lung tissue 
demonstrated HPyV 6 faint staining in respiratory epithelial cell. The second demonstrated 
intense staining dots which appeared to be associated with the nuclear membrane and was 
seen in “nests” of tumour cells. Immunohostochemical staining for the HPyV 6 LTAg has not 
been previously described, but as for other polyomaviruses it is believed that this protein in 
largely located in the nucleus. The HPyV 6 genome amplified in this patient produced 
numerous synonymous amino acid changes, four of which were not found in the limited 
number of published HPyV 6 genomes.   
 
Low HPyV 7 viral loads were detected in normal and tumour lung tissues, but convincing 
immunohistochemical staining of HPyV 7 viral proteins was not seen.  Recently, HPyV 7 has 
 been detected in pruritic skin rashes in two immunocompromised patients at HPyV 7 copy 
numbers exceeded 3000 copies per cell which was confirmed with IHC staining for specific 
viral proteins. [72] In the study described here, HPyV 7 positive lung tissue with a maximum 
load of 5.5 x10-3 copies per cell were detected, therefore it was unsurprising that viral protein 
could not be detected with IHC staining. Although detection of HPyV 7 was of interest in 
lung tissue, the low viral loads, episomal nature of infection, and weak staining suggested a 
mechanism of reactivation rather that involvement in oncogenesis. 
 
To our knowledge this is the first report of HPyV6 & 7 in lung tissue. In general, HPyV 6 and 
7 were detected at low viral load with limited viral sequence changes, and sparse LTAg 
detection in epithelial cells. However an interesting case of HPyV 6 positive tumour tissue 
with LTAg expression in large numbers of tumour cells suggested a potential role of HPyV 
6 in a limited number of NSCLCs. Additional studies investigating both host cell oncogenes 
and HPyV 6 characterization are warranted in NSCLC.    
6.4.9 Other Infectious agents detected in Brisbane lung cancer cohort 
 
Through previous observations it was well recognized that co-detection of different viruses 
was common in many specimens. For this reason testing for a number of other viruses 
known or suspected to have involvement in human cancer was also included in this study. 
A large proportion of the lung cancer samples had positive detections, particularly for EBV, 
HHV6, CMV and adenoviruses. However all these viruses were detected at low viral load, 
which may suggest that they were detected due to infiltrating lymphocytes, as has previously 
been demonstrated for EBV in breast carcinomas.[73] In many cases multiple potentially 
oncogenic viruses were detected in a single lung tumour tissue. The potential synergistic 
relationship of multiple viruses that target different cell cycling and proliferation pathways 
 also warrants further investigation, and has been reported by others, but falls outside the 
main scope of this study.[74]  
6.4.10 Conclusions and further experiments 
 
Of great interest were the MCPyV detections in the Brisbane lung cancer cohort, particularly 
given the positive IHC staining of LTAg within the tumour cells. If MCPyV is involved in cell 
transformation, with similar mechanisms as MCC, then viral gene truncations and integration 
of the virus would be detected. Early experiments point to the linearization of MCPyV in lung 
cancer tissues. However overall MCPyV load in NSCLC was 1000 lower than MCPyV load 
found in MCC, suggesting only 1 in 1000 cells contain a copy of MCPyV genome. Sero-
responses to MCPyV early proteins were significantly higher in MCC patients than in 
controls. However the sero-response to MCPyV early proteins was not significantly raised 
in a subset of MCPyV positive NSCLC in this cohort. Despite the inability to amplify MCPyV 
using dRCA methods, the low MCPyV viral load and lack of MCPyV specific T-antigen sero-
response suggested that, if MCPyV viral integration has occurred, it was not clonal and may 
have occurred after cell transformation. Although MCPyV results in NSCLC were intriguing, 
further investigation of the virus is required to draw any conclusions into the role, if any of 
MCPyV in lung carcinoma. Chapter seven of this thesis will further characterize the MCPyV 
genome in the context of NSCLC and its potential integration in the samples collected for 
the Brisbane lung cancer cohort.  
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CHAPTER SEVEN 
 
Characterising the Role of MCPyV in a Subset of NSCLC 
 
  
  
7.1 Introduction 
 
In Chapter six it was demonstrated that MCPyV DNA and proteins can be detected in tumour 
cells of a subset of NSCLC. However, MCPyV’s role, if any, in cell transformation in NSCLC 
needs to be further investigated.  
7.1.1 Merkel cell polyomavirus in non-cancer tissues 
 
The tissue tropism for MCPyV is still debated. It can be readily found on healthy human skin, 
respiratory and oral swabs, urogenital samples and in many tissue specimens, but it is found 
at highest viral load, as assembled virions on the skin.[1]–[4] Therefore, MCPyV may be part 
of the normal skin flora and is systematically distributed. Also, care must be taken when 
studying MCPyV by sensitive methods, such as PCR, as it can be readily detected in 
sewerage and environmental samples.[5] MCPyV primary infection is thought to be 
asymptomatic and is speculated to occur through a cutaneous or faecal-oral route. In the 
general population, seroprevalence of MCPyV is high with ranging from 46 – 87.5% in 
adults. Evidence of increasing antibody titres with increasing age, suggested that similar to 
JCPyV and BKPyV asymptomatic viral reactivation maybe common.[6]–[11] 
7.1.2 Merkel cell carcinoma  
 
MCPyV was first discovered integrated into merkel cell carcinoma (MCC) tissues, and since 
this time various other publications throughout the world have reported integrated and 
episomal forms of MCPyV in MCC tissues.[12]–[17] While exposure to MCPyV is high in the 
general population (up to 88% seroprevalence), in MCC patients the seroresponse to 
MCPyV T-antigens may be 59 times higher than non-MCC control populations.[8] Specific 
antibody reactivity to a common antigen region in the STAg/LTAg protein is almost 
 exclusively seen in MCC patients, and these decrease rapidly after excision of the MCC 
tumour. Such antibody response also correlates with MCPyV DNA load detected in MCC 
tissues. [9] The re-emergence of the seroresponse to STAg/LTAg antigens in MCC patients 
has also been successfully used as a diagnostic pre-curser to the development of metastatic 
disease.[9], [18]     
7.1.3 Proposed mechanisms for MCPyV induced cell transformation in MCC 
 
MCPyV DNA and proteins have been detected in almost all MCC tissues.[19] The detection 
of MCPyV LTAg expression in tumour cells and the increased serological response to 
MCPyV antigens in MCC patients demonstrates that MCPyV is very likely to have a causal 
role in the development of MCC.[9], [14], [19] Although the aetiology of MCPyV induced 
oncogenesis is not fully characterised, the non-structural proteins or tumour antigens are 
thought to play a vital role.[20] The MCPyV genome produces four non-structural proteins, 
STAg, LTAg, 57kT and ALTO proteins, from alternative splicing of a single transcript (Figure 
7.1). By studying mutations of these proteins in MCC tissues and cell lines that contain 
integrated MCPyV, researchers are starting to uncover the role of MCPyV in MCC 
carcinogenesis.[14], [20], [21] Evidence suggested that, due to the near ubiquity of MCPyV 
in the general population, MCPyV induced cell transformation in MCC occurs through two 
or more biologically rare events. The order of these events is unclear,  however 97% of 
MCCs contain a monoclonally integrated MCPyV genome with MCPyV sequence variations 
that prematurely truncate viral proteins.[14], [19]–[21] These truncations usually occur in the 
second exon of LTAg, producing non-productive MCPyV infections. In contrast MCPyV 
found in non-MCC neoplastic tissue and a variety of other specimens from patients without 
cancer was usually episomal, with full-length MCPyV sequences that did not contain coding 
truncations.[2], [3] Mutation studies suggested that the most important proteins in cell 
transformation were the LTAg and STAg, while to date little is known about the role of 57Kt 
 and ALTO protein in the MCPyV lifecycle.[22], [23] MCPyV LTAg truncations were most 
commonly found between the origin binding (OBD) and helicase domains. (Figure 7.1) By 
truncating this segment of the MCPyV LTAg genome the transcript still retained cell cycling 
and proliferation binding sites such as PP2A and pRB, which can continue to have 
proliferation effects on the cell. However by truncating the OBD and helicase domains, the 
promotion of viral replication by MCPyV LTAg was inhibited. This is process is vital to virus 
replication, as the combination of binding of LTAg around the OBD and the helicase domain 
partially unwinds the MCPyV double stranded DNA genome. In productive infections this 
would enhance the binding of host replication machinery and promote polyomavirus 
replication. However once the viral genome becomes integrated this process would cause 
replication forks in the host genome which are catastrophic to the cell. The truncation of the 
LTAg is often a single base pair change that encodes a premature stop codon, however 
deletions, insertions and integration sites have also been described in MCPyV genomes 
detected in MCC.[12], [17] Unlike SV40, MCPyV LTAg is not thought to inactivate the p53 
apoptotic pathway. The OBD contains regions that bind and stimulate the p53 pathway 
which may cause additional selective pressure to remove the C-terminal segment of the 
MCPyV LTAg for MCPyV induced tumourgenesis.[24] 
 
In addition, MCPyV unlike other human PyVs cannot efficiently replicate with the expression 
of LTAg alone, and also requires STAg expression.[23] In fact, cell transformation seems to 
be dependent on the expression of STAg, again unlike SV40, where LTAg alone can 
transform cells. Traditionally in SV40, STAg is proposed to stimulate cell proliferation largely 
through interaction with PP2A. However through MCPyV PP2A knockdown models it was 
shown that this site has only a marginal effect on cell transformation activity.[25] Instead, 
MCPyV STAg is thought to act by increasing hyper-phosphorylation of 4E-BP1, a regulator 
of cap-dependant translation.[25] MCPyV STAg also encodes an LTAg stabilisation domain 
 (LSD) at the distal 3’ region of STAg. The LSD interacts with the cellular factor SCFfbw7 
complex, which targets MCPyV LTAg for proteisomal degradation.[26] However this is 
inhibited by the LSD domain on the STAg and allows for the extended half-life of the MCPyV 
LTAg. Interestingly, the deregulation of SCFfbw7 is found in numerous cancers, with the loss 
of fbw7 contributing to genomic instability.[27]–[30]   
 
Figure 7.1 Illustration of spliced variants of the MCPyV early coding region. The early coding region 
produces four proteins, LTAg, STAg, 57kT and ALTO. LTAg, STAg and 57kT proteins all contain a Cr1 
(LXXLL) and DnaJ (HPDKGG) binding domain. STAg uniquely encodes the LTAg binding domain 
(LBD), PP4C and PP2A binding site. The largest transcript LTAg encodes numerous cell cycling, 
proliferation and anti-apoptotic binding domains including pRB (LXCXE) binding motif, origin binding 
domain (OBD), zinc finger, Leucine finger and ATP/helicase domain. 57kT seems to play a limited role 
in cell transformation however along with the LTAg encodes the unique MCPyV unique region (MUR) 
which contains the nuclear localisation signal (NSL), the pRB (LXCXE) binding motif and the hVam6p 
recognition sequences.  Little is known about the ALTO protein, however initial mutatgensis studies 
report it is not critical to cell transformation.  
 
 
 
 7.1.4 Role of MCPyV structural proteins in cell transformation 
 
The majority of polymorphisms found in the MCPyV genome that render the virus replication 
incompetent are found in the LTAg binding region. However truncations can occur in 
structural proteins or the NCCR and several reports of full length un-truncated MCPyV 
sequences have been detected in MCC tissues.[12], [17], [31] In these cases it is poorly 
understood how the virus evades cell destruction through virion induced cell lysis or 
replication fork errors, but polymorphisms in key pathways for virus entry, virion production, 
packaging and virion release may be involved.[23], [31]–[33] MCPyV encodes for three 
structural proteins, VP1, VP2 and VP3 these proteins are involved in cell entry, virus 
packaging and unpackaging, transport of viral proteins in and out of the nucleus and virion 
release from the cell.[34] VP1 forms the surface of the virion and is involved in cell surface 
recognition and uptake into the cell. MCPyV viral entry requires sequential attachment to 
glycosaminoglycans which is unique compared to other human polyomaviruses, but also 
requires binding to the linear Neu5Ac-α2,3-Gal disaccharide. This motif is found on 
numerous suflated carbohydrates. [35] Mutations in the recognition site for Neu5Ac-α2,3-
Gal in MCPyV VP1 coding sequences greatly diminish MCPyV infectivity.  In SV40, VP3 
deletion mutants significantly affect infectivity, and VP3 is also essential for viriron 
assembly.[36], [37] However, recently it was shown that VP3 is not expressed during 
MCPyV infection, and that VP2 is important in post-attachment cell entry in some cell lines, 
but not required in others. Interestingly, deletion mutants that did not express VP2 showed 
reduced infectivity in A549 cells (lung cell line).[38]   
7.1.5 Proposed involvement of Merkel cell polyomavirus in other cancers 
 
Merkel cell polyomavirus DNA has also been detected in a variety of other tumour tissues, 
including haematological malignancies, SSC and BCC skin carcinomas, bladder, breast, 
 gastrointestinal, lung, cervical, Langerhans cell histiocytosis and Kaposi’s sarcoma.[12], 
[21], [39]–[55] Typically, MCC patients have a higher risk of developing a secondary cancer 
than the general population.[56]–[59] Several investigations have focused on the detection 
of MCPyV in chronic lymphocytic leukaemia (CLL) as there was an epidemiological link 
between patients with MCC who then go on to develop CLL.[60] Additionally,  several groups 
have reported MCPyV lymphotropism by detecting MCPyV in PBMCs. [21], [41], [61] 
Truncated MCPyV LTAg DNA sequences have been reported in 6 of 19 MCPyV-positive 
leukemic cells.[40] However other studies investigating MCPyV’s role in CLL have been 
varied and inconclusive.[39], [42] Overall, a prevalence of MCPyV DNA of 0 – 33 % has 
been reported in CLL cohorts, but with a significantly lower MCPyV viral load in CLL tissues 
compared to MCC specimens. Similarly, MCPyV DNA has been detected in up to 40% of 
SSC and BCC skin carcinomas.[62], [63] MCPyV has also been reported in cancers other 
than MCC, but at a significantly lower viral load (1000 fold reduction) than that detected in 
MCC patients. In these cases the MCPyV genome is almost always reported in an episomal 
state, with the exception of the report of two cases of integrated MCPyV in NSCLC.[48]    
 
7.1.6 Novel mechanism for polyomavirus induced cell transformation 
 
SV40, MCPyV, and HPV all become clonally integrated into the host cell genome. This 
integration event is often coupled with mutations within the viral genome that enhance the 
expression of proteins to stimulate cell cycling and proliferation, whilst inhibiting the 
production of virus particles. Recently a novel polyomavirus was discovered in raccoons 
which developed high-grade tumours of the frontal lobe and olfactory tract.[64] 
Phylogenetically Raccoon polyomavirus (RacPyV) is most closely related to MCPyV. 
RacPyV was detected with immunohistochemical staining, demonstrating the presence of 
LTAg within neoplastic cells. RacPyV was present at high viral load in the tumour cells and 
 low load in surrounding normal tissue. Expression of tumour antigens was high, although, 
unlike SV40 or MCPyV, the virus was present in an episomal state, thus representing a 
novel mechanism for PyV-induced tumourgenesis .[65]  Additional studies have detected 
high level expression of RacPyV encoded miRNAs in the tumour tissue from these raccoons. 
Normally these miRNA serve to down-regulate the expression of the early coding region, 
yet in tumour cells abundant expression appears to be tolerated. MCPyV also encodes a 
highly homologous miRNA, but expression levels are low in MCC, suggesting that a different 
mechanism for viral induced cell transformation occurs between RacPyV and MCPyV, even 
though phylogenetically these viruses are highly related. [66] 
7.1.7 MCPyV involvement in lung carcinoma 
 
As previously described in Chapter six of this thesis, five studies have demonstrated the 
presence of MCPyV in NSCLC.[48], [49], [51]–[53] Three (Chinese, Chilean and Greek) of 
the five studies used archival FFPE tissues which allowed limited characterisation of the 
MCPyV harboured in NSCLC tissues.[49], [51], [53] All five studies were conducted with 
limited (>20) or no normal lung control tissues. A major strength of the cohort used in this 
study was the parallel testing of matched histological normal lung tissue from all 100 
participants. MCPyV detection in normal tissues (11/11) was higher than in tumour tissue 
(8/11) with histological staining demonstrating that MCPyV can infect normal respiratory 
epithelial cells. MCPyV has previously been reported in respiratory secretions, and 
replication of synthetic MCPyV constructs was supported in NSCLC cell lines (H1299).[33], 
[67]–[70] Therefore confirming the presence of MCPyV in tumour cells rather than 
surrounding stromal tissue is vital in determining if MCPyV has a role in cell transformation. 
Only two previous studies confirmed the presence of MCPyV LTAg in transformed cells in 
NSCLC tissue.[48], [53] Of particular interest were the patients in the Brisbane cohort where 
MCPyV is found predominately in tumour cells. MCPyV integration into two MCPyV DNA 
 positive NSCLC tissues was recently reported. [48]  This finding is highly significant and is 
the first report of MCPyV integration in a neoplasia other than MCC. Hashida also reports 
truncations within the MCPyV genome that would render the virus replication incompetent. 
However this study did not conduct any investigations to determine if the integration sites 
detected were clonal and therefore occurred before cell transformation. The low viral load 
of MCPyV DNA detected by Hashida et al, of approximately 1 copy per 100 cells may 
suggest that MCPyV DNA is not integrated into all tumour cells, and therefore was not 
clonally integrated. To date no other study has confirmed Hashida’s findings of MCPyV 
integration in NSCLC. Chinese and Greek studies have focused on the presence of MCPyV 
DNA in NSCLC with changes in host cell epigenetics [51], [53] The study conducted in 
Greece investigated the presence of MCPyV, JCPyV and BKPyV in 110 FFPE NSCLC 
blocks, finding similar results to our study with a prevalence of 9.1% of MCPyV DNA in 
NSCLC.[51].  
 
This Chapter of the study further characterises the detection of MCPyV in paired normal and 
tumour tissue from the Brisbane cohort of lung cancer patients. Whole MCPyV genome 
sequences and MCPyV integration are examined, and compared to the MCPyV detected in 
MCC patients.  
 
 
 
 
 
 
 
 7.2 Materials and Methods 
 
7.2.1 Specimens utilised in this Study 
 
7.2.1.1 Fresh frozen lung tissue 
 
An additional 25mg fresh frozen tissue specimens, both from normal and tumour lung tissue 
was obtained from the Australasian Biospecimens Network (ABN) for the 11 MCPyV PCR 
positive patients. These specimens were extracted as previous described in Chapter 6 
section 6.2.3. 
7.2.1.2 Formalin-fixed paraffin embedded merkel cell carcinoma tissue 
 
Additional FFPE slices (8 x 4µM in thickness) were cut from the MCC control tissue block 
(MCC 849), previously described in Chapter 6, section 6.2.16. These slices were extracted 
for total nucleic acid as previously described in Chapter 5, section 5.2.2.  
7.2.2 Whole genome sequencing of MCPyV 
 
Whole genome sequencing for MCPyV was performed as previously described in section 
4.2.9 with MCPyV nested walking primers (Chapter 6, Table 6.4). Sequencing was 
performed on all eleven MCPyV PCR positive lung tissue extracts and the FFPE MCC 
control tissue. Sequence variability was previously noted between MCPyV whole genomes, 
particularly from MCC tissues where polymorphisms cause premature truncation of viral 
proteins. To reduce the impact of sequence variability on PCR amplification of the MCPyV 
genome, two walking primer sets were designed around every 400bp in the MCPyV 
genome. Primers were designed so that nested PCR, with a different combination of inner 
and outer primers could be used on samples for which segments of the MCPyV genome 
 failed to amplify. Although sequence variation between MCPyV genomes is impossible to 
predict we attempted to control for the impact of sequence variation by comparing the 
nucleotide sequence of MCPyV walking primers and nucleotide sequences of the 43 MCPyV 
whole genomes publically available. A detail evaluation can be found in Appendix A7.1. 
Briefly, we examined the polymorphism within the nucleotide sequence of MCPyV walking 
primers compared to all the MCPyV whole genomes. We recorded the frequency of 
polymorphisms among available MCPyV genomes and the position of the polymorphisms 
within the primer sequence. Sequence variation within the first 5 bases of the forward 
primers or the last 5 base of reverse primers was highlighted as these polymorphisms would 
likely prevent amplification. In all cases a different combination of primers could be used to 
amplify the MCPyV region affected by walking primer mismatches within these critical 
regions. 
 
MCPyV whole genome sequences from lung tissues were compared to a previously 
published MCPyV construct designed to express full length MCPyV proteins in 293 cell lines. 
This construct is the consensus sequence of 7 full-length genomes isolated from blood and 
respiratory samples (accession number JF813003). Genome sequences produced from this 
study were also compared to the published MCPyV whole genomes obtained from MCC 
tissues, EU375803 and EU375804 (index cases of MCPyV in MCC).  Sequence data were 
aligned, manipulated and translated using Geneious 8.0.5 and CLC Bio Genomics 
Workbench 6.5 software.   
7.2.3 Determining MCPyV integration using degenerate human primers 
 
Potential integration of MCPyV into the human genome was determined by the method used 
in section 5.2.7 to determine BKPyV integration in bladder carcinomas. Specific nested 
walking primers were designed for MCPyV and can be found in Table 7.1. This methodology 
 was described in detail in Chapter five section 5.2.7 and all master mixes and PCR 
conditions were identical.  
 
Table 7.1 Oligonucleotide sequences of nested MCPyV walking primers 
Oligo Name Sequence 5'-3' Product size 
MCV Walk 1F tcatttgctcctctgctgtttc 447 
MCV Walk 1R agactacaatgctggcgagaca  
MCV W1F inner actccttctgcatatagacaagatgga  
MCV W 1R inner tacaagcgcacttagaatctctaagttg  
MCV Walk 2F ttaaaggattatatgcaaagtggatataatg 468 
MCV Walk 2R tcccgaagctgaatcctcct  
MCV W2F inner agaggtcctgggtgcatgc  
MCV W 2R inner cattctttgaatttagtggtcccatatata  
MCV Walk 3F catctaggttgacgaggccc 624 
MCV Walk 3R gaccccccaaattttcgct  
MCV W 3F inner atgggaccactaaattcaaagaatg   
MCV W 3R inner cttcggggtggtgaagga  
MCV Walk 4F gaggcctcgtcatctcagtttac 535 
MCV Walk 4R tgagcagtggcttattctcttgc  
MCV W 4F inner gaatacatatcctcctccttcaccac  
MCV W 4R inner aattattatacatttcaggcatcttattca  
MCV Walk 5F tgtgaattaggatgtattttattgtttataacttt 509 
MCV Walk 5R ttacatagcatttctgtcctggtcat  
MCV W 5F inner gcatagagtatttgctattaagaatttttgc  
MCV W 5R inner aacctccttttggctagaacagtgt  
MCV Walk 6F tctcgcctcaaacctcacaa 502 
MCV Walk 6R tattttgccctttcacatcctca  
MCV W 6F inner gctcatcattctaatgctaagctattttat  
MCV W 6R inner tttatccaaagcacatcctagttcaa  
MCV Walk 7F tagatttgctagaagggaaggcc 498 
MCV Walk 7R cactctgtaaaatttgcttccagtttt  
MCV W 7F inner ctgtccatctgataaactgcctttt  
MCV W 7R inner ttgtaagcaaggcttaaaggttgtatc  
MCV Walk 8F ttccctggatcagaacatgga 493 
MCV Walk 8R gtttacccaaagccctctgttg  
MCV W 8F inner gaagaattcttcaaagtggaaccac  
MCV W 8R inner gtaacattccaaagtaatcagcaggata  
MCV Walk 9F tggctttctttttgagaggcc 503 
MCV Walk 9R cagactcctacagttcttcaatttagtaatactc  
MCV W 9F inner gtcctttcagtggcgcctt  
MCV W 9R inner gtaacattccaaagtaatcagcaggata  
MCV Walk 10F gagccatttttccactggtttt 551 
 MCV Walk 10R cacattgcagatgtgggagg  
MCV W 10F inner ccccactatgtgtgcacagc   
MCV W 10R inner ttcattattgggacatgaaaagagttc  
MCV Walk 11F aggaataccagcaccataatcatga 551 
MCV Walk 11R gcagcaaactccagattggc  
MCV W 11F inner catgtcccaataatgaacattaattaaag  
MCV W 11R inner ctaggccttagtggatatatttctcctg  
MCV Walk 12F tgcttttctttttggtgcca 551 
MCV Walk 12R tgaggctttagctcaacttggg  
MCV W 12F inner tgtaattcaggagaaatatatccactaagg  
MCV W 12R inner aatttctcattagtggcttctttggtt  
MCV Walk 13F cagtttggagaatgaagccataag 445 
MCV Walk 13R  tcatttcctggagaggcgg  
MCV W 13F inner accttggttaaccaaagaagcca  
MCV W 13R inner taaacaaaactttttttctttctgtttgg  
MCV Walk 14F cgtctccctcccaaacagaa 372 
MCV Walk 14R ggactaaatccatcttgtctatatgcag  
MCV W 14F Inner gtttatcagtcaaactccgcctc  
MCV W 14R inner  agcaaatgagctacctcactaagga  
Human tag primer gcttgcgtgcatgtcgactgttcannnnnnncgcgt  
Human tag inner primer gcttgcgtgcatgtcgactgttca  
N= degenerate base that will bind to all nucleotides with equal affinity.  
 
7.2.4 Confirmatory PCR to amplify potential MCPyV/ human integration sites 
 
To confirm the presence within the tumour tissue of sequences identified with the integration 
detection method outlined in section 7.2.5, a series of PCR assays which targeted 
sequences outside the original primer sets (Table 7.1) were designed (Table 7.2). PCR 
master mix and conditions are described in detail in section 5.2.8.  
 
Table 7.2 Oligonucleotide sequences for confirmatory PCR to amplify predicted human MCPyV 
integration sites. 
Oligo Name Sequence 5'-3' Product size 
MCV Walk 13.5 F aaagcctccgggcctc 450 
Chrom11_rev ggaggctgaggcaggaga  
MCV Walk 14 F cgtctccctcccaaacagaa 220 
Chrom11_rev2 cagcactttgggaggcca  
 
 7.2.5 Determining potential MCPyV Integration sites using DIPS-PCR 
 
The method previously described for the detection of integrated papillomavirus sequences 
by ligation-mediated PCR (DIPS-PCR) was modified to amplify MCPyV sequences.[12], [71] 
Primers specific for MCPyV and the primer for the adaptor sequence are shown in Table 
7.3.  For all MCPyV-positive lung tissues and the FFPE MCC control tissue, 1ug of total 
DNA was digested with the restriction enzyme Taq1 (New England Biolabs, Ipswich MA, 
USA). DNA was incubated with 1µl of Taq1 enzyme at 65ᵒC for 1 hour, including 5µl of 10x 
Cutsmart buffer to a final volume of 50 µl. This mix was then heat inactivated at 80ᵒC for 20 
minutes. Long and short synthetic adaptors specific for the overhangs produced by Taq1 
digestion were used (Geneworks, Australia) (Table 7.3). A double stranded adapter was 
produced by annealing a 25µM equimolar mix of each adaptor in 66mM Tris HCl pH 7.4 
buffer, in a water bath heated to 90ᵒC and allowed to cool overnight. The double stranded 
adaptor together with the digested lung tissue extracts were ligated overnight at 14ᵒC using 
the Promega T4 DNA Ligase kit (Promega, Australia). This reaction consisted of 6 units of 
T4 Ligase, 12 µl of 2x T4 buffer, 50pmol of double stranded adaptors and 100ng of digested 
lung tissue extract to a final volume of 25 µl. The ligation was diluted with 40 µl of water 
before 2 µl of this volume was added to the linear MCPyV-specific amplification reaction. 
MCPyV linear PCR amplification was performed in a total volume of 50 μl in a thermal cycler 
(BioRad DNA Engine Peltier Thermal Cycler, BioRad, Australia). First-round, linear PCR (40 
cycles) was carried out using a HotStar Taq Master mix (Qiagen, Australia), 5 μl of 10x PCR 
buffer, 10 μl of Buffer Q, 1.5 μl of 10mM dNTPs, 0.2 μM primer of each MCPyV specific 
primer labelled viral primer a (Table 7.3) and 0.75 of HotStar Taq. PCR parameters were: 
initial activation at 95°C for 15 min, followed by 40 cycles consisting of denaturation at 95°C 
for 30 sec, primer annealing at 50°C for 1 min, primer extension 72°C for 3 min and final 
extension 72°C for 7 min. For the second, exponential PCR, 2 μl of the PCR product was 
 subjected to amplification as described above, except that 2 primers (the viral primer b, 
together with the adapter-specific AP1 primer, (each 0.4 μM (Table 7.3)) were used and 30 
PCR cycles carried out. PCR products were analyzed on 2% agarose gels stained with 
ethidium bromide and read by transillumination. If single clear bands were present, 
unpurified DNA was then prepared for Sanger sequencing at the Australian Genome 
Research Facility (Brisbane, Australia). Multiple bands were excised from the agarose gel 
and purified as per the manufactures instructions (Qiagen gel purification kit, Qiagen, 
Australia) Following sequencing, data was aligned and manipulated with Bioedit Sequence 
Alignment Editor version 7.0.9.0.[72], Geneious 8.0.5 and CLC Bio Genomics Workbench 
6.5 software. Sequences were identified using the NCBI BLASTn database, identifying 
sequences other than human and mouse.   
 
Table 7.3 Oligonucleotide and adaptor sequences for linear and exponential DIPS-PCR reactions. 
Primers and adaptors and amplification methods all adapted from previously published methods.[12], 
[71] 
Primer Sequence 5' to 3' orientation PCR reaction 
MCV_1f_a tttgctcctctgctgtttctgc Linear 
MCV_1f_b cctaaataggaaagaaagagaggctc Exponential 
MCV_2f_a gattttgcagaggtcctgggtg Linear 
MCV_2f_b gtattagctgtaagttgtctcgccag Exponential 
MCV_3f_a gtactttcccatctaggttgacgagg Linear 
MCV_3f_b tggagatcaggaggattcagcttc Exponential 
MCV_4f_a gatatacctcccgaacaccatgag Linear 
MCV_4f_b gatccagtagcagagaggagaccac Exponential 
MCV_5f_a gctctgcaagctctgctagttcag Linear 
MCV_5f_b cagcaagttttacaagcactccacc Exponential 
MCV_6f_a ctcagaaaaccatttgccaacaag Linear 
MCV_6f_b cgcagacactgttctagccaaaag Exponential 
MCV_7f_a gccttgaatataaactgtccatctg Linear 
MCV_7f_b gccttttgaactaggatgtgctttg Exponential 
MCV_8f_a agctggtcaggaccctctgctc Linear 
MCV_8f_b gccctgaggaaactgaggaaac Exponential 
MCV_1r_a ggcgagacaacttacagctaatacaag Linear 
MCV_1r_b ccaggacctctgcaaaatctagc Exponential 
MCV_2r_a cagagcctctctttctttcctatttag Linear 
MCV_2r_b gaaacagcagaggagcaaatgag Exponential 
 MCV_3r_a gctactgaactaagtgccaccacag Linear 
MCV_3r_b aactttggaagctattcttacaggag Exponential 
MCV_4r_a tctccaaactgttagtggtataggctc Linear 
MCV_4r_b tctaataactgtgggggtgaggttg Exponential 
MCV_5r_a tcctgaacatataggaggaactctgc Linear 
MCV_5r_b aaactccagattggcttcttcctc Exponential 
MCV_6r_a cctgatcttcctactacttcaaactg Linear 
MCV_6r_b cagccaaagggatcatctccag Exponential 
MCV_7r_a aaactgtttacccaaagccctctg Linear 
MCV_7r_b agtaatcagcaggataagggcaag Exponential 
MCV_8r_a ttgggtttcctcagtttcctcag Linear 
MCV_8r_b cagagggtcctgaccagcttc Exponential 
AP1 ggccatcagtcagcagtcgtag Exponential 
AL1 gggccatcagtcagcagtcgtagccggatccagacttacacgtt Long Adaptor 
AS1 PO4-cgcaacgtgtaagtctg-NH2 Short Adaptor 
 
 
7.2.6 Plasmid control for MCPyV DIPS-PCR 
 
A MCPyV plasmid control was generated for the DIPS-PCR reaction. This plasmid was used 
to determine if steps in the DIPS-PCR protocol were optimal and to calculate the sensitivity 
of this method to detect MCPyV/host junctions, in samples with low viral template 
concentration. This plasmid was produced by Life Technologies (Life Technologies 
Australia, Pty Ltd). Briefly, the designed insert sequence contained the rtPCR MCPyV 1.1 
target region which included a 285bp region of the LTAg of MCPyV which could be amplified 
with the MCV_2f_a and b primers. This sequence was joined with 301bp of human 
chromosome 5 sequence and a Taq1 digestion recognition sequence. When digested and 
amplified the PCR products should produce a 360bp sequence product that contains 87bp 
of MCPyV LTAg sequence and 270bp of human chromosome 5 sequence confirming the 
MCPyV/chromosome 5 artificial junction (see Figure 7.2). The final construct was verified by 
sequencing. The sequence congruence within the insertion sites was 100%. Serial dilutions 
of the plasmid were made in RNAse/DNAse free water (Qiagen, Australia).  
 
 Ten concentrations (1000ng to 1e10-5ng) of the MCPyV DIPS-PCR control plasmid were 
examined by diluting plasmid DNA into RNA/DNA free water. Digestion and ligation were 
then conducted as per the methods in section 7.2.5. The PCR methodology was optimised 
by amplifying the control plasmid at two different annealing temperatures, 50 and 55ᵒC in 
both linear and exponential reactions. Parallel reactions were also used to evaluate if 
increasing HotStar Taq concentrations from 0.25µl to 0.75µl improved MCPyV DIPS-PCR 
sensitivity.   
 
Figure 7.2 Illustration of MCPyV DIPS-PCR control plasmid insert; the plasmid insert sequence 
contained a synthetic oligonucleotide junction between MCPyV LTAg and chromosome 5 (highlighted 
in green). The chromosome 5 sequence also contained a Taq1 restriction site (highlighted in yellow). 
 
MCPyV LTAg sequence is underlined (between 525-810 MCPyV LTAg). Chromosome 5 sequence is not 
underlined. The junction between MCPyV LTAg and chromosome 5 is highlighted in green. Nucleotide 
sequence highlighted in aqua is the primer sequence for MCV_2f_a and b (Table 7.2). Red highlighted 
sequence is the nucleotide sequence for rtPCR assay MCV 1.1 (Detailed in Chapter 6, section 6.2.5). 
Sequence highlighted in yellow is a Taq1 recognition site.   
 
7.3 Results 
 
7.3.1 Whole genome sequencing of MCPyV positive lung tissues 
 
Whole genome sequencing was completed for all MCPyV-positive lung tissue. Figure 7.3 
illustrates the three MCPyV genomes detected from PCR categories defined in Chapter 6 
section 6.3.3. These were 7.4C; MCPyV positives detected only or predominately in normal 
 lung tissue, 7.4D; MCPyV PCR positive predominately detected in tumour lung tissues and 
7.4E; MCPyV PCR positive detected at equivalent copy numbers in both normal and tumour 
tissue (Figure 7.3). Additional sequence data for all MCPyV positive lung tissues is shown 
in Appendix A7.2. In general, sequences from matched normal and tumour specimens were 
identical. The data shown for whole genomes were derived from tissues with the highest 
MCPyV load. The MCPyV sequences from patients LC1 and LC10 contained sequence 
differences for the normal and tumour tissues.  Complete sequence data for these 
sequences are provided in Appendix 7.2. The MCPyV viral load was very low in both the 
normal (0.04 x10-3 MCPyV copies per cell) and tumour (0.03 x10-3 MCPyV copies per cell) 
tissue of patient LC1 and this resulted in an inability to amplify the whole genome.  
7.3.1.1 MCPyV predominately detected in normal lung tissues 
 
MCPyV was predominately detected in the normal lung tissues of patients LC5, 9, 44, 65 
and 69. Patients LC5 and LC9 are depicted in section C of Figure 7.4. Full length MCPyV 
was sequenced in all patients in this category with the exception of patient LC5. In patient 
LC9 only one non-synonymous change was noted in the whole genome sequence of virus 
found in normal tissue. This was located at position 3875bp within the VP1 coding region 
and resulted in a glutamine to glutamic acid amino acid change. This non-synonymous 
change has been commonly reported in MCPyV genomes and was found in 8 of the 43 
MCPyV whole genome sequences publically available.   
   
Significant portions of the MCPyV sequence in the normal tissue of patient LC5 could not 
be amplified, including a portion of the second exon of the LTAg between 2210bp to 2465bp. 
(targeted by walking primer sets 5 and 6). The majority of the coding region for VP1 2 & 3 
also failed to amplify, and no sequence information was obtained between 3650bp and 
4860bp of the genome (targeted by walking primer sets 10, 11 and 12). The lack of sequence 
 in the VP2 region was supported by the inability to amplify MCPyV in this sample using the 
MCPyV confirmatory PCR primers which amplify a region in the VP2 protein. Polymorphism 
within the MCPyV sequences targeted by the walking primers have been analysed for all of 
the 43 MCPyV whole genomes available, and are shown in Appendix A7.1. Generally, 
primer mismatches were only found in a single MCPyV sequence, and these mismatches 
could be overcome by using different combinations of walking primers.  
 
7.3.1.2 MCPyV predominately detected in tumour lung tissues 
 
Tumour tissue from patients LC7 and LC61 fall within this category. Full-length MCPyV 
sequence was amplified from the normal and tumour tissue of patient LC61. These were 
identical and non-synonymous changes were not detected in the genomes. In contrast the 
sequencing of MCPyV detected in the tumour tissue of patient LC7 revealed areas in the 
LTAg, VP1, 2 & 3 sequence that could not be amplified. These included a 400bp portion of 
LTAg exon 2 between 920bp and 1390bp (walking primer sets 2 and 3). A significant portion 
of the the LTAg gene was also not amplified between 3935bp and 3970bp (primer set 10) 
and 4490 to 4900bp (primer set 11 and 12). Low levels of viral template in the normal lung 
tissue of this patient prevented the generation of MCPyV sequence data for this specimen.  
7.3.1.3 MCPyV detected in normal and tumour lung tissues at equivalent viral load  
 
An identical full-length MCPyV sequence could be found in the normal and tumour tissue of 
patient LC4. This sequence contained only one non-synonymous change in the early coding 
region of VP2. This single base change encodes for a premature stop codon which 
significantly truncates the VP2 protein from 241 amino acids to 26 amino acid length protein.  
In comparison the complete MCPyV viral genome was also sequenced in the normal and 
tumour tissue of patient LC48. However, this sequence demonstrated numerous 
 synonymous base changes throughout the genome, but only one non-synonymous change 
at 3875bp in the VP1 coding region. This single base pair change produced an amino acid 
change from glutamine to glutamic acid. This non-synonymous base change is common and 
was also detected in the normal tissue of LC9 and in 8 of the 43 MCPyV whole genome 
sequences publically available.     
 
7.3.1.4 MCC control tissue 
 
To compare MCPyV sequence data obtained from a MCC tissue to that detected in lung 
tissues, FFPE MCC-positive control tissues were amplified. Around 3000bp of the 3’ end of 
the LTAg to the early coding region of the VP2/VP3 sequence could not be detected, which 
was targeted by MCPyV walking primer sets 3 to 12.    
 
 
 Figure 7.3 Comparison of MCPyV whole genome sequencing, derived from non-cancerous specimens, 
merkel cell carcinoma and lung tissue. 7.4A illustrates the MCPyV genome with the coding orientation 
for structural and non-structural viral proteins. 7.4B compares the MCPyV genomes detected in a 
MCPyV full-length construct (Accession no. JF813003) and three MCC derived truncated MCPyV 
genomes (MCC350, Accession no. EU375803, MCC339 Accession no. EU375804, MCC849 was 
sequenced for this study). 7.4C compares MCPyV sequences detected predominately in normal lung 
tissue and not in matched tumour specimens. 7.4D compares sequences detected predominately in 
tumour tissues and not matched normal lung tissues. 7.4E compares sequences from tissues with 
equivalent MCPyV viral load in matched normal and tumour lung tissue.    
 
Round unfilled circle represent synonymous base changes, red circles indicate non-synonymous changes, 
dashed lines indicate deletions, double horizontal lines indicate base changes that lead to a premature stop 
codon, arrow heads indicate 3 – 5bp insertions and incomplete lines indicate areas of the MCPyV genome 
which could not be sequenced.  
 
7.3.2 MCPyV integration 
 
Difficulties amplifying MCPyV using the phi29 rolling circle amplification method could 
suggest that the MCPyV contained within the lung tissues could be linearized and integrated 
into the host genome. Therefore attempts were made to investigate potential integration 
 sites with the same methodology previously used to demonstrate BKPyV integration in 
bladder carcinoma (section 5.2.7).  
 
Three MCPyV lung cancer specimens were selected to determine potential MCPyV 
integration; LC4, 10 and 48 as both the tumour and normal tissues were positive and had 
relatively high viral loads. 
 
Second round PCR products were visualised on 2% agarose gels to achieve greater 
separation between product bands for excision. The strongest bands were found around 
120bp in size and corresponded to amplification of LC48 normal and tumour tissues using 
the primer MCPyV F 14 inner. (Figure 7.4) 
 
Figure 7.4 Agarose gel electrophoresis of second round products investigating potential MCPyV 
integration site 
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 All ten clones from both LC48 normal and tumour tissues produced highly similar products 
of 110bp in length. Subsequent sequencing and BlastN searches of these showed it 
contained both MCPyV and human chromosome 11 sequence (Figure 6.2). The 64bp 
human sequence had 100% homology with homo sapiens (ST5) on chromosome 11 
(position 151,796). However only a 23bp portion of MCPyV sequence was found. This 
sequence directly corresponded to MCV W14F Inner primer sequence which binds to the 
NCCR region. The last 9bp of this primer sequence were also the first 9bp in the 
chromosome 11 sequence, and the high homology with the 3’ end of MCV W14 inner primer 
may have been sufficient to produce this product without genuine MCPyV chromosome 11 
integration. After the 64bp region of chromosome 11, seven bases were found that did not 
correspond to the chromosome 11 and were variable between all the cloned sequence 
products from LC48 tissues. The 3’ end of the cloned sequence corresponded to the exact 
25bp sequence of the second round human tag primer.  
 
 
Figure 7.5 Homologous sequence found in all five clones of the LC48 tissues. Sequence contains both 
MCPyV and chromosome 11 human sequence.    
 
 
 
 
 
 
 
 
 
MCPyV Inner 14 
Forward primer 
sequence 
Human tag primer 
sequence 
GTTTATCAGTCAAACTCCGCCTCCCGGGTTCAAGTGATTCTCCTGCCTCAGCCTCCCAAGTAGCTGGTATTACACGCGTTCGTCCTGAACAGTCGACATGCACGCAAGCA 
Chromosome 11 
sequence 
Homologous sequence 
between chromosome 
11 and primer 
Variable sequence no 
homology with 
chromosome 11 or 
primer 
 7.3.3 Confirmation of MCPyV/human integration sites 
 
Confirmatory PCRs were conducted to produce a 450bp or 220bp larger 
MCPyV/Chromosome 11 product. No PCR products from either of these PCR reactions 
could be visualized on a 2% agarose gel.   
7.3.4 Investigating MCPyV integration using MCPyV DIPS-PCR 
 
DIPS-PCR was conducted on MCPyV positive lung tissues from patients 4, 5, 7, 48 and 61. 
Tumour tissue specimens were utilised for patients 4, 7, 48 and 61, whereas only normal 
lung tissue for patient 5 was positive by PCR and histology, and was used in the DIPSPCR 
experiments.   
 
Amplification was visualised on agarose gels with clear single bands in many cases (Figure 
7.6). However sequencing produced low quality sequences in almost all samples. High 
quality sequence data was produced for the normal tissue of lung cancer patient 5 using 
primer set MCV_8F_B. This reaction produced a 238bp product, with a 198bp portion of this 
sequence sharing 100% sequence identity (expect value 4e-93) with Human DNA sequence 
from clone RP11-161P17 on chromosome 13 (51816 to 52013). However the remaining 
40bp of sequence had little homology with any other human or viral sequence.  
 Figure 7.6 Visualisation of amplification products from DIPS-PCR amplification using a set eight 
MCPyV nested walking primers. Highlighted bands were excised and sequenced however only low 
quality useable sequence data was generated for the band highlighted in black. However human 
sequence from chromosome 13 was detected from the band on agarose gel 2 highlighted in red. Bands 
in agarose gel 1 row 7 were amplified by primer set MCV_8F_b, bands in agarose gel 1 row 14 were 
amplified by primer set MCV_7R_b, bands in agarose gel 1 row 1 were amplified by primer set 
MCV_8R_b, and bands in agarose gel 2 row 5 were amplified by primer set MCV_8F_b. 
   
 
7.3.5 Amplification of control plasmid for MCPyV DIPS-PCR 
 
Amplification of eight serial dilutions of the DIPS-PCR control plasmid DNA produced the 
expected 400bp product. Sanger sequencing confirmed 100% homology between the 
designed plasmid sequence and eight concentrations (1000ng to 1x10-3ng) of MCPyV DIPS-
PCR products. Optimal conditions were determined to be an annealing temperature of 50ᵒC 
and 0.75µl of HotStar Taq for both linear and exponential reactions. These conditions 
showed a limit of sensitivity for the DIPS-PCR reaction as 1x10-3ng of control plasmid DNA 
per reaction. Plasmid dilutions were also examined by the rtPCR MCPyV 1.1 assay, and 
 showed that 1x10-3ng DIPS-PCR plasmid concentration produced a Ct value of 28, which 
was equivalent to approximately 100 copies of MCPyV DNA per reaction.  
 
7.4 Discussion 
 
This Chapter of the study has further characterised the presence of MCPyV in paired normal 
and tumour tissue from patients with lung carcinomas. Whole MCPyV genome sequences 
and MCPyV sero-reactivity was examined, with particular interest in patients who had 
MCPyV predominately detected in tumour tissue.   
7.4.1 Whole genome sequencing  
 
Whole genome sequencing was performed using multiple sets of walking primers to 
determine the existence of genome truncations, deletions or nucleotide substitutions. This 
approach was used because previous attempts to amplify MCPyV in positive lung tissue 
using the dRCA method was unsuccessful (Chapter 6), suggesting that viral genome 
sequences were present in a linear conformation. Truncations of the coding sequence for 
MCPyV LTAg have predominately been found in patients with MCC, and these genomes 
typically display coding mutations or integration sites that truncate viral proteins and thereby 
render the virus replication incompetent. Although MCPyV genome truncations have rarely 
been reported in non-MCC specimens, they have been detected in cases of CLL, and in two 
cases of NSCLC. [2], [40], [45], [48] 
 
In this study, the examination of MCPyV positive lung tissues, showed that, with the 
exception of one normal specimen, all MCPyV positive normal lung tissues demonstrated 
full-length untruncated MCPyV genome sequences. This suggested that MCPyV harboured 
in this tissue type was the result of a productive infection. In contrast, in 1 of 2 subjects in 
 whom MCPyV was detected at higher copy number in tumour tissues there was evidence 
of MCPyV coding truncations and deletions within the MCPyV genome. This was also 
observed in 2 of 4 subjects with demonstrated presence of MCPyV genome in both tumour 
and normal tissue.  
 
One MCPyV-positive patient (LC4) was found with a single nucleotide substitution that led 
to a premature stop codon in the N-terminal coding region of VP2. This sequence was 
identified in both normal and tumour lung tissue. The MCPyV truncation in VP2 significantly 
reduced the VP2 protein in size from 241 to 26 amino acids. This was a unique observation 
and was the first report of a coding truncation of the MCPyV VP2 protein. Other groups have 
demonstrated the importance of VP2 in virus infectivity, therefore this truncation would 
significantly affect the ability of the virus to reinfect other cells.[38] However, evidence from 
immunohistochemical staining and PCR showed that MCPyV LTAg proteins were present 
in tumour and respiratory epithelial cells suggesting that MCPyV was actively infecting cells 
in this patient. Additionally, this patient showed the highest virus copy number per cell of all 
the MCPyV-positive normal and lung tumour tissue examined, again suggesting continued 
MCPyV infectivity. One possible explanation for this may be that tumour cells have lost 
control of cell cycling, making them a highly permissive cell type for MCPyV replication. 
Therefore MCPyV replication could occur as a ‘passenger’ with the virus exploiting cells that 
lack replication control, and thus allows rapid and unchecked virus replication. However this 
did not explain the high MCPyV viral load also detected in normal lung tissue, where the cell 
may not have lost cell cycle control.  
  
Another potential mechanism may be that host epigenetic factors, possible due to 
environmental carcinogens, work in synergy with virus-induced cell cycle stimulation, 
proliferation and genomic instability, which is sufficient to transform the cell. In this 
 mechanism a VP2 truncation, such as the one found in LC4, could be producing high titres 
of MCPyV early proteins whilst limiting the MCPyV natural infection cycle by reducing or 
even eliminating the capacity for virion exit from the host cell. However this explanation only 
partially explains the high viral load in this patient in the absence of viral integration.  
 
No other cases of MCPyV polymorphism that encode premature stop codons were found in 
either normal or tumour lung tissue. However, several patients had portions of the MCPyV 
genome which could not be amplified with the method used. This included a patient (LC7) 
where MCPyV was predominately found in tumour tissue. In these tissues, segments of the 
C-terminal region of LTAg, VP1, 2 and 3 could not be amplified. Such loss of the late coding 
region of MCPyV was often seen with MCPyV integration in MCC. In other patients, who 
predominately had MCPyV detected in lung tumour tissue, full-length MCPyV sequences 
were present. Surprisingly, a single case of MCPyV-positive normal lung tissue produced a 
MCPyV sequence with regions that could not be amplified suggesting significant deletions 
in the genome. The loss of the late coding region in this patient was supported by the inability 
to amplify the region targeted by the VP2 rtPCR despite the copy number of MCPyV in this 
sample being 10 fold greater than the established sensitivity of the rtPCR.  
 
Potentially, MCPyV sequence variation could have affected the homology with primer 
binding sites. This assay was designed to use four walking primers to amplify each 400bp 
region of the MCPyV genome and further, this PCR could be nested to allow additional 
sensitivity. Despite this, no combination of primers was successful in producing a positive 
MCPyV sequence in these regions, thus providing further evidence that portions of the 
MCPyV genome were absent in some normal and tumour lung tissue. 
  
 Tissues from two other MCPyV-positive patients (LC1 and LC10) failed to amplify MCPyV 
genome segments from the late coding region. However, in these patients the MCPyV copy 
numbers per cell was very low (0.01 – 0.03 x10-3 copies per cell) which may be below the 
limit of sensitivity of the walking primers, thereby preventing amplification.  
7.4.2 MCPyV integration into NSCLC 
 
The potential integration of MCPyV was investigated using two methods, the first was a 
modified method originally used to amplify integrated forms of HBV. This method was 
successfully used in Chapter 5 to amplify the virus-host junction of BKPyV in a bladder 
carcinoma. Attempts to amplify MCPyV host junctions in three MCPyV positive lung 
carcinomas failed to produce evidence of MCPyV integration. Amplified products only 
produced 25bp of MCPyV specific sequence which was identical to the MCPyV primer used 
in the reaction. The 3’end of this MCPyV primer sequence contained a 9bp stretch which 
had 100% homology the amplified segment in chromosome 11, suggesting that the reaction 
was primed from this non-specific homology rather than a genuine MCPyV host junction. 
Attempts to amplify a larger sequence external to the proposed chromosome 11/MCPyV 
junction site were also unsuccessful. Therefore this method failed to provide conclusive 
evidence of MCPyV integration in a subset of positive lung carcinomas. However MCPyV 
integration has been reported for two MCPyV positive NSCLC in the Japanese cohort. In 
the Japanese study viral integration was investigated using a modified method from studies 
identifying viral integration of papillomaviruses in cervical cancer (DIPS-PCR).[71] The 
DIPS-PCR method is commonly used to determine viral integration junctions in MCC. [12], 
[17]. The DIPS-PCR method may offer an increased sensitivity over the modified HBV 
integration methodology.  However this approach also failed to detect MCPyV integration 
sites using the DIPS-PCR methodology in any of the MCPyV positive lung tissues. Previous 
studies had not reported the sensitivities of these methods, and therefore a control plasmid 
 was used in this study to infer the MCPyV viral copy number required to identify potential 
integration sites. Even though the DIPS-PCR assay had a limit of sensitivity of 100 copies 
of MCPyV DNA per reaction, only one of the patients (LC4) showed a MCPyV viral load that 
was equivalent or greater to this limit of sensitivity. Therefore MCPyV integration events may 
still have occurred, but were not detected using the current methods. 
 
It cannot be ruled out however that the MCPyV integration event may be polyclonal and 
occurs after the initial cell transformation event. In this case MCPyV may have numerous 
different integration sites, and it is unlikely that the modified HBV integration PCR or the 
DIPS-PCR method will be sensitive enough to detect these viral host junctions. Alternatively 
MCPyV may be episomal, but contain secondary structures that are inhibiting amplification 
by dRCA. 
  
Although MCPyV was frequently detected in NSCLC, no evidence was found of MCPyV 
integration, nor was there a significant increase in seroresponse to MCPyV early proteins, 
which is a prognostic indicator in MCC patients. Therefore these results suggested that it is 
unlikely MCPyV acts as a direct carcinogen in the Brisbane cohort of NSCLC, and that 
MCPyV may not contribute to cell transformation with a similar mechanism as reported in 
MCPyV induced MCC. However, the results do raise additional questions why MCPyV was 
detected within the lung carcinomas at all. It may be speculated that the role of MCPyV in 
the lung could fall into two potential scenarios. 
  
1) MCPyV is an opportunistic passenger in lung tissue, and reactivation of the virus may 
occur due to a decrease in immune surveillance after the development of transformed 
cells or normal lung cells develop pre-cancerous epigenetic changes. MCPyV utilises 
these cellular changes which promote cell cycling, and in turn this enables favourable 
 conditions for polyomavirus replication. This unchecked replication leads to MCPyV 
polymorphism and DNA damage to both the virus and host cell, which would explain 
the loss of MCPyV genomic sequence and or MCPyV polymorphism detected in 
normal and tumour tissues.  
2) MCPyV virus reactivation in normal lung tissue causes genomic instability and blocks 
DNA damage repair pathways, leading to sporadic mutations in the host cell genome 
as well as in MCPyV that lead to cell transformation. This would also explain the 
MCPyV genome polyomorphism detected in some cases of NSCLC. The continual 
expression of early MCPyV proteins is not required to maintain the transformed 
phenotype, therefore MCPyV contributes to cell transformation using an indirect 
pathway.   
Early evidence from this Brisbane cohort of samples suggests that MCPyV may be 
involved through both potential scenarios. Clearly MCPyV has the ability to stimulate cell 
cycling and proliferation through numerous pathways, however the question remains if 
MCPyV is a causal agent in generating these cell cycling changes or does it simply utilise 
these alterations to promote viral replication?  
 
Although the discovery of partial and truncated MCPyV sequences in normal and 
neoplasmic lung tissue is of great interest, further viral and host cell characterisation is 
required to fully understand the role MCPyV, if any, in the development of NSCLC. 
Further experiments are planned as part of a post-doctoral project using unbiased deep 
sequencing to examine if MCPyV is integrated polyclonally or if segments of MCPyV 
sequence are indeed absent in some tumour lung tissue and their controls.      
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 CHAPTER EIGHT 
 
General Discussion 
 An abundance of newly described polyomaviruses have been uncovered with the aid of Next 
Generation Sequencing techniques, however only a few have been implicated as a potential 
cause of pathology. Although understanding the tissue tropism of the ten novel 
polyomaviruses is in its infancy, evidence suggests that they infect a variety of tissues, such 
as skin, respiratory, gastrointestinal and endothelium. New members of the polyomavirus 
family have also been detected in cattle, dolphins and fish, suggesting that other human 
polyomaviruses remain to be discovered. This parallels the papillomavirus family where 
more than 150 members have been shown to infect humans.  
8.1 Newly described polyomavirus acquisition in the respiratory tract  
 
This thesis has focused on newly described polyomaviruses detected within the respiratory 
tract and has generated important new data to demonstrate that WUPyV, KIPyV and 
MWPyV were highly prevalent in the respiratory tract of children under 5 years of age. This 
was similar to the results of previous serology studies finding that polyomaviruses were 
acquired very early in life, and this study supported those findings by demonstrating that 
primary infection of WUPyV, KIPyV and MWPyV occurred around children’s first birthday. 
The vast majority of previous studies investigating the potential pathogenicity of newly 
described polyomaviruses have been conducted retrospectively and generally on samples 
from hospital-based cohorts involving patients with a high disease burden. Therefore these 
previous studies were not designed to assess the true prevalence or pathology of 
polyomaviruses in the general population, which made it almost impossible to determine 
potential pathogenicity.  The study designed for this Thesis sought to address these 
limitations, by use of a prospectively sampled cohort of children. The results presented 
therefore were, to our knowledge, the first to accurately assess first acquisition following 
birth, and the first to perform a statistical assessment of virus presence with presentation of 
clinical disease. 
 8.2 Newly described polyomaviruses and respiratory disease  
 
Without the ability to culture the majority of polyomaviruses in vitro, a well-controlled 
longitudinal study was the only way to truly assess the potential pathogenicity of this 
expanding virus family. However, despite the well-designed longitudinal cohort described in 
this thesis, the co-detection and complex pattern of multiple virus acquisition within the first 
two years of life limited the ability to definitively determine symptomology associated with 
any polyomavirus. However, this study provided new data which demonstrated that primary 
infection of WUPyV, KIPyV and MWPyV was accompanied with mild respiratory symptoms 
in one third of infections in healthy children under the age of two years.  
 
Interestingly this study was the first to show that MWPyV was most prevalent polyomavirus 
detected in the respiratory tract of young children, yet it was not detected in any specimens 
collected from immunocompromised subjects. This may suggest that a robust primary 
infection and the development of long-term immunity against MWPyV may be sufficient to 
prevent or control reactivation, even when the immune system is impaired. However, due to 
the focus of study for this thesis being the respiratory tract, limited examination of 
gastrointestinal specimens from immunocompromised patients was conducted. Therefore it 
is possible that MWPyV may have tropism for the gastrointestinal tract and cause pathology 
in this body site. Evidence also suggests that MWPyV has a tropism for the skin as it has 
been detected in anal warts in immunocompromised patients. Indeed, many of the newly 
described polyomaviruses have pathology associated with the skin. Given the prevalence 
of MWPyV in children under two years of age, one that was only exceeded by the detection 
of rhinoviruses,  MWPyV requires further investigation, especially in 
immunocompromsied patients.  
 
 An important finding of this study was the evidence showing that WUPyV and KIPyV have 
an aetiological role in respiratory tract illness. High WUPyV and KIPyV loads were detected 
in respiratory secretions with evidence of active viral replication through the detection of viral 
RNA. This was supported by the detection of KIPyV only, in two kidney transplant recipients 
who developed respiratory tract disease. These patients were highly immunocompromised, 
and had elevated viral loads at each time point, suggesting that, like BKPyV, reactivation 
and development of KIPyV associated pathology was highly immune dependent and 
profound immunosuppression was required before pathology was noted. In both cases 
evidence of viral reactivation was present before organ transplantation, suggesting this 
might be a requirement of KIPyV-associated pathology or that reactivation required long-
term immunosuppression for high load viral replication to develop. This finding is of great 
significance in the context of patient management and is further highlighted by previous 
reports of fatal KIPyV infections in transplant patients.[1] Like the best practice for BKPyV-
associated nephropathy, determining KIPyV reactivation by monitoring viral load will allow 
treatment of clinical disease through the reduction of immunosuppression. Considering the 
findings of this study showing a strong association of WUPyV, MWPyV and particularly 
KIPyV with the respiratory tract, this suggested a preferential tropism for this organ. Further 
studies of these viruses particularly in the immunocompromised are likely to answer 
important questions about their pathogenesis.    
 
Evidence for a pathogenic role of HPyV 6, 7 and STLPyV was inconclusive. If present in 
respiratory samples from immunocompromised patients, these viruses had low viral load 
without evidence of respiratory symptoms. Although outside the scope of this study, an 
examination of specimens from the skin and gastrointestinal tract may provide a better 
insight into their role as pathogens. Further longitudinal studies, particularly on 
immunocompromised populations, with collection of blood, urine, respiratory, skin and 
 gastrointestinal specimens would increase our current understanding of the newly described 
polyomaviruses in immunocompromised populations.  
 
8.3 Newly described polyomaviruses as oncogenic viruses. 
 
Polyomaviruses have a long and controversial history as potential oncogenic agents. Until 
the recent discovery of clonally integrated MCPyV in MCC carcinoma, the general 
consensus in the research community was that human polyomaviruses did not have a 
causal role in human carcinogenesis. However, the discovery of MCPyV renewed the 
research interest in the role polyomaviruses could play in cell transformation. This was also 
supported by the growing evidence that HPV plays a role in many different cancer types, 
including cervical, head and neck and genital cancers. HPV and polyomaviruses were once 
considered a single family due to their many genetic similarities, including the mechanisms 
of viral replication which promote cell cycling. This provides ample suggestion that PyVs 
may act in an analogous fashion to HPV in oncogenesis.  
 
Here we described BKPyV integration in a patient who had received a renal transplant and 
had a lengthy history of active BKPyV replication within the urogenital tract. In this case 
study BKPyV viral integration was demonstrated with further evidence of over-production of 
BKPyV T-antigens without the production of BKPyV virions. This study demonstrated that 
BKPyV can act through a similar oncogenic pathway as SV40 and MCPyV. Given the 
evidence that transplant recipients are at a much higher risk of developing cancers, it seems 
likely that opportunistic pathogens, such as polyomaviruses could play a role in cell 
transformation. However further understanding of why only a small number of transplant 
recipients developed polyomavirus associated pathology is still elusive. It is clear that the 
immune system has a major role in controlling polyomavirus associated disease. However 
 it is undoubtedly a complex multi-factorial process, which may develop over several 
decades, is difficult to study experimentally and requires a cross disciplinary approach by 
researchers in the fields of oncology, infectious diseases and immunology.  This was also a 
limitation of the study described in this Thesis, which used retrospectively collected samples. 
Hence it is difficult to determine if viral pathogens play a role in cell transformation, or if the 
polyomavirus is a benign passenger within immune or cancer cells. The BKPyV bladder 
cancer study described here and many previous studies have used formalin fixed paraffin 
embedded archival tissues, where DNA quality is usually poor and often confounds 
molecular detection and characterisation of pathogens. The use of FFPE tissues also limits 
the sensitivity of expression assays used to determine increased expression of pathogen 
encoded tumour antigens. However FFPE tissues do allow for the detection of pathogen 
encoded proteins through the use of histological staining. Histological investigations are 
vitally important to determine if pathogen encoded antigens are present in tumour tissue or 
have been carried into the tissues by immune cells or are harboured with cells of 
histologically normal phenotype. Therefore, when designing the lung cancer cohort only 
fresh frozen tissue were used, with a matched normal lung specimen to increase the quality 
of both histological and molecular markers of polyomavirus presence. This was considered 
to be essential in this study, and allowed the definitive determination for the presence of this 
polyomavirus as a potentially oncogenic pathogen. However, even with the successful 
demonstration of this in a well-designed sample cohort, the histological and molecular 
results alone were not sufficient to determine oncogenic causality.  
 
Earlier evidence for MCPyV in MCC, together with results in this study for BKPyV in bladder 
cancer, suggested that integration of viral genome is a prerequisite for oncogenesis. 
However, the examination of the NSCLC cohort in this study failed to show viral integration, 
even though evidence may suggest that the viral genome was present in a linear 
 confirmation. The most likely conclusion for these findings, is that MCPyV does not act 
through the same mechanism as MCC in its role as an oncogenic agent. This assertion was 
also supported by the results of MCPyV-specific serology which showed a seroreactivity 
pattern in the NCCLC subjects that was distinctly different from that previously described for 
MCC patients.  Clearly, significant research still needs to be performed to determine the role 
of MCPyV in lung cancer. Interestingly the recent description of Raccoon polyomavirus, 
which is believed to be the causal agent of olfactory tumours in Raccoons, shows the virus 
to be episomal and demonstrates a different oncogenic pathway that does not require viral 
integration. Phylogenetically MCPyV is most closely related to RacPyV, further suggesting 
that polyomaviruses may contribute to oncogenesis using several different mechanisms. 
      
Currently almost all recognised oncogenic pathogens act through a direct mechanism which 
requires the continual presence of viral or bacterial proteins to maintain transformed 
phenotype. However, increasing speculation suggests infectious agents act through a ‘hit 
and run’ mechanism, where the infectious agent is an additional factor in cell transformation. 
For example by causing genomic instability or preventing DNA repair. This instability causes 
sporadic mutations within the host cells that are detrimental to cell cycling, cell proliferation 
or cellular repair. After the sporadic mutations have occurred, the requirement for continued 
expression of viral proteins is not needed and therefore the infectious agent may be cleared 
before the tumour is detected. Such a mechanism may result in an underestimation of the 
pathogen’s role in cancer tissue cohorts.  It could be speculated that if MCPyV is contributing 
to cell transformation in NSCLC, this occurs through an indirect mechanism, which would 
be difficult to demonstrate experimentally. Additionally, MCPyV could have several roles 
within the lung, that may also confound attempts to understands its role within NSCLC as; 
1) an opportunistic pathogen that can reactivate in healthy or tumour lung tissue,  2) a 
contributor to cell transformation in some patients with additional predisposing 
 environmental or genetic factors, or  3) an agent that reactivates and stimulates genomic 
instability and/or deactivates DNA damage repair and alters the host’s oncogenic response 
through sporadic mutation.  
 
Determining if infectious agents have a role in human cell transformation is a difficult process 
and researchers are becoming sceptical of results which only use molecular methods to 
detect agents in cancer tissues. It has been recommended that several robust techniques 
must be used to examine the role of infectious agents in cell transformation, [2] and that 
these criteria should be used to determine a causal association. However it is recognised 
that many of De Paoli & Carbone’s [2] criteria are difficult to determine, particularly for the 
proposed ‘hit and run’ mechanisms and for viruses that are difficult to culture and therefore 
cannot be studied in animal models. At a minimum it is recommended that researchers use 
several approaches to determine the presence of the infectious agent in tumour cells at 
higher abundance than normal tissue, and show the presence of the viral agent before cell 
transformation occurs.  
 
During this thesis many different experiment techniques were used, including molecular 
methods and classical histology and virology, to examine the role of PyVs in carcinoma 
tissues. Future studies need to be conducted on specimens where sufficient and correctly 
stored tissue is available, together with matched normal control tissue.  
 
8.4 Key outcomes of this research study 
 
At the commencement of this study, little was known about the biology, epidemiology and 
pathogenesis of the new human polyomaviruses. This research has sought to address this 
knowledge gap. As a result, the outcomes of this project have contributed to a better 
 understanding of the potential role the new human polyomaviruses play in disease, and 
have given an insight of their putative involvement in oncogenesis. 
 
The key outcomes for the study described in this thesis may be summarised as follows: 
 
Chapter 2:  
 A sensitive and specific set of molecular techniques were developed to accurately 
determine the presence of, and characterise, the new human polyomaviruses in a 
variety of clinical specimens.  
 Results showed that the newly discovered human polyomaviruses HPyV6, 7, 9, TSPyV 
and MWPyV were present only in the respiratory and gastrointestinal tract, primarily in 
children with or without disease manifestation.  
 Findings confirmed the results of serology by others that acquisition of these viruses 
appeared to occur at an early age.  
 Results supported the hypothesis that transmission of the new polyomaviruses is by the 
oral-faecal route. 
 
Chapter 3:  
 Examination of sequentially collected respiratory and faecal samples from children 
enrolled in a birth cohort study showed that all polyomaviruses were frequently detected 
in children under 2 years of age, with MWPyV the second most common virus detected 
after rhinoviruses.  
 It was shown that first virus acquisition may occur as early as 1 month after birth. 
 Strong evidence was found to demonstrate replication of WUPyV and KIPyV in the 
respiratory tract following first infection, and together with MWPyV there was a 
significant association of presence of these viruses with mild clinical disease. 
  
Chapter 4:   
 In renal transplant recipients the new human polyomaviruses were readily detected in 
respiratory samples, but in contrast to immunocompetent subjects, these viruses were 
also present in blood and urine samples demonstrating systemic spread. 
 Persistent longtitudinal detection of KIPyV in the respiratory tract of some renal 
transplant recipients undergoing high level immunosuppression coincided with the 
presentation of respiratory tract disease, showing that this virus is likely be a respiratory 
pathogen in this patient group.   
 MCPyV was the polyomavirus detected at highest prevalence in this patient cohort. As 
this virus is the only human polyomavirus shown to have a role in oncogenesis, this 
finding is significant and has wider implications for the development of cancer, not only 
in organ transplantation recipients, but also in other populations. 
 
Chapter 5:  
 Human polyomavirus BKPyV was detected in biopsy tissues from two renal transplant 
recipients with micropapillary urothelial carcinoma. 
 Evidence of BKPyV integration into the host genome at the junction located in the VP1 
coding sequence was demonstrated. This finding confirmed the role of BKPyV, and 
possibly human polyomaviruses generally, as potential oncogenic agents. 
 
Chapter 6: 
 MCPyV was detected by PCR exclusively in tissue biopsies from patients with Non 
Small Cell Lung Carcinoma. 
 The presence of MCPyV proteins in these tissues was confirmed by immuno-
histochemical staining. 
  Experimental evidence indicated that the viral genome maybe present as a linear 
molecule suggesting integration into the host cell genome. 
 The serological response to MCPyV tumour antigens in NSCLC patients differs from the 
serological response observed in patients with Merkel cell carcinoma. 
 
Chapter 7: 
 MCPyV coding truncations were demonstrated in the biopsy tissues from some patients 
with NSCLC.  
 Integration of MCPyV genome sequences into the host cell genome could not be 
demonstrated. 
 
8.5 Thesis Conclusions 
 
The prominent findings from the study described in this thesis include the association of 
KIPyV with mild respiratory symptoms in healthy children and in immunocompromised renal 
transplant recipients. This indicates that KIPyV should be considered iin any laboratory 
investigations of immunocompromised patients with respiratory disease where other 
pathogens cannot be identified. 
   
This thesis has also presented evidence of the presence of polyomaviruses in human 
carcinomas, both in long term immunocompromised patients and immunocompetent 
individuals. There was a strong indication of virus presence in tumour cells, with a likelihood 
they may be actively involved in cell transformation. However, in lung carcinoma evidence 
suggested this was not through viral integration as a direct carcinogen, but rather that 
viruses may play an as yet undefined role in cell transformation as an indirect carcinogen. 
 Interestingly, multiple potentially oncogenic viruses were detected in one tumour specimen, 
raising questions about the impact from multiply viral proteins on cell cycling.   
 
Ongoing research will characterise host and viral changes within the MCPyV tissues using 
unbiased deep sequencing in which genomic and viral DNA will be sequenced with 
significant coverage to be able to demonstrate if host genome changes are present in 
MCPyV positive tissue. This approach will also confirm if viral changes, including viral 
integration, or regions where MCPyV could not be sequenced are present within MCPyV 
positive normal and tumour tissues.  
 
Two other research groups have postulated that host cell mutations, such as EGRF and 
BRAF are associated with MCPyV, with the theory that MCPyV induced genomic instability 
could be responsible for the development of these sporadic mutations. However, the 
correlation between MCPyV and EGRF may be the result of the high rate of EGRF mutation 
in Asian populations rather than being induced by MCPyV. As such, the Brisbane Lung 
Cancer Cohort would be an ideal sample set to investigate the role of MCPyV in NSCLC as 
these contain both matched histological normal and tumour tissues from a population of 
predominantly European descent.  
 
These further studies are likely to resolve the question about viral genome integration, and 
its effect on cell transformation, and, together with the results of the study described in this 
thesis, will form the basis of further research to elucidate the putative novel role of MCPyV 
in the development of non-small cell lung carcinoma. 
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APPENDIX ONE 
 
Synthetic control plasmids 
 
  
 A1.1 Introduction 
 
It is difficult to obtain clinical specimens positive for some of the human polyomaviruses, 
particularly those discovered in the last 2 years. Therefore synthetic plasmids were 
constructed containing target regions of the newly described polyomavirus genomes. These 
plasmids were then used as positive controls to be used on all screening and confirmatory 
rtPCR assays to ensure the integrity of PCR master mixes. In addition to polyomavirus 
targets the ERV3 target region was also added to one of the synthetic plasmid which allowed 
the calculation of polyomavirus genome copy number in comparison to human cell number.  
Below is the design and sequence of the five synthetic plasmids constructed and used for 
this thesis.  
A1.2 Mega synthetic plasmid 1 
 
The Primer and probe targets for assays WU-F, KI-D, JCV, HPyV 6-A, HPyV 7-D, HPyV 9 
– VP1, SV40 SL1 and MCV 1.1 were amplified and cloned into a pMA-RQ plasmid. Plasmid 
construction was performed by the GeneArt service, Life Technologies (Australia). The final 
construct was purified and quantified using UV spectroscopy. The final construct was 
sequenced verified, the final sequence of the inserted sequence can be found in Figure 
A2.1. A final concentration of 5µg of plasmid DNA was received in the laboratory and 
hydrated with 50µl of water. Using the weight of the total plasmid construct the copy number 
of plasmid per microliter was calculated to be 2.89 x1010 copies.  
 
 
 
 
 Figure A1.2 Inserted sequence into mega synthetic control plasmid one.  
TCCAAACCTTCTTCTCTCCTGTCAACAGTGGCCAGCCCCCCAACTATGAGATGCTCAAGGAGGAGCACGAGGTGGataGC
CGACAGCCGTTGGATATAAAGGGTCACCATTTTTATTTCAGATGGGCATATTGCTTGCTGTGCCTGAAAatCACAGGTGG
TTTTCTATAAATTTTGTACTTTTCTTTATGATATTTGCTTAAAATACAGTGAATGCATTGGCATTCGTGATTGTAGCCAT
GAATGCATACATCCCACTGCTTCatAAGGGAGGGAACCTATATTTCTTTTGaCTCATACACCCAAAGTATAGATGATGCA
GACAGCAtaTTCAAGAAGTTACCCAAAGGCTAGAtatACCAGGTGGGTGATGAAGACATTTGGTCCCTCAGGGTGGCATT
CAACTTCTCCTTTAAAACATTCAGGCGatGAGGAAGGAAACACTCCCCAGTATACTATACCTCAATGGATGCTTTTTGTT
CTTGAGGAGCTACAAAAAGAAGTGAAtaCTAGGGAACAATTTGAATATCAGGAACAAGTTAGGCTGAGGCGGGAGATAGG
GGGTTCAGAGCCTAGATCTGGACACTATatCAGGGAAGGGTTGCAAATATCATTTGGGCACACCTATGATAATATTGATG
AAGCAGACAGTATTCAGCAAGTAACTGAGAGGTGGGAAGCTCAAAGCCAAAGTCCTAATGTGCatAGCTCAGAAGTGACT
TCTCTATGTTTGATGAGGTTAGTACAAAATTTCCTTGGGAAGAATATGGAACTTTAAAGGATTATATGCAAAGTGGATAT
AATGCTAGATTTTGCAGAGGTCCTGGGTGCATGCTTAAGCAACTTAGAGATTCTAAGTGCGCTTGTATTAGCTGTAAGTT
GTCTCGCCAGCATTGTataTAATACGACTCACTATAGGGGAGATTGAGCTATGCATTTGTTTTGaTGCAGAAATACTAAG
AAGATCTGTGGATACCTCATCGaAGGAATTAGAAAATGTTTCAGATGCACCCTTTAGTGAGGGTTAATTata 
Oligonucleotide targets for different polyomavirus targets are highlighted in different colour and listed in order 
of appearance 5’ to 3’. WU-F primer and probe sequences highlighted in green, KI-D primer and probe 
sequences highlighted in yellow, JCV primer and probe sequences highlighted in blue, HPyV 6-A primer and 
probe sequences highlighted in red, HPyV 7-D primer and probe sequences highlighted in orange, HPyV 9-
VP1 primer and probe sequences highlighted in purple, SV40 SL1 primer and probe sequences highlighted 
in pink, MCV1.1 primer and probe sequences highlighted in dark blue.  
 
A1.2 Mega synthetic plasmid 2 
 
This plasmid was constructed as described above in section A3.2.1. The Oligonucleotide 
targets contained in this plasmid are; KI-E, MCV 2.0, BKV V3a, HPyV 6-D, HPyV 7-E, HPyV 
9-LT, SV40–LT and ERV3.  A final concentration of 5µg of plasmid DNA was received in the 
laboratory and hydrated with 50µl of water. Using the weight of the total plasmid construct 
the copy number of plasmid per microliter was calculated to be 2.98x1010 copies.  
 
 
 
 Figure A1.2 Inserted sequence into mega synthetic control plasmid two.  
TCCAAACCTTCTTCTCTCCTGTCAACAGCGGCCAGCCCCCCAACTATGAGATGCTCAAGGAGGAGCACGAGGTGGataGA
ACTTCTACTGTCCTTGACACAGGTAAGACTGGGGACCCTTTGTAGGCCAAAGGAGAGTGAAGGGTAACTGAAATGCTAAG
ACTGTAAGTTCTAATCCatGGCAGCATCCCGGCTTAGGTATACATTGCCTTTTGGGTGTTTTACAGGTGGATGATGCTTT
TCTTTTTGGatCCTTACCCAATTTCCTTTTTGCTAAGTGACCTTATAAACAGGAGAACCCAGAGAGTGGATGGGCAGCCT
ATGTATataTTGAGGAGCTGGACAAAGAGATTAAGGAAGATGCCTTGTCACAGAAAAGGAAATGGACCAATTCAAAAGCT
TCCCAGATAAAGACATTCAGTCTTTGCATTTTCTGGGGATCTCCACCTTTATCTGGATGATACTTTTTGCTGGCTAATCT
AACCTTATGCTGTATGAGGGGatCAAACTCCCTCCACCATTTACCCCATGACCCCCCTTCTGGATCTTCATTTTTTCTTT
CACAGTAGGAAAATGGAGTTTCAGTAAAGTATGGAGAatGATGGCATTTCTTCTGAGCAAAACAGGTTTTCCTCATTAAA
GGCATTCCACCACTGCTCCCATTCATCAGTTCCATAGGTTGGAATCTAAAtaCATGGGAAGCAAGGGAACTAATGatTCT
TCCCTCGAACCTGCACCATCAAGTCAtatAAATTCTGTATTGCTCGCTGGGtaTAATACGACTCACTATAGGGCATAATT
GAACTTGTCAATGGTTTTGTaCTCGGCAGATGGGAGAGATGGTGTGaAGATATAAAGACCACAATTATGCCTGAACCCTT
TAGTGAGGGTTAATTata 
Oligonucleotide targets for different polyomavirus targets are highlighted in different colour and listed in order 
of appearance 5’ to 3’. KI-E primer and probe sequences highlighted in red, MCV 2.0 primer and probe 
sequences highlighted in blue, BKV V3a primer and probe sequences highlighted in yellow, HPyV 6-D primer 
and probe sequences highlighted in green, HPyV 7-E primer and probe sequences highlighted in purple, 
HPyV 9-LT primer and probe sequences highlighted in pink, SV40 LT primer and probe sequences highlighted 
in light blue, ERV3 primer and probe sequences highlighted in dark blue.  
 
A1.3 MWPyV synthetic plasmid  
 
This plasmid was constructed by IDT and contained the oligonucleotide sequences for 
MWPyV-E and MWPyV – ES105. A final concentration of 5µg of plasmid DNA was received 
in the laboratory and hydrated with 100µl of water. Using the weight of the total plasmid 
construct the copy number of plasmid per microliter was calculated to be 1.98x1010 copies.  
 
 
 
 
 
 Figure A1.3 Inserted sequence into MWPyV control plasmid. 
CAGGGCCGGACACCACAATGACAGTTGAGGTCATTCTTCAACCAAGGATGGGCAATGATGTAAAAACAAACAAATGGTAT
GGCTATCACAATGCAGATCTTGCTCATCAAAGCCTTGATTGAATTCTTCCCACCACTGTTCCCACTGTGAGGTGCCATAT
TCTGGAACCTTAACCAGAAAATCTTAGGTAAAGCATTGATGGACAGCCAATGGATGGGACTGATAATCAAGTACAGGATG
TAACTGTGTTCCAAGGAACAGAACCTCTTCCAGGAGATTTGAGAAGGCCCCGGTTCTTCCTCATCACTGGGAGCAAAAGA
TTCATTACAACTTAAATCTTCATCCCATCCTCTA 
Oligonucleotide targets for different MWPyV targets are highlighted in different colour and listed in order of 
appearance 5’ to 3’. MW-E primer and probe sequences highlighted in pink, MWPyV – ES105 primer and 
probe sequences highlighted in yellow. 
 
A1.4 HPyV 12 synthetic plasmid 
 
This plasmid was constructed by GeneArt services at Life Technologies (Life Technologies, 
Australia) as previously described in section A3.2.1. This construct only contained the 
oligonucleotides for the HPyV 12-VP1 assay. (Figure A3.2.4) A final concentration of 5µg of 
plasmid DNA was received in the laboratory and hydrated with 50µl of water. Using the 
weight of the total plasmid construct the copy number of plasmid per microliter was 
calculated to be 2.88x1010 copies.  
 
Figure A1.4 Inserted sequence into HPyV 12 VP1 control plasmid. 
 
CCCTACTTATGTGGGAAGCTGTCAGTGTGAAAACTGAAGTAATTGGCTCTAATACACTTATGAATGTGCATGATTAGTCG
ACTAGGACTGACAATGGGGTAGGCCATCCTGTAGTGGGCTCTACATACCACATGTTTGCAGTAGGTGGGGAACCCCTA 
Oligonucleotide sequences for the HPyV 12 –VP1 assay are highlighted in green. 
 
 
A1.5 STLPyV synthetic plasmid 
 
This plasmid was constructed by GeneArt services at Life Technologies (Life Technologies, 
Australia) as previously described in section A3.2.1. This construct only contained the 
 oligonucleotides for the STLPyV assays, STLPyV – LT and STLPyV – VP1. (Figure A3.2.5) 
A final concentration of 5µg of plasmid DNA was received in the laboratory and hydrated 
with 50µl of water. Using the weight of the total plasmid construct the copy number of 
plasmid per microliter was calculated to be 3.62x1010 copies.  
 
Figure A1.5 Inserted sequence into STLPyV control plasmid. 
 
AAGAAGTTGAAAATGGCTCCAAAAAGAAAATCTAGATGCACCTCACAGACATGTCCAATGGACACCTGTAATCCTAGGAG
GAGAAGATGTGAATATGATCCATCAAAAATTTCCCTTATCAGAATGCATGAACCCCCTATATATGGAACCCCCGCCTTTA
GAGAGTGGTGGTTCTACCAGCAGAGATGCAGAGGTCCCTTCATCATCACTGCAGTTAAAAGATTCATTGCAAGTTAAATC
ATCTTCAAAAGGTTGATTAAATTCTTCCCACCATTGCTCCCAAGCAGGAGTACCATATTGTCCGCCCTAAAAAGAAAAAC 
Oligonucleotide sequences for the STLPyV –VP1 assay are highlighted in yellow and STLPyV – LT in blue. 
 
A1.2.6 TSPyV synthetic plasmid 
 
This construct was kindly provided by Els van der Meijden from the Leiden University 
Medical Center, Leiden, Netherlands. This construct contains the entire LTAg ORF in the 
backbone of the puc19 plasmid. The TSPyV construct was sent on filter paper and eluted in 
100ul of water. Ten spectrophotomy reading averaged 9.185ng/µl or 1.9 x109 plasmid copies 
per microliter.  
 
  
  
APPENDIX 2 
 
ORChID symptom diary 
 
  
 A2.1 Example of ORChID symptom diary 
 
An example of the symptom diary used to collect parental reports of symptoms for the 
duration of the ORChID study. Clinical data were broadly categorized as upper respiratory 
(ear infection, runny nose, cough, sore throat and muscle aches), lower respiratory 
(wheezing, shortness of breath, pulmonary congestion and pneumonia), non-specific (fever, 
chills, headaches, irritability and decreased activity) and gastrointestinal (more than 3 lose 
stools in 24 hours and any number of vomits) 
Figure A2.1 Illustration of ORChID symptom diary 
 
 
 
 
 
 
  
  
APPENDIX A3 
 
Assay design for WUPyV and KIPyV reverse transcriptase real-time 
PCR assays 
 
  
 A3.1 Introduction  
 
To confirm the presence of WUPyV and KIPyV LTAg mRNA two assays were designed to 
specifically amplify PyV RNA. Initially experiments to quantify PyV mRNA were hampered 
by the inability to digest polyomavirus DNA from nasal swabs. This is believed to be due the 
very stable double stranded circular structure of the polyomaviruses genome.  
 
A3.1 Primer design WUPyV LTAg exon- exon RTPCRs 
 
Two WUPyV reverse primers were designed specific to the LTAg mRNA sequence. The last 
7bp of the primer are homologous with the mRNA only (bold italic Figure 3.1) whilst the 
remaining 20bp are complementary to both the DNA and mRNA sequence.  More than 3 
mismatches in the 3’ homology of reverse primers to target sequence results in little or no 
amplification even when high target sequence is present.  
The second WUPyV exon primer WU – Exon R2 had an additional mismatch added to the 
7 base from the 3’ end (base A changed to G labelled red in Table 3.1). This was added to 
further destabilise the potential binding to WUPyV LTAg DNA 
 
Figure A3.1. Binding of exon-exon primer to WUPyV DNA 
Binding after intron 
DNA----------TATTATAGATACCCACATATGGTACCCCAGACTGGGATT                 
REVERSE PRIMER—-GTAGAATACCCACATATGGTACCCCAG 
 
 
 Table A3.1. WUPyV LTAg expression exon junction primer design 
Assay Name Oligo Name Sequence 5’ to 3’ length Tm GC 
content 
WUPyV  
Exon-exon  
WU – Exon 
F1 
AGAGTGTGTTAGTACAGTGCACC
AACTAA 
29 59.7 41.4 
WU – Exon 
R1 
CTGGGGTACCATATGTGGGTATT
CTAC 
27 60.7 48.1 
WU – Exon 
R2 
GGGGTACCATATGTGGGTGTTCT
AC 
25 60.4 52 
Two reverse primers designed to amplify over the exon-exon junction found in the STAg and LTAg binding 
region. Base labelled red in primer sequence of WU Exon R2 added to further destabilise any binding with the 
specific mRNA sequence compared to the intron DNA.  
 
A3.2. Primer design KIPyV LTAg exon- exon RTPCRs 
Two KIPyV reverse primers were designed specific to the LTAg mRNA sequence. The last 
7bp of the primer are homologous with the mRNA only (bold italic Figure 1) whilst the 
remaining 20bp are complementary to both the DNA and mRNA sequence.   
The second WUPyV exon primer WU – Exon R2 had an additional mismatch added to the 
7 base from the 3’ end (base A changed to G labelled red in Table 3.2). This was added to 
further destabilise the potential binding to WUPyV LTAg DNA 
 
Figure A3.2 Binding of exon-exon primer to KIPyV DNA 
Binding after intron 
DNA----------TTTTGTTGTATAGATACCTACATACGGTACACCTGACTGG     
REV PRIMER----------TTCTCAGTACCTACATACGGTACACCTG 
 
Table A3.2 KIPyV LTAg expression exon junction primer design 
Assay 
Name 
Oligo Name Sequence 5’ to 3’ length Tm 
GC 
content 
KIPyV 
Exon-
exon 
 
KI – Exon F1 AATATCATCCAGATAAAGGAGGAAATGA 28 59 32.1 
KI – Exon R1 CAGGTGTACCGTATGTAGGTACTGAGAA 29 58.7 46.4 
KI – Exon R2 GGTGTACCGTATGTAGGTACTGGGAA 27 69.2 50 
Two reverse primers designed to amplify over the exon-exon junction found in the STAg and LTAg binding 
region.  
  
 
APPENDIX A4 
 
Immunhistochemical staining controls for HPyV 6 & 7 using 
transfected HeLa cells   
 
  
 Appendix A4.1 Immunhistochemical staining controls for HPyV 6 & 7 using transfected HeLa 
cells   
 
Only a few studies have investigated the presence of HPyV 6 & 7 in human tissues, therefore 
we transfected HeLa cells with transfection plasmids to produce STAg proteins. Cell pellets 
were then stained with three antibodies, xt7 a nonspecific PyV STAg antibody that binds to 
the STAg of human polyomaviruses, 2t10 which specifically binds to the STAg of HPyV 7 
and has no cross-reactivity and 1t1 which was designed to bind to the STAg of HPyV6 but 
has cross-reactivity with the STAg of HPyV7, MCPyV and weak reactivity to MWPyV. 
Staining of expression plasmids can be found below in Figure A4.1 and A4.2.  
 
Figure A4.1 Staining of HeLa cell pellets that have been transfected with p6t which produces the LTAg 
proteins from HPyV6. A) Staining with xt7 antibody which is nonspecific and will stain STAg protein 
from all human PyVS. Black arrows show nuclear staining for STAg. x200 magnification. B) Isotype 
negative control x200 magnification C) Slide stained with 2t10 which specifically stains HPyV 7 STAg. 
No positive cells present. Image at x200 magnification. D) Isotype negative control x200 magnification 
E) Staining with 1t1 which specifically binds STAg from HPyV 6 however it has cross-reactivity with 
HPyV7, MCPyV and weakly with MWPyV. Black arrows show nuclear staining for STAg. Image at x200 
magnification. Black arrows show nuclear staining for HPyV 6 STAg.  F) Isotype negative control x200 
magnification. G) Mock HeLa cell transfection slide stained with xt7 and no staining seen. H)  Mock 
HeLa cell transfection slide stained with 1t1 and no staining seen. 
A) B) 
  
 
 
 
 
 
 
  
 
C) 
 
 
D) 
  
E) F) 
 
 
G) H) 
  
 
 
 
 Figure A4.2 Staining of HeLa cell pellets that have been transfected with p7t which produces the LTAg 
proteins from HPyV7. A) Staining with xt7 antibody which is nonspecific and will stain STAg protein 
from all human PyVS. Black arrows show nuclear staining for STAg. x200 magnification. B) Isotype 
negative control x200 magnification C) Slide stained with 2t10 which specifically stains HPyV 7 STAg. 
Black arrows show nuclear staining for STAg. Image at x200 magnification. D) Isotype negative control 
x200 magnification E) Staining with 1t1 which specifically binds STAg from HPyV 6 however it has 
cross-reactivity with HPyV7, MCPyV and weakly with MWPyV. Black arrows show nuclear staining for 
STAg. Image at x200 magnification. Black arrows show nuclear staining for HPyV 7 STAg.  F) Isotype 
negative control x200 magnification. G) Mock HeLa cell transfection slide stained with 2t10 and no 
staining seen. H)  Mock HeLa cell transfection slide stained with 1t1 and no staining seen. 
A) B) 
  
C) D) 
  
E) F) 
  
  
  
G) 
 
H) 
  
 
  
  
APPENDIX A5 
 
Immunohistochemistry staining of MCPyV 
 
  
 A5.1 Optimization of MCPyV immunohistochemistry staining using antibodies AB3 and 
CM2B4 
 
A block of FFPE confirmed MCC positive control tissue was obtained from Sullivan 
Nicolaides pathology. General morphology of this tissue is demonstrated with hematoxylin 
and eosin staining in Figure A5.1. Control MCC tissue was also stained with MCPyV LTAg 
specific antibodies CM2B4 (Figure A5.2) and AB3 (Figure A5.3) and included isotype 
negative control staining for each antibody. Strong nuclear staining with MCPyV LTAg 
antibodies was present in both the low and high magnification in MCC tissue, however AB3 
staining was only present in tumour cells, whereas staining with CM2B4 was less confined 
to the tumour tissue. Personal communication with researches at the DNA tumour virus 
conference suggested that CM2B4 was less specific than AB3 and could stain lymphocytes 
without the presence of MCPyV LTAg. Experiments of determine this potential artefact were 
conducted using MCPyV PCR negative adenoid tissue (Figure A5.4). The specificity of both 
antibodies is seen by staining this tissue, strong nuclear staining is seen with CM2B4 
antibody in lymphocytes, whereas no staining is seen with AB3. Staining with AB3 is also 
more intense than staining with the CM2B4 antibody. To determine if non-specific staining 
was occurring in lung tissue, a MCPyV PCR negative lung tissue (LC66) was also staining 
with both CM2B4 and AB3 this staining showed no MCPyV staining with either antibody 
(Figure A5.5). These experiments demonstrate that CM2B4 has affinity to lymphocytes that 
could potential confound lung tissue staining and AB3 has superior specificity and potential 
sensitivity.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 Figure A5.1 Hematoxylin and eosin staining of MCC control tissue demonstrating morphology of the 
MCC tissue. A) 20x B) insert box at 200x magnification 
 
A) B) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 Figure A5.2 CM2B4 MCPyV LTAg staining of MCC control tissue. A)20x B) insert box at 200x 
magnification. Black arrow indicates nest of tumour cells all with strong nuclear staining of the CM2B4 
antibody. Red arrows indicate stromal cells that are not stained by CM2B4. Blue arrow indicates 
potential lymphocyte staining with CM2B4. CM2B4 isotype negative staining of MCC control tissue. C) 
20x D) insert box at 200x magnification. No staining seen.  
 
A) B) 
 
 
C) D) 
 
 
 
 
 
 
 
 
 
 
 
  
 
Figure A5.3 AB3 staining for MCPyV LTAg in MCC control tissue. A) 20x B) insert box at 200x 
magnification. Black arrow indicates margin of tumour and normal tissue with tumour cell 
demonstrating strong nuclear staining with AB3 antibodies, however no staining was seen in stromal 
tissue (red arrow) AB3 isotype negative MCC control tissue, showing no staining. C) 20x D) insert box 
at 200x magnification     
A) B) 
 
 
C) D) 
 
 
 
 
 
 
 
  
Figure A5.4 MCPyV negative adenoid tissue. A) Stained with CM2B4 20x B) insert box at 200x 
magnification. Arrows indicate lymphocytes staining strongly with CM2B4 antibody confirm 
nonspecific staining in this cell type.  C) Stained with AB3 20x D) insert box at 200x magnification. No 
staining is noted using AB3 in MCPyV negative adenoid tissue. 
A) B) 
 
 
C) D) 
 
 
 
 
 
 
 
 
 
 
  
 
Figure A5.5 Lung MCPyV negative tissue; LC66 Tumour H&E. A) 20x B) insert box at 200x 
magnification, C) LC66 Tumour CM2B4 20x D) insert box at 200x magnification, E) LC66 Tumour AB3 
20x F) insert box at 200x magnification 
 
A) B) 
 
 
C) D) 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
E) 
 
 
 
F) 
 
 
 
 
A5.2 Immunohistochemistry staining MCPyV positive lung tissues 
 
Eleven lung cancer patients had MCPyV detected in their lung tissues. 
Immunohistochemical staining was conducted on the normal and tumour FFPE tissue using 
two specific MCPyV LTAg antibodies, CM2B4 and AB3. Optimization of 
immunohistochemical staining demonstrated that MCPyV LTAg AB3 antibody had 
increased specificity over CM2B4 can be found in Appendix A6.1. Therefore, antibody AB3 
was selected to be used in the downstream analyses of all lung tissue staining. MCPyV 
LTAg immunohistochemistry confirmed all but one patient’s MCPyV positive lung tissue 
results. Staining of slides from patient LC1 had no evidence of MCPyV LTAg nuclear 
staining.  
In this appendix the additional seven MCPyV PCR positive lung tissues that are not found 
in the thesis body are presented including corresponding H&E staining Figure A6.2.1 to 
 A6.2. Staining from patient LC9, 44, 65 and 69 represents category A) where patients had 
MCPyV PCR positive normal lung tissue with no, or low load MCPyV DNA detection in 
corresponding tumour tissue. Patient LC61 represents category B) where MCPyV PCR 
positivity was found predominately in tumour lung tissue. Patients LC1 and LC10 represent 
examples from category C) where equivalent MCPyV DNA load was detected in both normal 
and tumour tissues. For each tissue, staining intensity was classified in figure legends as; 
+1 few cells positive, ++ more than 30% of all cells positive, +++ more than 50% of cells 
positive. 
A5.2 MCPyV Immunohistochistry stain for Category A) MCPyV PCR results – Patients 
predominately MCPyV positive in normal lung tissue. 
  
Antibody staining in normal and tumour tissue for patients LC9, 44, 65 and 69 is illustrated 
in Figures A5.2.1 to A5.2.8. Staining was isolated to respiratory epithelial cells within the 
normal lung tissue of all four patients, with tumour tissue only clearly positive for patient 
LC69 (Figure A5.2.8). 
 
 
 
 
 
 
 
 
 
 
 Figure A5.2.1 MCPyV category A) LC9 Normal H&E. A) 20x B) insert box at 200x magnification, C) LC9 
Normal AB3 20x D) insert box at 200x magnification. Black arrow indicates weak nuclear staining in 
sparse epithelial cells with AB3. 
A) B) 
 
 
C) D) 
 
 
 
 
 
 
 Figure A5.2.2 MCPyV category A) LC9 Tumour H&E. A) 20x B) insert box at 200x magnification, C) LC9 
Tumour AB3 20x D) insert box at 200x magnification. No staining seen.  
A) B) 
 
 
C) D) 
 
 
 
 
 
 
 
 
  
Figure A5.2.3 MCPyV category A) LC44 Normal no H&E staining available, A) LC44 Normal AB3 20x B) 
insert box at 200x magnification.  
A) B) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 Figure A5.2.4 MCPyV category A) LC44 Tumour H&E. A) 20x B) insert box at 200x magnification, C) 
LC44 Tumour AB3 20x D) insert box at 200x magnification. No nuclear staining seen. 
A) B) 
 
 
C) D) 
 
 
 
 
 
 
 
 Figure A5.2.5 MCPyV category A) LC65 Normal H&E. A) 20x B) insert box at 200x magnification, C) 
LC65 Normal AB3 20x D) insert box at 200x magnification.  
A) B) 
 
 
C) D) 
 
 
 
 
 
 
 
 Figure A5.2.6 MCPyV category A) LC65 Tumour H&E. A) 20x B) insert box at 200x magnification, C) 
LC65 Tumour AB3 20x D) insert box at 200x magnification. Black arrows indicate nuclear staining in 
some D) insert box at 200x magnification. Black arrows indicate nuclear staining of all tumour cells in 
tumour nests but no staining of surrounding immune and stromal cells. 
A) B) 
 
 
C) D) 
 
 
 
 
 
 Figure A5.2.7 MCPyV category A) LC69 Normal H&E. A) 20x B) insert box at 200x magnification, C) 
LC69 Normal AB3 20x D) insert box at 200x magnification. Black arrow indicates positive nuclear 
staining in the respiratory epithelial cells but not in lung stroma (red arrow) 
A) B) 
 
 
C) D) 
 
 
 
 
 
 
 Figure A5.2.8 MCPyV category A) LC69 Tumour H&E. A) 20x B) insert box at 200x magnification, C) 
LC69 Tumour AB3 20x D) insert box at 200x magnification. Black arrows indicate nuclear staining in 
tumour cells compared to negative stroma (red arrow) with sparse staining in lymphocytes (blue arrow) 
A) B) 
 
 
C) D) 
 
 
 
 
 
 
 A5.3 MCPyV immunohistochistry stain for Category B) MCPyV PCR results – Patients 
predominately MCPyV positive in lung tumour tissue. 
 
MCPyV LTAg staining for patient LC61 will be represented in this section (Figure A5.3.1). 
Sporadic nuclear staining of respiratory epithelial cells is noted in normal tissue and some 
weak nuclear positive tumour cells staining in nests of tumour cells was also seen.   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 Figure A5.3.1 MCPyV category B) LC61 Normal H&E. A) 20x B) insert box at 200x magnification, C) 
LC61 Normal AB3 20x D) insert box at 200x magnification, black arrows shows weak nuclear staining 
of respiratory epithelial cells.  
A) B) 
 
 
C) D) 
 
 
 
 
 
 Figure A5.3.2 MCPyV category B) LC61 Tumour H&E. A) 20x B) insert box at 200x magnification, C) 
LC61 Tumour AB3 20x D) insert box at 200x magnification. Black arrows indicate nuclear staining for 
MCPyV LTAg in tumour cells 
A) B) 
 
 
C) D) 
 
 
 
 
 
 A5.4 MCPyV immunohistochistry stain for Category C) MCPyV PCR results – Patients had 
equivalent MCPyV viral loads in both normal and tumour lung tissues. 
 
MCPyV LTAg staining for patient LC1 and LC10 will be represented in this section. No clear 
nuclear staining was noted in the normal or tumour tissue collected from patient LC1. 
Sporadic nuclear staining of respiratory epithelial cells is noted in normal tissue of patient 
LC10 and MCPyV LTAg positive tumour cells staining is seem in almost all cells within 
tumour nest.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 Figure A5.4.1 MCPyV category C) LC1 Normal H&E. A) 20x B) insert box at 200x magnification, C) LC1 
Normal stained with AB3 20x D) insert box at 200x magnification. No staining seen. 
A) B) 
 
 
C) D) 
 
 
 
 
 
 
 Figure A5.4.2 MCPyV category C) LC1 Tumour H&E. A) 20x B) insert box at 200x magnification, C) LC1 
Normal AB3 20x D) insert box at 200x magnification. No staining seen. 
A) B) 
 
 
C) D) 
 
 
 
 
 
 
 
 
 Figure A5.4.3 MCPyV category C) LC10 Normal H&E. A) 20x B) insert box at 200x magnification, C) 
LC10 Normal AB3 20x D) insert box at 200x magnification. Black arrows show strong nuclear staining 
in the majority of respiratory epithelial cells.  
A) B) 
 
 
C) D) 
 
 
 
 
 
 Figure A5.3.4 MCPyV category C) LC10 Tumour H&E. A) 20x B) insert box at 200x magnification, C) 
LC10 Tumour AB3 20x D) Insert box at 200x magnification. Black arrows show large numbers of tumour 
cells with nuclear staining for AB3. 
A) B) 
 
 
C) D) 
 
 
 
 
  
  
APPENDIX A6 
 
Immunohistochemistry staining HPyV 6 and 7 positive lung tissues 
 
  
 Appendix A6.1 immunohistochemical staining for HPyV 6 PCR positive lung tissues 
 
Three patients had positive HPyV 6 tissue samples by rtPCR, these tissues were stained 
with the antibody 1t1.Two patients, LC29 and LC66 had the highest PCR copy number for 
HPyV 6 were illustrated in the body of the thesis. The remaining HPyV 6 patient LC73 is 
presented here (Figure A6.1).  Patient LC73 was also PCR positive for HPyV 7 and stained 
with 2t10 is also illustrated below, the antibody 2t10 is specific for HPyV 7 STAg (Figure 
A6.1D). However 1t1 has cross-reactivity with HPyV 6 STAg, therefore for these tissue there 
is a possibility the HPyV 6 staining is also staining HPyV 7.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 Figure A6.1 LC73 Normal tissue H&E. A) 20x B) insert box at 200x magnification, C) LC73 Normal 1t1 
20x D) insert box at 200x magnification. Black arrows indicate cells staining with 1t1, although this 
staining appears to be arefact as 1t1 should stain in the nucleus and staining looks cytoplasmic. D) 
LC73 Normal 2t10 20x D) insert box at 200x magnification. Black arrows indicate cells staining with 
2t10, which look similar to the cytoplasmic staining with 1t1. As this patient is positive for  both HPyV 
6 &7 staining with both antibodies is expected, however staining doesn’t appear to be nuclear therefore 
likely to be artefact.  
A) B) 
 
 
C) D) 
 
 
 
 
 
 
  
E) 
 
F) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 Figure A6.2 LC73 Tumour H&E. A) 20x B) insert box at 200x magnification, C) LC73 Tumour 1t1 20x D) 
insert box at 200x magnification. D) LC73 Tumour 2t10 20x D) insert box at 200x magnification. 
A) B) 
 
 
C) D) 
 
 
 
 
 
 
 
 
 
 
 
 
 E) F) 
 
 
 
Appendix A6.3.1 immunohistochemical staining for HPyV 7 PCR positive lung tissues 
 
Four patients had positive staining for HPyV 7, one patient, LC44 was also positive for 
MCPyV and staining was not attempted for HPyV 7 due to insufficient FFPE slides. The 
other three patients were stained with the specific antibody for HPyV 7 STAg. Staining for 
both the normal and tumour tissue from HPyV 7 PCR positive patient; LC65, 73 and 74 can 
be found in Figure 6.3 to Figure 6.6. A few cells contained sparse nuclear staining of the 
HPyV 7 STAg antibody in the normal lung tissue of LC74 (Figure A6.5). No other patients 
demonstrated nuclear staining for the HPyV 7 STAg antibody in any lung specimens.  
 
 
 
 
 
 
 Figure A6.3 Lung HPyV 7 positive tissue; LC65 Normal H&E. A) 20x B) insert box at 200x magnification, 
C) LC65 Normal 2t10 20x D) insert box at 200x magnification. 
A) B) 
 
 
C) D) 
 
 
 
 
 
 
 Figure A6.3.4 Lung HPyV 7 positive tissue; LC65 Tumour H&E. A) 20x B) insert box at 200x 
magnification, C) LC65 Tumour 2t10 20x D) insert box at 200x magnification. 
A) B) 
 
 
C) D) 
 
 
 
 
 
 Figure A6.5 Lung HPyV 7 positive tissue; LC74 Normal H&E. A) 20x B) insert box at 200x magnification, 
C) LC74 Normal 2t10 20x D) insert box at 200x magnification. Black arrows may indicate low level 
nuclear staining for HPyV 7. 
A) B) 
 
 
C) D) 
 
 
 
 
 
 
 Figure A6.6 Lung HPyV 7 positive tissue; LC74 Tumour H&E. A) 20x B) insert box at 200x magnification, 
C) LC74 Tumour 2t10 20x D) insert box at 200x magnification. 
A) B) 
 
 
C) D) 
 
 
 
 
  
  
APPENDIX A7 
 
Potential impact of sequence variation on MCPyV whole genome 
sequencing   
 A7.1 – MCPyV walking primer design and the potential impact of sequence variation of 
MCPyV whole genome sequencing in MCPyV positive NSCLC.    
 
Primer sequences were compared to the 43 MCPyV whole genome sequences available; 
these included 30 MCPyV positive healthy skin swabs, 9 Merkel cell carcinomas, 1 
peripherial blood specimen, 1 fecal specimen, 1 skin swab from a patient with Kaposi 
sarcoma, sequence from MCPyV positive cell line MKL-1 which contains one integrated full-
length MCPyV copy per cell and a consensus full-length MCPyV construct. While primer 
sequences were designed within conserved areas of the MCPyV genome however priming 
mismatched were unavoidable in some cases (Accession numbers of MCPyV whole 
genomes, JF812999, JF813000, JF813001, JF813002, JF813003, JN383838, JN383839, 
JN383840, JN383841, JQ479315, JQ479316, JQ479317, JQ479318, JQ479319, 
JQ479320, KC571692, FJ464337, FJ173815, EU375803, EU375804, KF266963, 
KF266965, HM011538, HM011539, HM011540, HM011541, HM011542, HM011543, 
HM011544, HM011545, HM011546, HM011547, HM011548, HM011549, HM011550, 
HM011551, HM011552, HM011553, HM011554, HM011555, HM011556, HM011557, 
KF266964, NC_010277).  A list of oligonucleotide mismatches can be found in Table A7.1 
which identify polymorphisms between primers sequences and all publically available 
MCPyV whole sequence data. Although mistmatches can be found in the walking primer 
sequences generally only a few publically available MCPyV sequences were affected. 
Single base pair changes in primer sequences that fall outside the first 10bp of the 5’ end of 
forward primers and the last 10bp of the 3’ end of reverse primers should only have a small 
effect on amplification. However mutations that affect the 5’ and 3’ binding ends of MCPyV 
primers could significantly reduce amplification and have been underlines in Table A7.1. 
However the use of different combinations of oligonucleotides from the 4 primers designed 
in this region should overcome most of these amplification problems.  
 Table A7.1 The 43 publically available genomes for MCPyV were aligned with MCPyV walking primer 
sequences to demonstrate the effect MCPyV sequence variation could have on the ability to amplify 
the whole MCPyV genome.   
Primer name  
No. of 
mismatches 
Frequency of 
mismatch in 43 
MCPyV genomes Mismatch position 
MCV Walk 1F 1 1 5bp from 3'end of primer 
MCV Walk 1R none     
MCV W1F inner 
2 a. 2 b. 1 
a. 17bp from 5'end of primer b. 10bp from 5'end 
of primer 
MCV W 1R inner none     
MCV Walk 2F 1 1 15bp from 5' end of primer 
MCV Walk 2R 1 1 8bp from 3'end of primer 
MCV W2F inner none     
MCV W 2R inner none     
MCV Walk 3F none     
MCV Walk 3R 1 1 3bp from 5' end of primer 
MCV W 3F inner none     
MCV W 3R inner none     
MCV Walk 4F 1 1 9bp from 5' end of primer 
MCV Walk 4R none     
MCV W 4F inner 
3 a. 1 b. 2 c. 2 
a. 5bp from 5'end of primer b. 6bp from 5'end of 
primer c. 8bp from 5'end of primer 
MCV W 4R inner 1 2 2bp from 5' end of primer 
MCV Walk 5F 1 1 9bp from 3'end of primer 
MCV Walk 5R 2 a. 3 b. 2 a. 9bp from 5'end b. 6bp from 3'end of primer  
MCV W 5F inner 2 a. 1 b. 1 a 7bp from 3'end b. 12bp from 5'end of primer 
MCV W 5R inner 1 1 12bp from 5'end of primer 
MCV Walk 6F 1 1 4bp from 5'end of primer 
MCV Walk 6R 1 1 2bp from 3' end of primer 
MCV W 6F inner 2 a. 1 b. 1 a. 11bp from 5'end b. 7bp from 3'end of primer 
MCV W 6R inner 4 
a. 1 b. 1 c. 1 d. 1 
a. 6bp, b. 11bp, c. 17bp d. 18bp  from 5'end of 
primer 
MCV Walk 7F 2 
a. 2 b. 2 
a. 11bp from 5' end of primer b. 7bp from 3' end 
of primer 
MCV Walk 7R none     
MCV W 7F inner 3 
a. 7 b. 2 c. 14 
a. 10bp from 5'end of primer, b. 17bp from 5'end 
of primer, c. 8bp from 3' end of primer 
MCV W 7R inner none     
MCV Walk 8F none     
MCV Walk 8R 1 3 10bp from 5'end of primer 
MCV W 8F inner none     
MCV W 8R inner 1 3 7bp from 5' end of primer 
MCV Walk 9F 1 1 2bp from 3' end of primer 
MCV Walk 9R 4 
a. 6 b. 6 c. 1 d. 1 
a. 1bp from 3'end b. 11bp from 5'end c. 11bp 
from 3'end d. 2bp from 3'end of primer 
MCV W 9F inner none     
MCV W 9R inner 1 3 7bp from 5' end of primer 
MCV Walk 10F 1 2 6bp from 3' end of primer 
MCV Walk 10R 1 1 5bp from 3'end of primer 
MCV W 10F inner 3 a. 3 b. 1 c. 1 a. 1bp b. 3bp end c. 12bp from 5' end of primer 
MCV W 10R inner 1 2 2bp from 5' end of primer 
MCV Walk 11F 2 a. 1 b.2 a. 7bp from 5'end b. 1bp from 3'end of primer 
MCV Walk 11R 1 2 1bp from 5'end of primer 
MCV W 11F inner 1 1 1bp from 5'end of primer 
MCV W 11R inner 1 1 4bp from 5'end of primer 
MCV Walk 12F 1 6 8bp from 3'end of primer 
MCV Walk 12R 1 1 1bp from 5'end of primer 
    
 MCV W 12F inner 2 a. 1 b. 1 a. 3bp b. 12bp from 5'end of primers 
MCV W 12R inner none     
MCV Walk 13F 1 1 12bp from 5'end of primer 
MCV Walk 13R  4 
a. 1 b. 1 c. 1 d. 1 
a. 1bp from 5'end b. single nucleotide deletion 
at 12bp c. 14bp from 5' end d. 15bp from 5'end 
of primer 
MCV W 13F inner none     
MCV W 13R inner none     
MCV Walk 14F none     
MCV Walk 14R 3 
a. 1 b. 1 c. 1 
a. 10bp from 5'end of primer, b. 11bp from 5'end 
of primer, c. 3bp from 3' end of primer 
MCV W 14F Inner 2 
a. 1 b. 1 
a. 7bp from 3'end of primer b. single nucleotide 
deletion 2bp from 3'end of primer 
MCV W 14R inner  1 1 14bp from 5' end of primer 
Polymorphisms that occur within the first 10bp of the 5’end for forward primers and the last 10bp of the 3’end 
for reverse primers could significantly impact the amplification of segments of the MCPyV genome and have 
been underlined. 
  
  
APPENDIX A8 
 
Whole genome sequencing of MCPyV positive lung tissues 
 
  
 A8.1 Whole genome sequencing of MCPyV positive lung tissues 
 
Whole genome sequencing was completed for all MCPyV-positive lung tissue. Figure A8.1 
illustrates the MCPyV genomes, which were not presented in the body of the thesis. These 
are divided into three established PCR categories. These were A8.1C; MCPyV positives 
detected only or predominately in normal lung tissue, A8.1D; MCPyV PCR positive detected 
at equivalent copy numbers in both normal and tumour tissue. All tissues that fell into 
Category B) or contained MCPyV predominately or only in tumour tissues can be found in 
the body of the thesis (Chapter 7). In general, sequences from matched normal and tumour 
specimens were identical.  
A8.2 MCPyV predominately detected in normal lung tissues 
 
MCPyV was predominately detected in the normal lung tissues of patients LC5, 9, 44, 65 
and 69. Patients LC65 and LC69 are depicted in section C of Figure 7.4. In patient LC44 
and LC65 no non-synonymous changes were noted over the whole MCPyV genome. Patient 
LC69 had only one non-synonymous change this was located at position XXXXbp within the 
VP1 coding region and resulted in a glutamine to glutamic acid amino acid change. This 
non-synonymous change has been commonly reported in MCPyV genomes and is found in 
8 of the 43 MCPyV whole genome sequences publically available.     
A8.3 MCPyV detected in normal and tumour lung tissues at equivalent viral load  
 
The MCPyV sequences from patients LC1 and LC10 contained sequence differences 
between the normal and tumour tissues, therefore they are illustrated separately below. The 
MCPyV viral load was very low in both the normal (0.04 x10-3 MCPyV copies per cell) and 
tumour (0.03 x10-3 MCPyV copies per cell) tissue of patient LC1 and this resulted in an 
inability to amplify the whole genome. MCPyV sequence was not amplified between 0-165bp 
 of the NCCR, 578-1775bp and 2171-2812bp of the STAg and LTAg in the normal tissue of 
patient LC1, portions of the VP1 between 3267 and 3557bp and VP2/3 between 4490 and 
5387bp also could not be amplified. Overall more MCPyV sequence was obtained from 
patient LC1’s tumour tissue with only a small portion of LTAg between 911 and 1390bp was 
not sequenced, segments of the VP1 (3264 to 3549) and VP2/3 (4954- 4431 and 4936 and 
5296bp) were also not amplified.  
Full length MCPyV with three synonymous changes was detected from the normal tissue of 
patient LC10. Indentical MCPyV was detected in the corresponding tumour specimen, 
however this sequence also contained several region where MCPyV could not be amplified. 
These include a 303bp region at the C-terminal region of LTAg, between 2547 and 2850bp. 
The N-terminal region of the VP1 protein (3277 and 3556) and segments of the NCCR (99 
to 198 and 5254 and 5279)    
 
A8.4 MCC control tissue 
 
To compare MCPyV sequence data obtained from a MCC tissue (MCC 849) to that detected 
in lung tissues, FFPE MCC-positive control tissues were amplified (Figure A8.1B). Around 
3000bp of the 3’ end of the LTAg to the early coding region of the VP2/VP3 sequence could 
not be detected, which was targeted by MCPyV walking primer sets 3 to 12.    
 Figure A8.1 Comparison of MCPyV whole genome sequencing, derived from non-cancerous 
specimens, merkel cell carcinoma and lung tissue. A8.1A illustrates the MCPyV genome with the 
coding orientation for structural and non-structural viral proteins. 8.1B compares the MCPyV genomes 
detected in a MCPyV full-length construct (Accession no. JF813003) and three MCC derived truncated 
MCPyV genomes (MCC350, Accession no. EU375803, MCC339 Accession no. EU375804, MCC849 was 
sequenced for this study). A8.1C compares MCPyV sequences detected predominately in normal lung 
tissue and not in matched tumour specimens.  8.1D compares sequences from tissues with equivalent 
MCPyV viral load in matched normal and tumour lung tissue.    
 
 
 
 
 
 
 
 
 
